id	sid	tid	token	lemma	pos
gs-3214	1	1	georgian	georgian	PROPN
gs-3214	1	2	scientists/	scientists/	NUM
gs-3214	1	3	.	.	PUNCT
gs-3214	2	1	6	6	NUM
gs-3214	2	2	n	n	NUM
gs-3214	2	3	3	3	NUM
gs-3214	2	4	,	,	PUNCT
gs-3214	2	5	2024	2024	NUM
gs-3214	2	6	263	263	NUM
gs-3214	2	7	georgian	georgian	PROPN
gs-3214	2	8	scientists	scientist	NOUN
gs-3214	2	9	vol	vol	NOUN
gs-3214	2	10	.	.	PROPN
gs-3214	3	1	6	6	NUM
gs-3214	3	2	issue	issue	NOUN
gs-3214	3	3	4	4	NUM
gs-3214	3	4	,	,	PUNCT
gs-3214	3	5	2024	2024	NUM
gs-3214	3	6	https://doi.org/10.52340/gs.2024.06.04.24	https://doi.org/10.52340/gs.2024.06.04.24	NOUN
gs-3214	3	7	the	the	DET
gs-3214	3	8	scientific	scientific	ADJ
gs-3214	3	9	discussion	discussion	NOUN
gs-3214	3	10	of	of	ADP
gs-3214	3	11	some	some	DET
gs-3214	3	12	issues	issue	NOUN
gs-3214	3	13	of	of	ADP
gs-3214	3	14	features	feature	NOUN
gs-3214	3	15	and	and	CCONJ
gs-3214	3	16	challenges	challenge	NOUN
gs-3214	3	17	of	of	ADP
gs-3214	3	18	using	use	VERB
gs-3214	3	19	of	of	ADP
gs-3214	3	20	car	car	NOUN
gs-3214	3	21	-	-	PUNCT
gs-3214	3	22	t	t	NOUN
gs-3214	3	23	cells	cell	NOUN
gs-3214	3	24	in	in	ADP
gs-3214	3	25	immunotherapy	immunotherapy	NOUN
gs-3214	3	26	nodar	nodar	PROPN
gs-3214	3	27	sulashvili1	sulashvili1	PROPN
gs-3214	3	28	,	,	PUNCT
gs-3214	3	29	magda	magda	PROPN
gs-3214	3	30	davitashvili2	davitashvili2	PROPN
gs-3214	3	31	,	,	PUNCT
gs-3214	3	32	nana	nana	PROPN
gs-3214	3	33	gorgaslidze3	gorgaslidze3	PROPN
gs-3214	3	34	,	,	PUNCT
gs-3214	3	35	luiza	luiza	PROPN
gs-3214	3	36	gabunia4	gabunia4	PROPN
gs-3214	3	37	,	,	PUNCT
gs-3214	3	38	margarita	margarita	PROPN
gs-3214	3	39	beglaryan5	beglaryan5	PROPN
gs-3214	3	40	,	,	PUNCT
gs-3214	3	41	nato	nato	PROPN
gs-3214	3	42	alavidze6	alavidze6	PROPN
gs-3214	3	43	,	,	PUNCT
gs-3214	3	44	igor	igor	PROPN
gs-3214	3	45	seniuk7	seniuk7	PROPN
gs-3214	3	46	,	,	PUNCT
gs-3214	3	47	vira	vira	PROPN
gs-3214	3	48	kravchenko8	kravchenko8	PROPN
gs-3214	3	49	,	,	PUNCT
gs-3214	3	50	nino	nino	PROPN
gs-3214	3	51	abuladze9	abuladze9	PROPN
gs-3214	3	52	,	,	PUNCT
gs-3214	3	53	ketevani	ketevani	PROPN
gs-3214	3	54	gabunia10	gabunia10	PROPN
gs-3214	3	55	,	,	PUNCT
gs-3214	3	56	marina	marina	NOUN
gs-3214	3	57	giorgobiani11	giorgobiani11	NOUN
gs-3214	3	58	,	,	PUNCT
gs-3214	3	59	marika	marika	PROPN
gs-3214	3	60	sulashvili12	sulashvili12	PROPN
gs-3214	3	61	1md	1md	NOUN
gs-3214	3	62	,	,	PUNCT
gs-3214	3	63	phd	phd	NOUN
gs-3214	3	64	,	,	PUNCT
gs-3214	3	65	doctor	doctor	NOUN
gs-3214	3	66	of	of	ADP
gs-3214	3	67	theoretical	theoretical	ADJ
gs-3214	3	68	medicine	medicine	NOUN
gs-3214	3	69	in	in	ADP
gs-3214	3	70	pharmaceutical	pharmaceutical	ADJ
gs-3214	3	71	and	and	CCONJ
gs-3214	3	72	pharmacological	pharmacological	ADJ
gs-3214	3	73	sciences	science	NOUN
gs-3214	3	74	,	,	PUNCT
gs-3214	3	75	invited	invite	VERB
gs-3214	3	76	lecturer	lecturer	NOUN
gs-3214	3	77	(	(	PUNCT
gs-3214	3	78	invited	invite	VERB
gs-3214	3	79	professor	professor	NOUN
gs-3214	3	80	)	)	PUNCT
gs-3214	3	81	of	of	ADP
gs-3214	3	82	scientific	scientific	ADJ
gs-3214	3	83	research	research	NOUN
gs-3214	3	84	-	-	PUNCT
gs-3214	3	85	skills	skill	NOUN
gs-3214	3	86	center	center	NOUN
gs-3214	3	87	at	at	ADP
gs-3214	3	88	tbilisi	tbilisi	PROPN
gs-3214	3	89	state	state	PROPN
gs-3214	3	90	medical	medical	PROPN
gs-3214	3	91	university	university	PROPN
gs-3214	3	92	;	;	PUNCT
gs-3214	3	93	https://orcid.org/0000-0002-9005-8577	https://orcid.org/0000-0002-9005-8577	PROPN
gs-3214	3	94	e	e	PROPN
gs-3214	3	95	-	-	NOUN
gs-3214	3	96	mail	mail	NOUN
gs-3214	3	97	:	:	PUNCT
gs-3214	3	98	n.sulashvili@ug.edu.ge	n.sulashvili@ug.edu.ge	PROPN
gs-3214	3	99	2phd	2phd	NOUN
gs-3214	3	100	,	,	PUNCT
gs-3214	3	101	doctor	doctor	NOUN
gs-3214	3	102	of	of	ADP
gs-3214	3	103	biological	biological	ADJ
gs-3214	3	104	sciences	science	NOUN
gs-3214	3	105	,	,	PUNCT
gs-3214	3	106	professor	professor	NOUN
gs-3214	3	107	,	,	PUNCT
gs-3214	3	108	academician	academician	NOUN
gs-3214	3	109	,	,	PUNCT
gs-3214	3	110	georgian	georgian	PROPN
gs-3214	3	111	academy	academy	NOUN
gs-3214	3	112	of	of	ADP
gs-3214	3	113	ecological	ecological	ADJ
gs-3214	3	114	sciences	science	NOUN
gs-3214	3	115	,	,	PUNCT
gs-3214	3	116	program	program	NOUN
gs-3214	3	117	coordinator	coordinator	NOUN
gs-3214	3	118	of	of	ADP
gs-3214	3	119	quality	quality	NOUN
gs-3214	3	120	assurance	assurance	NOUN
gs-3214	3	121	of	of	ADP
gs-3214	3	122	ce	ce	PROPN
gs-3214	3	123	at	at	ADP
gs-3214	3	124	iakob	iakob	PROPN
gs-3214	3	125	gogebashvili	gogebashvili	NOUN
gs-3214	3	126	telavi	telavi	PROPN
gs-3214	3	127	state	state	PROPN
gs-3214	3	128	university	university	PROPN
gs-3214	3	129	(	(	PUNCT
gs-3214	3	130	tesau	tesau	NOUN
gs-3214	3	131	)	)	PUNCT
gs-3214	3	132	,	,	PUNCT
gs-3214	3	133	telavi	telavi	PROPN
gs-3214	3	134	,	,	PUNCT
gs-3214	3	135	georgia	georgia	PROPN
gs-3214	3	136	.	.	PUNCT
gs-3214	4	1	https://orcid.org/0009-0005-42136533	https://orcid.org/0009-0005-42136533	PROPN
gs-3214	4	2	3md	3md	NOUN
gs-3214	4	3	,	,	PUNCT
gs-3214	4	4	phd	phd	NOUN
gs-3214	4	5	,	,	PUNCT
gs-3214	4	6	doctor	doctor	NOUN
gs-3214	4	7	of	of	ADP
gs-3214	4	8	pharmaceutical	pharmaceutical	NOUN
gs-3214	4	9	sciences	science	NOUN
gs-3214	4	10	,	,	PUNCT
gs-3214	4	11	professor	professor	NOUN
gs-3214	4	12	of	of	ADP
gs-3214	4	13	tbilisi	tbilisi	PROPN
gs-3214	4	14	state	state	PROPN
gs-3214	4	15	medical	medical	PROPN
gs-3214	4	16	university	university	PROPN
gs-3214	4	17	,	,	PUNCT
gs-3214	4	18	head	head	NOUN
gs-3214	4	19	of	of	ADP
gs-3214	4	20	the	the	DET
gs-3214	4	21	department	department	NOUN
gs-3214	4	22	of	of	ADP
gs-3214	4	23	social	social	ADJ
gs-3214	4	24	and	and	CCONJ
gs-3214	4	25	clinical	clinical	ADJ
gs-3214	4	26	pharmacy	pharmacy	NOUN
gs-3214	4	27	,	,	PUNCT
gs-3214	4	28	tbilisi	tbilisi	PROPN
gs-3214	4	29	,	,	PUNCT
gs-3214	4	30	georgia	georgia	PROPN
gs-3214	4	31	.	.	PUNCT
gs-3214	5	1	https://orcid.org/0000-0002-4563-5224	https://orcid.org/0000-0002-4563-5224	PROPN
gs-3214	5	2	4md	4md	PROPN
gs-3214	5	3	,	,	PUNCT
gs-3214	5	4	phd	phd	NOUN
gs-3214	5	5	,	,	PUNCT
gs-3214	5	6	doctor	doctor	NOUN
gs-3214	5	7	of	of	ADP
gs-3214	5	8	medical	medical	ADJ
gs-3214	5	9	sciences	sciences	PROPN
gs-3214	5	10	,	,	PUNCT
gs-3214	5	11	professor	professor	NOUN
gs-3214	5	12	,	,	PUNCT
gs-3214	5	13	director	director	NOUN
gs-3214	5	14	of	of	ADP
gs-3214	5	15	the	the	DET
gs-3214	5	16	scientific	scientific	ADJ
gs-3214	5	17	research	research	NOUN
gs-3214	5	18	-	-	PUNCT
gs-3214	5	19	skills	skill	NOUN
gs-3214	5	20	center	center	NOUN
gs-3214	5	21	at	at	ADP
gs-3214	5	22	tbilisi	tbilisi	PROPN
gs-3214	5	23	state	state	PROPN
gs-3214	5	24	medical	medical	PROPN
gs-3214	5	25	university	university	PROPN
gs-3214	5	26	,	,	PUNCT
gs-3214	5	27	professor	professor	NOUN
gs-3214	5	28	https://orcid.org/0000-0003-0856-2684	https://orcid.org/0000-0003-0856-2684	PROPN
gs-3214	5	29	5md	5md	NOUN
gs-3214	5	30	,	,	PUNCT
gs-3214	5	31	phd	phd	NOUN
gs-3214	5	32	,	,	PUNCT
gs-3214	5	33	doctor	doctor	NOUN
gs-3214	5	34	of	of	ADP
gs-3214	5	35	pharmaceutical	pharmaceutical	NOUN
gs-3214	5	36	sciences	science	NOUN
gs-3214	5	37	,	,	PUNCT
gs-3214	5	38	academician	academician	NOUN
gs-3214	5	39	,	,	PUNCT
gs-3214	5	40	professor	professor	NOUN
gs-3214	5	41	of	of	ADP
gs-3214	5	42	yerevan	yerevan	PROPN
gs-3214	5	43	state	state	PROPN
gs-3214	5	44	medical	medical	PROPN
gs-3214	5	45	university	university	NOUN
gs-3214	5	46	,	,	PUNCT
gs-3214	5	47	head	head	NOUN
gs-3214	5	48	of	of	ADP
gs-3214	5	49	the	the	DET
gs-3214	5	50	department	department	PROPN
gs-3214	5	51	of	of	ADP
gs-3214	5	52	pharmaceutical	pharmaceutical	NOUN
gs-3214	5	53	management	management	NOUN
gs-3214	5	54	,	,	PUNCT
gs-3214	5	55	yerevan	yerevan	PROPN
gs-3214	5	56	,	,	PUNCT
gs-3214	5	57	armenia	armenia	PROPN
gs-3214	5	58	.	.	PUNCT
gs-3214	6	1	https://orcid.org/0000-0003-3697-6390	https://orcid.org/0000-0003-3697-6390	PROPN
gs-3214	6	2	6md	6md	PROPN
gs-3214	6	3	,	,	PUNCT
gs-3214	6	4	phd	phd	NOUN
gs-3214	6	5	,	,	PUNCT
gs-3214	6	6	doctor	doctor	NOUN
gs-3214	6	7	of	of	ADP
gs-3214	6	8	pharmaceutical	pharmaceutical	NOUN
gs-3214	6	9	sciences	science	NOUN
gs-3214	6	10	,	,	PUNCT
gs-3214	6	11	professor	professor	NOUN
gs-3214	6	12	of	of	ADP
gs-3214	6	13	akaki	akaki	PROPN
gs-3214	6	14	tsereteli	tsereteli	PROPN
gs-3214	6	15	state	state	PROPN
gs-3214	6	16	university	university	PROPN
gs-3214	6	17	,	,	PUNCT
gs-3214	6	18	faculty	faculty	NOUN
gs-3214	6	19	of	of	ADP
gs-3214	6	20	medicine	medicine	NOUN
gs-3214	6	21	,	,	PUNCT
gs-3214	6	22	department	department	NOUN
gs-3214	6	23	of	of	ADP
gs-3214	6	24	pharmacy	pharmacy	NOUN
gs-3214	6	25	,	,	PUNCT
gs-3214	6	26	kutaisi	kutaisi	PROPN
gs-3214	6	27	,	,	PUNCT
gs-3214	6	28	georgia	georgia	PROPN
gs-3214	6	29	.	.	PUNCT
gs-3214	7	1	professor	professor	PROPN
gs-3214	7	2	,	,	PUNCT
gs-3214	7	3	dean	dean	PROPN
gs-3214	7	4	faculty	faculty	NOUN
gs-3214	7	5	of	of	ADP
gs-3214	7	6	medicine	medicine	NOUN
gs-3214	7	7	at	at	ADP
gs-3214	7	8	east	east	PROPN
gs-3214	7	9	european	european	PROPN
gs-3214	7	10	university	university	PROPN
gs-3214	7	11	,	,	PUNCT
gs-3214	7	12	tbilisi	tbilisi	PROPN
gs-3214	7	13	,	,	PUNCT
gs-3214	7	14	georgia	georgia	PROPN
gs-3214	7	15	.	.	PUNCT
gs-3214	8	1	https://orcid.org/00000001-6695-5924	https://orcid.org/00000001-6695-5924	PROPN
gs-3214	8	2	7md	7md	PROPN
gs-3214	8	3	phd	phd	PROPN
gs-3214	8	4	,	,	PUNCT
gs-3214	8	5	doctor	doctor	NOUN
gs-3214	8	6	of	of	ADP
gs-3214	8	7	pharmaceutical	pharmaceutical	NOUN
gs-3214	8	8	sciences	science	NOUN
gs-3214	8	9	,	,	PUNCT
gs-3214	8	10	dean	dean	NOUN
gs-3214	8	11	of	of	ADP
gs-3214	8	12	faculty	faculty	NOUN
gs-3214	8	13	of	of	ADP
gs-3214	8	14	pharmacy	pharmacy	NOUN
gs-3214	8	15	at	at	ADP
gs-3214	8	16	national	national	PROPN
gs-3214	8	17	university	university	PROPN
gs-3214	8	18	of	of	ADP
gs-3214	8	19	pharmacy	pharmacy	NOUN
gs-3214	8	20	of	of	ADP
gs-3214	8	21	ukraine	ukraine	NOUN
gs-3214	8	22	,	,	PUNCT
gs-3214	8	23	associate	associate	ADJ
gs-3214	8	24	professor	professor	NOUN
gs-3214	8	25	of	of	ADP
gs-3214	8	26	biological	biological	ADJ
gs-3214	8	27	chemistry	chemistry	NOUN
gs-3214	8	28	department	department	NOUN
gs-3214	8	29	at	at	ADP
gs-3214	8	30	national	national	PROPN
gs-3214	8	31	university	university	PROPN
gs-3214	8	32	of	of	ADP
gs-3214	8	33	pharmacy	pharmacy	NOUN
gs-3214	8	34	,	,	PUNCT
gs-3214	8	35	kharkiv	kharkiv	PROPN
gs-3214	8	36	,	,	PUNCT
gs-3214	8	37	ukraine	ukraine	NOUN
gs-3214	8	38	.	.	PUNCT
gs-3214	9	1	https://orcid.org/0000-0003-3819-7331	https://orcid.org/0000-0003-3819-7331	PROPN
gs-3214	9	2	8md	8md	NOUN
gs-3214	9	3	,	,	PUNCT
gs-3214	9	4	phd	phd	NOUN
gs-3214	9	5	,	,	PUNCT
gs-3214	9	6	doctor	doctor	NOUN
gs-3214	9	7	of	of	ADP
gs-3214	9	8	pharmaceutical	pharmaceutical	NOUN
gs-3214	9	9	sciences	science	NOUN
gs-3214	9	10	,	,	PUNCT
gs-3214	9	11	academician	academician	NOUN
gs-3214	9	12	,	,	PUNCT
gs-3214	9	13	professor	professor	NOUN
gs-3214	9	14	,	,	PUNCT
gs-3214	9	15	head	head	NOUN
gs-3214	9	16	of	of	ADP
gs-3214	9	17	the	the	DET
gs-3214	9	18	biological	biological	ADJ
gs-3214	9	19	chemistry	chemistry	NOUN
gs-3214	9	20	department	department	NOUN
gs-3214	9	21	at	at	ADP
gs-3214	9	22	national	national	PROPN
gs-3214	9	23	university	university	PROPN
gs-3214	9	24	of	of	ADP
gs-3214	9	25	pharmacy	pharmacy	NOUN
gs-3214	9	26	,	,	PUNCT
gs-3214	9	27	kharkiv	kharkiv	PROPN
gs-3214	9	28	,	,	PUNCT
gs-3214	9	29	ukraine	ukraine	NOUN
gs-3214	9	30	.	.	PUNCT
gs-3214	10	1	9md	9md	ADJ
gs-3214	10	2	,	,	PUNCT
gs-3214	10	3	phd	phd	NOUN
gs-3214	10	4	,	,	PUNCT
gs-3214	10	5	doctor	doctor	NOUN
gs-3214	10	6	of	of	ADP
gs-3214	10	7	pharmaceutical	pharmaceutical	NOUN
gs-3214	10	8	sciences	science	NOUN
gs-3214	10	9	,	,	PUNCT
gs-3214	10	10	professor	professor	NOUN
gs-3214	10	11	of	of	ADP
gs-3214	10	12	akaki	akaki	PROPN
gs-3214	11	1	tsereteli	tsereteli	PROPN
gs-3214	11	2	state	state	PROPN
gs-3214	11	3	university	university	PROPN
gs-3214	11	4	,	,	PUNCT
gs-3214	11	5	faculty	faculty	NOUN
gs-3214	11	6	of	of	ADP
gs-3214	11	7	medicine	medicine	NOUN
gs-3214	11	8	,	,	PUNCT
gs-3214	11	9	department	department	NOUN
gs-3214	11	10	of	of	ADP
gs-3214	11	11	pharmacy	pharmacy	NOUN
gs-3214	11	12	,	,	PUNCT
gs-3214	11	13	kutaisi	kutaisi	PROPN
gs-3214	11	14	,	,	PUNCT
gs-3214	11	15	georgia	georgia	PROPN
gs-3214	11	16	.	.	PUNCT
gs-3214	12	1	https://orcid.org/0000-0003-2189-7470	https://orcid.org/0000-0003-2189-7470	PROPN
gs-3214	12	2	10md	10md	NUM
gs-3214	12	3	,	,	PUNCT
gs-3214	12	4	phd	phd	NOUN
gs-3214	12	5	,	,	PUNCT
gs-3214	12	6	doctor	doctor	NOUN
gs-3214	12	7	of	of	ADP
gs-3214	12	8	pharmaceutical	pharmaceutical	NOUN
gs-3214	12	9	sciences	science	NOUN
gs-3214	12	10	,	,	PUNCT
gs-3214	12	11	professor	professor	NOUN
gs-3214	12	12	of	of	ADP
gs-3214	12	13	akaki	akaki	PROPN
gs-3214	12	14	tsereteli	tsereteli	PROPN
gs-3214	12	15	state	state	PROPN
gs-3214	12	16	university	university	PROPN
gs-3214	12	17	,	,	PUNCT
gs-3214	12	18	faculty	faculty	NOUN
gs-3214	12	19	of	of	ADP
gs-3214	12	20	medicine	medicine	NOUN
gs-3214	12	21	,	,	PUNCT
gs-3214	12	22	department	department	NOUN
gs-3214	12	23	of	of	ADP
gs-3214	12	24	pharmacy	pharmacy	NOUN
gs-3214	12	25	,	,	PUNCT
gs-3214	12	26	kutaisi	kutaisi	PROPN
gs-3214	12	27	,	,	PUNCT
gs-3214	12	28	georgia	georgia	PROPN
gs-3214	12	29	.	.	PUNCT
gs-3214	13	1	https://orcid.org/0000-0002-5857-6593	https://orcid.org/0000-0002-5857-6593	PROPN
gs-3214	13	2	11md	11md	NOUN
gs-3214	13	3	,	,	PUNCT
gs-3214	13	4	phd	phd	NOUN
gs-3214	13	5	,	,	PUNCT
gs-3214	13	6	doctor	doctor	NOUN
gs-3214	13	7	of	of	ADP
gs-3214	13	8	medical	medical	ADJ
gs-3214	13	9	sciences	science	NOUN
gs-3214	13	10	,	,	PUNCT
gs-3214	13	11	professor	professor	NOUN
gs-3214	13	12	of	of	ADP
gs-3214	13	13	tbilisi	tbilisi	PROPN
gs-3214	13	14	state	state	PROPN
gs-3214	13	15	medical	medical	PROPN
gs-3214	13	16	university	university	PROPN
gs-3214	13	17	,	,	PUNCT
gs-3214	13	18	department	department	NOUN
gs-3214	13	19	of	of	ADP
gs-3214	13	20	hygiene	hygiene	NOUN
gs-3214	13	21	and	and	CCONJ
gs-3214	13	22	medical	medical	ADJ
gs-3214	13	23	ecology	ecology	NOUN
gs-3214	13	24	,	,	PUNCT
gs-3214	13	25	tbilisi	tbilisi	PROPN
gs-3214	13	26	,	,	PUNCT
gs-3214	13	27	georgia	georgia	PROPN
gs-3214	13	28	.	.	PUNCT
gs-3214	14	1	https://orcid.org/0000-0003-0686-5227	https://orcid.org/0000-0003-0686-5227	PROPN
gs-3214	14	2	12md	12md	NOUN
gs-3214	14	3	,	,	PUNCT
gs-3214	14	4	family	family	NOUN
gs-3214	14	5	doctor	doctor	NOUN
gs-3214	14	6	,	,	PUNCT
gs-3214	14	7	invited	invite	VERB
gs-3214	14	8	lecturer	lecturer	NOUN
gs-3214	14	9	of	of	ADP
gs-3214	14	10	tbilisi	tbilisi	PROPN
gs-3214	14	11	state	state	PROPN
gs-3214	14	12	medical	medical	PROPN
gs-3214	14	13	university	university	PROPN
gs-3214	14	14	,	,	PUNCT
gs-3214	14	15	department	department	NOUN
gs-3214	14	16	of	of	ADP
gs-3214	14	17	molecular	molecular	ADJ
gs-3214	14	18	and	and	CCONJ
gs-3214	14	19	medical	medical	ADJ
gs-3214	14	20	genetics	genetic	NOUN
gs-3214	14	21	;	;	PUNCT
gs-3214	14	22	https://orcid.org/0000-0002-6338-4262	https://orcid.org/0000-0002-6338-4262	X
gs-3214	14	23	abstract	abstract	ADJ
gs-3214	14	24	aim	aim	NOUN
gs-3214	14	25	of	of	ADP
gs-3214	14	26	the	the	DET
gs-3214	14	27	research	research	NOUN
gs-3214	14	28	was	be	AUX
gs-3214	14	29	to	to	PART
gs-3214	14	30	study	study	VERB
gs-3214	14	31	and	and	CCONJ
gs-3214	14	32	analyze	analyze	VERB
gs-3214	14	33	some	some	DET
gs-3214	14	34	issues	issue	NOUN
gs-3214	14	35	of	of	ADP
gs-3214	14	36	features	feature	NOUN
gs-3214	14	37	of	of	ADP
gs-3214	14	38	using	use	VERB
gs-3214	14	39	of	of	ADP
gs-3214	14	40	car	car	NOUN
gs-3214	14	41	-	-	PUNCT
gs-3214	14	42	t	t	NOUN
gs-3214	14	43	cells	cell	NOUN
gs-3214	14	44	in	in	ADP
gs-3214	14	45	immunotherapy	immunotherapy	NOUN
gs-3214	14	46	.	.	PUNCT
gs-3214	15	1	the	the	DET
gs-3214	15	2	characterization	characterization	NOUN
gs-3214	15	3	of	of	ADP
gs-3214	15	4	car	car	NOUN
gs-3214	15	5	-	-	PUNCT
gs-3214	15	6	t	t	NOUN
gs-3214	15	7	cell	cell	NOUN
gs-3214	15	8	products	product	NOUN
gs-3214	15	9	involves	involve	VERB
gs-3214	15	10	evaluating	evaluate	VERB
gs-3214	15	11	their	their	PRON
gs-3214	15	12	phenotype	phenotype	NOUN
gs-3214	15	13	,	,	PUNCT
gs-3214	15	14	genotype	genotype	NOUN
gs-3214	15	15	,	,	PUNCT
gs-3214	15	16	and	and	CCONJ
gs-3214	15	17	functional	functional	ADJ
gs-3214	15	18	attributes	attribute	NOUN
gs-3214	15	19	using	use	VERB
gs-3214	15	20	techniques	technique	NOUN
gs-3214	15	21	such	such	ADJ
gs-3214	15	22	as	as	ADP
gs-3214	15	23	flow	flow	NOUN
gs-3214	15	24	cytometry	cytometry	NOUN
gs-3214	15	25	,	,	PUNCT
gs-3214	15	26	pcr	pcr	NOUN
gs-3214	15	27	-	-	PUNCT
gs-3214	15	28	based	base	VERB
gs-3214	15	29	assays	assay	NOUN
gs-3214	15	30	,	,	PUNCT
gs-3214	15	31	and	and	CCONJ
gs-3214	15	32	cytotoxicity	cytotoxicity	NOUN
gs-3214	15	33	assays	assay	NOUN
gs-3214	15	34	.	.	PUNCT
gs-3214	16	1	long	long	ADJ
gs-3214	16	2	-	-	PUNCT
gs-3214	16	3	term	term	NOUN
gs-3214	16	4	stability	stability	NOUN
gs-3214	16	5	studies	study	NOUN
gs-3214	16	6	assess	assess	VERB
gs-3214	16	7	product	product	NOUN
gs-3214	16	8	viability	viability	NOUN
gs-3214	16	9	,	,	PUNCT
gs-3214	16	10	potency	potency	NOUN
gs-3214	16	11	,	,	PUNCT
gs-3214	16	12	and	and	CCONJ
gs-3214	16	13	cytokine	cytokine	VERB
gs-3214	16	14	secretion	secretion	NOUN
gs-3214	16	15	georgian	georgian	NOUN
gs-3214	16	16	scientists/	scientists/	NUM
gs-3214	16	17	.	.	PUNCT
gs-3214	17	1	6	6	NUM
gs-3214	17	2	n	n	NUM
gs-3214	17	3	3	3	NUM
gs-3214	17	4	,	,	PUNCT
gs-3214	17	5	2024	2024	NUM
gs-3214	17	6	264	264	NUM
gs-3214	17	7	profiles	profile	NOUN
gs-3214	17	8	across	across	ADP
gs-3214	17	9	different	different	ADJ
gs-3214	17	10	storage	storage	NOUN
gs-3214	17	11	conditions	condition	NOUN
gs-3214	17	12	to	to	PART
gs-3214	17	13	determine	determine	VERB
gs-3214	17	14	shelf	shelf	NOUN
gs-3214	17	15	-	-	PUNCT
gs-3214	17	16	life	life	NOUN
gs-3214	17	17	and	and	CCONJ
gs-3214	17	18	facilitate	facilitate	NOUN
gs-3214	17	19	product	product	NOUN
gs-3214	17	20	logistics	logistic	NOUN
gs-3214	17	21	.	.	PUNCT
gs-3214	18	1	biomarkers	biomarker	NOUN
gs-3214	18	2	serve	serve	VERB
gs-3214	18	3	as	as	ADP
gs-3214	18	4	crucial	crucial	ADJ
gs-3214	18	5	tools	tool	NOUN
gs-3214	18	6	in	in	ADP
gs-3214	18	7	the	the	DET
gs-3214	18	8	field	field	NOUN
gs-3214	18	9	of	of	ADP
gs-3214	18	10	cancer	cancer	NOUN
gs-3214	18	11	immunotherapy	immunotherapy	NOUN
gs-3214	18	12	,	,	PUNCT
gs-3214	18	13	aiding	aid	VERB
gs-3214	18	14	in	in	ADP
gs-3214	18	15	patient	patient	ADJ
gs-3214	18	16	selection	selection	NOUN
gs-3214	18	17	and	and	CCONJ
gs-3214	18	18	treatment	treatment	NOUN
gs-3214	18	19	optimization	optimization	NOUN
gs-3214	18	20	.	.	PUNCT
gs-3214	19	1	in	in	ADP
gs-3214	19	2	the	the	DET
gs-3214	19	3	context	context	NOUN
gs-3214	19	4	of	of	ADP
gs-3214	19	5	chimeric	chimeric	ADJ
gs-3214	19	6	antigen	antigen	ADJ
gs-3214	19	7	receptor	receptor	NOUN
gs-3214	19	8	(	(	PUNCT
gs-3214	19	9	car	car	NOUN
gs-3214	19	10	)	)	PUNCT
gs-3214	19	11	t	t	NOUN
gs-3214	19	12	cell	cell	NOUN
gs-3214	19	13	therapy	therapy	NOUN
gs-3214	19	14	,	,	PUNCT
gs-3214	19	15	biomarkers	biomarker	NOUN
gs-3214	19	16	play	play	VERB
gs-3214	19	17	a	a	DET
gs-3214	19	18	significant	significant	ADJ
gs-3214	19	19	role	role	NOUN
gs-3214	19	20	in	in	ADP
gs-3214	19	21	predicting	predict	VERB
gs-3214	19	22	treatment	treatment	NOUN
gs-3214	19	23	response	response	NOUN
gs-3214	19	24	,	,	PUNCT
gs-3214	19	25	identifying	identify	VERB
gs-3214	19	26	potential	potential	ADJ
gs-3214	19	27	toxicities	toxicity	NOUN
gs-3214	19	28	,	,	PUNCT
gs-3214	19	29	and	and	CCONJ
gs-3214	19	30	guiding	guide	VERB
gs-3214	19	31	personalized	personalize	VERB
gs-3214	19	32	treatment	treatment	NOUN
gs-3214	19	33	approaches	approach	NOUN
gs-3214	19	34	.	.	PUNCT
gs-3214	20	1	predictive	predictive	ADJ
gs-3214	20	2	biomarkers	biomarker	NOUN
gs-3214	20	3	in	in	ADP
gs-3214	20	4	car	car	NOUN
gs-3214	20	5	-	-	PUNCT
gs-3214	20	6	t	t	NOUN
gs-3214	20	7	cell	cell	NOUN
gs-3214	20	8	therapy	therapy	NOUN
gs-3214	20	9	commonly	commonly	ADV
gs-3214	20	10	center	center	NOUN
gs-3214	20	11	on	on	ADP
gs-3214	20	12	the	the	DET
gs-3214	20	13	profiles	profile	NOUN
gs-3214	20	14	of	of	ADP
gs-3214	20	15	tumor	tumor	NOUN
gs-3214	20	16	antigen	antigen	ADJ
gs-3214	20	17	expression	expression	NOUN
gs-3214	20	18	.	.	PUNCT
gs-3214	21	1	the	the	DET
gs-3214	21	2	selection	selection	NOUN
gs-3214	21	3	of	of	ADP
gs-3214	21	4	target	target	NOUN
gs-3214	21	5	antigens	antigen	NOUN
gs-3214	21	6	plays	play	VERB
gs-3214	21	7	a	a	DET
gs-3214	21	8	crucial	crucial	ADJ
gs-3214	21	9	role	role	NOUN
gs-3214	21	10	in	in	ADP
gs-3214	21	11	treatment	treatment	NOUN
gs-3214	21	12	outcomes	outcome	NOUN
gs-3214	21	13	,	,	PUNCT
gs-3214	21	14	with	with	ADP
gs-3214	21	15	higher	high	ADJ
gs-3214	21	16	and	and	CCONJ
gs-3214	21	17	more	more	ADV
gs-3214	21	18	consistent	consistent	ADJ
gs-3214	21	19	expression	expression	NOUN
gs-3214	21	20	levels	level	NOUN
gs-3214	21	21	correlating	correlate	VERB
gs-3214	21	22	with	with	ADP
gs-3214	21	23	better	well	ADJ
gs-3214	21	24	response	response	NOUN
gs-3214	21	25	rates	rate	NOUN
gs-3214	21	26	.	.	PUNCT
gs-3214	22	1	the	the	PRON
gs-3214	22	2	tumor	tumor	NOUN
gs-3214	22	3	microenvironment	microenvironment	NOUN
gs-3214	22	4	(	(	PUNCT
gs-3214	22	5	tme	tme	NOUN
gs-3214	22	6	)	)	PUNCT
gs-3214	22	7	significantly	significantly	ADV
gs-3214	22	8	influences	influence	VERB
gs-3214	22	9	car	car	NOUN
gs-3214	22	10	-	-	PUNCT
gs-3214	22	11	t	t	NOUN
gs-3214	22	12	cell	cell	NOUN
gs-3214	22	13	activity	activity	NOUN
gs-3214	22	14	.	.	PUNCT
gs-3214	23	1	biomarkers	biomarker	NOUN
gs-3214	23	2	reflecting	reflect	VERB
gs-3214	23	3	tme	tme	NOUN
gs-3214	23	4	features	feature	NOUN
gs-3214	23	5	,	,	PUNCT
gs-3214	23	6	such	such	ADJ
gs-3214	23	7	as	as	ADP
gs-3214	23	8	immune	immune	ADJ
gs-3214	23	9	cell	cell	NOUN
gs-3214	23	10	infiltration	infiltration	NOUN
gs-3214	23	11	,	,	PUNCT
gs-3214	23	12	cytokine	cytokine	ADJ
gs-3214	23	13	profiles	profile	NOUN
gs-3214	23	14	,	,	PUNCT
gs-3214	23	15	and	and	CCONJ
gs-3214	23	16	expression	expression	NOUN
gs-3214	23	17	of	of	ADP
gs-3214	23	18	inhibitory	inhibitory	ADJ
gs-3214	23	19	molecules	molecule	NOUN
gs-3214	23	20	,	,	PUNCT
gs-3214	23	21	offer	offer	VERB
gs-3214	23	22	insights	insight	NOUN
gs-3214	23	23	into	into	ADP
gs-3214	23	24	the	the	DET
gs-3214	23	25	immunosuppressive	immunosuppressive	ADJ
gs-3214	23	26	nature	nature	NOUN
gs-3214	23	27	of	of	ADP
gs-3214	23	28	the	the	DET
gs-3214	23	29	tme	tme	NOUN
gs-3214	23	30	and	and	CCONJ
gs-3214	23	31	its	its	PRON
gs-3214	23	32	effects	effect	NOUN
gs-3214	23	33	on	on	ADP
gs-3214	23	34	car	car	NOUN
gs-3214	23	35	-	-	PUNCT
gs-3214	23	36	t	t	NOUN
gs-3214	23	37	cell	cell	NOUN
gs-3214	23	38	effectiveness	effectiveness	NOUN
gs-3214	23	39	.	.	PUNCT
gs-3214	24	1	patients	patient	NOUN
gs-3214	24	2	with	with	ADP
gs-3214	24	3	an	an	DET
gs-3214	24	4	inflamed	inflame	VERB
gs-3214	24	5	tme	tme	NOUN
gs-3214	24	6	,	,	PUNCT
gs-3214	24	7	marked	mark	VERB
gs-3214	24	8	by	by	ADP
gs-3214	24	9	abundant	abundant	ADJ
gs-3214	24	10	effector	effector	NOUN
gs-3214	24	11	t	t	NOUN
gs-3214	24	12	cells	cell	NOUN
gs-3214	24	13	and	and	CCONJ
gs-3214	24	14	low	low	ADJ
gs-3214	24	15	expression	expression	NOUN
gs-3214	24	16	of	of	ADP
gs-3214	24	17	inhibitory	inhibitory	ADJ
gs-3214	24	18	molecules	molecule	NOUN
gs-3214	24	19	like	like	ADP
gs-3214	24	20	pd	pd	NOUN
gs-3214	24	21	-	-	PUNCT
gs-3214	24	22	l1	l1	PROPN
gs-3214	24	23	,	,	PUNCT
gs-3214	24	24	tend	tend	VERB
gs-3214	24	25	to	to	PART
gs-3214	24	26	respond	respond	VERB
gs-3214	24	27	better	well	ADV
gs-3214	24	28	to	to	ADP
gs-3214	24	29	car	car	NOUN
gs-3214	24	30	-	-	PUNCT
gs-3214	24	31	t	t	NOUN
gs-3214	24	32	cell	cell	NOUN
gs-3214	24	33	therapy	therapy	NOUN
gs-3214	24	34	.	.	PUNCT
gs-3214	25	1	cart	cart	NOUN
gs-3214	25	2	cells	cell	NOUN
gs-3214	25	3	demonstrate	demonstrate	VERB
gs-3214	25	4	bystander	bystander	NOUN
gs-3214	25	5	killing	killing	NOUN
gs-3214	25	6	effects	effect	NOUN
gs-3214	25	7	,	,	PUNCT
gs-3214	25	8	where	where	SCONJ
gs-3214	25	9	nearby	nearby	ADJ
gs-3214	25	10	tumor	tumor	NOUN
gs-3214	25	11	cells	cell	NOUN
gs-3214	25	12	without	without	ADP
gs-3214	25	13	the	the	DET
gs-3214	25	14	target	target	NOUN
gs-3214	25	15	antigen	antigen	NOUN
gs-3214	25	16	are	be	AUX
gs-3214	25	17	eradicated	eradicate	VERB
gs-3214	25	18	via	via	ADP
gs-3214	25	19	a	a	DET
gs-3214	25	20	phenomenon	phenomenon	NOUN
gs-3214	25	21	called	call	VERB
gs-3214	25	22	antigen	antigen	NOUN
gs-3214	25	23	spreading	spread	VERB
gs-3214	25	24	.	.	PUNCT
gs-3214	26	1	this	this	DET
gs-3214	26	2	process	process	NOUN
gs-3214	26	3	is	be	AUX
gs-3214	26	4	triggered	trigger	VERB
gs-3214	26	5	by	by	ADP
gs-3214	26	6	the	the	DET
gs-3214	26	7	release	release	NOUN
gs-3214	26	8	of	of	ADP
gs-3214	26	9	cytokines	cytokine	NOUN
gs-3214	26	10	and	and	CCONJ
gs-3214	26	11	the	the	DET
gs-3214	26	12	presentation	presentation	NOUN
gs-3214	26	13	of	of	ADP
gs-3214	26	14	tumor	tumor	NOUN
gs-3214	26	15	antigens	antigen	NOUN
gs-3214	26	16	by	by	ADP
gs-3214	26	17	antigen	antigen	ADV
gs-3214	26	18	-	-	PUNCT
gs-3214	26	19	presenting	present	VERB
gs-3214	26	20	cells	cell	NOUN
gs-3214	26	21	(	(	PUNCT
gs-3214	26	22	apcs	apc	NOUN
gs-3214	26	23	)	)	PUNCT
gs-3214	26	24	,	,	PUNCT
gs-3214	26	25	resulting	result	VERB
gs-3214	26	26	in	in	ADP
gs-3214	26	27	the	the	DET
gs-3214	26	28	activation	activation	NOUN
gs-3214	26	29	of	of	ADP
gs-3214	26	30	the	the	DET
gs-3214	26	31	body	body	NOUN
gs-3214	26	32	's	's	PART
gs-3214	26	33	own	own	ADJ
gs-3214	26	34	immune	immune	ADJ
gs-3214	26	35	effector	effector	NOUN
gs-3214	26	36	cells	cell	NOUN
gs-3214	26	37	against	against	ADP
gs-3214	26	38	the	the	DET
gs-3214	26	39	tumor	tumor	NOUN
gs-3214	26	40	cells	cell	NOUN
gs-3214	26	41	.	.	PUNCT
gs-3214	27	1	car	car	NOUN
gs-3214	27	2	-	-	PUNCT
gs-3214	27	3	t	t	NOUN
gs-3214	27	4	cells	cell	NOUN
gs-3214	27	5	exhibit	exhibit	VERB
gs-3214	27	6	strong	strong	ADJ
gs-3214	27	7	antitumor	antitumor	PROPN
gs-3214	27	8	capabilities	capability	NOUN
gs-3214	27	9	,	,	PUNCT
gs-3214	27	10	they	they	PRON
gs-3214	27	11	can	can	AUX
gs-3214	27	12	face	face	VERB
gs-3214	27	13	resistance	resistance	NOUN
gs-3214	27	14	mechanisms	mechanism	NOUN
gs-3214	27	15	within	within	ADP
gs-3214	27	16	the	the	DET
gs-3214	27	17	tumor	tumor	NOUN
gs-3214	27	18	microenvironment	microenvironment	NOUN
gs-3214	27	19	.	.	PUNCT
gs-3214	28	1	the	the	DET
gs-3214	28	2	immunosuppressive	immunosuppressive	ADJ
gs-3214	28	3	cell	cell	NOUN
gs-3214	28	4	populations	population	NOUN
gs-3214	28	5	like	like	ADP
gs-3214	28	6	regulatory	regulatory	ADJ
gs-3214	28	7	t	t	NOUN
gs-3214	28	8	cells	cell	NOUN
gs-3214	28	9	(	(	PUNCT
gs-3214	28	10	tregs	treg	NOUN
gs-3214	28	11	)	)	PUNCT
gs-3214	28	12	and	and	CCONJ
gs-3214	28	13	myeloid	myeloid	ADJ
gs-3214	28	14	-	-	PUNCT
gs-3214	28	15	derived	derive	VERB
gs-3214	28	16	suppressor	suppressor	NOUN
gs-3214	28	17	cells	cell	NOUN
gs-3214	28	18	(	(	PUNCT
gs-3214	28	19	mdscs	mdsc	NOUN
gs-3214	28	20	)	)	PUNCT
gs-3214	28	21	,	,	PUNCT
gs-3214	28	22	as	as	ADV
gs-3214	28	23	well	well	ADV
gs-3214	28	24	as	as	ADP
gs-3214	28	25	inhibitory	inhibitory	ADJ
gs-3214	28	26	cytokines	cytokine	NOUN
gs-3214	28	27	such	such	ADJ
gs-3214	28	28	as	as	ADP
gs-3214	28	29	transforming	transform	VERB
gs-3214	28	30	growth	growth	NOUN
gs-3214	28	31	factor	factor	NOUN
gs-3214	28	32	-	-	PUNCT
gs-3214	28	33	beta	beta	NOUN
gs-3214	28	34	(	(	PUNCT
gs-3214	28	35	tgf	tgf	PROPN
gs-3214	28	36	)	)	PUNCT
gs-3214	28	37	and	and	CCONJ
gs-3214	28	38	interleukin-10	interleukin-10	PROPN
gs-3214	28	39	(	(	PUNCT
gs-3214	28	40	il-10	il-10	NUM
gs-3214	28	41	)	)	PUNCT
gs-3214	28	42	.	.	PUNCT
gs-3214	29	1	the	the	DET
gs-3214	29	2	resistance	resistance	NOUN
gs-3214	29	3	mechanisms	mechanism	NOUN
gs-3214	29	4	,	,	PUNCT
gs-3214	29	5	strategies	strategy	NOUN
gs-3214	29	6	involve	involve	VERB
gs-3214	29	7	employing	employ	VERB
gs-3214	29	8	combination	combination	NOUN
gs-3214	29	9	therapies	therapy	NOUN
gs-3214	29	10	with	with	ADP
gs-3214	29	11	immune	immune	ADJ
gs-3214	29	12	checkpoint	checkpoint	NOUN
gs-3214	29	13	inhibitors	inhibitor	NOUN
gs-3214	29	14	,	,	PUNCT
gs-3214	29	15	cytokine	cytokine	ADJ
gs-3214	29	16	modulators	modulator	NOUN
gs-3214	29	17	,	,	PUNCT
gs-3214	29	18	and	and	CCONJ
gs-3214	29	19	targeted	target	VERB
gs-3214	29	20	therapies	therapy	NOUN
gs-3214	29	21	aimed	aim	VERB
gs-3214	29	22	at	at	ADP
gs-3214	29	23	disrupting	disrupt	VERB
gs-3214	29	24	immunosuppressive	immunosuppressive	ADJ
gs-3214	29	25	pathways	pathway	NOUN
gs-3214	29	26	.	.	PUNCT
gs-3214	30	1	car	car	NOUN
gs-3214	30	2	-	-	PUNCT
gs-3214	30	3	t	t	NOUN
gs-3214	30	4	cell	cell	NOUN
gs-3214	30	5	therapy	therapy	NOUN
gs-3214	30	6	has	have	AUX
gs-3214	30	7	revolutionized	revolutionize	VERB
gs-3214	30	8	cancer	cancer	NOUN
gs-3214	30	9	treatment	treatment	NOUN
gs-3214	30	10	by	by	ADP
gs-3214	30	11	harnessing	harness	VERB
gs-3214	30	12	the	the	DET
gs-3214	30	13	power	power	NOUN
gs-3214	30	14	of	of	ADP
gs-3214	30	15	the	the	DET
gs-3214	30	16	immune	immune	ADJ
gs-3214	30	17	system	system	NOUN
gs-3214	30	18	to	to	PART
gs-3214	30	19	target	target	VERB
gs-3214	30	20	and	and	CCONJ
gs-3214	30	21	eliminate	eliminate	VERB
gs-3214	30	22	tumor	tumor	NOUN
gs-3214	30	23	cells	cell	NOUN
gs-3214	30	24	.	.	PUNCT
gs-3214	31	1	keywords	keyword	NOUN
gs-3214	31	2	:	:	PUNCT
gs-3214	31	3	features	feature	NOUN
gs-3214	31	4	,	,	PUNCT
gs-3214	31	5	using	use	VERB
gs-3214	31	6	,	,	PUNCT
gs-3214	31	7	car	car	NOUN
gs-3214	31	8	-	-	PUNCT
gs-3214	31	9	t	t	NOUN
gs-3214	31	10	cells	cell	NOUN
gs-3214	31	11	,	,	PUNCT
gs-3214	31	12	immunotherapy	immunotherapy	NOUN
gs-3214	31	13	,	,	PUNCT
gs-3214	31	14	antibody	antibody	NOUN
gs-3214	31	15	.	.	PUNCT
gs-3214	32	1	introduction	introduction	NOUN
gs-3214	32	2	:	:	PUNCT
gs-3214	32	3	chimeric	chimeric	ADJ
gs-3214	32	4	antigen	antigen	ADJ
gs-3214	32	5	receptor	receptor	NOUN
gs-3214	32	6	(	(	PUNCT
gs-3214	32	7	car	car	NOUN
gs-3214	32	8	)	)	PUNCT
gs-3214	32	9	t	t	NOUN
gs-3214	32	10	cell	cell	NOUN
gs-3214	32	11	therapy	therapy	NOUN
gs-3214	32	12	has	have	AUX
gs-3214	32	13	transformed	transform	VERB
gs-3214	32	14	the	the	DET
gs-3214	32	15	approach	approach	NOUN
gs-3214	32	16	to	to	ADP
gs-3214	32	17	treating	treat	VERB
gs-3214	32	18	hematologic	hematologic	ADJ
gs-3214	32	19	cancers	cancer	NOUN
gs-3214	32	20	,	,	PUNCT
gs-3214	32	21	especially	especially	ADV
gs-3214	32	22	those	those	PRON
gs-3214	32	23	linked	link	VERB
gs-3214	32	24	to	to	ADP
gs-3214	32	25	b	b	NOUN
gs-3214	32	26	-	-	PUNCT
gs-3214	32	27	cell	cell	NOUN
gs-3214	32	28	abnormalities	abnormality	NOUN
gs-3214	32	29	.	.	PUNCT
gs-3214	33	1	this	this	DET
gs-3214	33	2	chapter	chapter	NOUN
gs-3214	33	3	delves	delve	VERB
gs-3214	33	4	into	into	ADP
gs-3214	33	5	the	the	DET
gs-3214	33	6	clinical	clinical	ADJ
gs-3214	33	7	uses	use	NOUN
gs-3214	33	8	of	of	ADP
gs-3214	33	9	car	car	NOUN
gs-3214	33	10	-	-	PUNCT
gs-3214	33	11	t	t	NOUN
gs-3214	33	12	cell	cell	NOUN
gs-3214	33	13	therapy	therapy	NOUN
gs-3214	33	14	for	for	ADP
gs-3214	33	15	hematologic	hematologic	NOUN
gs-3214	33	16	malignancies	malignancy	NOUN
gs-3214	33	17	,	,	PUNCT
gs-3214	33	18	highlighting	highlight	VERB
gs-3214	33	19	conditions	condition	NOUN
gs-3214	33	20	such	such	ADJ
gs-3214	33	21	as	as	ADP
gs-3214	33	22	acute	acute	ADJ
gs-3214	33	23	lymphoblastic	lymphoblastic	ADJ
gs-3214	33	24	leukemia	leukemia	NOUN
gs-3214	33	25	(	(	PUNCT
gs-3214	33	26	all	all	ADV
gs-3214	33	27	)	)	PUNCT
gs-3214	33	28	,	,	PUNCT
gs-3214	33	29	diffuse	diffuse	VERB
gs-3214	33	30	large	large	ADJ
gs-3214	33	31	b	b	NOUN
gs-3214	33	32	-	-	PUNCT
gs-3214	33	33	cell	cell	NOUN
gs-3214	33	34	lymphoma	lymphoma	NOUN
gs-3214	33	35	(	(	PUNCT
gs-3214	33	36	dlbcl	dlbcl	NOUN
gs-3214	33	37	)	)	PUNCT
gs-3214	33	38	,	,	PUNCT
gs-3214	33	39	and	and	CCONJ
gs-3214	33	40	multiple	multiple	ADJ
gs-3214	33	41	myeloma	myeloma	NOUN
gs-3214	33	42	.	.	PUNCT
gs-3214	34	1	it	it	PRON
gs-3214	34	2	also	also	ADV
gs-3214	34	3	addresses	address	VERB
gs-3214	34	4	the	the	DET
gs-3214	34	5	ongoing	ongoing	ADJ
gs-3214	34	6	challenges	challenge	NOUN
gs-3214	34	7	and	and	CCONJ
gs-3214	34	8	possibilities	possibility	NOUN
gs-3214	34	9	of	of	ADP
gs-3214	34	10	applying	apply	VERB
gs-3214	34	11	car	car	NOUN
gs-3214	34	12	-	-	PUNCT
gs-3214	34	13	t	t	NOUN
gs-3214	34	14	cell	cell	NOUN
gs-3214	34	15	therapy	therapy	NOUN
gs-3214	34	16	to	to	ADP
gs-3214	34	17	solid	solid	ADJ
gs-3214	34	18	tumors	tumor	NOUN
gs-3214	34	19	.	.	PUNCT
gs-3214	35	1	as	as	ADP
gs-3214	35	2	a	a	DET
gs-3214	35	3	groundbreaking	groundbreaking	ADJ
gs-3214	35	4	treatment	treatment	NOUN
gs-3214	35	5	for	for	ADP
gs-3214	35	6	patients	patient	NOUN
gs-3214	35	7	with	with	ADP
gs-3214	35	8	relapsed	relapse	VERB
gs-3214	35	9	or	or	CCONJ
gs-3214	35	10	refractory	refractory	NOUN
gs-3214	35	11	hematologic	hematologic	NOUN
gs-3214	35	12	diseases	disease	NOUN
gs-3214	35	13	,	,	PUNCT
gs-3214	35	14	car	car	NOUN
gs-3214	35	15	-	-	PUNCT
gs-3214	35	16	t	t	NOUN
gs-3214	35	17	cell	cell	NOUN
gs-3214	35	18	therapy	therapy	NOUN
gs-3214	35	19	offers	offer	VERB
gs-3214	35	20	the	the	DET
gs-3214	35	21	promise	promise	NOUN
gs-3214	35	22	of	of	ADP
gs-3214	35	23	lasting	last	VERB
gs-3214	35	24	and	and	CCONJ
gs-3214	35	25	often	often	ADV
gs-3214	35	26	curative	curative	ADJ
gs-3214	35	27	responses	response	NOUN
gs-3214	35	28	.	.	PUNCT
gs-3214	36	1	notably	notably	ADV
gs-3214	36	2	,	,	PUNCT
gs-3214	36	3	car	car	NOUN
gs-3214	36	4	-	-	PUNCT
gs-3214	36	5	t	t	NOUN
gs-3214	36	6	therapies	therapy	NOUN
gs-3214	36	7	that	that	PRON
gs-3214	36	8	target	target	VERB
gs-3214	36	9	the	the	DET
gs-3214	36	10	cd19	cd19	PROPN
gs-3214	36	11	antigen	antigen	NOUN
gs-3214	36	12	on	on	ADP
gs-3214	36	13	b	b	NOUN
gs-3214	36	14	cells	cell	NOUN
gs-3214	36	15	have	have	AUX
gs-3214	36	16	demonstrated	demonstrate	VERB
gs-3214	36	17	impressive	impressive	ADJ
gs-3214	36	18	clinical	clinical	ADJ
gs-3214	36	19	success	success	NOUN
gs-3214	36	20	across	across	ADP
gs-3214	36	21	various	various	ADJ
gs-3214	36	22	hematologic	hematologic	ADJ
gs-3214	36	23	malignancies	malignancy	NOUN
gs-3214	36	24	[	[	X
gs-3214	36	25	1	1	NUM
gs-3214	36	26	-	-	SYM
gs-3214	36	27	2	2	NUM
gs-3214	36	28	]	]	PUNCT
gs-3214	36	29	.	.	PUNCT
gs-3214	37	1	immunotherapy	immunotherapy	NOUN
gs-3214	37	2	includes	include	VERB
gs-3214	37	3	a	a	DET
gs-3214	37	4	variety	variety	NOUN
gs-3214	37	5	of	of	ADP
gs-3214	37	6	treatment	treatment	NOUN
gs-3214	37	7	strategies	strategy	NOUN
gs-3214	37	8	designed	design	VERB
gs-3214	37	9	to	to	PART
gs-3214	37	10	leverage	leverage	VERB
gs-3214	37	11	the	the	DET
gs-3214	37	12	immune	immune	ADJ
gs-3214	37	13	system	system	NOUN
gs-3214	37	14	’s	’s	PART
gs-3214	37	15	power	power	NOUN
gs-3214	37	16	to	to	PART
gs-3214	37	17	identify	identify	VERB
gs-3214	37	18	and	and	CCONJ
gs-3214	37	19	destroy	destroy	VERB
gs-3214	37	20	cancer	cancer	NOUN
gs-3214	37	21	cells	cell	NOUN
gs-3214	37	22	.	.	PUNCT
gs-3214	38	1	at	at	ADP
gs-3214	38	2	its	its	PRON
gs-3214	38	3	core	core	NOUN
gs-3214	38	4	,	,	PUNCT
gs-3214	38	5	cancer	cancer	NOUN
gs-3214	38	6	immunotherapy	immunotherapy	NOUN
gs-3214	38	7	seeks	seek	VERB
gs-3214	38	8	to	to	PART
gs-3214	38	9	utilize	utilize	VERB
gs-3214	38	10	the	the	DET
gs-3214	38	11	immune	immune	ADJ
gs-3214	38	12	system	system	NOUN
gs-3214	38	13	's	's	PART
gs-3214	38	14	natural	natural	ADJ
gs-3214	38	15	ability	ability	NOUN
gs-3214	38	16	to	to	PART
gs-3214	38	17	generate	generate	VERB
gs-3214	38	18	a	a	DET
gs-3214	38	19	targeted	target	VERB
gs-3214	38	20	and	and	CCONJ
gs-3214	38	21	lasting	lasting	ADJ
gs-3214	38	22	anti	anti	ADJ
gs-3214	38	23	-	-	ADJ
gs-3214	38	24	tumor	tumor	ADJ
gs-3214	38	25	response	response	NOUN
gs-3214	38	26	.	.	PUNCT
gs-3214	39	1	unlike	unlike	ADP
gs-3214	39	2	traditional	traditional	ADJ
gs-3214	39	3	treatments	treatment	NOUN
gs-3214	39	4	like	like	ADP
gs-3214	39	5	chemotherapy	chemotherapy	NOUN
gs-3214	39	6	and	and	CCONJ
gs-3214	39	7	radiation	radiation	NOUN
gs-3214	39	8	,	,	PUNCT
gs-3214	39	9	which	which	PRON
gs-3214	39	10	directly	directly	ADV
gs-3214	39	11	attack	attack	VERB
gs-3214	39	12	cancer	cancer	NOUN
gs-3214	39	13	cells	cell	NOUN
gs-3214	39	14	,	,	PUNCT
gs-3214	39	15	georgian	georgian	NOUN
gs-3214	39	16	scientists/	scientists/	NUM
gs-3214	39	17	.	.	PUNCT
gs-3214	40	1	6	6	NUM
gs-3214	40	2	n	n	NUM
gs-3214	40	3	3	3	NUM
gs-3214	40	4	,	,	PUNCT
gs-3214	40	5	2024	2024	NUM
gs-3214	40	6	265	265	NUM
gs-3214	40	7	immunotherapy	immunotherapy	NOUN
gs-3214	40	8	focuses	focus	VERB
gs-3214	40	9	on	on	ADP
gs-3214	40	10	activating	activate	VERB
gs-3214	40	11	or	or	CCONJ
gs-3214	40	12	adjusting	adjust	VERB
gs-3214	40	13	the	the	DET
gs-3214	40	14	immune	immune	ADJ
gs-3214	40	15	system	system	NOUN
gs-3214	40	16	to	to	PART
gs-3214	40	17	specifically	specifically	ADV
gs-3214	40	18	target	target	VERB
gs-3214	40	19	tumor	tumor	NOUN
gs-3214	40	20	cells	cell	NOUN
gs-3214	40	21	while	while	SCONJ
gs-3214	40	22	preserving	preserve	VERB
gs-3214	40	23	healthy	healthy	ADJ
gs-3214	40	24	tissues	tissue	NOUN
gs-3214	40	25	.	.	PUNCT
gs-3214	41	1	key	key	ADJ
gs-3214	41	2	aspects	aspect	NOUN
gs-3214	41	3	of	of	ADP
gs-3214	41	4	cancer	cancer	NOUN
gs-3214	41	5	immunotherapy	immunotherapy	NOUN
gs-3214	41	6	involve	involve	VERB
gs-3214	41	7	improving	improve	VERB
gs-3214	41	8	immune	immune	ADJ
gs-3214	41	9	recognition	recognition	NOUN
gs-3214	41	10	of	of	ADP
gs-3214	41	11	cancer	cancer	NOUN
gs-3214	41	12	cells	cell	NOUN
gs-3214	41	13	,	,	PUNCT
gs-3214	41	14	counteracting	counteract	VERB
gs-3214	41	15	the	the	DET
gs-3214	41	16	immunosuppressive	immunosuppressive	ADJ
gs-3214	41	17	factors	factor	NOUN
gs-3214	41	18	within	within	ADP
gs-3214	41	19	the	the	DET
gs-3214	41	20	tumor	tumor	NOUN
gs-3214	41	21	microenvironment	microenvironment	NOUN
gs-3214	41	22	,	,	PUNCT
gs-3214	41	23	and	and	CCONJ
gs-3214	41	24	fostering	foster	VERB
gs-3214	41	25	long	long	ADV
gs-3214	41	26	-	-	PUNCT
gs-3214	41	27	lasting	last	VERB
gs-3214	41	28	anti	anti	ADJ
gs-3214	41	29	-	-	ADJ
gs-3214	41	30	tumor	tumor	ADJ
gs-3214	41	31	immune	immune	ADJ
gs-3214	41	32	reactions	reaction	NOUN
gs-3214	41	33	.	.	PUNCT
gs-3214	42	1	for	for	ADP
gs-3214	42	2	example	example	NOUN
gs-3214	42	3	,	,	PUNCT
gs-3214	42	4	therapies	therapy	NOUN
gs-3214	42	5	like	like	ADP
gs-3214	42	6	checkpoint	checkpoint	NOUN
gs-3214	42	7	inhibitors	inhibitor	NOUN
gs-3214	42	8	and	and	CCONJ
gs-3214	42	9	car	car	NOUN
gs-3214	42	10	-	-	PUNCT
gs-3214	42	11	t	t	NOUN
gs-3214	42	12	cell	cell	NOUN
gs-3214	42	13	therapy	therapy	NOUN
gs-3214	42	14	are	be	AUX
gs-3214	42	15	designed	design	VERB
gs-3214	42	16	to	to	PART
gs-3214	42	17	target	target	VERB
gs-3214	42	18	antigens	antigen	NOUN
gs-3214	42	19	that	that	PRON
gs-3214	42	20	are	be	AUX
gs-3214	42	21	unique	unique	ADJ
gs-3214	42	22	or	or	CCONJ
gs-3214	42	23	primarily	primarily	ADV
gs-3214	42	24	found	find	VERB
gs-3214	42	25	on	on	ADP
gs-3214	42	26	cancer	cancer	NOUN
gs-3214	42	27	cells	cell	NOUN
gs-3214	42	28	,	,	PUNCT
gs-3214	42	29	thus	thus	ADV
gs-3214	42	30	reducing	reduce	VERB
gs-3214	42	31	potential	potential	ADJ
gs-3214	42	32	damage	damage	NOUN
gs-3214	42	33	to	to	ADP
gs-3214	42	34	normal	normal	ADJ
gs-3214	42	35	cells	cell	NOUN
gs-3214	42	36	.	.	PUNCT
gs-3214	43	1	checkpoint	checkpoint	NOUN
gs-3214	43	2	inhibitors	inhibitor	NOUN
gs-3214	43	3	,	,	PUNCT
gs-3214	43	4	including	include	VERB
gs-3214	43	5	pembrolizumab	pembrolizumab	NOUN
gs-3214	43	6	and	and	CCONJ
gs-3214	43	7	nivolumab	nivolumab	NOUN
gs-3214	43	8	,	,	PUNCT
gs-3214	43	9	work	work	NOUN
gs-3214	43	10	by	by	ADP
gs-3214	43	11	blocking	block	VERB
gs-3214	43	12	inhibitory	inhibitory	ADJ
gs-3214	43	13	signals	signal	NOUN
gs-3214	43	14	like	like	ADP
gs-3214	43	15	pd-1	pd-1	ADP
gs-3214	43	16	/	/	SYM
gs-3214	43	17	pd	pd	NOUN
gs-3214	43	18	-	-	PROPN
gs-3214	43	19	l1	l1	PROPN
gs-3214	43	20	and	and	CCONJ
gs-3214	43	21	ctla-4	ctla-4	NUM
gs-3214	43	22	,	,	PUNCT
gs-3214	43	23	effectively	effectively	ADV
gs-3214	43	24	unleashing	unleash	VERB
gs-3214	43	25	t	t	NOUN
gs-3214	43	26	cell	cell	NOUN
gs-3214	43	27	responses	response	NOUN
gs-3214	43	28	against	against	ADP
gs-3214	43	29	tumors	tumor	NOUN
gs-3214	43	30	.	.	PUNCT
gs-3214	44	1	additionally	additionally	ADV
gs-3214	44	2	,	,	PUNCT
gs-3214	44	3	therapies	therapy	NOUN
gs-3214	44	4	that	that	PRON
gs-3214	44	5	enhance	enhance	VERB
gs-3214	44	6	the	the	DET
gs-3214	44	7	presentation	presentation	NOUN
gs-3214	44	8	of	of	ADP
gs-3214	44	9	antigens	antigen	NOUN
gs-3214	44	10	,	,	PUNCT
gs-3214	44	11	such	such	ADJ
gs-3214	44	12	as	as	ADP
gs-3214	44	13	dendritic	dendritic	ADJ
gs-3214	44	14	cell	cell	NOUN
gs-3214	44	15	vaccines	vaccine	NOUN
gs-3214	44	16	and	and	CCONJ
gs-3214	44	17	tlr	tlr	PROPN
gs-3214	44	18	agonists	agonist	NOUN
gs-3214	44	19	,	,	PUNCT
gs-3214	44	20	help	help	VERB
gs-3214	44	21	the	the	DET
gs-3214	44	22	immune	immune	ADJ
gs-3214	44	23	system	system	NOUN
gs-3214	44	24	better	well	ADV
gs-3214	44	25	identify	identify	VERB
gs-3214	44	26	and	and	CCONJ
gs-3214	44	27	respond	respond	VERB
gs-3214	44	28	to	to	ADP
gs-3214	44	29	tumor	tumor	NOUN
gs-3214	44	30	antigens	antigen	NOUN
gs-3214	44	31	.	.	PUNCT
gs-3214	45	1	overall	overall	ADJ
gs-3214	45	2	,	,	PUNCT
gs-3214	45	3	cancer	cancer	NOUN
gs-3214	45	4	immunotherapy	immunotherapy	NOUN
gs-3214	45	5	represents	represent	VERB
gs-3214	45	6	a	a	DET
gs-3214	45	7	wide	wide	ADJ
gs-3214	45	8	range	range	NOUN
gs-3214	45	9	of	of	ADP
gs-3214	45	10	innovative	innovative	ADJ
gs-3214	45	11	approaches	approach	NOUN
gs-3214	45	12	,	,	PUNCT
gs-3214	45	13	each	each	PRON
gs-3214	45	14	targeting	target	VERB
gs-3214	45	15	different	different	ADJ
gs-3214	45	16	elements	element	NOUN
gs-3214	45	17	of	of	ADP
gs-3214	45	18	the	the	DET
gs-3214	45	19	immune	immune	ADJ
gs-3214	45	20	system	system	NOUN
gs-3214	45	21	or	or	CCONJ
gs-3214	45	22	the	the	DET
gs-3214	45	23	tumor	tumor	NOUN
gs-3214	45	24	environment	environment	NOUN
gs-3214	45	25	[	[	X
gs-3214	45	26	3	3	NUM
gs-3214	45	27	-	-	SYM
gs-3214	45	28	5	5	NUM
gs-3214	45	29	]	]	PUNCT
gs-3214	45	30	.	.	PUNCT
gs-3214	46	1	b	b	X
gs-3214	46	2	-	-	PUNCT
gs-3214	46	3	cell	cell	NOUN
gs-3214	46	4	acute	acute	ADJ
gs-3214	46	5	lymphoblastic	lymphoblastic	ADJ
gs-3214	46	6	leukemia	leukemia	NOUN
gs-3214	46	7	(	(	PUNCT
gs-3214	46	8	all	all	PRON
gs-3214	46	9	)	)	PUNCT
gs-3214	46	10	is	be	AUX
gs-3214	46	11	a	a	DET
gs-3214	46	12	type	type	NOUN
gs-3214	46	13	of	of	ADP
gs-3214	46	14	blood	blood	NOUN
gs-3214	46	15	cancer	cancer	NOUN
gs-3214	46	16	marked	mark	VERB
gs-3214	46	17	by	by	ADP
gs-3214	46	18	the	the	DET
gs-3214	46	19	rapid	rapid	ADJ
gs-3214	46	20	growth	growth	NOUN
gs-3214	46	21	of	of	ADP
gs-3214	46	22	immature	immature	ADJ
gs-3214	46	23	b	b	NOUN
gs-3214	46	24	-	-	PUNCT
gs-3214	46	25	cell	cell	NOUN
gs-3214	46	26	precursors	precursor	NOUN
gs-3214	46	27	.	.	PUNCT
gs-3214	47	1	while	while	SCONJ
gs-3214	47	2	advancements	advancement	NOUN
gs-3214	47	3	in	in	ADP
gs-3214	47	4	chemotherapy	chemotherapy	NOUN
gs-3214	47	5	and	and	CCONJ
gs-3214	47	6	stem	stem	NOUN
gs-3214	47	7	cell	cell	NOUN
gs-3214	47	8	transplants	transplant	NOUN
gs-3214	47	9	have	have	AUX
gs-3214	47	10	improved	improve	VERB
gs-3214	47	11	outcomes	outcome	NOUN
gs-3214	47	12	,	,	PUNCT
gs-3214	47	13	many	many	ADJ
gs-3214	47	14	patients	patient	NOUN
gs-3214	47	15	still	still	ADV
gs-3214	47	16	face	face	VERB
gs-3214	47	17	relapse	relapse	NOUN
gs-3214	47	18	or	or	CCONJ
gs-3214	47	19	treatment	treatment	NOUN
gs-3214	47	20	-	-	PUNCT
gs-3214	47	21	resistant	resistant	ADJ
gs-3214	47	22	disease	disease	NOUN
gs-3214	47	23	.	.	PUNCT
gs-3214	48	1	in	in	ADP
gs-3214	48	2	this	this	DET
gs-3214	48	3	context	context	NOUN
gs-3214	48	4	,	,	PUNCT
gs-3214	48	5	car	car	NOUN
gs-3214	48	6	-	-	PUNCT
gs-3214	48	7	t	t	NOUN
gs-3214	48	8	cell	cell	NOUN
gs-3214	48	9	therapy	therapy	NOUN
gs-3214	48	10	targeting	target	VERB
gs-3214	48	11	cd19	cd19	PROPN
gs-3214	48	12	has	have	AUX
gs-3214	48	13	emerged	emerge	VERB
gs-3214	48	14	as	as	ADP
gs-3214	48	15	an	an	DET
gs-3214	48	16	exciting	exciting	ADJ
gs-3214	48	17	treatment	treatment	NOUN
gs-3214	48	18	option	option	NOUN
gs-3214	48	19	.	.	PUNCT
gs-3214	49	1	clinical	clinical	ADJ
gs-3214	49	2	trials	trial	NOUN
gs-3214	49	3	for	for	ADP
gs-3214	49	4	car	car	NOUN
gs-3214	49	5	-	-	PUNCT
gs-3214	49	6	t	t	NOUN
gs-3214	49	7	therapies	therapy	NOUN
gs-3214	49	8	like	like	ADP
gs-3214	49	9	tisagenlecleucel	tisagenlecleucel	VERB
gs-3214	49	10	and	and	CCONJ
gs-3214	49	11	axicabtagene	axicabtagene	PROPN
gs-3214	49	12	ciloleucel	ciloleucel	PROPN
gs-3214	49	13	have	have	AUX
gs-3214	49	14	shown	show	VERB
gs-3214	49	15	remarkable	remarkable	ADJ
gs-3214	49	16	response	response	NOUN
gs-3214	49	17	rates	rate	NOUN
gs-3214	49	18	,	,	PUNCT
gs-3214	49	19	with	with	ADP
gs-3214	49	20	some	some	DET
gs-3214	49	21	patients	patient	NOUN
gs-3214	49	22	achieving	achieve	VERB
gs-3214	49	23	complete	complete	ADJ
gs-3214	49	24	remission	remission	NOUN
gs-3214	49	25	and	and	CCONJ
gs-3214	49	26	lasting	lasting	ADJ
gs-3214	49	27	responses	response	NOUN
gs-3214	49	28	.	.	PUNCT
gs-3214	50	1	importantly	importantly	ADV
gs-3214	50	2	,	,	PUNCT
gs-3214	50	3	long	long	ADJ
gs-3214	50	4	-	-	PUNCT
gs-3214	50	5	term	term	NOUN
gs-3214	50	6	follow	follow	NOUN
gs-3214	50	7	-	-	PUNCT
gs-3214	50	8	up	up	NOUN
gs-3214	50	9	from	from	ADP
gs-3214	50	10	these	these	DET
gs-3214	50	11	trials	trial	NOUN
gs-3214	50	12	indicates	indicate	VERB
gs-3214	50	13	that	that	SCONJ
gs-3214	50	14	a	a	DET
gs-3214	50	15	subset	subset	NOUN
gs-3214	50	16	of	of	ADP
gs-3214	50	17	patients	patient	NOUN
gs-3214	50	18	can	can	AUX
gs-3214	50	19	maintain	maintain	VERB
gs-3214	50	20	their	their	PRON
gs-3214	50	21	remission	remission	NOUN
gs-3214	50	22	,	,	PUNCT
gs-3214	50	23	showcasing	showcase	VERB
gs-3214	50	24	car	car	NOUN
gs-3214	50	25	-	-	PUNCT
gs-3214	50	26	t	t	NOUN
gs-3214	50	27	cell	cell	NOUN
gs-3214	50	28	therapy	therapy	NOUN
gs-3214	50	29	's	's	PART
gs-3214	50	30	potential	potential	NOUN
gs-3214	50	31	for	for	ADP
gs-3214	50	32	long	long	ADV
gs-3214	50	33	-	-	PUNCT
gs-3214	50	34	lasting	last	VERB
gs-3214	50	35	disease	disease	NOUN
gs-3214	50	36	control	control	NOUN
gs-3214	50	37	in	in	ADP
gs-3214	50	38	those	those	PRON
gs-3214	50	39	with	with	ADP
gs-3214	50	40	relapsed	relapse	VERB
gs-3214	50	41	or	or	CCONJ
gs-3214	50	42	refractory	refractory	NOUN
gs-3214	50	43	all	all	PRON
gs-3214	51	1	[	[	X
gs-3214	51	2	6	6	NUM
gs-3214	51	3	-	-	SYM
gs-3214	51	4	7	7	NUM
gs-3214	51	5	]	]	PUNCT
gs-3214	51	6	.	.	PUNCT
gs-3214	52	1	chimeric	chimeric	ADJ
gs-3214	52	2	antigen	antigen	ADJ
gs-3214	52	3	receptor	receptor	NOUN
gs-3214	52	4	t	t	NOUN
gs-3214	52	5	-	-	PUNCT
gs-3214	52	6	cell	cell	NOUN
gs-3214	52	7	(	(	PUNCT
gs-3214	52	8	car	car	NOUN
gs-3214	52	9	-	-	PUNCT
gs-3214	52	10	t	t	PROPN
gs-3214	52	11	)	)	PUNCT
gs-3214	52	12	therapy	therapy	NOUN
gs-3214	52	13	has	have	AUX
gs-3214	52	14	revolutionized	revolutionize	VERB
gs-3214	52	15	immunotherapy	immunotherapy	NOUN
gs-3214	52	16	by	by	ADP
gs-3214	52	17	harnessing	harness	VERB
gs-3214	52	18	the	the	DET
gs-3214	52	19	immune	immune	ADJ
gs-3214	52	20	system	system	NOUN
gs-3214	52	21	's	's	PART
gs-3214	52	22	power	power	NOUN
gs-3214	52	23	to	to	PART
gs-3214	52	24	target	target	VERB
gs-3214	52	25	and	and	CCONJ
gs-3214	52	26	destroy	destroy	VERB
gs-3214	52	27	cancer	cancer	NOUN
gs-3214	52	28	cells	cell	NOUN
gs-3214	52	29	.	.	PUNCT
gs-3214	53	1	this	this	DET
gs-3214	53	2	approach	approach	NOUN
gs-3214	53	3	involves	involve	VERB
gs-3214	53	4	engineering	engineering	NOUN
gs-3214	53	5	t	t	PROPN
gs-3214	53	6	cells	cell	NOUN
gs-3214	53	7	to	to	PART
gs-3214	53	8	express	express	VERB
gs-3214	53	9	synthetic	synthetic	ADJ
gs-3214	53	10	receptors	receptor	NOUN
gs-3214	53	11	that	that	PRON
gs-3214	53	12	recognize	recognize	VERB
gs-3214	53	13	specific	specific	ADJ
gs-3214	53	14	antigens	antigen	NOUN
gs-3214	53	15	on	on	ADP
gs-3214	53	16	tumor	tumor	NOUN
gs-3214	53	17	cells	cell	NOUN
gs-3214	53	18	,	,	PUNCT
gs-3214	53	19	offering	offer	VERB
gs-3214	53	20	unprecedented	unprecedented	ADJ
gs-3214	53	21	precision	precision	NOUN
gs-3214	53	22	and	and	CCONJ
gs-3214	53	23	efficacy	efficacy	NOUN
gs-3214	53	24	in	in	ADP
gs-3214	53	25	treating	treat	VERB
gs-3214	53	26	hematologic	hematologic	ADJ
gs-3214	53	27	malignancies	malignancy	NOUN
gs-3214	53	28	.	.	PUNCT
gs-3214	54	1	despite	despite	SCONJ
gs-3214	54	2	remarkable	remarkable	ADJ
gs-3214	54	3	success	success	NOUN
gs-3214	54	4	in	in	ADP
gs-3214	54	5	clinical	clinical	ADJ
gs-3214	54	6	trials	trial	NOUN
gs-3214	54	7	,	,	PUNCT
gs-3214	54	8	particularly	particularly	ADV
gs-3214	54	9	for	for	ADP
gs-3214	54	10	b	b	NOUN
gs-3214	54	11	-	-	PUNCT
gs-3214	54	12	cell	cell	NOUN
gs-3214	54	13	leukemias	leukemia	NOUN
gs-3214	54	14	and	and	CCONJ
gs-3214	54	15	lymphomas	lymphoma	NOUN
gs-3214	54	16	,	,	PUNCT
gs-3214	54	17	challenges	challenge	NOUN
gs-3214	54	18	such	such	ADJ
gs-3214	54	19	as	as	ADP
gs-3214	54	20	cytokine	cytokine	ADJ
gs-3214	54	21	release	release	NOUN
gs-3214	54	22	syndrome	syndrome	NOUN
gs-3214	54	23	,	,	PUNCT
gs-3214	54	24	neurotoxicity	neurotoxicity	NOUN
gs-3214	54	25	,	,	PUNCT
gs-3214	54	26	antigen	antigen	ADJ
gs-3214	54	27	escape	escape	NOUN
gs-3214	54	28	,	,	PUNCT
gs-3214	54	29	and	and	CCONJ
gs-3214	54	30	limited	limited	ADJ
gs-3214	54	31	efficacy	efficacy	NOUN
gs-3214	54	32	in	in	ADP
gs-3214	54	33	solid	solid	ADJ
gs-3214	54	34	tumors	tumor	NOUN
gs-3214	54	35	remain	remain	VERB
gs-3214	54	36	significant	significant	ADJ
gs-3214	54	37	.	.	PUNCT
gs-3214	55	1	advances	advance	NOUN
gs-3214	55	2	in	in	ADP
gs-3214	55	3	car	car	NOUN
gs-3214	55	4	design	design	NOUN
gs-3214	55	5	,	,	PUNCT
gs-3214	55	6	gene	gene	NOUN
gs-3214	55	7	editing	editing	NOUN
gs-3214	55	8	technologies	technology	NOUN
gs-3214	55	9	,	,	PUNCT
gs-3214	55	10	and	and	CCONJ
gs-3214	55	11	strategies	strategy	NOUN
gs-3214	55	12	to	to	PART
gs-3214	55	13	modulate	modulate	VERB
gs-3214	55	14	the	the	DET
gs-3214	55	15	tumor	tumor	NOUN
gs-3214	55	16	microenvironment	microenvironment	NOUN
gs-3214	55	17	are	be	AUX
gs-3214	55	18	addressing	address	VERB
gs-3214	55	19	these	these	DET
gs-3214	55	20	limitations	limitation	NOUN
gs-3214	55	21	,	,	PUNCT
gs-3214	55	22	paving	pave	VERB
gs-3214	55	23	the	the	DET
gs-3214	55	24	way	way	NOUN
gs-3214	55	25	for	for	ADP
gs-3214	55	26	broader	broad	ADJ
gs-3214	55	27	applications	application	NOUN
gs-3214	55	28	,	,	PUNCT
gs-3214	55	29	including	include	VERB
gs-3214	55	30	autoimmune	autoimmune	ADJ
gs-3214	55	31	and	and	CCONJ
gs-3214	55	32	infectious	infectious	ADJ
gs-3214	55	33	diseases	disease	NOUN
gs-3214	55	34	.	.	PUNCT
gs-3214	56	1	this	this	DET
gs-3214	56	2	review	review	NOUN
gs-3214	56	3	explores	explore	VERB
gs-3214	56	4	the	the	DET
gs-3214	56	5	mechanisms	mechanism	NOUN
gs-3214	56	6	,	,	PUNCT
gs-3214	56	7	current	current	ADJ
gs-3214	56	8	applications	application	NOUN
gs-3214	56	9	,	,	PUNCT
gs-3214	56	10	challenges	challenge	NOUN
gs-3214	56	11	,	,	PUNCT
gs-3214	56	12	and	and	CCONJ
gs-3214	56	13	future	future	ADJ
gs-3214	56	14	directions	direction	NOUN
gs-3214	56	15	of	of	ADP
gs-3214	56	16	car	car	NOUN
gs-3214	56	17	-	-	PUNCT
gs-3214	56	18	t	t	NOUN
gs-3214	56	19	cell	cell	NOUN
gs-3214	56	20	therapy	therapy	NOUN
gs-3214	56	21	,	,	PUNCT
gs-3214	56	22	highlighting	highlight	VERB
gs-3214	56	23	its	its	PRON
gs-3214	56	24	transformative	transformative	ADJ
gs-3214	56	25	potential	potential	NOUN
gs-3214	56	26	in	in	ADP
gs-3214	56	27	personalized	personalized	ADJ
gs-3214	56	28	medicine	medicine	NOUN
gs-3214	56	29	[	[	X
gs-3214	56	30	7	7	NUM
gs-3214	56	31	,	,	PUNCT
gs-3214	56	32	16,38,48,100	16,38,48,100	NUM
gs-3214	56	33	]	]	PUNCT
gs-3214	56	34	.	.	PUNCT
gs-3214	57	1	car	car	NOUN
gs-3214	57	2	-	-	PUNCT
gs-3214	57	3	t	t	NOUN
gs-3214	57	4	cell	cell	NOUN
gs-3214	57	5	therapy	therapy	NOUN
gs-3214	57	6	has	have	AUX
gs-3214	57	7	demonstrated	demonstrate	VERB
gs-3214	57	8	remarkable	remarkable	ADJ
gs-3214	57	9	potential	potential	NOUN
gs-3214	57	10	in	in	ADP
gs-3214	57	11	the	the	DET
gs-3214	57	12	treatment	treatment	NOUN
gs-3214	57	13	of	of	ADP
gs-3214	57	14	hematologic	hematologic	NOUN
gs-3214	57	15	malignancies	malignancy	NOUN
gs-3214	57	16	,	,	PUNCT
gs-3214	57	17	establishing	establish	VERB
gs-3214	57	18	itself	itself	PRON
gs-3214	57	19	as	as	ADP
gs-3214	57	20	a	a	DET
gs-3214	57	21	significant	significant	ADJ
gs-3214	57	22	advancement	advancement	NOUN
gs-3214	57	23	in	in	ADP
gs-3214	57	24	immunotherapy	immunotherapy	NOUN
gs-3214	57	25	.	.	PUNCT
gs-3214	58	1	however	however	ADV
gs-3214	58	2	,	,	PUNCT
gs-3214	58	3	several	several	ADJ
gs-3214	58	4	challenges	challenge	NOUN
gs-3214	58	5	and	and	CCONJ
gs-3214	58	6	issues	issue	NOUN
gs-3214	58	7	require	require	VERB
gs-3214	58	8	further	further	ADJ
gs-3214	58	9	exploration	exploration	NOUN
gs-3214	58	10	to	to	PART
gs-3214	58	11	maximize	maximize	VERB
gs-3214	58	12	its	its	PRON
gs-3214	58	13	clinical	clinical	ADJ
gs-3214	58	14	and	and	CCONJ
gs-3214	58	15	therapeutic	therapeutic	ADJ
gs-3214	58	16	potential	potential	NOUN
gs-3214	58	17	.	.	PUNCT
gs-3214	59	1	this	this	DET
gs-3214	59	2	discussion	discussion	NOUN
gs-3214	59	3	addresses	address	VERB
gs-3214	59	4	key	key	ADJ
gs-3214	59	5	aspects	aspect	NOUN
gs-3214	59	6	of	of	ADP
gs-3214	59	7	car	car	NOUN
gs-3214	59	8	-	-	PUNCT
gs-3214	59	9	t	t	NOUN
gs-3214	59	10	cell	cell	NOUN
gs-3214	59	11	therapy	therapy	NOUN
gs-3214	59	12	,	,	PUNCT
gs-3214	59	13	including	include	VERB
gs-3214	59	14	its	its	PRON
gs-3214	59	15	mechanisms	mechanism	NOUN
gs-3214	59	16	,	,	PUNCT
gs-3214	59	17	clinical	clinical	ADJ
gs-3214	59	18	applications	application	NOUN
gs-3214	59	19	,	,	PUNCT
gs-3214	59	20	challenges	challenge	NOUN
gs-3214	59	21	,	,	PUNCT
gs-3214	59	22	and	and	CCONJ
gs-3214	59	23	innovations	innovation	NOUN
gs-3214	59	24	,	,	PUNCT
gs-3214	59	25	providing	provide	VERB
gs-3214	59	26	a	a	DET
gs-3214	59	27	comprehensive	comprehensive	ADJ
gs-3214	59	28	understanding	understanding	NOUN
gs-3214	59	29	of	of	ADP
gs-3214	59	30	its	its	PRON
gs-3214	59	31	current	current	ADJ
gs-3214	59	32	state	state	NOUN
gs-3214	59	33	and	and	CCONJ
gs-3214	59	34	future	future	ADJ
gs-3214	59	35	directions	direction	NOUN
gs-3214	59	36	.	.	PUNCT
gs-3214	60	1	while	while	SCONJ
gs-3214	60	2	car	car	NOUN
gs-3214	60	3	-	-	PUNCT
gs-3214	60	4	t	t	NOUN
gs-3214	60	5	cell	cell	NOUN
gs-3214	60	6	therapy	therapy	NOUN
gs-3214	60	7	has	have	AUX
gs-3214	60	8	transformed	transform	VERB
gs-3214	60	9	cancer	cancer	NOUN
gs-3214	60	10	treatment	treatment	NOUN
gs-3214	60	11	,	,	PUNCT
gs-3214	60	12	its	its	PRON
gs-3214	60	13	broader	broad	ADJ
gs-3214	60	14	georgian	georgian	NOUN
gs-3214	60	15	scientists/	scientists/	NUM
gs-3214	60	16	.	.	PUNCT
gs-3214	61	1	6	6	NUM
gs-3214	61	2	n	n	NUM
gs-3214	61	3	3	3	NUM
gs-3214	61	4	,	,	PUNCT
gs-3214	61	5	2024	2024	NUM
gs-3214	61	6	266	266	NUM
gs-3214	61	7	application	application	NOUN
gs-3214	61	8	depends	depend	VERB
gs-3214	61	9	on	on	ADP
gs-3214	61	10	overcoming	overcome	VERB
gs-3214	61	11	significant	significant	ADJ
gs-3214	61	12	challenges	challenge	NOUN
gs-3214	61	13	.	.	PUNCT
gs-3214	62	1	through	through	ADP
gs-3214	62	2	technological	technological	ADJ
gs-3214	62	3	innovation	innovation	NOUN
gs-3214	62	4	,	,	PUNCT
gs-3214	62	5	strategic	strategic	ADJ
gs-3214	62	6	collaborations	collaboration	NOUN
gs-3214	62	7	,	,	PUNCT
gs-3214	62	8	and	and	CCONJ
gs-3214	62	9	continued	continued	ADJ
gs-3214	62	10	research	research	NOUN
gs-3214	62	11	,	,	PUNCT
gs-3214	62	12	car	car	NOUN
gs-3214	62	13	-	-	PUNCT
gs-3214	62	14	t	t	NOUN
gs-3214	62	15	cells	cell	NOUN
gs-3214	62	16	hold	hold	VERB
gs-3214	62	17	the	the	DET
gs-3214	62	18	promise	promise	NOUN
gs-3214	62	19	to	to	PART
gs-3214	62	20	not	not	PART
gs-3214	62	21	only	only	ADV
gs-3214	62	22	revolutionize	revolutionize	VERB
gs-3214	62	23	cancer	cancer	NOUN
gs-3214	62	24	treatment	treatment	NOUN
gs-3214	62	25	but	but	CCONJ
gs-3214	62	26	also	also	ADV
gs-3214	62	27	extend	extend	VERB
gs-3214	62	28	their	their	PRON
gs-3214	62	29	benefits	benefit	NOUN
gs-3214	62	30	to	to	ADP
gs-3214	62	31	other	other	ADJ
gs-3214	62	32	diseases	disease	NOUN
gs-3214	62	33	.	.	PUNCT
gs-3214	63	1	addressing	address	VERB
gs-3214	63	2	these	these	DET
gs-3214	63	3	scientific	scientific	ADJ
gs-3214	63	4	and	and	CCONJ
gs-3214	63	5	practical	practical	ADJ
gs-3214	63	6	challenges	challenge	NOUN
gs-3214	63	7	will	will	AUX
gs-3214	63	8	shape	shape	VERB
gs-3214	63	9	the	the	DET
gs-3214	63	10	next	next	ADJ
gs-3214	63	11	phase	phase	NOUN
gs-3214	63	12	of	of	ADP
gs-3214	63	13	car	car	NOUN
gs-3214	63	14	-	-	PUNCT
gs-3214	63	15	t	t	NOUN
gs-3214	63	16	therapy	therapy	NOUN
gs-3214	63	17	,	,	PUNCT
gs-3214	63	18	ensuring	ensure	VERB
gs-3214	63	19	its	its	PRON
gs-3214	63	20	place	place	NOUN
gs-3214	63	21	as	as	ADP
gs-3214	63	22	a	a	DET
gs-3214	63	23	cornerstone	cornerstone	NOUN
gs-3214	63	24	of	of	ADP
gs-3214	63	25	modern	modern	ADJ
gs-3214	63	26	medicine	medicine	NOUN
gs-3214	64	1	[	[	X
gs-3214	64	2	9,47,84	9,47,84	NUM
gs-3214	64	3	,	,	PUNCT
gs-3214	64	4	99	99	NUM
gs-3214	64	5	]	]	PUNCT
gs-3214	64	6	.	.	PUNCT
gs-3214	65	1	chimeric	chimeric	ADJ
gs-3214	65	2	antigen	antigen	ADJ
gs-3214	65	3	receptor	receptor	NOUN
gs-3214	65	4	t	t	NOUN
gs-3214	65	5	-	-	PUNCT
gs-3214	65	6	cell	cell	NOUN
gs-3214	65	7	(	(	PUNCT
gs-3214	65	8	car	car	NOUN
gs-3214	65	9	-	-	PUNCT
gs-3214	65	10	t	t	PROPN
gs-3214	65	11	)	)	PUNCT
gs-3214	65	12	therapy	therapy	NOUN
gs-3214	65	13	has	have	AUX
gs-3214	65	14	emerged	emerge	VERB
gs-3214	65	15	as	as	ADP
gs-3214	65	16	a	a	DET
gs-3214	65	17	groundbreaking	groundbreake	VERB
gs-3214	65	18	approach	approach	NOUN
gs-3214	65	19	in	in	ADP
gs-3214	65	20	the	the	DET
gs-3214	65	21	field	field	NOUN
gs-3214	65	22	of	of	ADP
gs-3214	65	23	immunotherapy	immunotherapy	NOUN
gs-3214	65	24	,	,	PUNCT
gs-3214	65	25	providing	provide	VERB
gs-3214	65	26	promising	promising	ADJ
gs-3214	65	27	outcomes	outcome	NOUN
gs-3214	65	28	in	in	ADP
gs-3214	65	29	the	the	DET
gs-3214	65	30	treatment	treatment	NOUN
gs-3214	65	31	of	of	ADP
gs-3214	65	32	certain	certain	ADJ
gs-3214	65	33	cancers	cancer	NOUN
gs-3214	65	34	.	.	PUNCT
gs-3214	66	1	however	however	ADV
gs-3214	66	2	,	,	PUNCT
gs-3214	66	3	its	its	PRON
gs-3214	66	4	clinical	clinical	ADJ
gs-3214	66	5	application	application	NOUN
gs-3214	66	6	is	be	AUX
gs-3214	66	7	associated	associate	VERB
gs-3214	66	8	with	with	ADP
gs-3214	66	9	complex	complex	ADJ
gs-3214	66	10	challenges	challenge	NOUN
gs-3214	66	11	and	and	CCONJ
gs-3214	66	12	unresolved	unresolved	ADJ
gs-3214	66	13	scientific	scientific	ADJ
gs-3214	66	14	issues	issue	NOUN
gs-3214	66	15	.	.	PUNCT
gs-3214	67	1	this	this	DET
gs-3214	67	2	article	article	NOUN
gs-3214	67	3	explores	explore	VERB
gs-3214	67	4	the	the	DET
gs-3214	67	5	features	feature	NOUN
gs-3214	67	6	of	of	ADP
gs-3214	67	7	car	car	NOUN
gs-3214	67	8	-	-	PUNCT
gs-3214	67	9	t	t	NOUN
gs-3214	67	10	cell	cell	NOUN
gs-3214	67	11	technology	technology	NOUN
gs-3214	67	12	,	,	PUNCT
gs-3214	67	13	its	its	PRON
gs-3214	67	14	mechanisms	mechanism	NOUN
gs-3214	67	15	,	,	PUNCT
gs-3214	67	16	potential	potential	ADJ
gs-3214	67	17	applications	application	NOUN
gs-3214	67	18	,	,	PUNCT
gs-3214	67	19	and	and	CCONJ
gs-3214	67	20	the	the	DET
gs-3214	67	21	obstacles	obstacle	NOUN
gs-3214	67	22	that	that	PRON
gs-3214	67	23	must	must	AUX
gs-3214	67	24	be	be	AUX
gs-3214	67	25	addressed	address	VERB
gs-3214	67	26	for	for	ADP
gs-3214	67	27	its	its	PRON
gs-3214	67	28	broader	broad	ADJ
gs-3214	67	29	use	use	NOUN
gs-3214	67	30	.	.	PUNCT
gs-3214	68	1	car	car	NOUN
gs-3214	68	2	-	-	PUNCT
gs-3214	68	3	t	t	NOUN
gs-3214	68	4	cell	cell	NOUN
gs-3214	68	5	therapy	therapy	NOUN
gs-3214	68	6	represents	represent	VERB
gs-3214	68	7	a	a	DET
gs-3214	68	8	revolutionary	revolutionary	ADJ
gs-3214	68	9	advancement	advancement	NOUN
gs-3214	68	10	in	in	ADP
gs-3214	68	11	personalized	personalized	ADJ
gs-3214	68	12	medicine	medicine	NOUN
gs-3214	68	13	.	.	PUNCT
gs-3214	69	1	by	by	ADP
gs-3214	69	2	genetically	genetically	ADV
gs-3214	69	3	engineering	engineering	NOUN
gs-3214	69	4	t	t	NOUN
gs-3214	69	5	cells	cell	NOUN
gs-3214	69	6	to	to	PART
gs-3214	69	7	express	express	VERB
gs-3214	69	8	chimeric	chimeric	ADJ
gs-3214	69	9	antigen	antigen	ADJ
gs-3214	69	10	receptors	receptor	NOUN
gs-3214	69	11	,	,	PUNCT
gs-3214	69	12	the	the	DET
gs-3214	69	13	immune	immune	ADJ
gs-3214	69	14	system	system	NOUN
gs-3214	69	15	can	can	AUX
gs-3214	69	16	be	be	AUX
gs-3214	69	17	reprogrammed	reprogramme	VERB
gs-3214	69	18	to	to	PART
gs-3214	69	19	target	target	VERB
gs-3214	69	20	specific	specific	ADJ
gs-3214	69	21	antigens	antigen	NOUN
gs-3214	69	22	on	on	ADP
gs-3214	69	23	malignant	malignant	ADJ
gs-3214	69	24	cells	cell	NOUN
gs-3214	69	25	.	.	PUNCT
gs-3214	70	1	initially	initially	ADV
gs-3214	70	2	approved	approve	VERB
gs-3214	70	3	for	for	ADP
gs-3214	70	4	hematologic	hematologic	NOUN
gs-3214	70	5	malignancies	malignancy	NOUN
gs-3214	70	6	,	,	PUNCT
gs-3214	70	7	car	car	NOUN
gs-3214	70	8	-	-	PUNCT
gs-3214	70	9	t	t	NOUN
gs-3214	70	10	therapy	therapy	NOUN
gs-3214	70	11	has	have	AUX
gs-3214	70	12	opened	open	VERB
gs-3214	70	13	new	new	ADJ
gs-3214	70	14	avenues	avenue	NOUN
gs-3214	70	15	for	for	ADP
gs-3214	70	16	treating	treat	VERB
gs-3214	70	17	cancers	cancer	NOUN
gs-3214	70	18	and	and	CCONJ
gs-3214	70	19	other	other	ADJ
gs-3214	70	20	diseases	disease	NOUN
gs-3214	70	21	.	.	PUNCT
gs-3214	71	1	despite	despite	SCONJ
gs-3214	71	2	its	its	PRON
gs-3214	71	3	success	success	NOUN
gs-3214	71	4	,	,	PUNCT
gs-3214	71	5	the	the	DET
gs-3214	71	6	therapy	therapy	NOUN
gs-3214	71	7	presents	present	VERB
gs-3214	71	8	unique	unique	ADJ
gs-3214	71	9	challenges	challenge	NOUN
gs-3214	71	10	,	,	PUNCT
gs-3214	71	11	including	include	VERB
gs-3214	71	12	toxicity	toxicity	NOUN
gs-3214	71	13	,	,	PUNCT
gs-3214	71	14	limited	limited	ADJ
gs-3214	71	15	efficacy	efficacy	NOUN
gs-3214	71	16	in	in	ADP
gs-3214	71	17	solid	solid	ADJ
gs-3214	71	18	tumors	tumor	NOUN
gs-3214	71	19	,	,	PUNCT
gs-3214	71	20	and	and	CCONJ
gs-3214	71	21	high	high	ADJ
gs-3214	71	22	manufacturing	manufacturing	NOUN
gs-3214	71	23	costs	cost	NOUN
gs-3214	71	24	.	.	PUNCT
gs-3214	72	1	goal	goal	NOUN
gs-3214	72	2	aim	aim	NOUN
gs-3214	72	3	of	of	ADP
gs-3214	72	4	the	the	DET
gs-3214	72	5	research	research	NOUN
gs-3214	72	6	was	be	AUX
gs-3214	72	7	to	to	PART
gs-3214	72	8	study	study	VERB
gs-3214	72	9	and	and	CCONJ
gs-3214	72	10	analyze	analyze	VERB
gs-3214	72	11	some	some	DET
gs-3214	72	12	issues	issue	NOUN
gs-3214	72	13	of	of	ADP
gs-3214	72	14	features	feature	NOUN
gs-3214	72	15	of	of	ADP
gs-3214	72	16	using	use	VERB
gs-3214	72	17	of	of	ADP
gs-3214	72	18	car	car	NOUN
gs-3214	72	19	-	-	PUNCT
gs-3214	72	20	t	t	NOUN
gs-3214	72	21	cells	cell	NOUN
gs-3214	72	22	in	in	ADP
gs-3214	72	23	immunotherapy	immunotherapy	NOUN
gs-3214	72	24	.	.	PUNCT
gs-3214	73	1	methodology	methodology	NOUN
gs-3214	73	2	:	:	PUNCT
gs-3214	73	3	the	the	DET
gs-3214	73	4	material	material	NOUN
gs-3214	73	5	of	of	ADP
gs-3214	73	6	the	the	DET
gs-3214	73	7	article	article	NOUN
gs-3214	73	8	was	be	AUX
gs-3214	73	9	the	the	DET
gs-3214	73	10	revised	revise	VERB
gs-3214	73	11	data	datum	NOUN
gs-3214	73	12	from	from	ADP
gs-3214	73	13	scientific	scientific	ADJ
gs-3214	73	14	publications	publication	NOUN
gs-3214	73	15	,	,	PUNCT
gs-3214	73	16	which	which	PRON
gs-3214	73	17	were	be	AUX
gs-3214	73	18	processed	process	VERB
gs-3214	73	19	,	,	PUNCT
gs-3214	73	20	analyzed	analyze	VERB
gs-3214	73	21	,	,	PUNCT
gs-3214	73	22	overviewed	overviewe	VERB
gs-3214	73	23	and	and	CCONJ
gs-3214	73	24	reviewed	review	VERB
gs-3214	73	25	by	by	ADP
gs-3214	73	26	generalization	generalization	NOUN
gs-3214	73	27	and	and	CCONJ
gs-3214	73	28	systematization	systematization	NOUN
gs-3214	73	29	.	.	PUNCT
gs-3214	74	1	research	research	NOUN
gs-3214	74	2	studies	study	NOUN
gs-3214	74	3	are	be	AUX
gs-3214	74	4	based	base	VERB
gs-3214	74	5	on	on	ADP
gs-3214	74	6	a	a	DET
gs-3214	74	7	review	review	NOUN
gs-3214	74	8	/	/	SYM
gs-3214	74	9	overview	overview	NOUN
gs-3214	74	10	assessment	assessment	NOUN
gs-3214	74	11	of	of	ADP
gs-3214	74	12	the	the	DET
gs-3214	74	13	development	development	NOUN
gs-3214	74	14	of	of	ADP
gs-3214	74	15	critical	critical	ADJ
gs-3214	74	16	visibility	visibility	NOUN
gs-3214	74	17	and	and	CCONJ
gs-3214	74	18	overlook	overlook	NOUN
gs-3214	74	19	of	of	ADP
gs-3214	74	20	the	the	DET
gs-3214	74	21	modern	modern	ADJ
gs-3214	74	22	scientific	scientific	ADJ
gs-3214	74	23	literature	literature	NOUN
gs-3214	74	24	.	.	PUNCT
gs-3214	75	1	use	use	VERB
gs-3214	75	2	the	the	DET
gs-3214	75	3	following	follow	VERB
gs-3214	75	4	databases	database	NOUN
gs-3214	75	5	(	(	PUNCT
gs-3214	75	6	for	for	ADP
gs-3214	75	7	extensive	extensive	ADJ
gs-3214	75	8	literature	literature	NOUN
gs-3214	75	9	searches	search	NOUN
gs-3214	75	10	to	to	PART
gs-3214	75	11	identify	identify	VERB
gs-3214	75	12	some	some	DET
gs-3214	75	13	issues	issue	NOUN
gs-3214	75	14	of	of	ADP
gs-3214	75	15	features	feature	NOUN
gs-3214	75	16	of	of	ADP
gs-3214	75	17	using	use	VERB
gs-3214	75	18	of	of	ADP
gs-3214	75	19	car	car	NOUN
gs-3214	75	20	-	-	PUNCT
gs-3214	75	21	t	t	NOUN
gs-3214	75	22	cells	cell	NOUN
gs-3214	75	23	in	in	ADP
gs-3214	75	24	immunotherapy	immunotherapy	NOUN
gs-3214	75	25	):	):	PUNCT
gs-3214	75	26	pubmed	pubmed	PROPN
gs-3214	75	27	,	,	PUNCT
gs-3214	75	28	scopus	scopus	PROPN
gs-3214	75	29	,	,	PUNCT
gs-3214	75	30	web	web	NOUN
gs-3214	75	31	of	of	ADP
gs-3214	75	32	science	science	NOUN
gs-3214	75	33	,	,	PUNCT
gs-3214	75	34	clinical	clinical	ADJ
gs-3214	75	35	key	key	NOUN
gs-3214	75	36	,	,	PUNCT
gs-3214	75	37	tomson	tomson	PROPN
gs-3214	75	38	reuters	reuters	PROPN
gs-3214	75	39	,	,	PUNCT
gs-3214	75	40	google	google	PROPN
gs-3214	75	41	scholar	scholar	NOUN
gs-3214	75	42	,	,	PUNCT
gs-3214	75	43	cochrane	cochrane	NOUN
gs-3214	75	44	library	library	NOUN
gs-3214	75	45	,	,	PUNCT
gs-3214	75	46	and	and	CCONJ
gs-3214	75	47	elsevier	elsevier	PROPN
gs-3214	75	48	foundations	foundation	NOUN
gs-3214	75	49	.	.	PUNCT
gs-3214	76	1	the	the	DET
gs-3214	76	2	methodology	methodology	NOUN
gs-3214	76	3	for	for	ADP
gs-3214	76	4	discussing	discuss	VERB
gs-3214	76	5	the	the	DET
gs-3214	76	6	scientific	scientific	ADJ
gs-3214	76	7	issues	issue	NOUN
gs-3214	76	8	and	and	CCONJ
gs-3214	76	9	features	feature	NOUN
gs-3214	76	10	of	of	ADP
gs-3214	76	11	car	car	NOUN
gs-3214	76	12	-	-	PUNCT
gs-3214	76	13	t	t	NOUN
gs-3214	76	14	cell	cell	NOUN
gs-3214	76	15	immunotherapy	immunotherapy	NOUN
gs-3214	76	16	involves	involve	VERB
gs-3214	76	17	a	a	DET
gs-3214	76	18	systematic	systematic	ADJ
gs-3214	76	19	approach	approach	NOUN
gs-3214	76	20	to	to	PART
gs-3214	76	21	review	review	VERB
gs-3214	76	22	,	,	PUNCT
gs-3214	76	23	analyze	analyze	VERB
gs-3214	76	24	,	,	PUNCT
gs-3214	76	25	and	and	CCONJ
gs-3214	76	26	synthesize	synthesize	VERB
gs-3214	76	27	current	current	ADJ
gs-3214	76	28	knowledge	knowledge	NOUN
gs-3214	76	29	in	in	ADP
gs-3214	76	30	this	this	DET
gs-3214	76	31	rapidly	rapidly	ADV
gs-3214	76	32	evolving	evolve	VERB
gs-3214	76	33	field	field	NOUN
gs-3214	76	34	.	.	PUNCT
gs-3214	77	1	below	below	ADV
gs-3214	77	2	is	be	AUX
gs-3214	77	3	the	the	DET
gs-3214	77	4	step	step	NOUN
gs-3214	77	5	-	-	PUNCT
gs-3214	77	6	by	by	ADP
gs-3214	77	7	-	-	PUNCT
gs-3214	77	8	step	step	NOUN
gs-3214	77	9	methodological	methodological	ADJ
gs-3214	77	10	framework	framework	NOUN
gs-3214	77	11	used	use	VERB
gs-3214	77	12	in	in	ADP
gs-3214	77	13	the	the	DET
gs-3214	77	14	article	article	NOUN
gs-3214	77	15	:	:	PUNCT
gs-3214	77	16	literature	literature	NOUN
gs-3214	77	17	review	review	NOUN
gs-3214	77	18	scope	scope	NOUN
gs-3214	77	19	and	and	CCONJ
gs-3214	77	20	sources	source	NOUN
gs-3214	77	21	:	:	PUNCT
gs-3214	77	22	a	a	DET
gs-3214	77	23	comprehensive	comprehensive	ADJ
gs-3214	77	24	literature	literature	NOUN
gs-3214	77	25	search	search	NOUN
gs-3214	77	26	was	be	AUX
gs-3214	77	27	conducted	conduct	VERB
gs-3214	77	28	using	use	VERB
gs-3214	77	29	academic	academic	ADJ
gs-3214	77	30	databases	database	NOUN
gs-3214	77	31	such	such	ADJ
gs-3214	77	32	as	as	ADP
gs-3214	77	33	pubmed	pubmed	PROPN
gs-3214	77	34	,	,	PUNCT
gs-3214	77	35	web	web	NOUN
gs-3214	77	36	of	of	ADP
gs-3214	77	37	science	science	NOUN
gs-3214	77	38	,	,	PUNCT
gs-3214	77	39	and	and	CCONJ
gs-3214	77	40	scopus	scopus	NOUN
gs-3214	77	41	.	.	PUNCT
gs-3214	78	1	keywords	keyword	NOUN
gs-3214	78	2	included	include	VERB
gs-3214	78	3	"	"	PUNCT
gs-3214	78	4	car	car	NOUN
gs-3214	78	5	-	-	PUNCT
gs-3214	78	6	t	t	NOUN
gs-3214	78	7	cells	cell	NOUN
gs-3214	78	8	,	,	PUNCT
gs-3214	78	9	"	"	PUNCT
gs-3214	78	10	"	"	PUNCT
gs-3214	78	11	chimeric	chimeric	ADJ
gs-3214	78	12	antigen	antigen	ADJ
gs-3214	78	13	receptor	receptor	NOUN
gs-3214	78	14	therapy	therapy	NOUN
gs-3214	78	15	,	,	PUNCT
gs-3214	78	16	"	"	PUNCT
gs-3214	78	17	"	"	PUNCT
gs-3214	78	18	immunotherapy	immunotherapy	NOUN
gs-3214	78	19	,	,	PUNCT
gs-3214	78	20	"	"	PUNCT
gs-3214	78	21	"	"	PUNCT
gs-3214	78	22	solid	solid	ADJ
gs-3214	78	23	tumors	tumor	NOUN
gs-3214	78	24	,	,	PUNCT
gs-3214	78	25	"	"	PUNCT
gs-3214	78	26	"	"	PUNCT
gs-3214	78	27	cytokine	cytokine	ADJ
gs-3214	78	28	release	release	NOUN
gs-3214	78	29	syndrome	syndrome	NOUN
gs-3214	78	30	,	,	PUNCT
gs-3214	78	31	"	"	PUNCT
gs-3214	78	32	and	and	CCONJ
gs-3214	78	33	"	"	PUNCT
gs-3214	78	34	gene	gene	NOUN
gs-3214	78	35	editing	editing	NOUN
gs-3214	78	36	.	.	PUNCT
gs-3214	78	37	"	"	PUNCT
gs-3214	79	1	inclusioncriteria	inclusioncriteria	NOUN
gs-3214	79	2	:	:	PUNCT
gs-3214	79	3	peer	peer	NOUN
gs-3214	79	4	-	-	PUNCT
gs-3214	79	5	reviewed	review	VERB
gs-3214	79	6	articles	article	NOUN
gs-3214	79	7	,	,	PUNCT
gs-3214	79	8	clinical	clinical	ADJ
gs-3214	79	9	trial	trial	NOUN
gs-3214	79	10	reports	report	NOUN
gs-3214	79	11	,	,	PUNCT
gs-3214	79	12	and	and	CCONJ
gs-3214	79	13	systematic	systematic	ADJ
gs-3214	79	14	reviews	review	NOUN
gs-3214	79	15	published	publish	VERB
gs-3214	79	16	in	in	ADP
gs-3214	79	17	the	the	DET
gs-3214	79	18	last	last	ADJ
gs-3214	79	19	10	10	NUM
gs-3214	79	20	years	year	NOUN
gs-3214	79	21	(	(	PUNCT
gs-3214	79	22	2013–2023	2013–2023	NUM
gs-3214	79	23	)	)	PUNCT
gs-3214	79	24	were	be	AUX
gs-3214	79	25	prioritized	prioritize	VERB
gs-3214	79	26	.	.	PUNCT
gs-3214	80	1	foundational	foundational	ADJ
gs-3214	80	2	studies	study	NOUN
gs-3214	80	3	and	and	CCONJ
gs-3214	80	4	seminal	seminal	ADJ
gs-3214	80	5	works	work	NOUN
gs-3214	80	6	from	from	ADP
gs-3214	80	7	earlier	early	ADJ
gs-3214	80	8	years	year	NOUN
gs-3214	80	9	were	be	AUX
gs-3214	80	10	included	include	VERB
gs-3214	80	11	for	for	ADP
gs-3214	80	12	historical	historical	ADJ
gs-3214	80	13	context	context	NOUN
gs-3214	80	14	.	.	PUNCT
gs-3214	81	1	georgian	georgian	NOUN
gs-3214	81	2	scientists/	scientists/	NUM
gs-3214	81	3	.	.	PUNCT
gs-3214	82	1	6	6	NUM
gs-3214	82	2	n	n	NUM
gs-3214	82	3	3	3	NUM
gs-3214	82	4	,	,	PUNCT
gs-3214	82	5	2024	2024	NUM
gs-3214	82	6	267	267	NUM
gs-3214	82	7	the	the	DET
gs-3214	82	8	selected	select	VERB
gs-3214	82	9	articles	article	NOUN
gs-3214	82	10	and	and	CCONJ
gs-3214	82	11	reports	report	NOUN
gs-3214	82	12	were	be	AUX
gs-3214	82	13	grouped	group	VERB
gs-3214	82	14	into	into	ADP
gs-3214	82	15	thematic	thematic	ADJ
gs-3214	82	16	categories	category	NOUN
gs-3214	82	17	to	to	PART
gs-3214	82	18	structure	structure	VERB
gs-3214	82	19	the	the	DET
gs-3214	82	20	discussion	discussion	NOUN
gs-3214	82	21	:	:	PUNCT
gs-3214	82	22	mechanisms	mechanism	NOUN
gs-3214	82	23	of	of	ADP
gs-3214	82	24	car	car	NOUN
gs-3214	82	25	-	-	PUNCT
gs-3214	82	26	t	t	NOUN
gs-3214	82	27	therapy	therapy	NOUN
gs-3214	82	28	.	.	PUNCT
gs-3214	83	1	current	current	ADJ
gs-3214	83	2	clinical	clinical	ADJ
gs-3214	83	3	applications	application	NOUN
gs-3214	83	4	.	.	PUNCT
gs-3214	84	1	challenges	challenge	NOUN
gs-3214	84	2	and	and	CCONJ
gs-3214	84	3	limitations	limitation	NOUN
gs-3214	84	4	,	,	PUNCT
gs-3214	84	5	including	include	VERB
gs-3214	84	6	toxicity	toxicity	NOUN
gs-3214	84	7	and	and	CCONJ
gs-3214	84	8	antigen	antigen	ADJ
gs-3214	84	9	escape	escape	NOUN
gs-3214	84	10	.	.	PUNCT
gs-3214	85	1	advances	advance	NOUN
gs-3214	85	2	in	in	ADP
gs-3214	85	3	car	car	NOUN
gs-3214	85	4	design	design	NOUN
gs-3214	85	5	and	and	CCONJ
gs-3214	85	6	manufacturing	manufacturing	NOUN
gs-3214	85	7	.	.	PUNCT
gs-3214	86	1	future	future	ADJ
gs-3214	86	2	perspectives	perspective	NOUN
gs-3214	86	3	and	and	CCONJ
gs-3214	86	4	innovations	innovation	NOUN
gs-3214	86	5	.	.	PUNCT
gs-3214	87	1	results	result	NOUN
gs-3214	87	2	and	and	CCONJ
gs-3214	87	3	discussion	discussion	NOUN
gs-3214	87	4	diffuse	diffuse	VERB
gs-3214	87	5	large	large	ADJ
gs-3214	87	6	b	b	NOUN
gs-3214	87	7	-	-	PUNCT
gs-3214	87	8	cell	cell	NOUN
gs-3214	87	9	lymphoma	lymphoma	NOUN
gs-3214	87	10	(	(	PUNCT
gs-3214	87	11	dlbcl	dlbcl	NOUN
gs-3214	87	12	)	)	PUNCT
gs-3214	87	13	is	be	AUX
gs-3214	87	14	the	the	DET
gs-3214	87	15	most	most	ADV
gs-3214	87	16	common	common	ADJ
gs-3214	87	17	subtype	subtype	NOUN
gs-3214	87	18	of	of	ADP
gs-3214	87	19	non	non	ADJ
gs-3214	87	20	-	-	ADJ
gs-3214	87	21	hodgkin	hodgkin	ADJ
gs-3214	87	22	lymphoma	lymphoma	NOUN
gs-3214	87	23	,	,	PUNCT
gs-3214	87	24	characterised	characterise	VERB
gs-3214	87	25	by	by	ADP
gs-3214	87	26	the	the	DET
gs-3214	87	27	proliferation	proliferation	NOUN
gs-3214	87	28	of	of	ADP
gs-3214	87	29	large	large	ADJ
gs-3214	87	30	b	b	NOUN
gs-3214	87	31	-	-	PUNCT
gs-3214	87	32	cell	cell	NOUN
gs-3214	87	33	lymphocytes	lymphocyte	NOUN
gs-3214	87	34	.	.	PUNCT
gs-3214	88	1	patients	patient	NOUN
gs-3214	88	2	with	with	ADP
gs-3214	88	3	relapsed	relapse	VERB
gs-3214	88	4	or	or	CCONJ
gs-3214	88	5	refractory	refractory	NOUN
gs-3214	88	6	dlbcl	dlbcl	NOUN
gs-3214	88	7	have	have	VERB
gs-3214	88	8	limited	limit	VERB
gs-3214	88	9	treatment	treatment	NOUN
gs-3214	88	10	options	option	NOUN
gs-3214	88	11	and	and	CCONJ
gs-3214	88	12	poor	poor	ADJ
gs-3214	88	13	prognosis	prognosis	NOUN
gs-3214	88	14	.	.	PUNCT
gs-3214	89	1	car	car	NOUN
gs-3214	89	2	-	-	PUNCT
gs-3214	89	3	t	t	NOUN
gs-3214	89	4	cell	cell	NOUN
gs-3214	89	5	therapy	therapy	NOUN
gs-3214	89	6	targeting	target	VERB
gs-3214	89	7	cd19	cd19	PROPN
gs-3214	89	8	has	have	AUX
gs-3214	89	9	emerged	emerge	VERB
gs-3214	89	10	as	as	ADP
gs-3214	89	11	a	a	DET
gs-3214	89	12	promising	promising	ADJ
gs-3214	89	13	therapeutic	therapeutic	ADJ
gs-3214	89	14	approach	approach	NOUN
gs-3214	89	15	for	for	ADP
gs-3214	89	16	these	these	DET
gs-3214	89	17	patients	patient	NOUN
gs-3214	89	18	.	.	PUNCT
gs-3214	90	1	clinical	clinical	ADJ
gs-3214	90	2	trials	trial	NOUN
gs-3214	90	3	investigating	investigate	VERB
gs-3214	90	4	car	car	NOUN
gs-3214	90	5	-	-	PUNCT
gs-3214	90	6	t	t	NOUN
gs-3214	90	7	cell	cell	NOUN
gs-3214	90	8	therapies	therapy	NOUN
gs-3214	90	9	,	,	PUNCT
gs-3214	90	10	such	such	ADJ
gs-3214	90	11	as	as	ADP
gs-3214	90	12	axicabtagene	axicabtagene	NOUN
gs-3214	90	13	ciloleucel	ciloleucel	PROPN
gs-3214	90	14	(	(	PUNCT
gs-3214	90	15	yescarta	yescarta	PROPN
gs-3214	90	16	)	)	PUNCT
gs-3214	90	17	and	and	CCONJ
gs-3214	90	18	brexucabtagene	brexucabtagene	ADJ
gs-3214	90	19	autoleucel	autoleucel	NOUN
gs-3214	90	20	(	(	PUNCT
gs-3214	90	21	tecartus	tecartus	NOUN
gs-3214	90	22	)	)	PUNCT
gs-3214	90	23	,	,	PUNCT
gs-3214	90	24	have	have	AUX
gs-3214	90	25	demonstrated	demonstrate	VERB
gs-3214	90	26	significant	significant	ADJ
gs-3214	90	27	response	response	NOUN
gs-3214	90	28	rates	rate	NOUN
gs-3214	90	29	,	,	PUNCT
gs-3214	90	30	with	with	ADP
gs-3214	90	31	durable	durable	ADJ
gs-3214	90	32	remissions	remission	NOUN
gs-3214	90	33	observed	observe	VERB
gs-3214	90	34	in	in	ADP
gs-3214	90	35	a	a	DET
gs-3214	90	36	subset	subset	NOUN
gs-3214	90	37	of	of	ADP
gs-3214	90	38	patients	patient	NOUN
gs-3214	90	39	.	.	PUNCT
gs-3214	91	1	importantly	importantly	ADV
gs-3214	91	2	,	,	PUNCT
gs-3214	91	3	real	real	ADJ
gs-3214	91	4	-	-	PUNCT
gs-3214	91	5	world	world	NOUN
gs-3214	91	6	data	datum	NOUN
gs-3214	91	7	and	and	CCONJ
gs-3214	91	8	long	long	ADJ
gs-3214	91	9	-	-	PUNCT
gs-3214	91	10	term	term	NOUN
gs-3214	91	11	follow	follow	NOUN
gs-3214	91	12	-	-	PUNCT
gs-3214	91	13	up	up	ADP
gs-3214	91	14	studies	study	NOUN
gs-3214	91	15	have	have	AUX
gs-3214	91	16	provided	provide	VERB
gs-3214	91	17	insights	insight	NOUN
gs-3214	91	18	into	into	ADP
gs-3214	91	19	the	the	DET
gs-3214	91	20	durability	durability	NOUN
gs-3214	91	21	of	of	ADP
gs-3214	91	22	responses	response	NOUN
gs-3214	91	23	and	and	CCONJ
gs-3214	91	24	the	the	DET
gs-3214	91	25	potential	potential	NOUN
gs-3214	91	26	for	for	ADP
gs-3214	91	27	long	long	ADJ
gs-3214	91	28	-	-	PUNCT
gs-3214	91	29	term	term	NOUN
gs-3214	91	30	disease	disease	NOUN
gs-3214	91	31	control	control	NOUN
gs-3214	91	32	with	with	ADP
gs-3214	91	33	car	car	NOUN
gs-3214	91	34	-	-	PUNCT
gs-3214	91	35	t	t	NOUN
gs-3214	91	36	cell	cell	NOUN
gs-3214	91	37	therapy	therapy	NOUN
gs-3214	91	38	in	in	ADP
gs-3214	91	39	relapsed	relapse	VERB
gs-3214	91	40	or	or	CCONJ
gs-3214	91	41	refractory	refractory	NOUN
gs-3214	91	42	dlbcl	dlbcl	NOUN
gs-3214	92	1	[	[	X
gs-3214	92	2	8	8	NUM
gs-3214	92	3	-	-	SYM
gs-3214	92	4	9	9	NUM
gs-3214	92	5	]	]	PUNCT
gs-3214	92	6	.	.	PUNCT
gs-3214	93	1	multiple	multiple	ADJ
gs-3214	93	2	myeloma	myeloma	PROPN
gs-3214	93	3	is	be	AUX
gs-3214	93	4	a	a	DET
gs-3214	93	5	plasma	plasma	NOUN
gs-3214	93	6	cell	cell	NOUN
gs-3214	93	7	neoplasm	neoplasm	NOUN
gs-3214	93	8	characterised	characterise	VERB
gs-3214	93	9	by	by	ADP
gs-3214	93	10	the	the	DET
gs-3214	93	11	clonal	clonal	ADJ
gs-3214	93	12	proliferation	proliferation	NOUN
gs-3214	93	13	of	of	ADP
gs-3214	93	14	malignant	malignant	ADJ
gs-3214	93	15	plasma	plasma	NOUN
gs-3214	93	16	cells	cell	NOUN
gs-3214	93	17	in	in	ADP
gs-3214	93	18	the	the	DET
gs-3214	93	19	bone	bone	NOUN
gs-3214	93	20	marrow	marrow	NOUN
gs-3214	93	21	.	.	PUNCT
gs-3214	94	1	despite	despite	SCONJ
gs-3214	94	2	recent	recent	ADJ
gs-3214	94	3	advances	advance	NOUN
gs-3214	94	4	in	in	ADP
gs-3214	94	5	treatment	treatment	NOUN
gs-3214	94	6	,	,	PUNCT
gs-3214	94	7	including	include	VERB
gs-3214	94	8	novel	novel	ADJ
gs-3214	94	9	targeted	target	VERB
gs-3214	94	10	therapies	therapy	NOUN
gs-3214	94	11	and	and	CCONJ
gs-3214	94	12	immune	immune	ADJ
gs-3214	94	13	modulatory	modulatory	ADJ
gs-3214	94	14	agents	agent	NOUN
gs-3214	94	15	,	,	PUNCT
gs-3214	94	16	many	many	ADJ
gs-3214	94	17	patients	patient	NOUN
gs-3214	94	18	with	with	ADP
gs-3214	94	19	multiple	multiple	ADJ
gs-3214	94	20	myeloma	myeloma	NOUN
gs-3214	94	21	experience	experience	NOUN
gs-3214	94	22	relapse	relapse	NOUN
gs-3214	94	23	or	or	CCONJ
gs-3214	94	24	refractory	refractory	NOUN
gs-3214	94	25	disease	disease	NOUN
gs-3214	94	26	.	.	PUNCT
gs-3214	95	1	car	car	NOUN
gs-3214	95	2	-	-	PUNCT
gs-3214	95	3	t	t	NOUN
gs-3214	95	4	cell	cell	NOUN
gs-3214	95	5	therapy	therapy	NOUN
gs-3214	95	6	targeting	target	VERB
gs-3214	95	7	b	b	NOUN
gs-3214	95	8	-	-	PUNCT
gs-3214	95	9	cell	cell	NOUN
gs-3214	95	10	maturation	maturation	NOUN
gs-3214	95	11	antigen	antigen	NOUN
gs-3214	95	12	(	(	PUNCT
gs-3214	95	13	bcma	bcma	PROPN
gs-3214	95	14	)	)	PUNCT
gs-3214	95	15	has	have	AUX
gs-3214	95	16	emerged	emerge	VERB
gs-3214	95	17	as	as	ADP
gs-3214	95	18	a	a	DET
gs-3214	95	19	promising	promising	ADJ
gs-3214	95	20	treatment	treatment	NOUN
gs-3214	95	21	modality	modality	NOUN
gs-3214	95	22	for	for	ADP
gs-3214	95	23	these	these	DET
gs-3214	95	24	patients	patient	NOUN
gs-3214	95	25	.	.	PUNCT
gs-3214	96	1	clinical	clinical	ADJ
gs-3214	96	2	trials	trial	NOUN
gs-3214	96	3	investigating	investigate	VERB
gs-3214	96	4	bcma	bcma	NOUN
gs-3214	96	5	-	-	PUNCT
gs-3214	96	6	targeted	target	VERB
gs-3214	96	7	car	car	NOUN
gs-3214	96	8	-	-	PUNCT
gs-3214	96	9	t	t	NOUN
gs-3214	96	10	cell	cell	NOUN
gs-3214	96	11	therapies	therapy	NOUN
gs-3214	96	12	,	,	PUNCT
gs-3214	96	13	such	such	ADJ
gs-3214	96	14	as	as	ADP
gs-3214	96	15	idecabtagene	idecabtagene	NOUN
gs-3214	96	16	vicleucel	vicleucel	NOUN
gs-3214	96	17	(	(	PUNCT
gs-3214	96	18	abecma	abecma	PROPN
gs-3214	96	19	)	)	PUNCT
gs-3214	96	20	and	and	CCONJ
gs-3214	96	21	ciltacabtagene	ciltacabtagene	PROPN
gs-3214	96	22	autoleucel	autoleucel	VERB
gs-3214	96	23	(	(	PUNCT
gs-3214	96	24	cilta	cilta	NOUN
gs-3214	96	25	-	-	PUNCT
gs-3214	96	26	cel	cel	PROPN
gs-3214	96	27	)	)	PUNCT
gs-3214	96	28	,	,	PUNCT
gs-3214	96	29	have	have	AUX
gs-3214	96	30	reported	report	VERB
gs-3214	96	31	high	high	ADJ
gs-3214	96	32	response	response	NOUN
gs-3214	96	33	rates	rate	NOUN
gs-3214	96	34	and	and	CCONJ
gs-3214	96	35	durable	durable	ADJ
gs-3214	96	36	remissions	remission	NOUN
gs-3214	96	37	in	in	ADP
gs-3214	96	38	patients	patient	NOUN
gs-3214	96	39	with	with	ADP
gs-3214	96	40	heavily	heavily	ADV
gs-3214	96	41	pretreated	pretreate	VERB
gs-3214	96	42	disease	disease	NOUN
gs-3214	96	43	.	.	PUNCT
gs-3214	97	1	notably	notably	ADV
gs-3214	97	2	,	,	PUNCT
gs-3214	97	3	long	long	ADJ
gs-3214	97	4	-	-	PUNCT
gs-3214	97	5	term	term	NOUN
gs-3214	97	6	follow	follow	NOUN
gs-3214	97	7	-	-	PUNCT
gs-3214	97	8	up	up	ADP
gs-3214	97	9	data	datum	NOUN
gs-3214	97	10	from	from	ADP
gs-3214	97	11	clinical	clinical	ADJ
gs-3214	97	12	trials	trial	NOUN
gs-3214	97	13	have	have	AUX
gs-3214	97	14	demonstrated	demonstrate	VERB
gs-3214	97	15	sustained	sustained	ADJ
gs-3214	97	16	responses	response	NOUN
gs-3214	97	17	and	and	CCONJ
gs-3214	97	18	durable	durable	ADJ
gs-3214	97	19	disease	disease	NOUN
gs-3214	97	20	control	control	NOUN
gs-3214	97	21	in	in	ADP
gs-3214	97	22	a	a	DET
gs-3214	97	23	subset	subset	NOUN
gs-3214	97	24	of	of	ADP
gs-3214	97	25	patients	patient	NOUN
gs-3214	97	26	,	,	PUNCT
gs-3214	97	27	highlighting	highlight	VERB
gs-3214	97	28	the	the	DET
gs-3214	97	29	potential	potential	NOUN
gs-3214	97	30	for	for	ADP
gs-3214	97	31	car	car	NOUN
gs-3214	97	32	-	-	PUNCT
gs-3214	97	33	t	t	NOUN
gs-3214	97	34	cell	cell	NOUN
gs-3214	97	35	therapy	therapy	NOUN
gs-3214	97	36	to	to	PART
gs-3214	97	37	provide	provide	VERB
gs-3214	97	38	long	long	ADJ
gs-3214	97	39	-	-	PUNCT
gs-3214	97	40	term	term	NOUN
gs-3214	97	41	benefit	benefit	NOUN
gs-3214	97	42	in	in	ADP
gs-3214	97	43	relapsed	relapse	VERB
gs-3214	97	44	or	or	CCONJ
gs-3214	97	45	refractory	refractory	NOUN
gs-3214	97	46	multiple	multiple	ADJ
gs-3214	97	47	myeloma	myeloma	NOUN
gs-3214	97	48	[	[	X
gs-3214	97	49	10	10	NUM
gs-3214	97	50	-	-	SYM
gs-3214	97	51	12	12	NUM
gs-3214	97	52	]	]	PUNCT
gs-3214	97	53	.	.	PUNCT
gs-3214	98	1	despite	despite	SCONJ
gs-3214	98	2	the	the	DET
gs-3214	98	3	success	success	NOUN
gs-3214	98	4	of	of	ADP
gs-3214	98	5	car	car	NOUN
gs-3214	98	6	-	-	PUNCT
gs-3214	98	7	t	t	NOUN
gs-3214	98	8	cell	cell	NOUN
gs-3214	98	9	therapy	therapy	NOUN
gs-3214	98	10	in	in	ADP
gs-3214	98	11	hematologic	hematologic	NOUN
gs-3214	98	12	malignancies	malignancy	NOUN
gs-3214	98	13	,	,	PUNCT
gs-3214	98	14	its	its	PRON
gs-3214	98	15	application	application	NOUN
gs-3214	98	16	in	in	ADP
gs-3214	98	17	solid	solid	ADJ
gs-3214	98	18	tumors	tumor	NOUN
gs-3214	98	19	has	have	AUX
gs-3214	98	20	been	be	AUX
gs-3214	98	21	more	more	ADV
gs-3214	98	22	challenging	challenging	ADJ
gs-3214	98	23	due	due	ADJ
gs-3214	98	24	to	to	ADP
gs-3214	98	25	tumor	tumor	NOUN
gs-3214	98	26	heterogeneity	heterogeneity	NOUN
gs-3214	98	27	,	,	PUNCT
gs-3214	98	28	antigen	antigen	ADJ
gs-3214	98	29	escape	escape	NOUN
gs-3214	98	30	mechanisms	mechanism	NOUN
gs-3214	98	31	,	,	PUNCT
gs-3214	98	32	and	and	CCONJ
gs-3214	98	33	immunosuppressive	immunosuppressive	ADJ
gs-3214	98	34	tumor	tumor	NOUN
gs-3214	98	35	micro	micro	NOUN
gs-3214	98	36	-	-	NOUN
gs-3214	98	37	environments	environment	NOUN
gs-3214	98	38	.	.	PUNCT
gs-3214	99	1	solid	solid	ADJ
gs-3214	99	2	tumors	tumor	NOUN
gs-3214	99	3	present	present	VERB
gs-3214	99	4	unique	unique	ADJ
gs-3214	99	5	challenges	challenge	NOUN
gs-3214	99	6	for	for	ADP
gs-3214	99	7	car	car	NOUN
gs-3214	99	8	-	-	PUNCT
gs-3214	99	9	t	t	NOUN
gs-3214	99	10	cell	cell	NOUN
gs-3214	99	11	therapy	therapy	NOUN
gs-3214	99	12	,	,	PUNCT
gs-3214	99	13	including	include	VERB
gs-3214	99	14	the	the	DET
gs-3214	99	15	lack	lack	NOUN
gs-3214	99	16	of	of	ADP
gs-3214	99	17	ideal	ideal	ADJ
gs-3214	99	18	tumor	tumor	NOUN
gs-3214	99	19	-	-	PUNCT
gs-3214	99	20	specific	specific	ADJ
gs-3214	99	21	antigens	antigen	NOUN
gs-3214	99	22	,	,	PUNCT
gs-3214	99	23	limited	limited	ADJ
gs-3214	99	24	t	t	PROPN
gs-3214	99	25	cell	cell	NOUN
gs-3214	99	26	infiltration	infiltration	NOUN
gs-3214	99	27	into	into	ADP
gs-3214	99	28	solid	solid	ADJ
gs-3214	99	29	tumors	tumor	NOUN
gs-3214	99	30	,	,	PUNCT
gs-3214	99	31	and	and	CCONJ
gs-3214	99	32	immunosuppressive	immunosuppressive	ADJ
gs-3214	99	33	factors	factor	NOUN
gs-3214	99	34	within	within	ADP
gs-3214	99	35	the	the	DET
gs-3214	99	36	tumor	tumor	NOUN
gs-3214	99	37	microenvironment	microenvironment	NOUN
gs-3214	99	38	.	.	PUNCT
gs-3214	100	1	however	however	ADV
gs-3214	100	2	,	,	PUNCT
gs-3214	100	3	ongoing	ongoing	ADJ
gs-3214	100	4	research	research	NOUN
gs-3214	100	5	efforts	effort	NOUN
gs-3214	100	6	are	be	AUX
gs-3214	100	7	focused	focus	VERB
gs-3214	100	8	on	on	ADP
gs-3214	100	9	addressing	address	VERB
gs-3214	100	10	these	these	DET
gs-3214	100	11	challenges	challenge	NOUN
gs-3214	100	12	through	through	ADP
gs-3214	100	13	innovative	innovative	ADJ
gs-3214	100	14	car	car	NOUN
gs-3214	100	15	designs	design	NOUN
gs-3214	100	16	,	,	PUNCT
gs-3214	100	17	combination	combination	NOUN
gs-3214	100	18	therapies	therapy	NOUN
gs-3214	100	19	,	,	PUNCT
gs-3214	100	20	and	and	CCONJ
gs-3214	100	21	strategies	strategy	NOUN
gs-3214	100	22	to	to	PART
gs-3214	100	23	enhance	enhance	VERB
gs-3214	100	24	t	t	NOUN
gs-3214	100	25	cell	cell	NOUN
gs-3214	100	26	trafficking	trafficking	NOUN
gs-3214	100	27	and	and	CCONJ
gs-3214	100	28	persistence	persistence	NOUN
gs-3214	100	29	within	within	ADP
gs-3214	100	30	solid	solid	ADJ
gs-3214	100	31	tumors	tumor	NOUN
gs-3214	101	1	[	[	X
gs-3214	101	2	13	13	NUM
gs-3214	101	3	-	-	SYM
gs-3214	101	4	14	14	NUM
gs-3214	101	5	]	]	PUNCT
gs-3214	101	6	.	.	PUNCT
gs-3214	102	1	georgian	georgian	NOUN
gs-3214	102	2	scientists/	scientists/	NUM
gs-3214	102	3	.	.	PUNCT
gs-3214	103	1	6	6	NUM
gs-3214	103	2	n	n	NUM
gs-3214	103	3	3	3	NUM
gs-3214	103	4	,	,	PUNCT
gs-3214	103	5	2024	2024	NUM
gs-3214	103	6	268	268	NUM
gs-3214	103	7	numerous	numerous	ADJ
gs-3214	103	8	clinical	clinical	ADJ
gs-3214	103	9	trials	trial	NOUN
gs-3214	103	10	are	be	AUX
gs-3214	103	11	underway	underway	ADJ
gs-3214	103	12	to	to	PART
gs-3214	103	13	evaluate	evaluate	VERB
gs-3214	103	14	the	the	DET
gs-3214	103	15	safety	safety	NOUN
gs-3214	103	16	and	and	CCONJ
gs-3214	103	17	efficacy	efficacy	NOUN
gs-3214	103	18	of	of	ADP
gs-3214	103	19	car	car	NOUN
gs-3214	103	20	-	-	PUNCT
gs-3214	103	21	t	t	NOUN
gs-3214	103	22	cell	cell	NOUN
gs-3214	103	23	therapy	therapy	NOUN
gs-3214	103	24	in	in	ADP
gs-3214	103	25	various	various	ADJ
gs-3214	103	26	solid	solid	ADJ
gs-3214	103	27	tumor	tumor	NOUN
gs-3214	103	28	types	type	NOUN
gs-3214	103	29	,	,	PUNCT
gs-3214	103	30	including	include	VERB
gs-3214	103	31	glioblastoma	glioblastoma	NOUN
gs-3214	103	32	,	,	PUNCT
gs-3214	103	33	pancreatic	pancreatic	ADJ
gs-3214	103	34	cancer	cancer	NOUN
gs-3214	103	35	,	,	PUNCT
gs-3214	103	36	and	and	CCONJ
gs-3214	103	37	ovarian	ovarian	ADJ
gs-3214	103	38	cancer	cancer	NOUN
gs-3214	103	39	.	.	PUNCT
gs-3214	104	1	these	these	DET
gs-3214	104	2	trials	trial	NOUN
gs-3214	104	3	employ	employ	VERB
gs-3214	104	4	novel	novel	ADJ
gs-3214	104	5	car	car	NOUN
gs-3214	104	6	constructs	construct	NOUN
gs-3214	104	7	targeting	target	VERB
gs-3214	104	8	tumor	tumor	NOUN
gs-3214	104	9	-	-	PUNCT
gs-3214	104	10	specific	specific	ADJ
gs-3214	104	11	antigens	antigen	NOUN
gs-3214	104	12	,	,	PUNCT
gs-3214	104	13	such	such	ADJ
gs-3214	104	14	as	as	ADP
gs-3214	104	15	egfrviii	egfrviii	NOUN
gs-3214	104	16	,	,	PUNCT
gs-3214	104	17	mesothelin	mesothelin	NOUN
gs-3214	104	18	,	,	PUNCT
gs-3214	104	19	and	and	CCONJ
gs-3214	104	20	muc16	muc16	NOUN
gs-3214	104	21	,	,	PUNCT
gs-3214	104	22	with	with	ADP
gs-3214	104	23	the	the	DET
gs-3214	104	24	aim	aim	NOUN
gs-3214	104	25	of	of	ADP
gs-3214	104	26	improving	improve	VERB
gs-3214	104	27	tumor	tumor	NOUN
gs-3214	104	28	recognition	recognition	NOUN
gs-3214	104	29	and	and	CCONJ
gs-3214	104	30	enhancing	enhance	VERB
gs-3214	104	31	anti	anti	ADJ
gs-3214	104	32	-	-	ADJ
gs-3214	104	33	tumor	tumor	ADJ
gs-3214	104	34	immune	immune	ADJ
gs-3214	104	35	responses	response	NOUN
gs-3214	104	36	.	.	PUNCT
gs-3214	105	1	early	early	ADJ
gs-3214	105	2	-	-	PUNCT
gs-3214	105	3	phase	phase	NOUN
gs-3214	105	4	clinical	clinical	ADJ
gs-3214	105	5	data	datum	NOUN
gs-3214	105	6	from	from	ADP
gs-3214	105	7	these	these	DET
gs-3214	105	8	trials	trial	NOUN
gs-3214	105	9	are	be	AUX
gs-3214	105	10	awaited	await	VERB
gs-3214	105	11	to	to	PART
gs-3214	105	12	determine	determine	VERB
gs-3214	105	13	the	the	DET
gs-3214	105	14	feasibility	feasibility	NOUN
gs-3214	105	15	and	and	CCONJ
gs-3214	105	16	clinical	clinical	ADJ
gs-3214	105	17	benefit	benefit	NOUN
gs-3214	105	18	of	of	ADP
gs-3214	105	19	car	car	NOUN
gs-3214	105	20	-	-	PUNCT
gs-3214	105	21	t	t	NOUN
gs-3214	105	22	cell	cell	NOUN
gs-3214	105	23	therapy	therapy	NOUN
gs-3214	105	24	in	in	ADP
gs-3214	105	25	solid	solid	ADJ
gs-3214	105	26	tumors	tumor	NOUN
gs-3214	105	27	.	.	PUNCT
gs-3214	106	1	real	real	ADJ
gs-3214	106	2	-	-	PUNCT
gs-3214	106	3	world	world	NOUN
gs-3214	106	4	data	datum	NOUN
gs-3214	106	5	and	and	CCONJ
gs-3214	106	6	long	long	ADJ
gs-3214	106	7	-	-	PUNCT
gs-3214	106	8	term	term	NOUN
gs-3214	106	9	follow	follow	NOUN
gs-3214	106	10	-	-	PUNCT
gs-3214	106	11	up	up	ADP
gs-3214	106	12	studies	study	NOUN
gs-3214	106	13	will	will	AUX
gs-3214	106	14	be	be	AUX
gs-3214	106	15	essential	essential	ADJ
gs-3214	106	16	to	to	PART
gs-3214	106	17	assess	assess	VERB
gs-3214	106	18	the	the	DET
gs-3214	106	19	durability	durability	NOUN
gs-3214	106	20	of	of	ADP
gs-3214	106	21	responses	response	NOUN
gs-3214	106	22	and	and	CCONJ
gs-3214	106	23	long	long	ADJ
gs-3214	106	24	-	-	PUNCT
gs-3214	106	25	term	term	NOUN
gs-3214	106	26	outcomes	outcome	NOUN
gs-3214	106	27	in	in	ADP
gs-3214	106	28	patients	patient	NOUN
gs-3214	106	29	with	with	ADP
gs-3214	106	30	solid	solid	ADJ
gs-3214	106	31	tumors	tumor	NOUN
gs-3214	106	32	treated	treat	VERB
gs-3214	106	33	with	with	ADP
gs-3214	106	34	car	car	NOUN
gs-3214	106	35	-	-	PUNCT
gs-3214	106	36	t	t	NOUN
gs-3214	106	37	cell	cell	NOUN
gs-3214	106	38	therapy	therapy	NOUN
gs-3214	106	39	[	[	X
gs-3214	106	40	15	15	NUM
gs-3214	106	41	-	-	SYM
gs-3214	106	42	16	16	NUM
gs-3214	106	43	]	]	PUNCT
gs-3214	106	44	.	.	PUNCT
gs-3214	107	1	mechanism	mechanism	NOUN
gs-3214	107	2	of	of	ADP
gs-3214	107	3	car	car	NOUN
gs-3214	107	4	-	-	PUNCT
gs-3214	107	5	t	t	NOUN
gs-3214	107	6	cell	cell	NOUN
gs-3214	107	7	therapy	therapy	NOUN
gs-3214	107	8	:	:	PUNCT
gs-3214	107	9	car	car	NOUN
gs-3214	107	10	-	-	PUNCT
gs-3214	107	11	t	t	NOUN
gs-3214	107	12	cells	cell	NOUN
gs-3214	107	13	are	be	AUX
gs-3214	107	14	t	t	NOUN
gs-3214	107	15	lymphocytes	lymphocyte	NOUN
gs-3214	107	16	genetically	genetically	ADV
gs-3214	107	17	modified	modify	VERB
gs-3214	107	18	to	to	PART
gs-3214	107	19	express	express	VERB
gs-3214	107	20	chimeric	chimeric	ADJ
gs-3214	107	21	antigen	antigen	ADJ
gs-3214	107	22	receptors	receptor	NOUN
gs-3214	107	23	(	(	PUNCT
gs-3214	107	24	cars	car	NOUN
gs-3214	107	25	)	)	PUNCT
gs-3214	107	26	.	.	PUNCT
gs-3214	108	1	cars	car	NOUN
gs-3214	108	2	combine	combine	VERB
gs-3214	108	3	an	an	DET
gs-3214	108	4	antigen	antigen	ADV
gs-3214	108	5	-	-	PUNCT
gs-3214	108	6	binding	bind	VERB
gs-3214	108	7	domain	domain	NOUN
gs-3214	108	8	(	(	PUNCT
gs-3214	108	9	usually	usually	ADV
gs-3214	108	10	derived	derive	VERB
gs-3214	108	11	from	from	ADP
gs-3214	108	12	a	a	DET
gs-3214	108	13	monoclonal	monoclonal	NOUN
gs-3214	108	14	antibody	antibody	NOUN
gs-3214	108	15	)	)	PUNCT
gs-3214	108	16	with	with	ADP
gs-3214	108	17	intracellular	intracellular	ADJ
gs-3214	108	18	signaling	signal	VERB
gs-3214	108	19	domains	domain	NOUN
gs-3214	108	20	that	that	PRON
gs-3214	108	21	activate	activate	VERB
gs-3214	108	22	the	the	DET
gs-3214	108	23	t	t	NOUN
gs-3214	108	24	cell	cell	NOUN
gs-3214	108	25	upon	upon	SCONJ
gs-3214	108	26	antigen	antigen	ADJ
gs-3214	108	27	recognition	recognition	NOUN
gs-3214	108	28	.	.	PUNCT
gs-3214	109	1	this	this	DET
gs-3214	109	2	mechanism	mechanism	NOUN
gs-3214	109	3	bypasses	bypass	VERB
gs-3214	109	4	the	the	DET
gs-3214	109	5	traditional	traditional	ADJ
gs-3214	109	6	major	major	ADJ
gs-3214	109	7	histocompatibility	histocompatibility	NOUN
gs-3214	109	8	complex	complex	NOUN
gs-3214	109	9	(	(	PUNCT
gs-3214	109	10	mhc)dependent	mhc)dependent	NOUN
gs-3214	109	11	antigen	antigen	NOUN
gs-3214	109	12	presentation	presentation	NOUN
gs-3214	109	13	,	,	PUNCT
gs-3214	109	14	allowing	allow	VERB
gs-3214	109	15	car	car	NOUN
gs-3214	109	16	-	-	PUNCT
gs-3214	109	17	t	t	NOUN
gs-3214	109	18	cells	cell	NOUN
gs-3214	109	19	to	to	PART
gs-3214	109	20	target	target	VERB
gs-3214	109	21	tumors	tumor	NOUN
gs-3214	109	22	with	with	ADP
gs-3214	109	23	higher	high	ADJ
gs-3214	109	24	specificity	specificity	NOUN
gs-3214	109	25	:	:	PUNCT
gs-3214	109	26	1	1	X
gs-3214	109	27	.	.	X
gs-3214	109	28	design	design	NOUN
gs-3214	109	29	of	of	ADP
gs-3214	109	30	cars	car	NOUN
gs-3214	109	31	:	:	PUNCT
gs-3214	109	32	antigen	antigen	ADJ
gs-3214	109	33	-	-	PUNCT
gs-3214	109	34	binding	bind	VERB
gs-3214	109	35	domain	domain	NOUN
gs-3214	109	36	:	:	PUNCT
gs-3214	109	37	single	single	ADJ
gs-3214	109	38	-	-	PUNCT
gs-3214	109	39	chain	chain	NOUN
gs-3214	109	40	variable	variable	ADJ
gs-3214	109	41	fragments	fragment	NOUN
gs-3214	109	42	(	(	PUNCT
gs-3214	109	43	scfvs	scfvs	NOUN
gs-3214	109	44	)	)	PUNCT
gs-3214	109	45	derived	derive	VERB
gs-3214	109	46	from	from	ADP
gs-3214	109	47	antibodies	antibody	NOUN
gs-3214	109	48	.	.	PUNCT
gs-3214	110	1	spacer	spacer	NOUN
gs-3214	110	2	domain	domain	NOUN
gs-3214	110	3	:	:	PUNCT
gs-3214	110	4	ensures	ensure	VERB
gs-3214	110	5	optimal	optimal	ADJ
gs-3214	110	6	antigen	antigen	ADJ
gs-3214	110	7	binding	bind	VERB
gs-3214	110	8	.	.	PUNCT
gs-3214	111	1	transmembrane	transmembrane	NOUN
gs-3214	111	2	and	and	CCONJ
gs-3214	111	3	signaling	signal	VERB
gs-3214	111	4	domains	domain	NOUN
gs-3214	111	5	:	:	PUNCT
gs-3214	111	6	critical	critical	ADJ
gs-3214	111	7	for	for	ADP
gs-3214	111	8	t	t	NOUN
gs-3214	111	9	-	-	PUNCT
gs-3214	111	10	cell	cell	NOUN
gs-3214	111	11	activation	activation	NOUN
gs-3214	111	12	and	and	CCONJ
gs-3214	111	13	function	function	NOUN
gs-3214	111	14	.	.	PUNCT
gs-3214	112	1	2	2	X
gs-3214	112	2	.	.	X
gs-3214	112	3	target	target	NOUN
gs-3214	112	4	antigens	antigen	NOUN
gs-3214	112	5	:	:	PUNCT
gs-3214	112	6	hematologic	hematologic	NOUN
gs-3214	112	7	malignancies	malignancy	NOUN
gs-3214	112	8	(	(	PUNCT
gs-3214	112	9	e.g.	e.g.	ADV
gs-3214	112	10	,	,	PUNCT
gs-3214	112	11	cd19	cd19	PROPN
gs-3214	112	12	for	for	ADP
gs-3214	112	13	b	b	NOUN
gs-3214	112	14	-	-	PUNCT
gs-3214	112	15	cell	cell	NOUN
gs-3214	112	16	malignancies	malignancy	NOUN
gs-3214	112	17	)	)	PUNCT
gs-3214	112	18	emerging	emerge	VERB
gs-3214	112	19	targets	target	NOUN
gs-3214	112	20	for	for	ADP
gs-3214	112	21	solid	solid	ADJ
gs-3214	112	22	tumors	tumor	NOUN
gs-3214	112	23	,	,	PUNCT
gs-3214	112	24	such	such	ADJ
gs-3214	112	25	as	as	ADP
gs-3214	112	26	her2	her2	PROPN
gs-3214	112	27	and	and	CCONJ
gs-3214	112	28	mesothelin	mesothelin	NOUN
gs-3214	112	29	.	.	PUNCT
gs-3214	113	1	case	case	NOUN
gs-3214	113	2	studies	study	NOUN
gs-3214	113	3	and	and	CCONJ
gs-3214	113	4	real	real	ADJ
gs-3214	113	5	-	-	PUNCT
gs-3214	113	6	world	world	NOUN
gs-3214	113	7	clinical	clinical	ADJ
gs-3214	113	8	experiences	experience	NOUN
gs-3214	113	9	provide	provide	VERB
gs-3214	113	10	valuable	valuable	ADJ
gs-3214	113	11	insights	insight	NOUN
gs-3214	113	12	into	into	ADP
gs-3214	113	13	the	the	DET
gs-3214	113	14	practical	practical	ADJ
gs-3214	113	15	application	application	NOUN
gs-3214	113	16	and	and	CCONJ
gs-3214	113	17	outcomes	outcome	NOUN
gs-3214	113	18	of	of	ADP
gs-3214	113	19	car	car	NOUN
gs-3214	113	20	-	-	PUNCT
gs-3214	113	21	t	t	NOUN
gs-3214	113	22	cell	cell	NOUN
gs-3214	113	23	therapy	therapy	NOUN
gs-3214	113	24	in	in	ADP
gs-3214	113	25	patients	patient	NOUN
gs-3214	113	26	with	with	ADP
gs-3214	113	27	hematologic	hematologic	NOUN
gs-3214	113	28	malignancies	malignancy	NOUN
gs-3214	113	29	and	and	CCONJ
gs-3214	113	30	solid	solid	ADJ
gs-3214	113	31	tumors	tumor	NOUN
gs-3214	113	32	.	.	PUNCT
gs-3214	114	1	these	these	DET
gs-3214	114	2	case	case	NOUN
gs-3214	114	3	reports	report	VERB
gs-3214	114	4	highlight	highlight	VERB
gs-3214	114	5	the	the	DET
gs-3214	114	6	heterogeneity	heterogeneity	NOUN
gs-3214	114	7	of	of	ADP
gs-3214	114	8	patient	patient	ADJ
gs-3214	114	9	responses	response	NOUN
gs-3214	114	10	,	,	PUNCT
gs-3214	114	11	ranging	range	VERB
gs-3214	114	12	from	from	ADP
gs-3214	114	13	complete	complete	ADJ
gs-3214	114	14	remissions	remission	NOUN
gs-3214	114	15	to	to	ADP
gs-3214	114	16	disease	disease	NOUN
gs-3214	114	17	progression	progression	NOUN
gs-3214	114	18	,	,	PUNCT
gs-3214	114	19	and	and	CCONJ
gs-3214	114	20	underscore	underscore	VERB
gs-3214	114	21	the	the	DET
gs-3214	114	22	importance	importance	NOUN
gs-3214	114	23	of	of	ADP
gs-3214	114	24	patient	patient	ADJ
gs-3214	114	25	selection	selection	NOUN
gs-3214	114	26	,	,	PUNCT
gs-3214	114	27	treatment	treatment	NOUN
gs-3214	114	28	optimization	optimization	NOUN
gs-3214	114	29	,	,	PUNCT
gs-3214	114	30	and	and	CCONJ
gs-3214	114	31	management	management	NOUN
gs-3214	114	32	of	of	ADP
gs-3214	114	33	adverse	adverse	ADJ
gs-3214	114	34	events	event	NOUN
gs-3214	114	35	in	in	ADP
gs-3214	114	36	maximizing	maximize	VERB
gs-3214	114	37	therapeutic	therapeutic	ADJ
gs-3214	114	38	outcomes	outcome	NOUN
gs-3214	114	39	.	.	PUNCT
gs-3214	115	1	long	long	ADJ
gs-3214	115	2	-	-	PUNCT
gs-3214	115	3	term	term	NOUN
gs-3214	115	4	follow	follow	NOUN
gs-3214	115	5	-	-	PUNCT
gs-3214	115	6	up	up	ADP
gs-3214	115	7	data	datum	NOUN
gs-3214	115	8	from	from	ADP
gs-3214	115	9	clinical	clinical	ADJ
gs-3214	115	10	trials	trial	NOUN
gs-3214	115	11	and	and	CCONJ
gs-3214	115	12	real	real	ADJ
gs-3214	115	13	-	-	PUNCT
gs-3214	115	14	world	world	NOUN
gs-3214	115	15	studies	study	NOUN
gs-3214	115	16	will	will	AUX
gs-3214	115	17	be	be	AUX
gs-3214	115	18	crucial	crucial	ADJ
gs-3214	115	19	to	to	PART
gs-3214	115	20	assess	assess	VERB
gs-3214	115	21	the	the	DET
gs-3214	115	22	durability	durability	NOUN
gs-3214	115	23	of	of	ADP
gs-3214	115	24	responses	response	NOUN
gs-3214	115	25	and	and	CCONJ
gs-3214	115	26	long	long	ADJ
gs-3214	115	27	-	-	PUNCT
gs-3214	115	28	term	term	NOUN
gs-3214	115	29	outcomes	outcome	NOUN
gs-3214	115	30	in	in	ADP
gs-3214	115	31	patients	patient	NOUN
gs-3214	115	32	treated	treat	VERB
gs-3214	115	33	with	with	ADP
gs-3214	115	34	car	car	NOUN
gs-3214	115	35	-	-	PUNCT
gs-3214	115	36	t	t	NOUN
gs-3214	115	37	cell	cell	NOUN
gs-3214	115	38	therapy	therapy	NOUN
gs-3214	115	39	[	[	X
gs-3214	115	40	17	17	NUM
gs-3214	115	41	-	-	SYM
gs-3214	115	42	18	18	NUM
gs-3214	115	43	]	]	PUNCT
gs-3214	115	44	.	.	PUNCT
gs-3214	116	1	in	in	ADP
gs-3214	116	2	conclusion	conclusion	NOUN
gs-3214	116	3	,	,	PUNCT
gs-3214	116	4	car	car	NOUN
gs-3214	116	5	-	-	PUNCT
gs-3214	116	6	t	t	NOUN
gs-3214	116	7	cell	cell	NOUN
gs-3214	116	8	therapy	therapy	NOUN
gs-3214	116	9	has	have	AUX
gs-3214	116	10	transformed	transform	VERB
gs-3214	116	11	the	the	DET
gs-3214	116	12	treatment	treatment	NOUN
gs-3214	116	13	landscape	landscape	NOUN
gs-3214	116	14	for	for	ADP
gs-3214	116	15	patients	patient	NOUN
gs-3214	116	16	with	with	ADP
gs-3214	116	17	relapsed	relapse	VERB
gs-3214	116	18	or	or	CCONJ
gs-3214	116	19	refractory	refractory	NOUN
gs-3214	116	20	hematologic	hematologic	NOUN
gs-3214	116	21	malignancies	malignancy	NOUN
gs-3214	116	22	,	,	PUNCT
gs-3214	116	23	offering	offer	VERB
gs-3214	116	24	the	the	DET
gs-3214	116	25	potential	potential	NOUN
gs-3214	116	26	for	for	ADP
gs-3214	116	27	durable	durable	ADJ
gs-3214	116	28	and	and	CCONJ
gs-3214	116	29	often	often	ADV
gs-3214	116	30	curative	curative	ADJ
gs-3214	116	31	responses	response	NOUN
gs-3214	116	32	.	.	PUNCT
gs-3214	117	1	while	while	SCONJ
gs-3214	117	2	challenges	challenge	NOUN
gs-3214	117	3	remain	remain	VERB
gs-3214	117	4	in	in	ADP
gs-3214	117	5	extending	extend	VERB
gs-3214	117	6	the	the	DET
gs-3214	117	7	benefits	benefit	NOUN
gs-3214	117	8	of	of	ADP
gs-3214	117	9	car	car	NOUN
gs-3214	117	10	-	-	PUNCT
gs-3214	117	11	t	t	NOUN
gs-3214	117	12	cell	cell	NOUN
gs-3214	117	13	therapy	therapy	NOUN
gs-3214	117	14	to	to	ADP
gs-3214	117	15	solid	solid	ADJ
gs-3214	117	16	tumors	tumor	NOUN
gs-3214	117	17	,	,	PUNCT
gs-3214	117	18	ongoing	ongoing	ADJ
gs-3214	117	19	research	research	NOUN
gs-3214	117	20	efforts	effort	NOUN
gs-3214	117	21	hold	hold	VERB
gs-3214	117	22	promise	promise	NOUN
gs-3214	117	23	for	for	ADP
gs-3214	117	24	expanding	expand	VERB
gs-3214	117	25	its	its	PRON
gs-3214	117	26	clinical	clinical	ADJ
gs-3214	117	27	applications	application	NOUN
gs-3214	117	28	and	and	CCONJ
gs-3214	117	29	improving	improve	VERB
gs-3214	117	30	outcomes	outcome	NOUN
gs-3214	117	31	for	for	ADP
gs-3214	117	32	patients	patient	NOUN
gs-3214	117	33	with	with	ADP
gs-3214	117	34	diverse	diverse	ADJ
gs-3214	117	35	cancer	cancer	NOUN
gs-3214	117	36	types	type	NOUN
gs-3214	117	37	.	.	PUNCT
gs-3214	118	1	continued	continue	VERB
gs-3214	118	2	investment	investment	NOUN
gs-3214	118	3	in	in	ADP
gs-3214	118	4	translational	translational	ADJ
gs-3214	118	5	research	research	NOUN
gs-3214	118	6	,	,	PUNCT
gs-3214	118	7	clinical	clinical	ADJ
gs-3214	118	8	trials	trial	NOUN
gs-3214	118	9	,	,	PUNCT
gs-3214	118	10	and	and	CCONJ
gs-3214	118	11	collaborative	collaborative	ADJ
gs-3214	118	12	initiatives	initiative	NOUN
gs-3214	118	13	is	be	AUX
gs-3214	118	14	essential	essential	ADJ
gs-3214	118	15	to	to	PART
gs-3214	118	16	realize	realize	VERB
gs-3214	118	17	the	the	DET
gs-3214	118	18	full	full	ADJ
gs-3214	118	19	potential	potential	NOUN
gs-3214	118	20	of	of	ADP
gs-3214	118	21	car	car	NOUN
gs-3214	118	22	-	-	PUNCT
gs-3214	118	23	t	t	NOUN
gs-3214	118	24	cell	cell	NOUN
gs-3214	118	25	therapy	therapy	NOUN
gs-3214	118	26	in	in	ADP
gs-3214	118	27	oncology	oncology	NOUN
gs-3214	118	28	.	.	PUNCT
gs-3214	119	1	the	the	DET
gs-3214	119	2	inception	inception	NOUN
gs-3214	119	3	of	of	ADP
gs-3214	119	4	chimeric	chimeric	ADJ
gs-3214	119	5	antigen	antigen	ADJ
gs-3214	119	6	receptor	receptor	NOUN
gs-3214	119	7	(	(	PUNCT
gs-3214	119	8	car	car	NOUN
gs-3214	119	9	)	)	PUNCT
gs-3214	119	10	t	t	NOUN
gs-3214	119	11	cell	cell	NOUN
gs-3214	119	12	therapy	therapy	NOUN
gs-3214	119	13	has	have	VERB
gs-3214	119	14	its	its	PRON
gs-3214	119	15	roots	root	NOUN
gs-3214	119	16	deeply	deeply	ADV
gs-3214	119	17	embedded	embed	VERB
gs-3214	119	18	in	in	ADP
gs-3214	119	19	the	the	DET
gs-3214	119	20	pioneering	pioneering	ADJ
gs-3214	119	21	strides	stride	NOUN
gs-3214	119	22	made	make	VERB
gs-3214	119	23	within	within	ADP
gs-3214	119	24	the	the	DET
gs-3214	119	25	realms	realm	NOUN
gs-3214	119	26	of	of	ADP
gs-3214	119	27	immunology	immunology	NOUN
gs-3214	119	28	and	and	CCONJ
gs-3214	119	29	genetic	genetic	ADJ
gs-3214	119	30	engineering	engineering	NOUN
gs-3214	119	31	,	,	PUNCT
gs-3214	119	32	heralding	herald	VERB
gs-3214	119	33	a	a	DET
gs-3214	119	34	transformative	transformative	ADJ
gs-3214	119	35	era	era	NOUN
gs-3214	119	36	in	in	ADP
gs-3214	119	37	the	the	DET
gs-3214	119	38	landscape	landscape	NOUN
gs-3214	119	39	of	of	ADP
gs-3214	119	40	cancer	cancer	NOUN
gs-3214	119	41	therapeutics	therapeutic	NOUN
gs-3214	119	42	.	.	PUNCT
gs-3214	120	1	while	while	SCONJ
gs-3214	120	2	conventional	conventional	ADJ
gs-3214	120	3	treatment	treatment	NOUN
gs-3214	120	4	modalities	modality	NOUN
gs-3214	120	5	such	such	ADJ
gs-3214	120	6	as	as	ADP
gs-3214	120	7	chemotherapy	chemotherapy	NOUN
gs-3214	120	8	and	and	CCONJ
gs-3214	120	9	radiation	radiation	NOUN
gs-3214	120	10	have	have	AUX
gs-3214	120	11	long	long	ADV
gs-3214	120	12	served	serve	VERB
gs-3214	120	13	as	as	ADP
gs-3214	120	14	the	the	DET
gs-3214	120	15	linchpins	linchpin	NOUN
gs-3214	120	16	of	of	ADP
gs-3214	120	17	oncological	oncological	ADJ
gs-3214	120	18	care	care	NOUN
gs-3214	120	19	,	,	PUNCT
gs-3214	120	20	their	their	PRON
gs-3214	120	21	efficacy	efficacy	NOUN
gs-3214	120	22	is	be	AUX
gs-3214	120	23	often	often	ADV
gs-3214	120	24	constrained	constrain	VERB
gs-3214	120	25	by	by	ADP
gs-3214	120	26	formidable	formidable	ADJ
gs-3214	120	27	limitations	limitation	NOUN
gs-3214	120	28	,	,	PUNCT
gs-3214	120	29	compounded	compound	VERB
gs-3214	120	30	by	by	ADP
gs-3214	120	31	the	the	DET
gs-3214	120	32	burdensome	burdensome	ADJ
gs-3214	120	33	toll	toll	NOUN
gs-3214	120	34	of	of	ADP
gs-3214	120	35	adverse	adverse	ADJ
gs-3214	120	36	effects	effect	NOUN
gs-3214	120	37	,	,	PUNCT
gs-3214	120	38	georgian	georgian	NOUN
gs-3214	120	39	scientists/	scientists/	NUM
gs-3214	120	40	.	.	PUNCT
gs-3214	121	1	6	6	NUM
gs-3214	121	2	n	n	NUM
gs-3214	121	3	3	3	NUM
gs-3214	121	4	,	,	PUNCT
gs-3214	121	5	2024	2024	NUM
gs-3214	121	6	269	269	NUM
gs-3214	121	7	particularly	particularly	ADV
gs-3214	121	8	evident	evident	ADJ
gs-3214	121	9	in	in	ADP
gs-3214	121	10	cases	case	NOUN
gs-3214	121	11	of	of	ADP
gs-3214	121	12	advanced	advanced	ADJ
gs-3214	121	13	or	or	CCONJ
gs-3214	121	14	recalcitrant	recalcitrant	ADJ
gs-3214	121	15	disease	disease	NOUN
gs-3214	121	16	.	.	PUNCT
gs-3214	122	1	the	the	DET
gs-3214	122	2	quest	quest	NOUN
gs-3214	122	3	for	for	ADP
gs-3214	122	4	more	more	ADV
gs-3214	122	5	efficacious	efficacious	ADJ
gs-3214	122	6	and	and	CCONJ
gs-3214	122	7	less	less	ADV
gs-3214	122	8	deleterious	deleterious	ADJ
gs-3214	122	9	therapeutic	therapeutic	ADJ
gs-3214	122	10	alternatives	alternative	NOUN
gs-3214	122	11	has	have	AUX
gs-3214	122	12	thus	thus	ADV
gs-3214	122	13	catalyzed	catalyze	VERB
gs-3214	122	14	a	a	DET
gs-3214	122	15	profound	profound	ADJ
gs-3214	122	16	exploration	exploration	NOUN
gs-3214	122	17	into	into	ADP
gs-3214	122	18	the	the	DET
gs-3214	122	19	promising	promising	ADJ
gs-3214	122	20	domain	domain	NOUN
gs-3214	122	21	of	of	ADP
gs-3214	122	22	immunotherapy	immunotherapy	NOUN
gs-3214	122	23	,	,	PUNCT
gs-3214	122	24	which	which	PRON
gs-3214	122	25	leverages	leverage	VERB
gs-3214	122	26	the	the	DET
gs-3214	122	27	innate	innate	ADJ
gs-3214	122	28	potential	potential	NOUN
gs-3214	122	29	of	of	ADP
gs-3214	122	30	the	the	DET
gs-3214	122	31	body	body	NOUN
gs-3214	122	32	's	's	PART
gs-3214	122	33	immune	immune	ADJ
gs-3214	122	34	system	system	NOUN
gs-3214	122	35	to	to	PART
gs-3214	122	36	selectively	selectively	ADV
gs-3214	122	37	target	target	VERB
gs-3214	122	38	and	and	CCONJ
gs-3214	122	39	eliminate	eliminate	VERB
gs-3214	122	40	malignant	malignant	ADJ
gs-3214	122	41	cells	cell	NOUN
gs-3214	122	42	[	[	X
gs-3214	122	43	19	19	NUM
gs-3214	122	44	-	-	SYM
gs-3214	122	45	20	20	NUM
gs-3214	122	46	]	]	PUNCT
gs-3214	122	47	.	.	PUNCT
gs-3214	123	1	car	car	NOUN
gs-3214	123	2	-	-	PUNCT
gs-3214	123	3	t	t	NOUN
gs-3214	123	4	cell	cell	NOUN
gs-3214	123	5	therapy	therapy	NOUN
gs-3214	123	6	,	,	PUNCT
gs-3214	123	7	emerging	emerge	VERB
gs-3214	123	8	from	from	ADP
gs-3214	123	9	the	the	DET
gs-3214	123	10	intricate	intricate	ADJ
gs-3214	123	11	domains	domain	NOUN
gs-3214	123	12	of	of	ADP
gs-3214	123	13	t	t	PROPN
gs-3214	123	14	cell	cell	NOUN
gs-3214	123	15	biology	biology	NOUN
gs-3214	123	16	and	and	CCONJ
gs-3214	123	17	cancer	cancer	NOUN
gs-3214	123	18	immunology	immunology	NOUN
gs-3214	123	19	,	,	PUNCT
gs-3214	123	20	stands	stand	VERB
gs-3214	123	21	as	as	ADP
gs-3214	123	22	a	a	DET
gs-3214	123	23	testament	testament	NOUN
gs-3214	123	24	to	to	ADP
gs-3214	123	25	the	the	DET
gs-3214	123	26	transformative	transformative	ADJ
gs-3214	123	27	potential	potential	ADJ
gs-3214	123	28	inherent	inherent	ADJ
gs-3214	123	29	in	in	ADP
gs-3214	123	30	this	this	DET
gs-3214	123	31	innovative	innovative	ADJ
gs-3214	123	32	therapeutic	therapeutic	ADJ
gs-3214	123	33	paradigm	paradigm	NOUN
gs-3214	123	34	.	.	PUNCT
gs-3214	124	1	t	t	NOUN
gs-3214	124	2	cells	cell	NOUN
gs-3214	124	3	,	,	PUNCT
gs-3214	124	4	the	the	DET
gs-3214	124	5	quintessential	quintessential	ADJ
gs-3214	124	6	vanguards	vanguard	NOUN
gs-3214	124	7	of	of	ADP
gs-3214	124	8	the	the	DET
gs-3214	124	9	adaptive	adaptive	ADJ
gs-3214	124	10	immune	immune	ADJ
gs-3214	124	11	system	system	NOUN
gs-3214	124	12	,	,	PUNCT
gs-3214	124	13	unparalleled	unparalleled	ADJ
gs-3214	124	14	capacity	capacity	NOUN
gs-3214	124	15	to	to	PART
gs-3214	124	16	discern	discern	VERB
gs-3214	124	17	and	and	CCONJ
gs-3214	124	18	eliminate	eliminate	VERB
gs-3214	124	19	aberrant	aberrant	ADJ
gs-3214	124	20	cells	cell	NOUN
gs-3214	124	21	.	.	PUNCT
gs-3214	125	1	by	by	ADP
gs-3214	125	2	ingeniously	ingeniously	ADV
gs-3214	125	3	engineering	engineer	VERB
gs-3214	125	4	t	t	NOUN
gs-3214	125	5	cells	cell	NOUN
gs-3214	125	6	to	to	PART
gs-3214	125	7	express	express	VERB
gs-3214	125	8	synthetic	synthetic	ADJ
gs-3214	125	9	receptors	receptor	NOUN
gs-3214	125	10	endowed	endow	VERB
gs-3214	125	11	with	with	ADP
gs-3214	125	12	the	the	DET
gs-3214	125	13	unique	unique	ADJ
gs-3214	125	14	ability	ability	NOUN
gs-3214	125	15	to	to	PART
gs-3214	125	16	recognize	recognize	VERB
gs-3214	125	17	tumor	tumor	NOUN
gs-3214	125	18	-	-	PUNCT
gs-3214	125	19	specific	specific	ADJ
gs-3214	125	20	antigens	antigen	NOUN
gs-3214	125	21	,	,	PUNCT
gs-3214	125	22	researchers	researcher	NOUN
gs-3214	125	23	have	have	AUX
gs-3214	125	24	embarked	embark	VERB
gs-3214	125	25	on	on	ADP
gs-3214	125	26	a	a	DET
gs-3214	125	27	monumental	monumental	ADJ
gs-3214	125	28	quest	quest	NOUN
gs-3214	125	29	to	to	PART
gs-3214	125	30	augment	augment	VERB
gs-3214	125	31	the	the	DET
gs-3214	125	32	precision	precision	NOUN
gs-3214	125	33	and	and	CCONJ
gs-3214	125	34	potency	potency	NOUN
gs-3214	125	35	of	of	ADP
gs-3214	125	36	the	the	DET
gs-3214	125	37	immune	immune	ADJ
gs-3214	125	38	response	response	NOUN
gs-3214	125	39	against	against	ADP
gs-3214	125	40	cancer	cancer	NOUN
gs-3214	125	41	.	.	PUNCT
gs-3214	126	1	this	this	DET
gs-3214	126	2	groundbreaking	groundbreake	VERB
gs-3214	126	3	approach	approach	NOUN
gs-3214	126	4	heralds	herald	VERB
gs-3214	126	5	a	a	DET
gs-3214	126	6	departure	departure	NOUN
gs-3214	126	7	from	from	ADP
gs-3214	126	8	conventional	conventional	ADJ
gs-3214	126	9	treatment	treatment	NOUN
gs-3214	126	10	modalities	modality	NOUN
gs-3214	126	11	,	,	PUNCT
gs-3214	126	12	offering	offer	VERB
gs-3214	126	13	the	the	DET
gs-3214	126	14	tantalizing	tantalizing	ADJ
gs-3214	126	15	promise	promise	NOUN
gs-3214	126	16	of	of	ADP
gs-3214	126	17	conferring	confer	VERB
gs-3214	126	18	enduring	enduring	ADJ
gs-3214	126	19	and	and	CCONJ
gs-3214	126	20	exquisitely	exquisitely	ADV
gs-3214	126	21	targeted	target	VERB
gs-3214	126	22	therapeutic	therapeutic	ADJ
gs-3214	126	23	effects	effect	NOUN
gs-3214	126	24	,	,	PUNCT
gs-3214	126	25	heralding	herald	VERB
gs-3214	126	26	a	a	DET
gs-3214	126	27	new	new	ADJ
gs-3214	126	28	dawn	dawn	NOUN
gs-3214	126	29	in	in	ADP
gs-3214	126	30	the	the	DET
gs-3214	126	31	age	age	NOUN
gs-3214	126	32	-	-	PUNCT
gs-3214	126	33	old	old	ADJ
gs-3214	126	34	battle	battle	NOUN
gs-3214	126	35	against	against	ADP
gs-3214	126	36	cancer	cancer	NOUN
gs-3214	126	37	[	[	X
gs-3214	126	38	21	21	NUM
gs-3214	126	39	-	-	SYM
gs-3214	126	40	22	22	NUM
gs-3214	126	41	]	]	PUNCT
gs-3214	126	42	.	.	PUNCT
gs-3214	127	1	current	current	ADJ
gs-3214	127	2	applications	application	NOUN
gs-3214	127	3	:	:	PUNCT
gs-3214	127	4	1	1	X
gs-3214	127	5	.	.	X
gs-3214	127	6	hematologic	hematologic	ADJ
gs-3214	127	7	malignancies	malignancy	NOUN
gs-3214	127	8	car	car	NOUN
gs-3214	127	9	-	-	PUNCT
gs-3214	127	10	t	t	NOUN
gs-3214	127	11	therapy	therapy	NOUN
gs-3214	127	12	has	have	AUX
gs-3214	127	13	shown	show	VERB
gs-3214	127	14	remarkable	remarkable	ADJ
gs-3214	127	15	success	success	NOUN
gs-3214	127	16	in	in	ADP
gs-3214	127	17	treating	treat	VERB
gs-3214	127	18	relapsed	relapse	VERB
gs-3214	127	19	or	or	CCONJ
gs-3214	127	20	refractory	refractory	NOUN
gs-3214	127	21	b	b	NOUN
gs-3214	127	22	-	-	PUNCT
gs-3214	127	23	cell	cell	NOUN
gs-3214	127	24	lymphomas	lymphoma	NOUN
gs-3214	127	25	and	and	CCONJ
gs-3214	127	26	leukemias	leukemia	NOUN
gs-3214	127	27	.	.	PUNCT
gs-3214	128	1	fda	fda	PROPN
gs-3214	128	2	-	-	PUNCT
gs-3214	128	3	approved	approve	VERB
gs-3214	128	4	car	car	NOUN
gs-3214	128	5	-	-	PUNCT
gs-3214	128	6	t	t	NOUN
gs-3214	128	7	products	product	NOUN
gs-3214	128	8	,	,	PUNCT
gs-3214	128	9	such	such	ADJ
gs-3214	128	10	as	as	ADP
gs-3214	128	11	tisagenlecleucel	tisagenlecleucel	ADJ
gs-3214	128	12	and	and	CCONJ
gs-3214	128	13	axicabtagene	axicabtagene	PROPN
gs-3214	128	14	ciloleucel	ciloleucel	PROPN
gs-3214	128	15	,	,	PUNCT
gs-3214	128	16	target	target	VERB
gs-3214	128	17	cd19	cd19	PROPN
gs-3214	128	18	,	,	PUNCT
gs-3214	128	19	achieving	achieve	VERB
gs-3214	128	20	significant	significant	ADJ
gs-3214	128	21	remission	remission	NOUN
gs-3214	128	22	rates	rate	NOUN
gs-3214	128	23	.	.	PUNCT
gs-3214	129	1	2	2	X
gs-3214	129	2	.	.	X
gs-3214	129	3	solid	solid	ADJ
gs-3214	129	4	tumors	tumor	NOUN
gs-3214	129	5	despite	despite	SCONJ
gs-3214	129	6	preclinical	preclinical	ADJ
gs-3214	129	7	successes	success	NOUN
gs-3214	129	8	,	,	PUNCT
gs-3214	129	9	car	car	NOUN
gs-3214	129	10	-	-	PUNCT
gs-3214	129	11	t	t	NOUN
gs-3214	129	12	therapy	therapy	NOUN
gs-3214	129	13	has	have	VERB
gs-3214	129	14	limited	limit	VERB
gs-3214	129	15	efficacy	efficacy	NOUN
gs-3214	129	16	in	in	ADP
gs-3214	129	17	solid	solid	ADJ
gs-3214	129	18	tumors	tumor	NOUN
gs-3214	129	19	due	due	ADJ
gs-3214	129	20	to	to	ADP
gs-3214	129	21	challenges	challenge	NOUN
gs-3214	129	22	such	such	ADJ
gs-3214	129	23	as	as	ADP
gs-3214	129	24	antigen	antigen	ADJ
gs-3214	129	25	heterogeneity	heterogeneity	NOUN
gs-3214	129	26	,	,	PUNCT
gs-3214	129	27	an	an	DET
gs-3214	129	28	immunosuppressive	immunosuppressive	ADJ
gs-3214	129	29	tumor	tumor	NOUN
gs-3214	129	30	microenvironment	microenvironment	NOUN
gs-3214	129	31	(	(	PUNCT
gs-3214	129	32	tme	tme	NOUN
gs-3214	129	33	)	)	PUNCT
gs-3214	129	34	,	,	PUNCT
gs-3214	129	35	and	and	CCONJ
gs-3214	129	36	physical	physical	ADJ
gs-3214	129	37	barriers	barrier	NOUN
gs-3214	129	38	like	like	ADP
gs-3214	129	39	extracellular	extracellular	ADJ
gs-3214	129	40	matrix	matrix	NOUN
gs-3214	129	41	components	component	NOUN
gs-3214	129	42	.	.	PUNCT
gs-3214	130	1	3	3	X
gs-3214	130	2	.	.	X
gs-3214	130	3	beyond	beyond	ADP
gs-3214	130	4	cancer	cancer	NOUN
gs-3214	130	5	autoimmune	autoimmune	ADJ
gs-3214	130	6	diseases	disease	NOUN
gs-3214	130	7	:	:	PUNCT
gs-3214	130	8	efforts	effort	NOUN
gs-3214	130	9	are	be	AUX
gs-3214	130	10	underway	underway	ADJ
gs-3214	130	11	to	to	PART
gs-3214	130	12	adapt	adapt	VERB
gs-3214	130	13	car	car	NOUN
gs-3214	130	14	-	-	PUNCT
gs-3214	130	15	t	t	NOUN
gs-3214	130	16	technology	technology	NOUN
gs-3214	130	17	to	to	PART
gs-3214	130	18	reset	reset	VERB
gs-3214	130	19	immune	immune	ADJ
gs-3214	130	20	responses	response	NOUN
gs-3214	130	21	in	in	ADP
gs-3214	130	22	diseases	disease	NOUN
gs-3214	130	23	like	like	ADP
gs-3214	130	24	lupus	lupus	NOUN
gs-3214	130	25	.	.	PUNCT
gs-3214	131	1	infectious	infectious	ADJ
gs-3214	131	2	diseases	disease	NOUN
gs-3214	131	3	:	:	PUNCT
gs-3214	131	4	car	car	NOUN
gs-3214	131	5	-	-	PUNCT
gs-3214	131	6	t	t	NOUN
gs-3214	131	7	cells	cell	NOUN
gs-3214	131	8	targeting	target	VERB
gs-3214	131	9	viral	viral	ADJ
gs-3214	131	10	antigens	antigen	NOUN
gs-3214	131	11	offer	offer	VERB
gs-3214	131	12	potential	potential	NOUN
gs-3214	131	13	for	for	ADP
gs-3214	131	14	chronic	chronic	ADJ
gs-3214	131	15	infections	infection	NOUN
gs-3214	131	16	like	like	ADP
gs-3214	131	17	hiv	hiv	PROPN
gs-3214	131	18	.	.	PUNCT
gs-3214	132	1	car	car	NOUN
gs-3214	132	2	-	-	PUNCT
gs-3214	132	3	t	t	PROPN
gs-3214	132	4	cell	cell	NOUN
gs-3214	132	5	therapy	therapy	NOUN
gs-3214	132	6	,	,	PUNCT
gs-3214	132	7	a	a	DET
gs-3214	132	8	revolutionary	revolutionary	ADJ
gs-3214	132	9	cancer	cancer	NOUN
gs-3214	132	10	treatment	treatment	NOUN
gs-3214	132	11	,	,	PUNCT
gs-3214	132	12	offers	offer	VERB
gs-3214	132	13	potentially	potentially	ADV
gs-3214	132	14	long	long	ADV
gs-3214	132	15	-	-	PUNCT
gs-3214	132	16	lasting	last	VERB
gs-3214	132	17	response	response	NOUN
gs-3214	132	18	in	in	ADP
gs-3214	132	19	patients	patient	NOUN
gs-3214	132	20	with	with	ADP
gs-3214	132	21	challenging	challenge	VERB
gs-3214	132	22	hematologic	hematologic	ADJ
gs-3214	132	23	cancers	cancer	NOUN
gs-3214	132	24	,	,	PUNCT
gs-3214	132	25	by	by	ADP
gs-3214	132	26	genetically	genetically	ADV
gs-3214	132	27	modifying	modify	VERB
gs-3214	132	28	a	a	DET
gs-3214	132	29	patient	patient	NOUN
gs-3214	132	30	’s	’s	PART
gs-3214	132	31	own	own	ADJ
gs-3214	132	32	t	t	NOUN
gs-3214	132	33	cells	cell	NOUN
gs-3214	132	34	to	to	PART
gs-3214	132	35	express	express	VERB
gs-3214	132	36	chimeric	chimeric	ADJ
gs-3214	132	37	antigen	antigen	ADJ
gs-3214	132	38	receptors	receptor	NOUN
gs-3214	132	39	(	(	PUNCT
gs-3214	132	40	cars	car	NOUN
gs-3214	132	41	)	)	PUNCT
gs-3214	132	42	,	,	PUNCT
gs-3214	132	43	enabling	enable	VERB
gs-3214	132	44	them	they	PRON
gs-3214	132	45	to	to	PART
gs-3214	132	46	identify	identify	VERB
gs-3214	132	47	and	and	CCONJ
gs-3214	132	48	attack	attack	VERB
gs-3214	132	49	the	the	DET
gs-3214	132	50	cancerous	cancerous	ADJ
gs-3214	132	51	cells	cell	NOUN
gs-3214	132	52	without	without	ADP
gs-3214	132	53	major	major	ADJ
gs-3214	132	54	histocompatibility	histocompatibility	NOUN
gs-3214	132	55	complex	complex	NOUN
gs-3214	132	56	(	(	PUNCT
gs-3214	132	57	mhc	mhc	PROPN
gs-3214	132	58	)	)	PUNCT
gs-3214	132	59	restrictions	restriction	NOUN
gs-3214	133	1	[	[	X
gs-3214	133	2	23	23	NUM
gs-3214	133	3	-	-	SYM
gs-3214	133	4	24	24	NUM
gs-3214	133	5	]	]	PUNCT
gs-3214	133	6	.	.	PUNCT
gs-3214	134	1	car	car	NOUN
gs-3214	134	2	-	-	PUNCT
gs-3214	134	3	t	t	NOUN
gs-3214	134	4	cell	cell	NOUN
gs-3214	134	5	therapy	therapy	NOUN
gs-3214	134	6	has	have	AUX
gs-3214	134	7	excelled	excel	VERB
gs-3214	134	8	in	in	ADP
gs-3214	134	9	treating	treat	VERB
gs-3214	134	10	hematologic	hematologic	ADJ
gs-3214	134	11	cancers	cancer	NOUN
gs-3214	134	12	,	,	PUNCT
gs-3214	134	13	notably	notably	ADV
gs-3214	134	14	with	with	ADP
gs-3214	134	15	cd19	cd19	PROPN
gs-3214	134	16	targeted	target	VERB
gs-3214	134	17	products	product	NOUN
gs-3214	134	18	like	like	ADP
gs-3214	134	19	tisagenlecleucel	tisagenlecleucel	PROPN
gs-3214	134	20	(	(	PUNCT
gs-3214	134	21	kymriah	kymriah	PROPN
gs-3214	134	22	)	)	PUNCT
gs-3214	134	23	and	and	CCONJ
gs-3214	134	24	axicabtagene	axicabtagene	PROPN
gs-3214	134	25	ciloleucel	ciloleucel	PROPN
gs-3214	134	26	(	(	PUNCT
gs-3214	134	27	yescarta	yescarta	PROPN
gs-3214	134	28	)	)	PUNCT
gs-3214	134	29	.	.	PUNCT
gs-3214	135	1	these	these	DET
gs-3214	135	2	treatments	treatment	NOUN
gs-3214	135	3	have	have	AUX
gs-3214	135	4	achieved	achieve	VERB
gs-3214	135	5	enduring	enduring	ADJ
gs-3214	135	6	remission	remission	NOUN
gs-3214	135	7	in	in	ADP
gs-3214	135	8	patients	patient	NOUN
gs-3214	135	9	with	with	ADP
gs-3214	135	10	relapsed	relapse	VERB
gs-3214	135	11	or	or	CCONJ
gs-3214	135	12	refractory	refractory	NOUN
gs-3214	135	13	b	b	NOUN
gs-3214	135	14	-	-	PUNCT
gs-3214	135	15	cell	cell	NOUN
gs-3214	135	16	acute	acute	ADJ
gs-3214	135	17	lymphoblastic	lymphoblastic	ADJ
gs-3214	135	18	leukaemia	leukaemia	NOUN
gs-3214	135	19	(	(	PUNCT
gs-3214	135	20	all	all	PRON
gs-3214	135	21	)	)	PUNCT
gs-3214	135	22	and	and	CCONJ
gs-3214	135	23	diffuse	diffuse	VERB
gs-3214	135	24	large	large	ADJ
gs-3214	135	25	b	b	NOUN
gs-3214	135	26	-	-	PUNCT
gs-3214	135	27	cell	cell	NOUN
gs-3214	135	28	lymphoma	lymphoma	NOUN
gs-3214	135	29	(	(	PUNCT
gs-3214	135	30	dlbcl	dlbcl	NOUN
gs-3214	135	31	)	)	PUNCT
gs-3214	135	32	,	,	PUNCT
gs-3214	135	33	culminating	culminate	VERB
gs-3214	135	34	in	in	ADP
gs-3214	135	35	fda	fda	PROPN
gs-3214	135	36	approval	approval	NOUN
gs-3214	135	37	and	and	CCONJ
gs-3214	135	38	acceptance	acceptance	NOUN
gs-3214	135	39	as	as	ADP
gs-3214	135	40	a	a	DET
gs-3214	135	41	standard	standard	ADJ
gs-3214	135	42	treatment	treatment	NOUN
gs-3214	135	43	for	for	ADP
gs-3214	135	44	specific	specific	ADJ
gs-3214	135	45	patient	patient	ADJ
gs-3214	135	46	groups	group	NOUN
gs-3214	136	1	[	[	X
gs-3214	136	2	25	25	NUM
gs-3214	136	3	-	-	SYM
gs-3214	136	4	26	26	NUM
gs-3214	136	5	]	]	PUNCT
gs-3214	136	6	.	.	PUNCT
gs-3214	137	1	georgian	georgian	PROPN
gs-3214	137	2	scientists/	scientists/	NUM
gs-3214	137	3	.	.	PUNCT
gs-3214	138	1	6	6	NUM
gs-3214	138	2	n	n	NUM
gs-3214	138	3	3	3	NUM
gs-3214	138	4	,	,	PUNCT
gs-3214	138	5	2024	2024	NUM
gs-3214	138	6	270	270	NUM
gs-3214	138	7	car	car	NOUN
gs-3214	138	8	-	-	PUNCT
gs-3214	138	9	t	t	NOUN
gs-3214	138	10	cells	cell	NOUN
gs-3214	138	11	activate	activate	VERB
gs-3214	138	12	upon	upon	SCONJ
gs-3214	138	13	encountering	encounter	VERB
gs-3214	138	14	tumor	tumor	NOUN
gs-3214	138	15	antigens	antigen	NOUN
gs-3214	138	16	initiating	initiate	VERB
gs-3214	138	17	activation	activation	NOUN
gs-3214	138	18	and	and	CCONJ
gs-3214	138	19	proliferation	proliferation	NOUN
gs-3214	138	20	,	,	PUNCT
gs-3214	138	21	triggering	trigger	VERB
gs-3214	138	22	the	the	DET
gs-3214	138	23	formation	formation	NOUN
gs-3214	138	24	of	of	ADP
gs-3214	138	25	immunological	immunological	ADJ
gs-3214	138	26	synapses	synapsis	NOUN
gs-3214	138	27	and	and	CCONJ
gs-3214	138	28	initiating	initiate	VERB
gs-3214	138	29	signing	sign	VERB
gs-3214	138	30	cascades	cascade	NOUN
gs-3214	138	31	.	.	PUNCT
gs-3214	139	1	car	car	NOUN
gs-3214	139	2	’s	’s	PART
gs-3214	139	3	intracellular	intracellular	ADJ
gs-3214	139	4	singing	singing	NOUN
gs-3214	139	5	domains	domain	NOUN
gs-3214	139	6	usually	usually	ADV
gs-3214	139	7	include	include	VERB
gs-3214	139	8	cd3	cd3	NOUN
gs-3214	139	9	,	,	PUNCT
gs-3214	139	10	housing	housing	NOUN
gs-3214	139	11	immunoreceptor	immunoreceptor	NOUN
gs-3214	139	12	tyrosine	tyrosine	NOUN
gs-3214	139	13	-	-	PUNCT
gs-3214	139	14	based	base	VERB
gs-3214	139	15	activation	activation	NOUN
gs-3214	139	16	motifs	motif	NOUN
gs-3214	139	17	(	(	PUNCT
gs-3214	139	18	itams	itam	NOUN
gs-3214	139	19	)	)	PUNCT
gs-3214	139	20	responsive	responsive	ADJ
gs-3214	139	21	for	for	ADP
gs-3214	139	22	triggering	trigger	VERB
gs-3214	139	23	t	t	PROPN
gs-3214	139	24	cell	cell	NOUN
gs-3214	139	25	activation	activation	NOUN
gs-3214	139	26	upon	upon	SCONJ
gs-3214	139	27	antigen	antigen	ADJ
gs-3214	139	28	recognition	recognition	NOUN
gs-3214	139	29	.	.	PUNCT
gs-3214	140	1	however	however	ADV
gs-3214	140	2	,	,	PUNCT
gs-3214	140	3	adding	add	VERB
gs-3214	140	4	co	co	AUX
gs-3214	140	5	stimulatory	stimulatory	ADJ
gs-3214	140	6	domains	domain	NOUN
gs-3214	140	7	like	like	ADP
gs-3214	140	8	cd28	cd28	PROPN
gs-3214	140	9	,	,	PUNCT
gs-3214	140	10	4	4	NUM
gs-3214	140	11	-	-	SYM
gs-3214	140	12	1bb(cd137	1bb(cd137	NUM
gs-3214	140	13	)	)	PUNCT
gs-3214	140	14	,	,	PUNCT
gs-3214	140	15	or	or	CCONJ
gs-3214	140	16	ox40(cd134	ox40(cd134	NOUN
gs-3214	140	17	)	)	PUNCT
gs-3214	140	18	to	to	ADP
gs-3214	140	19	car	car	NOUN
gs-3214	140	20	constructs	construct	NOUN
gs-3214	140	21	provide	provide	VERB
gs-3214	140	22	extra	extra	ADJ
gs-3214	140	23	signaling	signal	VERB
gs-3214	140	24	cues	cue	NOUN
gs-3214	140	25	that	that	PRON
gs-3214	140	26	boost	boost	VERB
gs-3214	140	27	t	t	NOUN
gs-3214	140	28	cell	cell	NOUN
gs-3214	140	29	activation	activation	NOUN
gs-3214	140	30	and	and	CCONJ
gs-3214	140	31	proliferation	proliferation	NOUN
gs-3214	140	32	.	.	PUNCT
gs-3214	141	1	cd28	cd28	PROPN
gs-3214	141	2	costimulation	costimulation	NOUN
gs-3214	141	3	enhances	enhance	VERB
gs-3214	141	4	easy	easy	ADJ
gs-3214	141	5	t	t	NOUN
gs-3214	141	6	cell	cell	NOUN
gs-3214	141	7	activation	activation	NOUN
gs-3214	141	8	and	and	CCONJ
gs-3214	141	9	effector	effector	NOUN
gs-3214	141	10	function	function	NOUN
gs-3214	141	11	through	through	ADP
gs-3214	141	12	increased	increase	VERB
gs-3214	141	13	cytokine	cytokine	NOUN
gs-3214	141	14	production	production	NOUN
gs-3214	141	15	,	,	PUNCT
gs-3214	141	16	metabolic	metabolic	NOUN
gs-3214	141	17	reprogramming	reprogramming	NOUN
gs-3214	141	18	,	,	PUNCT
gs-3214	141	19	and	and	CCONJ
gs-3214	141	20	survival	survival	NOUN
gs-3214	141	21	signaling	signal	VERB
gs-3214	141	22	pathways	pathway	NOUN
gs-3214	141	23	.	.	PUNCT
gs-3214	142	1	on	on	ADP
gs-3214	142	2	the	the	DET
gs-3214	142	3	contrary	contrary	NOUN
gs-3214	142	4	,	,	PUNCT
gs-3214	142	5	costimulation	costimulation	NOUN
gs-3214	142	6	through	through	ADP
gs-3214	142	7	receptors	receptor	NOUN
gs-3214	142	8	like	like	ADP
gs-3214	142	9	4	4	NUM
gs-3214	142	10	-	-	NUM
gs-3214	142	11	1bb	1bb	NOUN
gs-3214	142	12	and	and	CCONJ
gs-3214	142	13	ox40	ox40	PROPN
gs-3214	142	14	fosters	foster	VERB
gs-3214	142	15	t	t	NOUN
gs-3214	142	16	cell	cell	NOUN
gs-3214	142	17	persistence	persistence	NOUN
gs-3214	142	18	and	and	CCONJ
gs-3214	142	19	memory	memory	NOUN
gs-3214	142	20	formation	formation	NOUN
gs-3214	142	21	,	,	PUNCT
gs-3214	142	22	resulting	result	VERB
gs-3214	142	23	in	in	ADP
gs-3214	142	24	prolonged	prolonged	ADJ
gs-3214	142	25	antitumor	antitumor	PROPN
gs-3214	142	26	effectiveness	effectiveness	NOUN
gs-3214	142	27	and	and	CCONJ
gs-3214	142	28	improved	improved	ADJ
gs-3214	142	29	elimination	elimination	NOUN
gs-3214	142	30	of	of	ADP
gs-3214	142	31	tumors	tumor	NOUN
gs-3214	142	32	[	[	X
gs-3214	142	33	27	27	NUM
gs-3214	142	34	-	-	SYM
gs-3214	142	35	28	28	NUM
gs-3214	142	36	]	]	PUNCT
gs-3214	142	37	.	.	PUNCT
gs-3214	143	1	after	after	ADP
gs-3214	143	2	recognizing	recognize	VERB
gs-3214	143	3	antigens	antigen	NOUN
gs-3214	143	4	and	and	CCONJ
gs-3214	143	5	receiving	receive	VERB
gs-3214	143	6	co	co	ADJ
gs-3214	143	7	-	-	ADJ
gs-3214	143	8	stimulatory	stimulatory	ADJ
gs-3214	143	9	signals	signal	NOUN
gs-3214	143	10	,	,	PUNCT
gs-3214	143	11	activated	activate	VERB
gs-3214	143	12	car	car	NOUN
gs-3214	143	13	-	-	PUNCT
gs-3214	143	14	t	t	NOUN
gs-3214	143	15	cells	cell	NOUN
gs-3214	143	16	undergo	undergo	VERB
gs-3214	143	17	clonal	clonal	ADJ
gs-3214	143	18	expansion	expansion	NOUN
gs-3214	143	19	to	to	PART
gs-3214	143	20	produce	produce	VERB
gs-3214	143	21	a	a	DET
gs-3214	143	22	strong	strong	ADJ
gs-3214	143	23	effector	effector	NOUN
gs-3214	143	24	cell	cell	NOUN
gs-3214	143	25	population	population	NOUN
gs-3214	143	26	,	,	PUNCT
gs-3214	143	27	capable	capable	ADJ
gs-3214	143	28	of	of	ADP
gs-3214	143	29	exerting	exert	VERB
gs-3214	143	30	cytotoxic	cytotoxic	ADJ
gs-3214	143	31	activity	activity	NOUN
gs-3214	143	32	against	against	ADP
gs-3214	143	33	tumor	tumor	NOUN
gs-3214	143	34	cells	cell	NOUN
gs-3214	143	35	.	.	PUNCT
gs-3214	144	1	this	this	DET
gs-3214	144	2	proliferative	proliferative	ADJ
gs-3214	144	3	process	process	NOUN
gs-3214	144	4	is	be	AUX
gs-3214	144	5	driven	drive	VERB
gs-3214	144	6	by	by	ADP
gs-3214	144	7	cytokines	cytokine	NOUN
gs-3214	144	8	like	like	ADP
gs-3214	144	9	interleukin-2	interleukin-2	NOUN
gs-3214	144	10	(	(	PUNCT
gs-3214	144	11	il-2	il-2	NUM
gs-3214	144	12	)	)	PUNCT
gs-3214	144	13	,	,	PUNCT
gs-3214	144	14	interleukin-7	interleukin-7	PROPN
gs-3214	144	15	(	(	PUNCT
gs-3214	144	16	il-7	il-7	NOUN
gs-3214	144	17	)	)	PUNCT
gs-3214	144	18	,	,	PUNCT
gs-3214	144	19	and	and	CCONJ
gs-3214	144	20	interleukin-15	interleukin-15	PROPN
gs-3214	144	21	(	(	PUNCT
gs-3214	144	22	il-15	il-15	NOUN
gs-3214	144	23	)	)	PUNCT
gs-3214	144	24	,	,	PUNCT
gs-3214	144	25	which	which	PRON
gs-3214	144	26	enhance	enhance	VERB
gs-3214	144	27	t	t	PROPN
gs-3214	144	28	cell	cell	NOUN
gs-3214	144	29	growth	growth	NOUN
gs-3214	144	30	and	and	CCONJ
gs-3214	144	31	survival	survival	NOUN
gs-3214	144	32	.	.	PUNCT
gs-3214	145	1	optimizing	optimize	VERB
gs-3214	145	2	the	the	DET
gs-3214	145	3	activation	activation	NOUN
gs-3214	145	4	and	and	CCONJ
gs-3214	145	5	proliferation	proliferation	NOUN
gs-3214	145	6	kinetics	kinetic	NOUN
gs-3214	145	7	of	of	ADP
gs-3214	145	8	car	car	NOUN
gs-3214	145	9	-	-	PUNCT
gs-3214	145	10	t	t	NOUN
gs-3214	145	11	cells	cell	NOUN
gs-3214	145	12	is	be	AUX
gs-3214	145	13	essential	essential	ADJ
gs-3214	145	14	for	for	ADP
gs-3214	145	15	maximizing	maximize	VERB
gs-3214	145	16	therapeutic	therapeutic	ADJ
gs-3214	145	17	efficacy	efficacy	NOUN
gs-3214	145	18	while	while	SCONJ
gs-3214	145	19	minimizing	minimize	VERB
gs-3214	145	20	toxicities	toxicity	NOUN
gs-3214	145	21	.	.	PUNCT
gs-3214	146	1	strategies	strategy	NOUN
gs-3214	146	2	for	for	ADP
gs-3214	146	3	enhancing	enhance	VERB
gs-3214	146	4	car	car	NOUN
gs-3214	146	5	-	-	PUNCT
gs-3214	146	6	t	t	NOUN
gs-3214	146	7	cell	cell	NOUN
gs-3214	146	8	expansion	expansion	NOUN
gs-3214	146	9	include	include	VERB
gs-3214	146	10	cytokine	cytokine	ADJ
gs-3214	146	11	supplementation	supplementation	NOUN
gs-3214	146	12	,	,	PUNCT
gs-3214	146	13	co	co	ADJ
gs-3214	146	14	-	-	ADJ
gs-3214	146	15	stimulatory	stimulatory	ADJ
gs-3214	146	16	molecule	molecule	NOUN
gs-3214	146	17	engagement	engagement	NOUN
gs-3214	146	18	,	,	PUNCT
gs-3214	146	19	and	and	CCONJ
gs-3214	146	20	metabolic	metabolic	NOUN
gs-3214	146	21	modulation	modulation	NOUN
gs-3214	146	22	to	to	PART
gs-3214	146	23	promote	promote	VERB
gs-3214	146	24	an	an	DET
gs-3214	146	25	optimal	optimal	ADJ
gs-3214	146	26	balance	balance	NOUN
gs-3214	146	27	between	between	ADP
gs-3214	146	28	effector	effector	NOUN
gs-3214	146	29	and	and	CCONJ
gs-3214	146	30	memory	memory	NOUN
gs-3214	146	31	t	t	NOUN
gs-3214	146	32	cell	cell	NOUN
gs-3214	146	33	phenotypes	phenotype	NOUN
gs-3214	146	34	.	.	PUNCT
gs-3214	147	1	moreover	moreover	ADV
gs-3214	147	2	,	,	PUNCT
gs-3214	147	3	advancements	advancement	NOUN
gs-3214	147	4	in	in	ADP
gs-3214	147	5	car	car	NOUN
gs-3214	147	6	-	-	PUNCT
gs-3214	147	7	t	t	NOUN
gs-3214	147	8	cell	cell	NOUN
gs-3214	147	9	engineering	engineering	NOUN
gs-3214	147	10	,	,	PUNCT
gs-3214	147	11	including	include	VERB
gs-3214	147	12	integrating	integrate	VERB
gs-3214	147	13	inducible	inducible	ADJ
gs-3214	147	14	signaling	signal	VERB
gs-3214	147	15	modules	module	NOUN
gs-3214	147	16	and	and	CCONJ
gs-3214	147	17	employing	employ	VERB
gs-3214	147	18	synthetic	synthetic	ADJ
gs-3214	147	19	biology	biology	NOUN
gs-3214	147	20	techniques	technique	NOUN
gs-3214	147	21	,	,	PUNCT
gs-3214	147	22	provide	provide	VERB
gs-3214	147	23	avenues	avenue	NOUN
gs-3214	147	24	to	to	PART
gs-3214	147	25	refine	refine	VERB
gs-3214	147	26	car	car	NOUN
gs-3214	147	27	-	-	PUNCT
gs-3214	147	28	t	t	NOUN
gs-3214	147	29	cell	cell	NOUN
gs-3214	147	30	activation	activation	NOUN
gs-3214	147	31	kinetics	kinetic	NOUN
gs-3214	147	32	and	and	CCONJ
gs-3214	147	33	improve	improve	VERB
gs-3214	147	34	treatment	treatment	NOUN
gs-3214	147	35	effectiveness	effectiveness	NOUN
gs-3214	147	36	[	[	X
gs-3214	147	37	29	29	NUM
gs-3214	147	38	-	-	SYM
gs-3214	147	39	30	30	NUM
gs-3214	147	40	]	]	PUNCT
gs-3214	147	41	.	.	PUNCT
gs-3214	148	1	furthermore	furthermore	ADV
gs-3214	148	2	,	,	PUNCT
gs-3214	148	3	persistent	persistent	ADJ
gs-3214	148	4	research	research	NOUN
gs-3214	148	5	endeavors	endeavor	NOUN
gs-3214	148	6	are	be	AUX
gs-3214	148	7	exploring	explore	VERB
gs-3214	148	8	car	car	NOUN
gs-3214	148	9	-	-	PUNCT
gs-3214	148	10	t	t	NOUN
gs-3214	148	11	cell	cell	NOUN
gs-3214	148	12	therapy	therapy	NOUN
gs-3214	148	13	in	in	ADP
gs-3214	148	14	various	various	ADJ
gs-3214	148	15	hematologic	hematologic	NOUN
gs-3214	148	16	malignancies	malignancy	NOUN
gs-3214	148	17	and	and	CCONJ
gs-3214	148	18	solid	solid	ADJ
gs-3214	148	19	tumors	tumor	NOUN
gs-3214	148	20	.	.	PUNCT
gs-3214	149	1	despite	despite	SCONJ
gs-3214	149	2	hurdles	hurdle	NOUN
gs-3214	149	3	linked	link	VERB
gs-3214	149	4	to	to	ADP
gs-3214	149	5	tumor	tumor	NOUN
gs-3214	149	6	heterogeneity	heterogeneity	NOUN
gs-3214	149	7	and	and	CCONJ
gs-3214	149	8	immune	immune	ADJ
gs-3214	149	9	resistance	resistance	NOUN
gs-3214	149	10	,	,	PUNCT
gs-3214	149	11	early	early	ADJ
gs-3214	149	12	studies	study	NOUN
gs-3214	149	13	showcased	showcase	VERB
gs-3214	149	14	prospective	prospective	ADJ
gs-3214	149	15	expansion	expansion	NOUN
gs-3214	149	16	for	for	ADP
gs-3214	149	17	car	car	NOUN
gs-3214	149	18	-	-	PUNCT
gs-3214	149	19	t	t	NOUN
gs-3214	149	20	cell	cell	NOUN
gs-3214	149	21	therapy	therapy	NOUN
gs-3214	149	22	from	from	ADP
gs-3214	149	23	hematological	hematological	ADJ
gs-3214	149	24	malignancies	malignancy	NOUN
gs-3214	149	25	to	to	ADP
gs-3214	149	26	the	the	DET
gs-3214	149	27	domain	domain	NOUN
gs-3214	149	28	of	of	ADP
gs-3214	149	29	solid	solid	ADJ
gs-3214	149	30	tumor	tumor	NOUN
gs-3214	149	31	oncology	oncology	NOUN
gs-3214	149	32	[	[	X
gs-3214	149	33	31	31	NUM
gs-3214	149	34	-	-	SYM
gs-3214	149	35	32	32	NUM
gs-3214	149	36	]	]	PUNCT
gs-3214	149	37	.	.	PUNCT
gs-3214	150	1	toxicity	toxicity	NOUN
gs-3214	150	2	:	:	PUNCT
gs-3214	150	3	cytokine	cytokine	NOUN
gs-3214	150	4	release	release	NOUN
gs-3214	150	5	syndrome	syndrome	NOUN
gs-3214	150	6	(	(	PUNCT
gs-3214	150	7	crs	crs	PROPN
gs-3214	150	8	):	):	PUNCT
gs-3214	150	9	a	a	DET
gs-3214	150	10	potentially	potentially	ADV
gs-3214	150	11	life	life	NOUN
gs-3214	150	12	-	-	PUNCT
gs-3214	150	13	threatening	threaten	VERB
gs-3214	150	14	inflammatory	inflammatory	ADJ
gs-3214	150	15	response	response	NOUN
gs-3214	150	16	.	.	PUNCT
gs-3214	151	1	neurotoxicity	neurotoxicity	NOUN
gs-3214	151	2	:	:	PUNCT
gs-3214	151	3	also	also	ADV
gs-3214	151	4	known	know	VERB
gs-3214	151	5	as	as	ADP
gs-3214	151	6	immune	immune	ADJ
gs-3214	151	7	effector	effector	NOUN
gs-3214	151	8	cell	cell	NOUN
gs-3214	151	9	-	-	PUNCT
gs-3214	151	10	associated	associate	VERB
gs-3214	151	11	neurotoxicity	neurotoxicity	NOUN
gs-3214	151	12	syndrome	syndrome	NOUN
gs-3214	151	13	(	(	PUNCT
gs-3214	151	14	icans	ican	NOUN
gs-3214	151	15	)	)	PUNCT
gs-3214	151	16	,	,	PUNCT
gs-3214	151	17	with	with	ADP
gs-3214	151	18	unclear	unclear	ADJ
gs-3214	151	19	mechanisms	mechanism	NOUN
gs-3214	151	20	.	.	PUNCT
gs-3214	152	1	strategies	strategy	NOUN
gs-3214	152	2	:	:	PUNCT
gs-3214	152	3	steroids	steroid	NOUN
gs-3214	152	4	and	and	CCONJ
gs-3214	152	5	cytokine	cytokine	VERB
gs-3214	152	6	inhibitors	inhibitor	NOUN
gs-3214	152	7	,	,	PUNCT
gs-3214	152	8	such	such	ADJ
gs-3214	152	9	as	as	ADP
gs-3214	152	10	tocilizumab	tocilizumab	NOUN
gs-3214	152	11	,	,	PUNCT
gs-3214	152	12	are	be	AUX
gs-3214	152	13	used	use	VERB
gs-3214	152	14	for	for	ADP
gs-3214	152	15	management	management	NOUN
gs-3214	152	16	.	.	PUNCT
gs-3214	153	1	antigen	antigen	ADJ
gs-3214	153	2	escape	escape	NOUN
gs-3214	153	3	and	and	CCONJ
gs-3214	153	4	relapse	relapse	NOUN
gs-3214	153	5	:	:	PUNCT
gs-3214	153	6	tumors	tumor	NOUN
gs-3214	153	7	may	may	AUX
gs-3214	153	8	lose	lose	VERB
gs-3214	153	9	or	or	CCONJ
gs-3214	153	10	downregulate	downregulate	VERB
gs-3214	153	11	the	the	DET
gs-3214	153	12	target	target	NOUN
gs-3214	153	13	antigen	antigen	ADV
gs-3214	153	14	,	,	PUNCT
gs-3214	153	15	leading	lead	VERB
gs-3214	153	16	to	to	ADP
gs-3214	153	17	relapse	relapse	NOUN
gs-3214	153	18	.	.	PUNCT
gs-3214	154	1	combination	combination	NOUN
gs-3214	154	2	therapies	therapy	NOUN
gs-3214	154	3	and	and	CCONJ
gs-3214	154	4	dual	dual	ADJ
gs-3214	154	5	-	-	PUNCT
gs-3214	154	6	target	target	NOUN
gs-3214	154	7	car	car	NOUN
gs-3214	154	8	-	-	PUNCT
gs-3214	154	9	t	t	NOUN
gs-3214	154	10	cells	cell	NOUN
gs-3214	154	11	are	be	AUX
gs-3214	154	12	being	be	AUX
gs-3214	154	13	developed	develop	VERB
gs-3214	154	14	to	to	PART
gs-3214	154	15	address	address	VERB
gs-3214	154	16	this	this	DET
gs-3214	154	17	issue	issue	NOUN
gs-3214	154	18	.	.	PUNCT
gs-3214	155	1	manufacturing	manufacturing	NOUN
gs-3214	155	2	and	and	CCONJ
gs-3214	155	3	cost	cost	NOUN
gs-3214	155	4	:	:	PUNCT
gs-3214	155	5	car	car	NOUN
gs-3214	155	6	-	-	PUNCT
gs-3214	155	7	t	t	NOUN
gs-3214	155	8	therapy	therapy	NOUN
gs-3214	155	9	involves	involve	VERB
gs-3214	155	10	complex	complex	ADJ
gs-3214	155	11	,	,	PUNCT
gs-3214	155	12	labor	labor	NOUN
gs-3214	155	13	-	-	PUNCT
gs-3214	155	14	intensive	intensive	ADJ
gs-3214	155	15	processes	process	NOUN
gs-3214	155	16	including	include	VERB
gs-3214	155	17	leukapheresis	leukapheresis	NOUN
gs-3214	155	18	,	,	PUNCT
gs-3214	155	19	genetic	genetic	ADJ
gs-3214	155	20	modification	modification	NOUN
gs-3214	155	21	,	,	PUNCT
gs-3214	155	22	and	and	CCONJ
gs-3214	155	23	cell	cell	NOUN
gs-3214	155	24	expansion	expansion	NOUN
gs-3214	155	25	.	.	PUNCT
gs-3214	156	1	innovations	innovation	NOUN
gs-3214	156	2	such	such	ADJ
gs-3214	156	3	as	as	ADP
gs-3214	156	4	universal	universal	ADJ
gs-3214	156	5	or	or	CCONJ
gs-3214	156	6	"	"	PUNCT
gs-3214	156	7	off	off	ADP
gs-3214	156	8	-	-	PUNCT
gs-3214	156	9	the	the	DET
gs-3214	156	10	-	-	PUNCT
gs-3214	156	11	shelf	shelf	NOUN
gs-3214	156	12	"	"	PUNCT
gs-3214	156	13	car	car	NOUN
gs-3214	156	14	-	-	PUNCT
gs-3214	156	15	t	t	NOUN
gs-3214	156	16	products	product	NOUN
gs-3214	156	17	aim	aim	VERB
gs-3214	156	18	to	to	PART
gs-3214	156	19	simplify	simplify	VERB
gs-3214	156	20	production	production	NOUN
gs-3214	156	21	.	.	PUNCT
gs-3214	157	1	georgian	georgian	NOUN
gs-3214	157	2	scientists/	scientists/	NUM
gs-3214	157	3	.	.	PUNCT
gs-3214	158	1	6	6	NUM
gs-3214	158	2	n	n	NUM
gs-3214	158	3	3	3	NUM
gs-3214	158	4	,	,	PUNCT
gs-3214	158	5	2024	2024	NUM
gs-3214	158	6	271	271	NUM
gs-3214	158	7	solid	solid	ADJ
gs-3214	158	8	tumor	tumor	NOUN
gs-3214	158	9	microenvironment	microenvironment	NOUN
gs-3214	158	10	:	:	PUNCT
gs-3214	158	11	immunosuppression	immunosuppression	NOUN
gs-3214	158	12	:	:	PUNCT
gs-3214	158	13	tumor	tumor	NOUN
gs-3214	158	14	-	-	PUNCT
gs-3214	158	15	associated	associate	VERB
gs-3214	158	16	macrophages	macrophage	NOUN
gs-3214	158	17	(	(	PUNCT
gs-3214	158	18	tams	tam	NOUN
gs-3214	158	19	)	)	PUNCT
gs-3214	158	20	,	,	PUNCT
gs-3214	158	21	myeloid	myeloid	NOUN
gs-3214	158	22	-	-	PUNCT
gs-3214	158	23	derived	derive	VERB
gs-3214	158	24	suppressor	suppressor	NOUN
gs-3214	158	25	cells	cell	NOUN
gs-3214	158	26	(	(	PUNCT
gs-3214	158	27	mdscs	mdsc	NOUN
gs-3214	158	28	)	)	PUNCT
gs-3214	158	29	,	,	PUNCT
gs-3214	158	30	and	and	CCONJ
gs-3214	158	31	regulatory	regulatory	ADJ
gs-3214	158	32	t	t	NOUN
gs-3214	158	33	cells	cell	NOUN
gs-3214	158	34	(	(	PUNCT
gs-3214	158	35	tregs	treg	NOUN
gs-3214	158	36	)	)	PUNCT
gs-3214	158	37	inhibit	inhibit	VERB
gs-3214	158	38	car	car	NOUN
gs-3214	158	39	-	-	PUNCT
gs-3214	158	40	t	t	NOUN
gs-3214	158	41	activity	activity	NOUN
gs-3214	158	42	.	.	PUNCT
gs-3214	159	1	hypoxia	hypoxia	NOUN
gs-3214	159	2	and	and	CCONJ
gs-3214	159	3	acidity	acidity	NOUN
gs-3214	159	4	:	:	PUNCT
gs-3214	159	5	impair	impair	VERB
gs-3214	159	6	car	car	NOUN
gs-3214	159	7	-	-	PUNCT
gs-3214	159	8	t	t	NOUN
gs-3214	159	9	cell	cell	NOUN
gs-3214	159	10	metabolism	metabolism	NOUN
gs-3214	159	11	and	and	CCONJ
gs-3214	159	12	survival	survival	NOUN
gs-3214	159	13	.	.	PUNCT
gs-3214	160	1	the	the	DET
gs-3214	160	2	car	car	NOUN
gs-3214	160	3	-	-	PUNCT
gs-3214	160	4	t	t	NOUN
gs-3214	160	5	cell	cell	NOUN
gs-3214	160	6	therapy	therapy	NOUN
gs-3214	160	7	has	have	AUX
gs-3214	160	8	been	be	AUX
gs-3214	160	9	propelled	propel	VERB
gs-3214	160	10	forward	forward	ADV
gs-3214	160	11	by	by	ADP
gs-3214	160	12	remarkable	remarkable	ADJ
gs-3214	160	13	advances	advance	NOUN
gs-3214	160	14	in	in	ADP
gs-3214	160	15	genetic	genetic	ADJ
gs-3214	160	16	engineering	engineering	NOUN
gs-3214	160	17	technologies	technology	NOUN
gs-3214	160	18	,	,	PUNCT
gs-3214	160	19	including	include	VERB
gs-3214	160	20	viral	viral	ADJ
gs-3214	160	21	vector	vector	NOUN
gs-3214	160	22	-	-	PUNCT
gs-3214	160	23	mediated	mediate	VERB
gs-3214	160	24	gene	gene	NOUN
gs-3214	160	25	transfer	transfer	NOUN
gs-3214	160	26	and	and	CCONJ
gs-3214	160	27	the	the	DET
gs-3214	160	28	advent	advent	NOUN
gs-3214	160	29	of	of	ADP
gs-3214	160	30	sophisticated	sophisticated	ADJ
gs-3214	160	31	genome	genome	NOUN
gs-3214	160	32	editing	editing	NOUN
gs-3214	160	33	methodologies	methodology	NOUN
gs-3214	160	34	.	.	PUNCT
gs-3214	161	1	these	these	DET
gs-3214	161	2	pioneering	pioneering	ADJ
gs-3214	161	3	strides	stride	NOUN
gs-3214	161	4	have	have	AUX
gs-3214	161	5	paved	pave	VERB
gs-3214	161	6	the	the	DET
gs-3214	161	7	way	way	NOUN
gs-3214	161	8	for	for	ADP
gs-3214	161	9	the	the	DET
gs-3214	161	10	development	development	NOUN
gs-3214	161	11	of	of	ADP
gs-3214	161	12	increasingly	increasingly	ADV
gs-3214	161	13	intricate	intricate	ADJ
gs-3214	161	14	car	car	NOUN
gs-3214	161	15	designs	design	NOUN
gs-3214	161	16	,	,	PUNCT
gs-3214	161	17	distinguished	distinguish	VERB
gs-3214	161	18	by	by	ADP
gs-3214	161	19	their	their	PRON
gs-3214	161	20	unparalleled	unparalleled	ADJ
gs-3214	161	21	versatility	versatility	NOUN
gs-3214	161	22	in	in	ADP
gs-3214	161	23	targeting	target	VERB
gs-3214	161	24	a	a	DET
gs-3214	161	25	myriad	myriad	NOUN
gs-3214	161	26	of	of	ADP
gs-3214	161	27	tumor	tumor	NOUN
gs-3214	161	28	antigens	antigen	NOUN
gs-3214	161	29	,	,	PUNCT
gs-3214	161	30	including	include	VERB
gs-3214	161	31	surface	surface	NOUN
gs-3214	161	32	proteins	protein	NOUN
gs-3214	161	33	preferentially	preferentially	ADV
gs-3214	161	34	or	or	CCONJ
gs-3214	161	35	exclusively	exclusively	ADV
gs-3214	161	36	expressed	express	VERB
gs-3214	161	37	on	on	ADP
gs-3214	161	38	malignant	malignant	ADJ
gs-3214	161	39	cells	cell	NOUN
gs-3214	161	40	.	.	PUNCT
gs-3214	162	1	furthermore	furthermore	ADV
gs-3214	162	2	,	,	PUNCT
gs-3214	162	3	the	the	DET
gs-3214	162	4	judicious	judicious	ADJ
gs-3214	162	5	integration	integration	NOUN
gs-3214	162	6	of	of	ADP
gs-3214	162	7	costimulatory	costimulatory	NOUN
gs-3214	162	8	domains	domain	NOUN
gs-3214	162	9	into	into	ADP
gs-3214	162	10	car	car	NOUN
gs-3214	162	11	constructs	construct	NOUN
gs-3214	162	12	serves	serve	VERB
gs-3214	162	13	to	to	PART
gs-3214	162	14	potentiate	potentiate	VERB
gs-3214	162	15	t	t	NOUN
gs-3214	162	16	cell	cell	NOUN
gs-3214	162	17	activation	activation	NOUN
gs-3214	162	18	and	and	CCONJ
gs-3214	162	19	persistence	persistence	NOUN
gs-3214	162	20	,	,	PUNCT
gs-3214	162	21	thereby	thereby	ADV
gs-3214	162	22	further	far	ADV
gs-3214	162	23	amplifying	amplify	VERB
gs-3214	162	24	their	their	PRON
gs-3214	162	25	anti	anti	ADJ
gs-3214	162	26	-	-	ADJ
gs-3214	162	27	neoplastic	neoplastic	ADJ
gs-3214	162	28	efficacy	efficacy	NOUN
gs-3214	162	29	and	and	CCONJ
gs-3214	162	30	engendering	engender	VERB
gs-3214	162	31	the	the	DET
gs-3214	162	32	potential	potential	NOUN
gs-3214	162	33	for	for	ADP
gs-3214	162	34	sustained	sustain	VERB
gs-3214	162	35	therapeutic	therapeutic	ADJ
gs-3214	162	36	responses	response	NOUN
gs-3214	162	37	[	[	X
gs-3214	162	38	33	33	NUM
gs-3214	162	39	-	-	SYM
gs-3214	162	40	34	34	NUM
gs-3214	162	41	]	]	PUNCT
gs-3214	162	42	.	.	PUNCT
gs-3214	163	1	the	the	DET
gs-3214	163	2	clinical	clinical	ADJ
gs-3214	163	3	import	import	NOUN
gs-3214	163	4	of	of	ADP
gs-3214	163	5	car	car	NOUN
gs-3214	163	6	-	-	PUNCT
gs-3214	163	7	t	t	NOUN
gs-3214	163	8	cell	cell	NOUN
gs-3214	163	9	therapy	therapy	NOUN
gs-3214	163	10	lies	lie	VERB
gs-3214	163	11	in	in	ADP
gs-3214	163	12	its	its	PRON
gs-3214	163	13	extraordinary	extraordinary	ADJ
gs-3214	163	14	capacity	capacity	NOUN
gs-3214	163	15	to	to	PART
gs-3214	163	16	elicit	elicit	VERB
gs-3214	163	17	profound	profound	ADJ
gs-3214	163	18	and	and	CCONJ
gs-3214	163	19	durable	durable	ADJ
gs-3214	163	20	responses	response	NOUN
gs-3214	163	21	in	in	ADP
gs-3214	163	22	patients	patient	NOUN
gs-3214	163	23	grappling	grapple	VERB
gs-3214	163	24	with	with	ADP
gs-3214	163	25	refractory	refractory	NOUN
gs-3214	163	26	hematologic	hematologic	NOUN
gs-3214	163	27	malignancies	malignancy	NOUN
gs-3214	163	28	,	,	PUNCT
gs-3214	163	29	such	such	ADJ
gs-3214	163	30	as	as	ADP
gs-3214	163	31	b	b	NOUN
gs-3214	163	32	-	-	PUNCT
gs-3214	163	33	cell	cell	NOUN
gs-3214	163	34	acute	acute	ADJ
gs-3214	163	35	lymphoblastic	lymphoblastic	ADJ
gs-3214	163	36	leukemia	leukemia	NOUN
gs-3214	163	37	(	(	PUNCT
gs-3214	163	38	all	all	ADV
gs-3214	163	39	)	)	PUNCT
gs-3214	163	40	,	,	PUNCT
gs-3214	163	41	chronic	chronic	ADJ
gs-3214	163	42	lymphocytic	lymphocytic	ADJ
gs-3214	163	43	leukemia	leukemia	NOUN
gs-3214	163	44	(	(	PUNCT
gs-3214	163	45	cll	cll	PROPN
gs-3214	163	46	)	)	PUNCT
gs-3214	163	47	,	,	PUNCT
gs-3214	163	48	and	and	CCONJ
gs-3214	163	49	non	non	ADJ
gs-3214	163	50	-	-	ADJ
gs-3214	163	51	hodgkin	hodgkin	ADJ
gs-3214	163	52	lymphoma	lymphoma	NOUN
gs-3214	163	53	(	(	PUNCT
gs-3214	163	54	nhl	nhl	PROPN
gs-3214	163	55	)	)	PUNCT
gs-3214	163	56	.	.	PUNCT
gs-3214	164	1	remarkably	remarkably	ADV
gs-3214	164	2	,	,	PUNCT
gs-3214	164	3	patients	patient	NOUN
gs-3214	164	4	who	who	PRON
gs-3214	164	5	have	have	AUX
gs-3214	164	6	exhausted	exhaust	VERB
gs-3214	164	7	conventional	conventional	ADJ
gs-3214	164	8	treatment	treatment	NOUN
gs-3214	164	9	options	option	NOUN
gs-3214	164	10	have	have	AUX
gs-3214	164	11	borne	bear	VERB
gs-3214	164	12	witness	witness	NOUN
gs-3214	164	13	to	to	PART
gs-3214	164	14	complete	complete	ADJ
gs-3214	164	15	remissions	remission	NOUN
gs-3214	164	16	that	that	PRON
gs-3214	164	17	endure	endure	VERB
gs-3214	164	18	for	for	ADP
gs-3214	164	19	years	year	NOUN
gs-3214	164	20	following	follow	VERB
gs-3214	164	21	car	car	NOUN
gs-3214	164	22	-	-	PUNCT
gs-3214	164	23	t	t	NOUN
gs-3214	164	24	cell	cell	NOUN
gs-3214	164	25	therapy	therapy	NOUN
gs-3214	164	26	.	.	PUNCT
gs-3214	165	1	these	these	DET
gs-3214	165	2	unprecedented	unprecedented	ADJ
gs-3214	165	3	therapeutic	therapeutic	ADJ
gs-3214	165	4	outcomes	outcome	NOUN
gs-3214	165	5	have	have	AUX
gs-3214	165	6	sparked	spark	VERB
gs-3214	165	7	a	a	DET
gs-3214	165	8	conflagration	conflagration	NOUN
gs-3214	165	9	of	of	ADP
gs-3214	165	10	enthusiasm	enthusiasm	NOUN
gs-3214	165	11	and	and	CCONJ
gs-3214	165	12	optimism	optimism	NOUN
gs-3214	165	13	within	within	ADP
gs-3214	165	14	the	the	DET
gs-3214	165	15	hallowed	hallowed	ADJ
gs-3214	165	16	halls	hall	NOUN
gs-3214	165	17	of	of	ADP
gs-3214	165	18	the	the	DET
gs-3214	165	19	medical	medical	ADJ
gs-3214	165	20	fraternity	fraternity	NOUN
gs-3214	165	21	,	,	PUNCT
gs-3214	165	22	and	and	CCONJ
gs-3214	165	23	among	among	ADP
gs-3214	165	24	patients	patient	NOUN
gs-3214	165	25	and	and	CCONJ
gs-3214	165	26	their	their	PRON
gs-3214	165	27	families	family	NOUN
gs-3214	165	28	alike	alike	ADV
gs-3214	165	29	[	[	X
gs-3214	165	30	35	35	NUM
gs-3214	165	31	-	-	SYM
gs-3214	165	32	36	36	NUM
gs-3214	165	33	]	]	PUNCT
gs-3214	165	34	.	.	PUNCT
gs-3214	166	1	car	car	NOUN
gs-3214	166	2	-	-	PUNCT
gs-3214	166	3	t	t	NOUN
gs-3214	166	4	cell	cell	NOUN
gs-3214	166	5	therapy	therapy	NOUN
gs-3214	166	6	hinges	hinge	VERB
gs-3214	166	7	upon	upon	SCONJ
gs-3214	166	8	sophisticated	sophisticated	ADJ
gs-3214	166	9	engineering	engineering	NOUN
gs-3214	166	10	methods	method	NOUN
gs-3214	166	11	to	to	PART
gs-3214	166	12	furnish	furnish	VERB
gs-3214	166	13	t	t	NOUN
gs-3214	166	14	cells	cell	NOUN
gs-3214	166	15	with	with	ADP
gs-3214	166	16	chimeric	chimeric	ADJ
gs-3214	166	17	antigen	antigen	ADJ
gs-3214	166	18	receptors	receptor	NOUN
gs-3214	166	19	(	(	PUNCT
gs-3214	166	20	cars	car	NOUN
gs-3214	166	21	)	)	PUNCT
gs-3214	166	22	,	,	PUNCT
gs-3214	166	23	enabling	enable	VERB
gs-3214	166	24	them	they	PRON
gs-3214	166	25	to	to	PART
gs-3214	166	26	identify	identify	VERB
gs-3214	166	27	tumor	tumor	NOUN
gs-3214	166	28	antigens	antigen	NOUN
gs-3214	166	29	.	.	PUNCT
gs-3214	167	1	these	these	DET
gs-3214	167	2	cars	car	NOUN
gs-3214	167	3	are	be	AUX
gs-3214	167	4	artificial	artificial	ADJ
gs-3214	167	5	receptors	receptor	NOUN
gs-3214	167	6	made	make	VERB
gs-3214	167	7	up	up	ADP
gs-3214	167	8	of	of	ADP
gs-3214	167	9	different	different	ADJ
gs-3214	167	10	functional	functional	ADJ
gs-3214	167	11	segments	segment	NOUN
gs-3214	167	12	,	,	PUNCT
gs-3214	167	13	including	include	VERB
gs-3214	167	14	an	an	DET
gs-3214	167	15	extracellular	extracellular	ADJ
gs-3214	167	16	antigen	antigen	ADJ
gs-3214	167	17	binding	bind	VERB
gs-3214	167	18	sector	sector	NOUN
gs-3214	167	19	,	,	PUNCT
gs-3214	167	20	a	a	DET
gs-3214	167	21	hinge	hinge	NOUN
gs-3214	167	22	and	and	CCONJ
gs-3214	167	23	transmembrane	transmembrane	ADJ
gs-3214	167	24	domain	domain	NOUN
gs-3214	167	25	for	for	ADP
gs-3214	167	26	structural	structural	ADJ
gs-3214	167	27	support	support	NOUN
gs-3214	167	28	,	,	PUNCT
gs-3214	167	29	and	and	CCONJ
gs-3214	167	30	intracellular	intracellular	ADJ
gs-3214	167	31	signaling	signal	VERB
gs-3214	167	32	domain	domain	NOUN
gs-3214	167	33	for	for	ADP
gs-3214	167	34	cell	cell	NOUN
gs-3214	167	35	activation	activation	NOUN
gs-3214	167	36	.	.	PUNCT
gs-3214	168	1	the	the	DET
gs-3214	168	2	antigen	antigen	ADJ
gs-3214	168	3	binding	bind	VERB
gs-3214	168	4	domain	domain	NOUN
gs-3214	168	5	typically	typically	ADV
gs-3214	168	6	contains	contain	VERB
gs-3214	168	7	a	a	DET
gs-3214	168	8	single	single	ADJ
gs-3214	168	9	chain	chain	NOUN
gs-3214	168	10	variable	variable	NOUN
gs-3214	168	11	fragment	fragment	NOUN
gs-3214	168	12	sourced	source	VERB
gs-3214	168	13	from	from	ADP
gs-3214	168	14	a	a	DET
gs-3214	168	15	monoclonal	monoclonal	NOUN
gs-3214	168	16	antibody	antibody	NOUN
gs-3214	168	17	.	.	PUNCT
gs-3214	169	1	this	this	PRON
gs-3214	169	2	allows	allow	VERB
gs-3214	169	3	car	car	NOUN
gs-3214	169	4	-	-	PUNCT
gs-3214	169	5	t	t	NOUN
gs-3214	169	6	cells	cell	NOUN
gs-3214	169	7	to	to	PART
gs-3214	169	8	recognize	recognize	VERB
gs-3214	169	9	tumor	tumor	NOUN
gs-3214	169	10	associated	associate	VERB
gs-3214	169	11	antigens	antigen	NOUN
gs-3214	169	12	(	(	PUNCT
gs-3214	169	13	taas	taas	NOUN
gs-3214	169	14	)	)	PUNCT
gs-3214	169	15	without	without	ADP
gs-3214	169	16	relying	rely	VERB
gs-3214	169	17	on	on	ADP
gs-3214	169	18	the	the	DET
gs-3214	169	19	major	major	ADJ
gs-3214	169	20	histocompatibility	histocompatibility	NOUN
gs-3214	169	21	complex	complex	NOUN
gs-3214	169	22	(	(	PUNCT
gs-3214	169	23	mhc	mhc	PROPN
gs-3214	169	24	)	)	PUNCT
gs-3214	169	25	,	,	PUNCT
gs-3214	169	26	ensuring	ensure	VERB
gs-3214	169	27	precise	precise	ADJ
gs-3214	169	28	and	and	CCONJ
gs-3214	169	29	efficient	efficient	ADJ
gs-3214	169	30	targeting	target	VERB
gs-3214	169	31	[	[	X
gs-3214	169	32	37	37	NUM
gs-3214	169	33	-	-	SYM
gs-3214	169	34	38	38	NUM
gs-3214	169	35	]	]	PUNCT
gs-3214	169	36	.	.	PUNCT
gs-3214	170	1	diverse	diverse	ADJ
gs-3214	170	2	techniques	technique	NOUN
gs-3214	170	3	are	be	AUX
gs-3214	170	4	employed	employ	VERB
gs-3214	170	5	in	in	ADP
gs-3214	170	6	the	the	DET
gs-3214	170	7	engineering	engineering	NOUN
gs-3214	170	8	car	car	NOUN
gs-3214	170	9	-	-	PUNCT
gs-3214	170	10	t	t	NOUN
gs-3214	170	11	cells	cell	NOUN
gs-3214	170	12	,	,	PUNCT
gs-3214	170	13	including	include	VERB
gs-3214	170	14	both	both	CCONJ
gs-3214	170	15	viral	viral	ADJ
gs-3214	170	16	and	and	CCONJ
gs-3214	170	17	non	non	ADJ
gs-3214	170	18	-	-	ADJ
gs-3214	170	19	viral	viral	ADJ
gs-3214	170	20	gene	gene	NOUN
gs-3214	170	21	transfer	transfer	NOUN
gs-3214	170	22	methodology	methodology	NOUN
gs-3214	170	23	.	.	PUNCT
gs-3214	171	1	viral	viral	ADJ
gs-3214	171	2	vectors	vector	NOUN
gs-3214	171	3	such	such	ADJ
gs-3214	171	4	as	as	ADP
gs-3214	171	5	lentiviral	lentiviral	ADJ
gs-3214	171	6	and	and	CCONJ
gs-3214	171	7	retroviral	retroviral	ADJ
gs-3214	171	8	vectors	vector	NOUN
gs-3214	171	9	,	,	PUNCT
gs-3214	171	10	are	be	AUX
gs-3214	171	11	often	often	ADV
gs-3214	171	12	favored	favor	VERB
gs-3214	171	13	due	due	ADP
gs-3214	171	14	to	to	ADP
gs-3214	171	15	their	their	PRON
gs-3214	171	16	superior	superior	ADJ
gs-3214	171	17	transduction	transduction	NOUN
gs-3214	171	18	efficiency	efficiency	NOUN
gs-3214	171	19	and	and	CCONJ
gs-3214	171	20	stable	stable	ADJ
gs-3214	171	21	integration	integration	NOUN
gs-3214	171	22	into	into	ADP
gs-3214	171	23	the	the	DET
gs-3214	171	24	host	host	NOUN
gs-3214	171	25	genome	genome	NOUN
gs-3214	171	26	,	,	PUNCT
gs-3214	171	27	facilitating	facilitate	VERB
gs-3214	171	28	the	the	DET
gs-3214	171	29	efficient	efficient	ADJ
gs-3214	171	30	delivery	delivery	NOUN
gs-3214	171	31	of	of	ADP
gs-3214	171	32	car	car	NOUN
gs-3214	171	33	transgenes	transgene	NOUN
gs-3214	171	34	into	into	ADP
gs-3214	171	35	t	t	NOUN
gs-3214	171	36	cells	cell	NOUN
gs-3214	171	37	.	.	PUNCT
gs-3214	172	1	non	non	ADJ
gs-3214	172	2	-	-	ADJ
gs-3214	172	3	viral	viral	ADJ
gs-3214	172	4	techniques	technique	NOUN
gs-3214	172	5	,	,	PUNCT
gs-3214	172	6	such	such	ADJ
gs-3214	172	7	as	as	ADP
gs-3214	172	8	electroporation	electroporation	NOUN
gs-3214	172	9	and	and	CCONJ
gs-3214	172	10	transposon	transposon	NOUN
gs-3214	172	11	-	-	PUNCT
gs-3214	172	12	based	base	VERB
gs-3214	172	13	systems	system	NOUN
gs-3214	172	14	,	,	PUNCT
gs-3214	172	15	present	present	ADJ
gs-3214	172	16	alternative	alternative	ADJ
gs-3214	172	17	strategies	strategy	NOUN
gs-3214	172	18	for	for	ADP
gs-3214	172	19	car	car	NOUN
gs-3214	172	20	-	-	PUNCT
gs-3214	172	21	t	t	NOUN
gs-3214	172	22	cell	cell	NOUN
gs-3214	172	23	engineering	engineering	NOUN
gs-3214	172	24	,	,	PUNCT
gs-3214	172	25	offering	offer	VERB
gs-3214	172	26	advantages	advantage	NOUN
gs-3214	172	27	in	in	ADP
gs-3214	172	28	terms	term	NOUN
gs-3214	172	29	of	of	ADP
gs-3214	172	30	safety	safety	NOUN
gs-3214	172	31	and	and	CCONJ
gs-3214	172	32	scalability	scalability	NOUN
gs-3214	172	33	[	[	X
gs-3214	172	34	39	39	NUM
gs-3214	172	35	-	-	SYM
gs-3214	172	36	40	40	NUM
gs-3214	172	37	]	]	PUNCT
gs-3214	172	38	.	.	PUNCT
gs-3214	173	1	maximizing	maximize	VERB
gs-3214	173	2	car	car	NOUN
gs-3214	173	3	design	design	NOUN
gs-3214	173	4	is	be	AUX
gs-3214	173	5	imperative	imperative	ADJ
gs-3214	173	6	for	for	ADP
gs-3214	173	7	augmenting	augment	VERB
gs-3214	173	8	car	car	NOUN
gs-3214	173	9	-	-	PUNCT
gs-3214	173	10	t	t	NOUN
gs-3214	173	11	cell	cell	NOUN
gs-3214	173	12	potency	potency	NOUN
gs-3214	173	13	and	and	CCONJ
gs-3214	173	14	longevity	longevity	NOUN
gs-3214	173	15	.	.	PUNCT
gs-3214	174	1	vital	vital	ADJ
gs-3214	174	2	considerations	consideration	NOUN
gs-3214	174	3	involve	involve	VERB
gs-3214	174	4	choosing	choose	VERB
gs-3214	174	5	a	a	DET
gs-3214	174	6	suitable	suitable	ADJ
gs-3214	174	7	to	to	PART
gs-3214	174	8	target	target	VERB
gs-3214	174	9	tumor	tumor	NOUN
gs-3214	174	10	specific	specific	ADJ
gs-3214	174	11	antigens	antigen	NOUN
gs-3214	174	12	,	,	PUNCT
gs-3214	174	13	adjusting	adjust	VERB
gs-3214	174	14	spacer	spacer	NOUN
gs-3214	174	15	and	and	CCONJ
gs-3214	174	16	transmembrane	transmembrane	NOUN
gs-3214	174	17	domains	domain	NOUN
gs-3214	174	18	to	to	PART
gs-3214	174	19	encourage	encourage	VERB
gs-3214	174	20	car	car	NOUN
gs-3214	174	21	clustering	clustering	NOUN
gs-3214	174	22	and	and	CCONJ
gs-3214	174	23	signaling	signal	VERB
gs-3214	174	24	,	,	PUNCT
gs-3214	174	25	and	and	CCONJ
gs-3214	174	26	integrating	integrate	VERB
gs-3214	174	27	co	co	ADJ
gs-3214	174	28	-	-	ADJ
gs-3214	174	29	stimulatory	stimulatory	ADJ
gs-3214	174	30	domains	domain	NOUN
gs-3214	174	31	like	like	ADP
gs-3214	174	32	cd28	cd28	PROPN
gs-3214	174	33	,	,	PUNCT
gs-3214	174	34	4	4	NUM
gs-3214	174	35	-	-	SYM
gs-3214	174	36	1bb	1bb	NUM
gs-3214	174	37	,	,	PUNCT
gs-3214	174	38	or	or	CCONJ
gs-3214	174	39	ox40	ox40	PROPN
gs-3214	174	40	to	to	PART
gs-3214	174	41	bolster	bolster	VERB
gs-3214	174	42	t	t	NOUN
gs-3214	174	43	cell	cell	NOUN
gs-3214	174	44	activation	activation	NOUN
gs-3214	174	45	and	and	CCONJ
gs-3214	174	46	survival	survival	NOUN
gs-3214	175	1	[	[	X
gs-3214	175	2	41	41	NUM
gs-3214	175	3	-	-	SYM
gs-3214	175	4	42	42	NUM
gs-3214	175	5	]	]	PUNCT
gs-3214	175	6	.	.	PUNCT
gs-3214	176	1	georgian	georgian	PROPN
gs-3214	176	2	scientists/	scientists/	NUM
gs-3214	176	3	.	.	PUNCT
gs-3214	177	1	6	6	NUM
gs-3214	177	2	n	n	NUM
gs-3214	177	3	3	3	NUM
gs-3214	177	4	,	,	PUNCT
gs-3214	177	5	2024	2024	NUM
gs-3214	177	6	272	272	NUM
gs-3214	177	7	car	car	NOUN
gs-3214	177	8	-	-	PUNCT
gs-3214	177	9	t	t	NOUN
gs-3214	177	10	cell	cell	NOUN
gs-3214	177	11	therapy	therapy	NOUN
gs-3214	177	12	’s	’s	PART
gs-3214	177	13	success	success	NOUN
gs-3214	177	14	depends	depend	VERB
gs-3214	177	15	on	on	ADP
gs-3214	177	16	selecting	select	VERB
gs-3214	177	17	specific	specific	ADJ
gs-3214	177	18	target	target	NOUN
gs-3214	177	19	antigens	antigen	NOUN
gs-3214	177	20	expressed	express	VERB
gs-3214	177	21	on	on	ADP
gs-3214	177	22	tumor	tumor	NOUN
gs-3214	177	23	cells	cell	NOUN
gs-3214	177	24	while	while	SCONJ
gs-3214	177	25	avoiding	avoid	VERB
gs-3214	177	26	heathy	heathy	ADJ
gs-3214	177	27	tissues	tissue	NOUN
gs-3214	177	28	.	.	PUNCT
gs-3214	178	1	ideal	ideal	ADJ
gs-3214	178	2	antigens	antigen	NOUN
gs-3214	178	3	possess	possess	VERB
gs-3214	178	4	high	high	ADJ
gs-3214	178	5	expression	expression	NOUN
gs-3214	178	6	levels	level	NOUN
gs-3214	178	7	in	in	ADP
gs-3214	178	8	cancer	cancer	NOUN
gs-3214	178	9	cells	cell	NOUN
gs-3214	178	10	,	,	PUNCT
gs-3214	178	11	minimal	minimal	ADJ
gs-3214	178	12	presence	presence	NOUN
gs-3214	178	13	in	in	ADP
gs-3214	178	14	normal	normal	ADJ
gs-3214	178	15	tissues	tissue	NOUN
gs-3214	178	16	,	,	PUNCT
gs-3214	178	17	and	and	CCONJ
gs-3214	178	18	essential	essential	ADJ
gs-3214	178	19	in	in	ADP
gs-3214	178	20	oncogenesis	oncogenesis	NOUN
gs-3214	178	21	.	.	PUNCT
gs-3214	179	1	cd19	cd19	PROPN
gs-3214	179	2	is	be	AUX
gs-3214	179	3	among	among	ADP
gs-3214	179	4	thoroughly	thoroughly	ADV
gs-3214	179	5	investigated	investigate	VERB
gs-3214	179	6	target	target	NOUN
gs-3214	179	7	antigens	antigen	NOUN
gs-3214	179	8	in	in	ADP
gs-3214	179	9	car	car	NOUN
gs-3214	179	10	-	-	PUNCT
gs-3214	179	11	t	t	NOUN
gs-3214	179	12	cell	cell	NOUN
gs-3214	179	13	therapy	therapy	NOUN
gs-3214	179	14	,	,	PUNCT
gs-3214	179	15	notably	notably	ADV
gs-3214	179	16	for	for	ADP
gs-3214	179	17	hematologic	hematologic	ADJ
gs-3214	179	18	malignancies	malignancy	NOUN
gs-3214	179	19	like	like	ADP
gs-3214	179	20	b	b	NOUN
gs-3214	179	21	-	-	PUNCT
gs-3214	179	22	cell	cell	NOUN
gs-3214	179	23	acute	acute	ADJ
gs-3214	179	24	lymphoblastic	lymphoblastic	ADJ
gs-3214	179	25	leukemia	leukemia	NOUN
gs-3214	179	26	(	(	PUNCT
gs-3214	179	27	all	all	PRON
gs-3214	179	28	)	)	PUNCT
gs-3214	179	29	and	and	CCONJ
gs-3214	179	30	non	non	ADJ
gs-3214	179	31	-	-	ADJ
gs-3214	179	32	hodgkin	hodgkin	ADJ
gs-3214	179	33	lymphoma	lymphoma	NOUN
gs-3214	179	34	(	(	PUNCT
gs-3214	179	35	nhl	nhl	PROPN
gs-3214	179	36	)	)	PUNCT
gs-3214	179	37	.	.	PUNCT
gs-3214	180	1	as	as	SCONJ
gs-3214	180	2	a	a	DET
gs-3214	180	3	b	b	NOUN
gs-3214	180	4	cell	cell	NOUN
gs-3214	180	5	specific	specific	ADJ
gs-3214	180	6	surface	surface	NOUN
gs-3214	180	7	antigen	antigen	NOUN
gs-3214	180	8	expressed	express	VERB
gs-3214	180	9	across	across	ADP
gs-3214	180	10	all	all	DET
gs-3214	180	11	stages	stage	NOUN
gs-3214	180	12	of	of	ADP
gs-3214	180	13	b	b	NOUN
gs-3214	180	14	cell	cell	NOUN
gs-3214	180	15	development	development	NOUN
gs-3214	180	16	,	,	PUNCT
gs-3214	180	17	cd19	cd19	PROPN
gs-3214	180	18	presents	present	VERB
gs-3214	180	19	an	an	DET
gs-3214	180	20	attractive	attractive	ADJ
gs-3214	180	21	target	target	NOUN
gs-3214	180	22	for	for	ADP
gs-3214	180	23	car	car	NOUN
gs-3214	180	24	-	-	PUNCT
gs-3214	180	25	t	t	NOUN
gs-3214	180	26	cell	cell	NOUN
gs-3214	180	27	therapy	therapy	NOUN
gs-3214	180	28	.	.	PUNCT
gs-3214	181	1	clinical	clinical	ADJ
gs-3214	181	2	trials	trial	NOUN
gs-3214	181	3	of	of	ADP
gs-3214	181	4	cd19	cd19	PROPN
gs-3214	181	5	targeted	target	VERB
gs-3214	181	6	car	car	NOUN
gs-3214	181	7	-	-	PUNCT
gs-3214	181	8	t	t	NOUN
gs-3214	181	9	cells	cell	NOUN
gs-3214	181	10	,	,	PUNCT
gs-3214	181	11	such	such	ADJ
gs-3214	181	12	as	as	ADP
gs-3214	181	13	tisagenlecleucel	tisagenlecleucel	ADJ
gs-3214	181	14	and	and	CCONJ
gs-3214	181	15	axicabtagene	axicabtagene	PROPN
gs-3214	181	16	ciloleucel	ciloleucel	PROPN
gs-3214	181	17	,	,	PUNCT
gs-3214	181	18	have	have	AUX
gs-3214	181	19	demonstrated	demonstrate	VERB
gs-3214	181	20	remarkable	remarkable	ADJ
gs-3214	181	21	efficacy	efficacy	NOUN
gs-3214	181	22	in	in	ADP
gs-3214	181	23	inducing	induce	VERB
gs-3214	181	24	lasting	last	VERB
gs-3214	181	25	remissions	remission	NOUN
gs-3214	181	26	in	in	ADP
gs-3214	181	27	patients	patient	NOUN
gs-3214	181	28	with	with	ADP
gs-3214	181	29	relapsed	relapse	VERB
gs-3214	181	30	or	or	CCONJ
gs-3214	181	31	refractory	refractory	NOUN
gs-3214	181	32	b	b	NOUN
gs-3214	181	33	-	-	PUNCT
gs-3214	181	34	cell	cell	NOUN
gs-3214	181	35	malignancies	malignancy	NOUN
gs-3214	181	36	[	[	X
gs-3214	181	37	43	43	NUM
gs-3214	181	38	-	-	SYM
gs-3214	181	39	44	44	NUM
gs-3214	181	40	]	]	PUNCT
gs-3214	181	41	.	.	PUNCT
gs-3214	182	1	new	new	ADJ
gs-3214	182	2	target	target	NOUN
gs-3214	182	3	antigens	antigen	NOUN
gs-3214	182	4	beyond	beyond	ADP
gs-3214	182	5	cd19	cd19	PROPN
gs-3214	182	6	are	be	AUX
gs-3214	182	7	sought	seek	VERB
gs-3214	182	8	for	for	ADP
gs-3214	182	9	car	car	NOUN
gs-3214	182	10	-	-	PUNCT
gs-3214	182	11	t	t	NOUN
gs-3214	182	12	cell	cell	NOUN
gs-3214	182	13	therapy	therapy	NOUN
gs-3214	182	14	in	in	ADP
gs-3214	182	15	various	various	ADJ
gs-3214	182	16	hematologic	hematologic	NOUN
gs-3214	182	17	and	and	CCONJ
gs-3214	182	18	solid	solid	ADJ
gs-3214	182	19	tumors	tumor	NOUN
gs-3214	182	20	,	,	PUNCT
gs-3214	182	21	including	include	VERB
gs-3214	182	22	cd20	cd20	PROPN
gs-3214	182	23	,	,	PUNCT
gs-3214	182	24	cd22	cd22	PROPN
gs-3214	182	25	,	,	PUNCT
gs-3214	182	26	cd30	cd30	PROPN
gs-3214	182	27	,	,	PUNCT
gs-3214	182	28	and	and	CCONJ
gs-3214	182	29	cd123	cd123	PROPN
gs-3214	182	30	in	in	ADP
gs-3214	182	31	hematologic	hematologic	NOUN
gs-3214	182	32	malignancies	malignancy	NOUN
gs-3214	182	33	,	,	PUNCT
gs-3214	182	34	and	and	CCONJ
gs-3214	182	35	her2	her2	PROPN
gs-3214	182	36	,	,	PUNCT
gs-3214	182	37	egfr	egfr	ADJ
gs-3214	182	38	,	,	PUNCT
gs-3214	182	39	mesothelial	mesothelial	ADJ
gs-3214	182	40	,	,	PUNCT
gs-3214	182	41	and	and	CCONJ
gs-3214	182	42	gd2	gd2	NOUN
gs-3214	182	43	in	in	ADP
gs-3214	182	44	solid	solid	ADJ
gs-3214	182	45	tumors	tumor	NOUN
gs-3214	182	46	.	.	PUNCT
gs-3214	183	1	antigen	antigen	ADJ
gs-3214	183	2	diversity	diversity	NOUN
gs-3214	183	3	,	,	PUNCT
gs-3214	183	4	loss	loss	NOUN
gs-3214	183	5	variants	variant	NOUN
gs-3214	183	6	,	,	PUNCT
gs-3214	183	7	and	and	CCONJ
gs-3214	183	8	potential	potential	ADJ
gs-3214	183	9	toxicities	toxicity	NOUN
gs-3214	183	10	emphasize	emphasize	VERB
gs-3214	183	11	the	the	DET
gs-3214	183	12	need	need	NOUN
gs-3214	183	13	of	of	ADP
gs-3214	183	14	meticulous	meticulous	ADJ
gs-3214	183	15	antigen	antigen	ADJ
gs-3214	183	16	selection	selection	NOUN
gs-3214	183	17	and	and	CCONJ
gs-3214	183	18	precinct	precinct	ADJ
gs-3214	183	19	evaluation	evaluation	NOUN
gs-3214	183	20	.	.	PUNCT
gs-3214	184	1	car	car	NOUN
gs-3214	184	2	’s	’s	PART
gs-3214	184	3	intracellular	intracellular	ADJ
gs-3214	184	4	singing	singing	NOUN
gs-3214	184	5	domains	domain	NOUN
gs-3214	184	6	usually	usually	ADV
gs-3214	184	7	include	include	VERB
gs-3214	184	8	cd3	cd3	VERB
gs-3214	184	9	,	,	PUNCT
gs-3214	184	10	housing	housing	NOUN
gs-3214	184	11	immunoreceptor	immunoreceptor	NOUN
gs-3214	184	12	tyrosine	tyrosine	NOUN
gs-3214	184	13	-	-	PUNCT
gs-3214	184	14	based	base	VERB
gs-3214	184	15	activation	activation	NOUN
gs-3214	184	16	motifs	motif	NOUN
gs-3214	184	17	(	(	PUNCT
gs-3214	184	18	itams	itam	NOUN
gs-3214	184	19	)	)	PUNCT
gs-3214	184	20	responsive	responsive	ADJ
gs-3214	184	21	for	for	ADP
gs-3214	184	22	triggering	trigger	VERB
gs-3214	184	23	t	t	PROPN
gs-3214	184	24	cell	cell	NOUN
gs-3214	184	25	activation	activation	NOUN
gs-3214	184	26	upon	upon	SCONJ
gs-3214	184	27	antigen	antigen	ADJ
gs-3214	184	28	recognition	recognition	NOUN
gs-3214	184	29	.	.	PUNCT
gs-3214	185	1	however	however	ADV
gs-3214	185	2	,	,	PUNCT
gs-3214	185	3	adding	add	VERB
gs-3214	185	4	co	co	AUX
gs-3214	185	5	stimulatory	stimulatory	ADJ
gs-3214	185	6	domains	domain	NOUN
gs-3214	185	7	like	like	ADP
gs-3214	185	8	cd28	cd28	PROPN
gs-3214	185	9	,	,	PUNCT
gs-3214	185	10	4	4	NUM
gs-3214	185	11	-	-	SYM
gs-3214	185	12	1bb(cd137	1bb(cd137	NUM
gs-3214	185	13	)	)	PUNCT
gs-3214	185	14	,	,	PUNCT
gs-3214	185	15	or	or	CCONJ
gs-3214	185	16	ox40(cd134	ox40(cd134	NOUN
gs-3214	185	17	)	)	PUNCT
gs-3214	185	18	to	to	ADP
gs-3214	185	19	car	car	NOUN
gs-3214	185	20	constructs	construct	NOUN
gs-3214	185	21	provide	provide	VERB
gs-3214	185	22	extra	extra	ADJ
gs-3214	185	23	signaling	signal	VERB
gs-3214	185	24	cues	cue	NOUN
gs-3214	185	25	that	that	PRON
gs-3214	185	26	boost	boost	VERB
gs-3214	185	27	t	t	NOUN
gs-3214	185	28	cell	cell	NOUN
gs-3214	185	29	activation	activation	NOUN
gs-3214	185	30	and	and	CCONJ
gs-3214	185	31	proliferation	proliferation	NOUN
gs-3214	185	32	.	.	PUNCT
gs-3214	186	1	after	after	ADP
gs-3214	186	2	recognizing	recognize	VERB
gs-3214	186	3	antigens	antigen	NOUN
gs-3214	186	4	and	and	CCONJ
gs-3214	186	5	receiving	receive	VERB
gs-3214	186	6	co	co	ADJ
gs-3214	186	7	-	-	ADJ
gs-3214	186	8	stimulatory	stimulatory	ADJ
gs-3214	186	9	signals	signal	NOUN
gs-3214	186	10	,	,	PUNCT
gs-3214	186	11	activated	activate	VERB
gs-3214	186	12	car	car	NOUN
gs-3214	186	13	-	-	PUNCT
gs-3214	186	14	t	t	NOUN
gs-3214	186	15	cells	cell	NOUN
gs-3214	186	16	undergo	undergo	VERB
gs-3214	186	17	clonal	clonal	ADJ
gs-3214	186	18	expansion	expansion	NOUN
gs-3214	186	19	to	to	PART
gs-3214	186	20	produce	produce	VERB
gs-3214	186	21	a	a	DET
gs-3214	186	22	strong	strong	ADJ
gs-3214	186	23	effector	effector	NOUN
gs-3214	186	24	cell	cell	NOUN
gs-3214	186	25	population	population	NOUN
gs-3214	186	26	,	,	PUNCT
gs-3214	186	27	capable	capable	ADJ
gs-3214	186	28	of	of	ADP
gs-3214	186	29	exerting	exert	VERB
gs-3214	186	30	cytotoxic	cytotoxic	ADJ
gs-3214	186	31	activity	activity	NOUN
gs-3214	186	32	against	against	ADP
gs-3214	186	33	tumor	tumor	NOUN
gs-3214	186	34	cells	cell	NOUN
gs-3214	186	35	.	.	PUNCT
gs-3214	187	1	this	this	DET
gs-3214	187	2	proliferative	proliferative	ADJ
gs-3214	187	3	process	process	NOUN
gs-3214	187	4	is	be	AUX
gs-3214	187	5	driven	drive	VERB
gs-3214	187	6	by	by	ADP
gs-3214	187	7	cytokines	cytokine	NOUN
gs-3214	187	8	like	like	ADP
gs-3214	187	9	interleukin-2	interleukin-2	NOUN
gs-3214	187	10	(	(	PUNCT
gs-3214	187	11	il-2	il-2	NUM
gs-3214	187	12	)	)	PUNCT
gs-3214	187	13	,	,	PUNCT
gs-3214	187	14	interleukin-7	interleukin-7	PROPN
gs-3214	187	15	(	(	PUNCT
gs-3214	187	16	il-7	il-7	NOUN
gs-3214	187	17	)	)	PUNCT
gs-3214	187	18	,	,	PUNCT
gs-3214	187	19	and	and	CCONJ
gs-3214	187	20	interleukin-15	interleukin-15	PROPN
gs-3214	187	21	(	(	PUNCT
gs-3214	187	22	il-15	il-15	NOUN
gs-3214	187	23	)	)	PUNCT
gs-3214	187	24	,	,	PUNCT
gs-3214	187	25	which	which	PRON
gs-3214	187	26	enhance	enhance	VERB
gs-3214	187	27	t	t	PROPN
gs-3214	187	28	cell	cell	NOUN
gs-3214	187	29	growth	growth	NOUN
gs-3214	187	30	and	and	CCONJ
gs-3214	187	31	survival	survival	NOUN
gs-3214	187	32	[	[	X
gs-3214	187	33	45	45	NUM
gs-3214	187	34	-	-	SYM
gs-3214	187	35	46	46	NUM
gs-3214	187	36	]	]	PUNCT
gs-3214	187	37	.	.	PUNCT
gs-3214	188	1	optimizing	optimize	VERB
gs-3214	188	2	the	the	DET
gs-3214	188	3	activation	activation	NOUN
gs-3214	188	4	and	and	CCONJ
gs-3214	188	5	proliferation	proliferation	NOUN
gs-3214	188	6	kinetics	kinetic	NOUN
gs-3214	188	7	of	of	ADP
gs-3214	188	8	car	car	NOUN
gs-3214	188	9	-	-	PUNCT
gs-3214	188	10	t	t	NOUN
gs-3214	188	11	cells	cell	NOUN
gs-3214	188	12	is	be	AUX
gs-3214	188	13	essential	essential	ADJ
gs-3214	188	14	for	for	ADP
gs-3214	188	15	maximizing	maximize	VERB
gs-3214	188	16	therapeutic	therapeutic	ADJ
gs-3214	188	17	efficacy	efficacy	NOUN
gs-3214	188	18	while	while	SCONJ
gs-3214	188	19	minimizing	minimize	VERB
gs-3214	188	20	toxicities	toxicity	NOUN
gs-3214	188	21	.	.	PUNCT
gs-3214	189	1	strategies	strategy	NOUN
gs-3214	189	2	for	for	ADP
gs-3214	189	3	enhancing	enhance	VERB
gs-3214	189	4	car	car	NOUN
gs-3214	189	5	-	-	PUNCT
gs-3214	189	6	t	t	NOUN
gs-3214	189	7	cell	cell	NOUN
gs-3214	189	8	expansion	expansion	NOUN
gs-3214	189	9	include	include	VERB
gs-3214	189	10	cytokine	cytokine	ADJ
gs-3214	189	11	supplementation	supplementation	NOUN
gs-3214	189	12	,	,	PUNCT
gs-3214	189	13	co	co	ADJ
gs-3214	189	14	-	-	ADJ
gs-3214	189	15	stimulatory	stimulatory	ADJ
gs-3214	189	16	molecule	molecule	NOUN
gs-3214	189	17	engagement	engagement	NOUN
gs-3214	189	18	,	,	PUNCT
gs-3214	189	19	and	and	CCONJ
gs-3214	189	20	metabolic	metabolic	NOUN
gs-3214	189	21	modulation	modulation	NOUN
gs-3214	189	22	to	to	PART
gs-3214	189	23	promote	promote	VERB
gs-3214	189	24	an	an	DET
gs-3214	189	25	optimal	optimal	ADJ
gs-3214	189	26	balance	balance	NOUN
gs-3214	189	27	between	between	ADP
gs-3214	189	28	effector	effector	NOUN
gs-3214	189	29	and	and	CCONJ
gs-3214	189	30	memory	memory	NOUN
gs-3214	189	31	t	t	NOUN
gs-3214	189	32	cell	cell	NOUN
gs-3214	189	33	phenotypes	phenotype	NOUN
gs-3214	189	34	.	.	PUNCT
gs-3214	190	1	moreover	moreover	ADV
gs-3214	190	2	,	,	PUNCT
gs-3214	190	3	advancements	advancement	NOUN
gs-3214	190	4	in	in	ADP
gs-3214	190	5	car	car	NOUN
gs-3214	190	6	-	-	PUNCT
gs-3214	190	7	t	t	NOUN
gs-3214	190	8	cell	cell	NOUN
gs-3214	190	9	engineering	engineering	NOUN
gs-3214	190	10	,	,	PUNCT
gs-3214	190	11	including	include	VERB
gs-3214	190	12	integrating	integrate	VERB
gs-3214	190	13	inducible	inducible	ADJ
gs-3214	190	14	signaling	signal	VERB
gs-3214	190	15	modules	module	NOUN
gs-3214	190	16	and	and	CCONJ
gs-3214	190	17	employing	employ	VERB
gs-3214	190	18	synthetic	synthetic	ADJ
gs-3214	190	19	biology	biology	NOUN
gs-3214	190	20	techniques	technique	NOUN
gs-3214	190	21	,	,	PUNCT
gs-3214	190	22	provide	provide	VERB
gs-3214	190	23	avenues	avenue	NOUN
gs-3214	190	24	to	to	PART
gs-3214	190	25	refine	refine	VERB
gs-3214	190	26	car	car	NOUN
gs-3214	190	27	-	-	PUNCT
gs-3214	190	28	t	t	NOUN
gs-3214	190	29	cell	cell	NOUN
gs-3214	190	30	activation	activation	NOUN
gs-3214	190	31	kinetics	kinetic	NOUN
gs-3214	190	32	and	and	CCONJ
gs-3214	190	33	improve	improve	VERB
gs-3214	190	34	treatment	treatment	NOUN
gs-3214	190	35	effectiveness	effectiveness	NOUN
gs-3214	190	36	.	.	PUNCT
gs-3214	191	1	however	however	ADV
gs-3214	191	2	,	,	PUNCT
gs-3214	191	3	notwithstanding	notwithstanding	ADP
gs-3214	191	4	its	its	PRON
gs-3214	191	5	considerable	considerable	ADJ
gs-3214	191	6	promise	promise	NOUN
gs-3214	191	7	,	,	PUNCT
gs-3214	191	8	car	car	NOUN
gs-3214	191	9	-	-	PUNCT
gs-3214	191	10	t	t	NOUN
gs-3214	191	11	cell	cell	NOUN
gs-3214	191	12	therapy	therapy	NOUN
gs-3214	191	13	is	be	AUX
gs-3214	191	14	not	not	PART
gs-3214	191	15	without	without	ADP
gs-3214	191	16	its	its	PRON
gs-3214	191	17	formidable	formidable	ADJ
gs-3214	191	18	challenges	challenge	NOUN
gs-3214	191	19	and	and	CCONJ
gs-3214	191	20	limitations	limitation	NOUN
gs-3214	191	21	.	.	PUNCT
gs-3214	192	1	issues	issue	NOUN
gs-3214	192	2	such	such	ADJ
gs-3214	192	3	as	as	ADP
gs-3214	192	4	cytokine	cytokine	ADJ
gs-3214	192	5	release	release	NOUN
gs-3214	192	6	syndrome	syndrome	NOUN
gs-3214	192	7	(	(	PUNCT
gs-3214	192	8	crs	crs	PROPN
gs-3214	192	9	)	)	PUNCT
gs-3214	192	10	,	,	PUNCT
gs-3214	192	11	neurotoxicity	neurotoxicity	NOUN
gs-3214	192	12	,	,	PUNCT
gs-3214	192	13	the	the	DET
gs-3214	192	14	risk	risk	NOUN
gs-3214	192	15	of	of	ADP
gs-3214	192	16	on	on	ADP
gs-3214	192	17	-	-	PUNCT
gs-3214	192	18	target	target	VERB
gs-3214	192	19	/	/	SYM
gs-3214	192	20	off	off	ADP
gs-3214	192	21	-	-	PUNCT
gs-3214	192	22	tumor	tumor	NOUN
gs-3214	192	23	toxicities	toxicity	NOUN
gs-3214	192	24	,	,	PUNCT
gs-3214	192	25	and	and	CCONJ
gs-3214	192	26	the	the	DET
gs-3214	192	27	circumscribed	circumscribed	ADJ
gs-3214	192	28	durability	durability	NOUN
gs-3214	192	29	of	of	ADP
gs-3214	192	30	responses	response	NOUN
gs-3214	192	31	in	in	ADP
gs-3214	192	32	select	select	ADJ
gs-3214	192	33	patient	patient	NOUN
gs-3214	192	34	cohorts	cohort	NOUN
gs-3214	192	35	underscore	underscore	VERB
gs-3214	192	36	the	the	DET
gs-3214	192	37	pressing	press	VERB
gs-3214	192	38	exigency	exigency	NOUN
gs-3214	192	39	for	for	ADP
gs-3214	192	40	continued	continue	VERB
gs-3214	192	41	research	research	NOUN
gs-3214	192	42	and	and	CCONJ
gs-3214	192	43	refinement	refinement	NOUN
gs-3214	192	44	.	.	PUNCT
gs-3214	193	1	additionally	additionally	ADV
gs-3214	193	2	,	,	PUNCT
gs-3214	193	3	the	the	DET
gs-3214	193	4	formidable	formidable	ADJ
gs-3214	193	5	financial	financial	ADJ
gs-3214	193	6	impediments	impediment	NOUN
gs-3214	193	7	associated	associate	VERB
gs-3214	193	8	with	with	ADP
gs-3214	193	9	car	car	NOUN
gs-3214	193	10	-	-	PUNCT
gs-3214	193	11	t	t	NOUN
gs-3214	193	12	cell	cell	NOUN
gs-3214	193	13	therapy	therapy	NOUN
gs-3214	193	14	pose	pose	VERB
gs-3214	193	15	significant	significant	ADJ
gs-3214	193	16	hurdles	hurdle	NOUN
gs-3214	193	17	to	to	ADP
gs-3214	193	18	accessibility	accessibility	NOUN
gs-3214	193	19	for	for	ADP
gs-3214	193	20	a	a	DET
gs-3214	193	21	considerable	considerable	ADJ
gs-3214	193	22	segment	segment	NOUN
gs-3214	193	23	of	of	ADP
gs-3214	193	24	patients	patient	NOUN
gs-3214	193	25	,	,	PUNCT
gs-3214	193	26	thereby	thereby	ADV
gs-3214	193	27	accentuating	accentuate	VERB
gs-3214	193	28	the	the	DET
gs-3214	193	29	imperative	imperative	NOUN
gs-3214	193	30	to	to	ADP
gs-3214	193	31	redress	redress	NOUN
gs-3214	193	32	issues	issue	NOUN
gs-3214	193	33	of	of	ADP
gs-3214	193	34	affordability	affordability	NOUN
gs-3214	193	35	and	and	CCONJ
gs-3214	193	36	equitable	equitable	ADJ
gs-3214	193	37	distribution	distribution	NOUN
gs-3214	193	38	through	through	ADP
gs-3214	193	39	strategic	strategic	ADJ
gs-3214	193	40	policymaking	policymaking	NOUN
gs-3214	193	41	and	and	CCONJ
gs-3214	193	42	resource	resource	NOUN
gs-3214	193	43	allocation	allocation	NOUN
gs-3214	193	44	[	[	X
gs-3214	193	45	47	47	NUM
gs-3214	193	46	-	-	SYM
gs-3214	193	47	48	48	NUM
gs-3214	193	48	]	]	PUNCT
gs-3214	193	49	.	.	PUNCT
gs-3214	194	1	car	car	NOUN
gs-3214	194	2	-	-	PUNCT
gs-3214	194	3	t	t	NOUN
gs-3214	194	4	cells	cell	NOUN
gs-3214	194	5	exert	exert	VERB
gs-3214	194	6	their	their	PRON
gs-3214	194	7	anti	anti	ADJ
gs-3214	194	8	-	-	ADJ
gs-3214	194	9	cancer	cancer	ADJ
gs-3214	194	10	impacts	impact	NOUN
gs-3214	194	11	through	through	ADP
gs-3214	194	12	diverse	diverse	ADJ
gs-3214	194	13	mechanisms	mechanism	NOUN
gs-3214	194	14	,	,	PUNCT
gs-3214	194	15	such	such	ADJ
gs-3214	194	16	as	as	ADP
gs-3214	194	17	direct	direct	ADJ
gs-3214	194	18	cell	cell	NOUN
gs-3214	194	19	killing	killing	NOUN
gs-3214	194	20	,	,	PUNCT
gs-3214	194	21	release	release	NOUN
gs-3214	194	22	of	of	ADP
gs-3214	194	23	cytokines	cytokine	NOUN
gs-3214	194	24	,	,	PUNCT
gs-3214	194	25	and	and	CCONJ
gs-3214	194	26	attracting	attract	VERB
gs-3214	194	27	immune	immune	ADJ
gs-3214	194	28	cells	cell	NOUN
gs-3214	194	29	.	.	PUNCT
gs-3214	195	1	when	when	SCONJ
gs-3214	195	2	they	they	PRON
gs-3214	195	3	encounter	encounter	VERB
gs-3214	195	4	tumor	tumor	NOUN
gs-3214	195	5	cells	cell	NOUN
gs-3214	195	6	displaying	display	VERB
gs-3214	195	7	specific	specific	ADJ
gs-3214	195	8	antigens	antigen	NOUN
gs-3214	195	9	,	,	PUNCT
gs-3214	195	10	car	car	NOUN
gs-3214	195	11	-	-	PUNCT
gs-3214	195	12	t	t	NOUN
gs-3214	195	13	cells	cell	NOUN
gs-3214	195	14	activate	activate	VERB
gs-3214	195	15	various	various	ADJ
gs-3214	195	16	actions	action	NOUN
gs-3214	195	17	to	to	PART
gs-3214	195	18	eradicate	eradicate	VERB
gs-3214	195	19	cancerous	cancerous	ADJ
gs-3214	195	20	cells	cell	NOUN
gs-3214	195	21	and	and	CCONJ
gs-3214	195	22	prompt	prompt	VERB
gs-3214	195	23	tumor	tumor	NOUN
gs-3214	195	24	shrinkage	shrinkage	NOUN
gs-3214	195	25	.	.	PUNCT
gs-3214	196	1	georgian	georgian	NOUN
gs-3214	196	2	scientists/	scientists/	NUM
gs-3214	196	3	.	.	PUNCT
gs-3214	197	1	6	6	NUM
gs-3214	197	2	n	n	NUM
gs-3214	197	3	3	3	NUM
gs-3214	197	4	,	,	PUNCT
gs-3214	197	5	2024	2024	NUM
gs-3214	197	6	273	273	NUM
gs-3214	197	7	direct	direct	ADJ
gs-3214	197	8	cytotoxicity	cytotoxicity	NOUN
gs-3214	197	9	is	be	AUX
gs-3214	197	10	achieved	achieve	VERB
gs-3214	197	11	through	through	ADP
gs-3214	197	12	the	the	DET
gs-3214	197	13	secretion	secretion	NOUN
gs-3214	197	14	of	of	ADP
gs-3214	197	15	cytolytic	cytolytic	ADJ
gs-3214	197	16	substances	substance	NOUN
gs-3214	197	17	like	like	ADP
gs-3214	197	18	perforin	perforin	NOUN
gs-3214	197	19	and	and	CCONJ
gs-3214	197	20	granzymes	granzyme	NOUN
gs-3214	197	21	,	,	PUNCT
gs-3214	197	22	as	as	ADV
gs-3214	197	23	well	well	ADV
gs-3214	197	24	as	as	ADP
gs-3214	197	25	the	the	DET
gs-3214	197	26	presentation	presentation	NOUN
gs-3214	197	27	of	of	ADP
gs-3214	197	28	death	death	NOUN
gs-3214	197	29	receptor	receptor	NOUN
gs-3214	197	30	ligands	ligand	NOUN
gs-3214	197	31	like	like	ADP
gs-3214	197	32	fas	fas	PROPN
gs-3214	197	33	ligand	ligand	PROPN
gs-3214	197	34	(	(	PUNCT
gs-3214	197	35	fasl	fasl	PROPN
gs-3214	197	36	)	)	PUNCT
gs-3214	197	37	and	and	CCONJ
gs-3214	197	38	tumor	tumor	NOUN
gs-3214	197	39	necrosis	necrosis	NOUN
gs-3214	197	40	factor	factor	NOUN
gs-3214	197	41	-	-	PUNCT
gs-3214	197	42	related	relate	VERB
gs-3214	197	43	apoptosis	apoptosis	NOUN
gs-3214	197	44	-	-	PUNCT
gs-3214	197	45	inducing	induce	VERB
gs-3214	197	46	ligand	ligand	NOUN
gs-3214	197	47	(	(	PUNCT
gs-3214	197	48	trail	trail	NOUN
gs-3214	197	49	)	)	PUNCT
gs-3214	197	50	,	,	PUNCT
gs-3214	197	51	which	which	DET
gs-3214	197	52	trigger	trigger	NOUN
gs-3214	197	53	apoptosis	apoptosis	NOUN
gs-3214	197	54	in	in	ADP
gs-3214	197	55	targeted	target	VERB
gs-3214	197	56	cells.[16	cells.[16	NOUN
gs-3214	197	57	]	]	PUNCT
gs-3214	197	58	additionally	additionally	ADV
gs-3214	197	59	,	,	PUNCT
gs-3214	197	60	car	car	NOUN
gs-3214	197	61	-	-	PUNCT
gs-3214	197	62	t	t	NOUN
gs-3214	197	63	cells	cell	NOUN
gs-3214	197	64	exhibit	exhibit	VERB
gs-3214	197	65	activation	activation	NOUN
gs-3214	197	66	-	-	PUNCT
gs-3214	197	67	induced	induce	VERB
gs-3214	197	68	cell	cell	NOUN
gs-3214	197	69	surface	surface	NOUN
gs-3214	197	70	markers	marker	NOUN
gs-3214	197	71	such	such	ADJ
gs-3214	197	72	as	as	ADP
gs-3214	197	73	cd107a	cd107a	PROPN
gs-3214	197	74	(	(	PUNCT
gs-3214	197	75	lamp-1	lamp-1	PROPN
gs-3214	197	76	)	)	PUNCT
gs-3214	197	77	,	,	PUNCT
gs-3214	197	78	signaling	signal	VERB
gs-3214	197	79	degranulation	degranulation	NOUN
gs-3214	197	80	and	and	CCONJ
gs-3214	197	81	cytolytic	cytolytic	ADJ
gs-3214	197	82	function	function	NOUN
gs-3214	198	1	[	[	X
gs-3214	198	2	49	49	NUM
gs-3214	198	3	-	-	SYM
gs-3214	198	4	50	50	NUM
gs-3214	198	5	]	]	PUNCT
gs-3214	198	6	.	.	PUNCT
gs-3214	199	1	apart	apart	ADV
gs-3214	199	2	from	from	ADP
gs-3214	199	3	their	their	PRON
gs-3214	199	4	direct	direct	ADJ
gs-3214	199	5	cytotoxic	cytotoxic	ADJ
gs-3214	199	6	effects	effect	NOUN
gs-3214	199	7	,	,	PUNCT
gs-3214	199	8	car	car	NOUN
gs-3214	199	9	-	-	PUNCT
gs-3214	199	10	t	t	NOUN
gs-3214	199	11	cells	cell	NOUN
gs-3214	199	12	release	release	VERB
gs-3214	199	13	pro	pro	ADJ
gs-3214	199	14	-	-	ADJ
gs-3214	199	15	inflammatory	inflammatory	ADJ
gs-3214	199	16	cytokines	cytokine	NOUN
gs-3214	199	17	like	like	ADP
gs-3214	199	18	interferon	interferon	NOUN
gs-3214	199	19	-	-	PUNCT
gs-3214	199	20	gamma	gamma	NOUN
gs-3214	199	21	(	(	PUNCT
gs-3214	199	22	ifn	ifn	PROPN
gs-3214	199	23	)	)	PUNCT
gs-3214	199	24	,	,	PUNCT
gs-3214	199	25	tumor	tumor	NOUN
gs-3214	199	26	necrosis	necrosis	NOUN
gs-3214	199	27	factor	factor	NOUN
gs-3214	199	28	-	-	PUNCT
gs-3214	199	29	alpha	alpha	NOUN
gs-3214	199	30	(	(	PUNCT
gs-3214	199	31	tnf	tnf	PROPN
gs-3214	199	32	)	)	PUNCT
gs-3214	199	33	,	,	PUNCT
gs-3214	199	34	and	and	CCONJ
gs-3214	199	35	interleukin-2	interleukin-2	NOUN
gs-3214	199	36	(	(	PUNCT
gs-3214	199	37	il-2	il-2	NUM
gs-3214	199	38	)	)	PUNCT
gs-3214	199	39	.	.	PUNCT
gs-3214	200	1	these	these	DET
gs-3214	200	2	cytokines	cytokine	NOUN
gs-3214	200	3	play	play	VERB
gs-3214	200	4	a	a	DET
gs-3214	200	5	crucial	crucial	ADJ
gs-3214	200	6	role	role	NOUN
gs-3214	200	7	in	in	ADP
gs-3214	200	8	stimulating	stimulate	VERB
gs-3214	200	9	the	the	DET
gs-3214	200	10	recruitment	recruitment	NOUN
gs-3214	200	11	and	and	CCONJ
gs-3214	200	12	activation	activation	NOUN
gs-3214	200	13	of	of	ADP
gs-3214	200	14	immune	immune	ADJ
gs-3214	200	15	cells	cell	NOUN
gs-3214	200	16	within	within	ADP
gs-3214	200	17	the	the	DET
gs-3214	200	18	tumor	tumor	NOUN
gs-3214	200	19	microenvironment	microenvironment	NOUN
gs-3214	200	20	.	.	PUNCT
gs-3214	201	1	by	by	ADP
gs-3214	201	2	fostering	foster	VERB
gs-3214	201	3	the	the	DET
gs-3214	201	4	influx	influx	NOUN
gs-3214	201	5	of	of	ADP
gs-3214	201	6	innate	innate	ADJ
gs-3214	201	7	immune	immune	ADJ
gs-3214	201	8	cells	cell	NOUN
gs-3214	201	9	like	like	ADP
gs-3214	201	10	macrophages	macrophage	NOUN
gs-3214	201	11	and	and	CCONJ
gs-3214	201	12	natural	natural	ADJ
gs-3214	201	13	killer	killer	NOUN
gs-3214	201	14	(	(	PUNCT
gs-3214	201	15	nk	nk	PROPN
gs-3214	201	16	)	)	PUNCT
gs-3214	201	17	cells	cell	NOUN
gs-3214	201	18	,	,	PUNCT
gs-3214	201	19	these	these	DET
gs-3214	201	20	cytokines	cytokine	NOUN
gs-3214	201	21	enhance	enhance	VERB
gs-3214	201	22	the	the	DET
gs-3214	201	23	antitumor	antitumor	PROPN
gs-3214	201	24	immune	immune	ADJ
gs-3214	201	25	response	response	NOUN
gs-3214	201	26	through	through	ADP
gs-3214	201	27	mechanisms	mechanism	NOUN
gs-3214	201	28	such	such	ADJ
gs-3214	201	29	as	as	ADP
gs-3214	201	30	antibody	antibody	NOUN
gs-3214	201	31	-	-	PUNCT
gs-3214	201	32	dependent	dependent	ADJ
gs-3214	201	33	cellular	cellular	ADJ
gs-3214	201	34	cytotoxicity	cytotoxicity	NOUN
gs-3214	201	35	(	(	PUNCT
gs-3214	201	36	adcc	adcc	NOUN
gs-3214	201	37	)	)	PUNCT
gs-3214	201	38	and	and	CCONJ
gs-3214	201	39	phagocytosis	phagocytosis	VERB
gs-3214	201	40	[	[	X
gs-3214	201	41	51	51	NUM
gs-3214	201	42	-	-	SYM
gs-3214	201	43	52	52	NUM
gs-3214	201	44	]	]	PUNCT
gs-3214	201	45	.	.	PUNCT
gs-3214	202	1	car	car	NOUN
gs-3214	202	2	-	-	PUNCT
gs-3214	202	3	t	t	NOUN
gs-3214	202	4	cells	cell	NOUN
gs-3214	202	5	demonstrate	demonstrate	VERB
gs-3214	202	6	bystander	bystander	NOUN
gs-3214	202	7	killing	killing	NOUN
gs-3214	202	8	effects	effect	NOUN
gs-3214	202	9	,	,	PUNCT
gs-3214	202	10	where	where	SCONJ
gs-3214	202	11	nearby	nearby	ADJ
gs-3214	202	12	tumor	tumor	NOUN
gs-3214	202	13	cells	cell	NOUN
gs-3214	202	14	without	without	ADP
gs-3214	202	15	the	the	DET
gs-3214	202	16	target	target	NOUN
gs-3214	202	17	antigen	antigen	NOUN
gs-3214	202	18	are	be	AUX
gs-3214	202	19	eradicated	eradicate	VERB
gs-3214	202	20	via	via	ADP
gs-3214	202	21	a	a	DET
gs-3214	202	22	phenomenon	phenomenon	NOUN
gs-3214	202	23	called	call	VERB
gs-3214	202	24	antigen	antigen	NOUN
gs-3214	202	25	spreading	spread	VERB
gs-3214	202	26	.	.	PUNCT
gs-3214	203	1	this	this	DET
gs-3214	203	2	process	process	NOUN
gs-3214	203	3	is	be	AUX
gs-3214	203	4	triggered	trigger	VERB
gs-3214	203	5	by	by	ADP
gs-3214	203	6	the	the	DET
gs-3214	203	7	release	release	NOUN
gs-3214	203	8	of	of	ADP
gs-3214	203	9	cytokines	cytokine	NOUN
gs-3214	203	10	and	and	CCONJ
gs-3214	203	11	the	the	DET
gs-3214	203	12	presentation	presentation	NOUN
gs-3214	203	13	of	of	ADP
gs-3214	203	14	tumor	tumor	NOUN
gs-3214	203	15	antigens	antigen	NOUN
gs-3214	203	16	by	by	ADP
gs-3214	203	17	antigen	antigen	ADV
gs-3214	203	18	-	-	PUNCT
gs-3214	203	19	presenting	present	VERB
gs-3214	203	20	cells	cell	NOUN
gs-3214	203	21	(	(	PUNCT
gs-3214	203	22	apcs	apc	NOUN
gs-3214	203	23	)	)	PUNCT
gs-3214	203	24	,	,	PUNCT
gs-3214	203	25	resulting	result	VERB
gs-3214	203	26	in	in	ADP
gs-3214	203	27	the	the	DET
gs-3214	203	28	activation	activation	NOUN
gs-3214	203	29	of	of	ADP
gs-3214	203	30	the	the	DET
gs-3214	203	31	body	body	NOUN
gs-3214	203	32	's	's	PART
gs-3214	203	33	own	own	ADJ
gs-3214	203	34	immune	immune	ADJ
gs-3214	203	35	effector	effector	NOUN
gs-3214	203	36	cells	cell	NOUN
gs-3214	203	37	against	against	ADP
gs-3214	203	38	the	the	DET
gs-3214	203	39	tumor	tumor	NOUN
gs-3214	203	40	cells	cell	NOUN
gs-3214	203	41	.	.	PUNCT
gs-3214	204	1	although	although	SCONJ
gs-3214	204	2	car	car	NOUN
gs-3214	204	3	-	-	PUNCT
gs-3214	204	4	t	t	NOUN
gs-3214	204	5	cells	cell	NOUN
gs-3214	204	6	exhibit	exhibit	VERB
gs-3214	204	7	strong	strong	ADJ
gs-3214	204	8	antitumor	antitumor	PROPN
gs-3214	204	9	capabilities	capability	NOUN
gs-3214	204	10	,	,	PUNCT
gs-3214	204	11	they	they	PRON
gs-3214	204	12	can	can	AUX
gs-3214	204	13	face	face	VERB
gs-3214	204	14	resistance	resistance	NOUN
gs-3214	204	15	mechanisms	mechanism	NOUN
gs-3214	204	16	within	within	ADP
gs-3214	204	17	the	the	DET
gs-3214	204	18	tumor	tumor	NOUN
gs-3214	204	19	microenvironment	microenvironment	NOUN
gs-3214	204	20	.	.	PUNCT
gs-3214	205	1	these	these	PRON
gs-3214	205	2	include	include	VERB
gs-3214	205	3	immunosuppressive	immunosuppressive	ADJ
gs-3214	205	4	cell	cell	NOUN
gs-3214	205	5	populations	population	NOUN
gs-3214	205	6	like	like	ADP
gs-3214	205	7	regulatory	regulatory	ADJ
gs-3214	205	8	t	t	NOUN
gs-3214	205	9	cells	cell	NOUN
gs-3214	205	10	(	(	PUNCT
gs-3214	205	11	tregs	treg	NOUN
gs-3214	205	12	)	)	PUNCT
gs-3214	205	13	and	and	CCONJ
gs-3214	205	14	myeloid	myeloid	ADJ
gs-3214	205	15	-	-	PUNCT
gs-3214	205	16	derived	derive	VERB
gs-3214	205	17	suppressor	suppressor	NOUN
gs-3214	205	18	cells	cell	NOUN
gs-3214	205	19	(	(	PUNCT
gs-3214	205	20	mdscs	mdsc	NOUN
gs-3214	205	21	)	)	PUNCT
gs-3214	205	22	,	,	PUNCT
gs-3214	205	23	as	as	ADV
gs-3214	205	24	well	well	ADV
gs-3214	205	25	as	as	ADP
gs-3214	205	26	inhibitory	inhibitory	ADJ
gs-3214	205	27	cytokines	cytokine	NOUN
gs-3214	205	28	such	such	ADJ
gs-3214	205	29	as	as	ADP
gs-3214	205	30	transforming	transform	VERB
gs-3214	205	31	growth	growth	NOUN
gs-3214	205	32	factor	factor	NOUN
gs-3214	205	33	-	-	PUNCT
gs-3214	205	34	beta	beta	NOUN
gs-3214	205	35	(	(	PUNCT
gs-3214	205	36	tgf	tgf	PROPN
gs-3214	205	37	)	)	PUNCT
gs-3214	205	38	and	and	CCONJ
gs-3214	205	39	interleukin-10	interleukin-10	PROPN
gs-3214	205	40	(	(	PUNCT
gs-3214	205	41	il-10	il-10	NUM
gs-3214	205	42	)	)	PUNCT
gs-3214	205	43	.	.	PUNCT
gs-3214	206	1	to	to	PART
gs-3214	206	2	counteract	counteract	VERB
gs-3214	206	3	these	these	DET
gs-3214	206	4	resistance	resistance	NOUN
gs-3214	206	5	mechanisms	mechanism	NOUN
gs-3214	206	6	,	,	PUNCT
gs-3214	206	7	strategies	strategy	NOUN
gs-3214	206	8	involve	involve	VERB
gs-3214	206	9	employing	employ	VERB
gs-3214	206	10	combination	combination	NOUN
gs-3214	206	11	therapies	therapy	NOUN
gs-3214	206	12	with	with	ADP
gs-3214	206	13	immune	immune	ADJ
gs-3214	206	14	checkpoint	checkpoint	NOUN
gs-3214	206	15	inhibitors	inhibitor	NOUN
gs-3214	206	16	,	,	PUNCT
gs-3214	206	17	cytokine	cytokine	ADJ
gs-3214	206	18	modulators	modulator	NOUN
gs-3214	206	19	,	,	PUNCT
gs-3214	206	20	and	and	CCONJ
gs-3214	206	21	targeted	target	VERB
gs-3214	206	22	therapies	therapy	NOUN
gs-3214	206	23	aimed	aim	VERB
gs-3214	206	24	at	at	ADP
gs-3214	206	25	disrupting	disrupt	VERB
gs-3214	206	26	immunosuppressive	immunosuppressive	ADJ
gs-3214	206	27	pathways	pathway	NOUN
gs-3214	207	1	[	[	X
gs-3214	207	2	53	53	NUM
gs-3214	207	3	-	-	SYM
gs-3214	207	4	54	54	NUM
gs-3214	207	5	]	]	PUNCT
gs-3214	207	6	.	.	PUNCT
gs-3214	208	1	although	although	SCONJ
gs-3214	208	2	car	car	NOUN
gs-3214	208	3	-	-	PUNCT
gs-3214	208	4	t	t	NOUN
gs-3214	208	5	cell	cell	NOUN
gs-3214	208	6	therapy	therapy	NOUN
gs-3214	208	7	has	have	AUX
gs-3214	208	8	shown	show	VERB
gs-3214	208	9	impressive	impressive	ADJ
gs-3214	208	10	effectiveness	effectiveness	NOUN
gs-3214	208	11	in	in	ADP
gs-3214	208	12	clinical	clinical	ADJ
gs-3214	208	13	trials	trial	NOUN
gs-3214	208	14	,	,	PUNCT
gs-3214	208	15	it	it	PRON
gs-3214	208	16	comes	come	VERB
gs-3214	208	17	with	with	ADP
gs-3214	208	18	distinct	distinct	ADJ
gs-3214	208	19	toxicities	toxicity	NOUN
gs-3214	208	20	,	,	PUNCT
gs-3214	208	21	such	such	ADJ
gs-3214	208	22	as	as	ADP
gs-3214	208	23	cytokine	cytokine	ADJ
gs-3214	208	24	release	release	NOUN
gs-3214	208	25	syndrome	syndrome	NOUN
gs-3214	208	26	(	(	PUNCT
gs-3214	208	27	crs	crs	PROPN
gs-3214	208	28	)	)	PUNCT
gs-3214	208	29	and	and	CCONJ
gs-3214	208	30	neurotoxicity	neurotoxicity	NOUN
gs-3214	208	31	,	,	PUNCT
gs-3214	208	32	presenting	present	VERB
gs-3214	208	33	considerable	considerable	ADJ
gs-3214	208	34	hurdles	hurdle	NOUN
gs-3214	208	35	in	in	ADP
gs-3214	208	36	patient	patient	ADJ
gs-3214	208	37	care	care	NOUN
gs-3214	208	38	and	and	CCONJ
gs-3214	208	39	management	management	NOUN
gs-3214	208	40	.	.	PUNCT
gs-3214	209	1	cytokine	cytokine	ADJ
gs-3214	209	2	release	release	NOUN
gs-3214	209	3	syndrome	syndrome	NOUN
gs-3214	209	4	(	(	PUNCT
gs-3214	209	5	crs	crs	PROPN
gs-3214	209	6	)	)	PUNCT
gs-3214	209	7	is	be	AUX
gs-3214	209	8	a	a	DET
gs-3214	209	9	systemic	systemic	ADJ
gs-3214	209	10	inflammatory	inflammatory	ADJ
gs-3214	209	11	reaction	reaction	NOUN
gs-3214	209	12	marked	mark	VERB
gs-3214	209	13	by	by	ADP
gs-3214	209	14	the	the	DET
gs-3214	209	15	swift	swift	ADJ
gs-3214	209	16	discharge	discharge	NOUN
gs-3214	209	17	of	of	ADP
gs-3214	209	18	pro	pro	ADJ
gs-3214	209	19	-	-	ADJ
gs-3214	209	20	inflammatory	inflammatory	ADJ
gs-3214	209	21	cytokines	cytokine	NOUN
gs-3214	209	22	,	,	PUNCT
gs-3214	209	23	such	such	ADJ
gs-3214	209	24	as	as	ADP
gs-3214	209	25	interleukin-6	interleukin-6	PROPN
gs-3214	209	26	(	(	PUNCT
gs-3214	209	27	il-6	il-6	NUM
gs-3214	209	28	)	)	PUNCT
gs-3214	209	29	,	,	PUNCT
gs-3214	209	30	interferon	interferon	NOUN
gs-3214	209	31	-	-	PUNCT
gs-3214	209	32	gamma	gamma	NOUN
gs-3214	209	33	(	(	PUNCT
gs-3214	209	34	ifn	ifn	PROPN
gs-3214	209	35	)	)	PUNCT
gs-3214	209	36	,	,	PUNCT
gs-3214	209	37	and	and	CCONJ
gs-3214	209	38	tumor	tumor	NOUN
gs-3214	209	39	necrosis	necrosis	NOUN
gs-3214	209	40	factor	factor	NOUN
gs-3214	209	41	-	-	PUNCT
gs-3214	209	42	alpha	alpha	NOUN
gs-3214	209	43	(	(	PUNCT
gs-3214	209	44	tnf	tnf	PROPN
gs-3214	209	45	)	)	PUNCT
gs-3214	209	46	,	,	PUNCT
gs-3214	209	47	triggered	trigger	VERB
gs-3214	209	48	by	by	ADP
gs-3214	209	49	the	the	DET
gs-3214	209	50	activation	activation	NOUN
gs-3214	209	51	of	of	ADP
gs-3214	209	52	car	car	NOUN
gs-3214	209	53	-	-	PUNCT
gs-3214	209	54	t	t	NOUN
gs-3214	209	55	cells.[20	cells.[20	NOUN
gs-3214	209	56	]	]	PUNCT
gs-3214	209	57	crs	crs	PROPN
gs-3214	209	58	can	can	AUX
gs-3214	209	59	present	present	VERB
gs-3214	209	60	with	with	ADP
gs-3214	209	61	a	a	DET
gs-3214	209	62	variety	variety	NOUN
gs-3214	209	63	of	of	ADP
gs-3214	209	64	symptoms	symptom	NOUN
gs-3214	209	65	,	,	PUNCT
gs-3214	209	66	ranging	range	VERB
gs-3214	209	67	from	from	ADP
gs-3214	209	68	mild	mild	ADJ
gs-3214	209	69	flu	flu	NOUN
gs-3214	209	70	-	-	PUNCT
gs-3214	209	71	like	like	ADJ
gs-3214	209	72	manifestations	manifestation	NOUN
gs-3214	209	73	to	to	ADP
gs-3214	209	74	severe	severe	ADJ
gs-3214	209	75	complications	complication	NOUN
gs-3214	209	76	,	,	PUNCT
gs-3214	209	77	including	include	VERB
gs-3214	209	78	hypotension	hypotension	NOUN
gs-3214	209	79	,	,	PUNCT
gs-3214	209	80	capillary	capillary	ADJ
gs-3214	209	81	leak	leak	NOUN
gs-3214	209	82	syndrome	syndrome	NOUN
gs-3214	209	83	,	,	PUNCT
gs-3214	209	84	and	and	CCONJ
gs-3214	209	85	multi	multi	ADJ
gs-3214	209	86	organ	organ	NOUN
gs-3214	209	87	dysfunction	dysfunction	NOUN
gs-3214	209	88	,	,	PUNCT
gs-3214	209	89	which	which	PRON
gs-3214	209	90	can	can	AUX
gs-3214	209	91	be	be	AUX
gs-3214	209	92	life	life	NOUN
gs-3214	209	93	-	-	PUNCT
gs-3214	209	94	threatening	threaten	VERB
gs-3214	209	95	[	[	X
gs-3214	209	96	55	55	NUM
gs-3214	209	97	-	-	SYM
gs-3214	209	98	56	56	NUM
gs-3214	209	99	]	]	PUNCT
gs-3214	209	100	.	.	PUNCT
gs-3214	210	1	the	the	DET
gs-3214	210	2	pathophysiology	pathophysiology	NOUN
gs-3214	210	3	of	of	ADP
gs-3214	210	4	crs	crs	PROPN
gs-3214	210	5	revolves	revolve	VERB
gs-3214	210	6	around	around	ADP
gs-3214	210	7	the	the	DET
gs-3214	210	8	activation	activation	NOUN
gs-3214	210	9	of	of	ADP
gs-3214	210	10	car	car	NOUN
gs-3214	210	11	-	-	PUNCT
gs-3214	210	12	t	t	NOUN
gs-3214	210	13	cells	cell	NOUN
gs-3214	210	14	,	,	PUNCT
gs-3214	210	15	prompting	prompt	VERB
gs-3214	210	16	the	the	DET
gs-3214	210	17	release	release	NOUN
gs-3214	210	18	of	of	ADP
gs-3214	210	19	cytokines	cytokine	NOUN
gs-3214	210	20	,	,	PUNCT
gs-3214	210	21	which	which	PRON
gs-3214	210	22	in	in	ADP
gs-3214	210	23	turn	turn	NOUN
gs-3214	210	24	triggers	trigger	VERB
gs-3214	210	25	systemic	systemic	ADJ
gs-3214	210	26	immune	immune	ADJ
gs-3214	210	27	activation	activation	NOUN
gs-3214	210	28	and	and	CCONJ
gs-3214	210	29	endothelial	endothelial	ADJ
gs-3214	210	30	dysfunction	dysfunction	NOUN
gs-3214	210	31	.	.	PUNCT
gs-3214	211	1	crs	crs	NOUN
gs-3214	211	2	severity	severity	NOUN
gs-3214	211	3	is	be	AUX
gs-3214	211	4	associated	associate	VERB
gs-3214	211	5	with	with	ADP
gs-3214	211	6	the	the	DET
gs-3214	211	7	expansion	expansion	NOUN
gs-3214	211	8	of	of	ADP
gs-3214	211	9	car	car	NOUN
gs-3214	211	10	-	-	PUNCT
gs-3214	211	11	t	t	NOUN
gs-3214	211	12	cells	cell	NOUN
gs-3214	211	13	and	and	CCONJ
gs-3214	211	14	the	the	DET
gs-3214	211	15	extent	extent	NOUN
gs-3214	211	16	of	of	ADP
gs-3214	211	17	tumor	tumor	NOUN
gs-3214	211	18	burden	burden	NOUN
gs-3214	211	19	,	,	PUNCT
gs-3214	211	20	with	with	ADP
gs-3214	211	21	elevated	elevated	ADJ
gs-3214	211	22	rates	rate	NOUN
gs-3214	211	23	noted	note	VERB
gs-3214	211	24	in	in	ADP
gs-3214	211	25	patients	patient	NOUN
gs-3214	211	26	with	with	ADP
gs-3214	211	27	more	more	ADV
gs-3214	211	28	extensive	extensive	ADJ
gs-3214	211	29	disease	disease	NOUN
gs-3214	211	30	.	.	PUNCT
gs-3214	212	1	the	the	DET
gs-3214	212	2	handling	handling	NOUN
gs-3214	212	3	of	of	ADP
gs-3214	212	4	crs	crs	PROPN
gs-3214	212	5	necessitates	necessitate	VERB
gs-3214	212	6	the	the	DET
gs-3214	212	7	implementation	implementation	NOUN
gs-3214	212	8	of	of	ADP
gs-3214	212	9	supportive	supportive	ADJ
gs-3214	212	10	interventions	intervention	NOUN
gs-3214	212	11	,	,	PUNCT
gs-3214	212	12	including	include	VERB
gs-3214	212	13	fluid	fluid	ADJ
gs-3214	212	14	resuscitation	resuscitation	NOUN
gs-3214	212	15	,	,	PUNCT
gs-3214	212	16	vasopressor	vasopressor	NOUN
gs-3214	212	17	assistance	assistance	NOUN
gs-3214	212	18	,	,	PUNCT
gs-3214	212	19	and	and	CCONJ
gs-3214	212	20	antipyretic	antipyretic	ADJ
gs-3214	212	21	agents	agent	NOUN
gs-3214	212	22	,	,	PUNCT
gs-3214	212	23	aimed	aim	VERB
gs-3214	212	24	at	at	ADP
gs-3214	212	25	alleviating	alleviate	VERB
gs-3214	212	26	symptoms	symptom	NOUN
gs-3214	212	27	and	and	CCONJ
gs-3214	212	28	maintaining	maintain	VERB
gs-3214	212	29	stable	stable	ADJ
gs-3214	212	30	hemodynamics	hemodynamic	NOUN
gs-3214	212	31	.	.	PUNCT
gs-3214	213	1	moreover	moreover	ADV
gs-3214	213	2	,	,	PUNCT
gs-3214	213	3	tocilizumab	tocilizumab	NOUN
gs-3214	213	4	,	,	PUNCT
gs-3214	213	5	a	a	DET
gs-3214	213	6	monoclonal	monoclonal	NOUN
gs-3214	213	7	antibody	antibody	NOUN
gs-3214	213	8	targeting	target	VERB
gs-3214	213	9	the	the	DET
gs-3214	213	10	georgian	georgian	NOUN
gs-3214	213	11	scientists/	scientists/	NUM
gs-3214	213	12	.	.	PUNCT
gs-3214	214	1	6	6	NUM
gs-3214	214	2	n	n	NUM
gs-3214	214	3	3	3	NUM
gs-3214	214	4	,	,	PUNCT
gs-3214	214	5	2024	2024	NUM
gs-3214	214	6	274	274	NUM
gs-3214	214	7	interleukin-6	interleukin-6	NUM
gs-3214	214	8	receptor	receptor	NOUN
gs-3214	214	9	,	,	PUNCT
gs-3214	214	10	has	have	AUX
gs-3214	214	11	surfaced	surface	VERB
gs-3214	214	12	as	as	ADP
gs-3214	214	13	a	a	DET
gs-3214	214	14	fundamental	fundamental	ADJ
gs-3214	214	15	treatment	treatment	NOUN
gs-3214	214	16	for	for	ADP
gs-3214	214	17	crs	crs	PROPN
gs-3214	214	18	,	,	PUNCT
gs-3214	214	19	offering	offer	VERB
gs-3214	214	20	prompt	prompt	ADJ
gs-3214	214	21	and	and	CCONJ
gs-3214	214	22	potent	potent	ADJ
gs-3214	214	23	inhibition	inhibition	NOUN
gs-3214	214	24	of	of	ADP
gs-3214	214	25	cytokine	cytokine	ADJ
gs-3214	214	26	activity	activity	NOUN
gs-3214	214	27	to	to	PART
gs-3214	214	28	mitigate	mitigate	VERB
gs-3214	214	29	widespread	widespread	ADJ
gs-3214	214	30	inflammation	inflammation	NOUN
gs-3214	214	31	[	[	X
gs-3214	214	32	57	57	NUM
gs-3214	214	33	-	-	SYM
gs-3214	214	34	58	58	NUM
gs-3214	214	35	]	]	PUNCT
gs-3214	214	36	.	.	PUNCT
gs-3214	215	1	neurotoxicity	neurotoxicity	NOUN
gs-3214	215	2	,	,	PUNCT
gs-3214	215	3	termed	term	VERB
gs-3214	215	4	as	as	ADP
gs-3214	215	5	immune	immune	ADJ
gs-3214	215	6	effector	effector	NOUN
gs-3214	215	7	cell	cell	NOUN
gs-3214	215	8	-	-	PUNCT
gs-3214	215	9	associated	associate	VERB
gs-3214	215	10	neurotoxicity	neurotoxicity	NOUN
gs-3214	215	11	syndrome	syndrome	NOUN
gs-3214	215	12	(	(	PUNCT
gs-3214	215	13	icans	ican	NOUN
gs-3214	215	14	)	)	PUNCT
gs-3214	215	15	,	,	PUNCT
gs-3214	215	16	represents	represent	VERB
gs-3214	215	17	an	an	DET
gs-3214	215	18	additional	additional	ADJ
gs-3214	215	19	potentially	potentially	ADV
gs-3214	215	20	severe	severe	ADJ
gs-3214	215	21	complication	complication	NOUN
gs-3214	215	22	of	of	ADP
gs-3214	215	23	car	car	NOUN
gs-3214	215	24	-	-	PUNCT
gs-3214	215	25	t	t	NOUN
gs-3214	215	26	cell	cell	NOUN
gs-3214	215	27	therapy	therapy	NOUN
gs-3214	215	28	,	,	PUNCT
gs-3214	215	29	marked	mark	VERB
gs-3214	215	30	by	by	ADP
gs-3214	215	31	neurological	neurological	ADJ
gs-3214	215	32	manifestations	manifestation	NOUN
gs-3214	215	33	like	like	ADP
gs-3214	215	34	confusion	confusion	NOUN
gs-3214	215	35	,	,	PUNCT
gs-3214	215	36	aphasia	aphasia	NOUN
gs-3214	215	37	,	,	PUNCT
gs-3214	215	38	seizures	seizure	NOUN
gs-3214	215	39	,	,	PUNCT
gs-3214	215	40	and	and	CCONJ
gs-3214	215	41	encephalopathy	encephalopathy	NOUN
gs-3214	215	42	.	.	PUNCT
gs-3214	216	1	while	while	SCONJ
gs-3214	216	2	the	the	DET
gs-3214	216	3	pathophysiology	pathophysiology	NOUN
gs-3214	216	4	of	of	ADP
gs-3214	216	5	neurotoxicity	neurotoxicity	NOUN
gs-3214	216	6	remains	remain	VERB
gs-3214	216	7	inadequately	inadequately	ADV
gs-3214	216	8	elucidated	elucidated	ADJ
gs-3214	216	9	,	,	PUNCT
gs-3214	216	10	it	it	PRON
gs-3214	216	11	is	be	AUX
gs-3214	216	12	believed	believe	VERB
gs-3214	216	13	to	to	PART
gs-3214	216	14	entail	entail	VERB
gs-3214	216	15	endothelial	endothelial	ADJ
gs-3214	216	16	activation	activation	NOUN
gs-3214	216	17	,	,	PUNCT
gs-3214	216	18	disruption	disruption	NOUN
gs-3214	216	19	of	of	ADP
gs-3214	216	20	the	the	DET
gs-3214	216	21	blood	blood	NOUN
gs-3214	216	22	-	-	PUNCT
gs-3214	216	23	brain	brain	NOUN
gs-3214	216	24	barrier	barrier	NOUN
gs-3214	216	25	,	,	PUNCT
gs-3214	216	26	and	and	CCONJ
gs-3214	216	27	neuro	neuro	PROPN
gs-3214	216	28	inflammation	inflammation	NOUN
gs-3214	216	29	mediated	mediate	VERB
gs-3214	216	30	by	by	ADP
gs-3214	216	31	cytokines	cytokine	NOUN
gs-3214	216	32	.	.	PUNCT
gs-3214	217	1	neurotoxicity	neurotoxicity	NOUN
gs-3214	217	2	typically	typically	ADV
gs-3214	217	3	arises	arise	VERB
gs-3214	217	4	simultaneously	simultaneously	ADV
gs-3214	217	5	with	with	ADP
gs-3214	217	6	cytokine	cytokine	ADJ
gs-3214	217	7	release	release	NOUN
gs-3214	217	8	syndrome	syndrome	NOUN
gs-3214	217	9	(	(	PUNCT
gs-3214	217	10	crs	crs	PROPN
gs-3214	217	11	)	)	PUNCT
gs-3214	217	12	or	or	CCONJ
gs-3214	217	13	shortly	shortly	ADV
gs-3214	217	14	thereafter	thereafter	ADV
gs-3214	217	15	,	,	PUNCT
gs-3214	217	16	implying	imply	VERB
gs-3214	217	17	shared	share	VERB
gs-3214	217	18	underlying	underlie	VERB
gs-3214	217	19	mechanisms	mechanism	NOUN
gs-3214	217	20	.	.	PUNCT
gs-3214	218	1	nonetheless	nonetheless	ADV
gs-3214	218	2	,	,	PUNCT
gs-3214	218	3	neurotoxicity	neurotoxicity	NOUN
gs-3214	218	4	can	can	AUX
gs-3214	218	5	also	also	ADV
gs-3214	218	6	present	present	VERB
gs-3214	218	7	autonomously	autonomously	ADV
gs-3214	218	8	from	from	ADP
gs-3214	218	9	crs	crs	PROPN
gs-3214	218	10	,	,	PUNCT
gs-3214	218	11	underscoring	underscore	VERB
gs-3214	218	12	the	the	DET
gs-3214	218	13	diverse	diverse	ADJ
gs-3214	218	14	nature	nature	NOUN
gs-3214	218	15	of	of	ADP
gs-3214	218	16	toxicities	toxicity	NOUN
gs-3214	218	17	associated	associate	VERB
gs-3214	218	18	with	with	ADP
gs-3214	218	19	car	car	NOUN
gs-3214	218	20	-	-	PUNCT
gs-3214	218	21	t	t	NOUN
gs-3214	218	22	cell	cell	NOUN
gs-3214	218	23	therapy	therapy	NOUN
gs-3214	218	24	.	.	PUNCT
gs-3214	219	1	the	the	DET
gs-3214	219	2	management	management	NOUN
gs-3214	219	3	of	of	ADP
gs-3214	219	4	neurotoxicity	neurotoxicity	NOUN
gs-3214	219	5	necessitates	necessitate	VERB
gs-3214	219	6	vigilant	vigilant	ADJ
gs-3214	219	7	neurological	neurological	ADJ
gs-3214	219	8	surveillance	surveillance	NOUN
gs-3214	219	9	and	and	CCONJ
gs-3214	219	10	swift	swift	ADJ
gs-3214	219	11	intervention	intervention	NOUN
gs-3214	219	12	to	to	PART
gs-3214	219	13	forestall	forestall	VERB
gs-3214	219	14	advancement	advancement	NOUN
gs-3214	219	15	toward	toward	ADP
gs-3214	219	16	critical	critical	ADJ
gs-3214	219	17	conditions	condition	NOUN
gs-3214	219	18	like	like	ADP
gs-3214	219	19	cerebral	cerebral	ADJ
gs-3214	219	20	edema	edema	NOUN
gs-3214	219	21	and	and	CCONJ
gs-3214	219	22	seizures	seizure	NOUN
gs-3214	219	23	.	.	PUNCT
gs-3214	220	1	corticosteroids	corticosteroid	NOUN
gs-3214	220	2	and	and	CCONJ
gs-3214	220	3	antiepileptic	antiepileptic	ADJ
gs-3214	220	4	drugs	drug	NOUN
gs-3214	220	5	might	might	AUX
gs-3214	220	6	be	be	AUX
gs-3214	220	7	employed	employ	VERB
gs-3214	220	8	to	to	PART
gs-3214	220	9	alleviate	alleviate	VERB
gs-3214	220	10	neuro	neuro	PROPN
gs-3214	220	11	inflammation	inflammation	NOUN
gs-3214	220	12	and	and	CCONJ
gs-3214	220	13	manage	manage	VERB
gs-3214	220	14	seizure	seizure	NOUN
gs-3214	220	15	activity	activity	NOUN
gs-3214	220	16	,	,	PUNCT
gs-3214	220	17	while	while	SCONJ
gs-3214	220	18	intensive	intensive	ADJ
gs-3214	220	19	supportive	supportive	ADJ
gs-3214	220	20	measures	measure	NOUN
gs-3214	220	21	such	such	ADJ
gs-3214	220	22	as	as	ADP
gs-3214	220	23	sedation	sedation	NOUN
gs-3214	220	24	and	and	CCONJ
gs-3214	220	25	mechanical	mechanical	ADJ
gs-3214	220	26	ventilation	ventilation	NOUN
gs-3214	220	27	might	might	AUX
gs-3214	220	28	be	be	AUX
gs-3214	220	29	warranted	warrant	VERB
gs-3214	220	30	in	in	ADP
gs-3214	220	31	severe	severe	ADJ
gs-3214	220	32	instances	instance	NOUN
gs-3214	220	33	.	.	PUNCT
gs-3214	221	1	in	in	ADP
gs-3214	221	2	general	general	ADJ
gs-3214	221	3	,	,	PUNCT
gs-3214	221	4	addressing	address	VERB
gs-3214	221	5	car	car	NOUN
gs-3214	221	6	-	-	PUNCT
gs-3214	221	7	t	t	NOUN
gs-3214	221	8	cell	cell	NOUN
gs-3214	221	9	-	-	PUNCT
gs-3214	221	10	associated	associate	VERB
gs-3214	221	11	toxicities	toxicity	NOUN
gs-3214	221	12	demands	demand	VERB
gs-3214	221	13	a	a	DET
gs-3214	221	14	multidisciplinary	multidisciplinary	ADJ
gs-3214	221	15	strategy	strategy	NOUN
gs-3214	221	16	,	,	PUNCT
gs-3214	221	17	entailing	entail	VERB
gs-3214	221	18	tight	tight	ADJ
gs-3214	221	19	cooperation	cooperation	NOUN
gs-3214	221	20	among	among	ADP
gs-3214	221	21	oncologists	oncologist	NOUN
gs-3214	221	22	,	,	PUNCT
gs-3214	221	23	intensivists	intensivist	NOUN
gs-3214	221	24	,	,	PUNCT
gs-3214	221	25	neurologists	neurologist	NOUN
gs-3214	221	26	,	,	PUNCT
gs-3214	221	27	and	and	CCONJ
gs-3214	221	28	supportive	supportive	ADJ
gs-3214	221	29	care	care	NOUN
gs-3214	221	30	experts	expert	NOUN
gs-3214	221	31	.	.	PUNCT
gs-3214	222	1	this	this	DET
gs-3214	222	2	collaborative	collaborative	ADJ
gs-3214	222	3	approach	approach	NOUN
gs-3214	222	4	aims	aim	VERB
gs-3214	222	5	to	to	PART
gs-3214	222	6	enhance	enhance	VERB
gs-3214	222	7	patient	patient	ADJ
gs-3214	222	8	outcomes	outcome	NOUN
gs-3214	222	9	and	and	CCONJ
gs-3214	222	10	diminish	diminish	VERB
gs-3214	222	11	treatment	treatment	NOUN
gs-3214	222	12	-	-	PUNCT
gs-3214	222	13	related	relate	VERB
gs-3214	222	14	adverse	adverse	ADJ
gs-3214	222	15	effects	effect	NOUN
gs-3214	222	16	and	and	CCONJ
gs-3214	222	17	mortality	mortality	NOUN
gs-3214	222	18	rates	rate	NOUN
gs-3214	222	19	[	[	X
gs-3214	222	20	59	59	NUM
gs-3214	222	21	-	-	SYM
gs-3214	222	22	61	61	NUM
gs-3214	222	23	]	]	PUNCT
gs-3214	222	24	.	.	PUNCT
gs-3214	223	1	the	the	DET
gs-3214	223	2	process	process	NOUN
gs-3214	223	3	begins	begin	VERB
gs-3214	223	4	with	with	ADP
gs-3214	223	5	the	the	DET
gs-3214	223	6	engagement	engagement	NOUN
gs-3214	223	7	of	of	ADP
gs-3214	223	8	car	car	NOUN
gs-3214	223	9	-	-	PUNCT
gs-3214	223	10	t	t	NOUN
gs-3214	223	11	cells	cell	NOUN
gs-3214	223	12	with	with	ADP
gs-3214	223	13	target	target	NOUN
gs-3214	223	14	antigens	antigen	NOUN
gs-3214	223	15	on	on	ADP
gs-3214	223	16	tumor	tumor	NOUN
gs-3214	223	17	cells	cell	NOUN
gs-3214	223	18	,	,	PUNCT
gs-3214	223	19	triggering	trigger	VERB
gs-3214	223	20	intracellular	intracellular	ADJ
gs-3214	223	21	signaling	signal	VERB
gs-3214	223	22	cascades	cascade	NOUN
gs-3214	223	23	.	.	PUNCT
gs-3214	224	1	this	this	DET
gs-3214	224	2	activation	activation	NOUN
gs-3214	224	3	induces	induce	VERB
gs-3214	224	4	the	the	DET
gs-3214	224	5	secretion	secretion	NOUN
gs-3214	224	6	of	of	ADP
gs-3214	224	7	various	various	ADJ
gs-3214	224	8	cytokines	cytokine	NOUN
gs-3214	224	9	,	,	PUNCT
gs-3214	224	10	creating	create	VERB
gs-3214	224	11	a	a	DET
gs-3214	224	12	localized	localized	ADJ
gs-3214	224	13	inflammatory	inflammatory	ADJ
gs-3214	224	14	environment	environment	NOUN
gs-3214	224	15	within	within	ADP
gs-3214	224	16	the	the	DET
gs-3214	224	17	tumor	tumor	NOUN
gs-3214	224	18	microenvironment	microenvironment	NOUN
gs-3214	224	19	.	.	PUNCT
gs-3214	225	1	the	the	DET
gs-3214	225	2	release	release	NOUN
gs-3214	225	3	of	of	ADP
gs-3214	225	4	cytokines	cytokine	NOUN
gs-3214	225	5	leads	lead	VERB
gs-3214	225	6	to	to	ADP
gs-3214	225	7	the	the	DET
gs-3214	225	8	activation	activation	NOUN
gs-3214	225	9	of	of	ADP
gs-3214	225	10	endothelial	endothelial	ADJ
gs-3214	225	11	cells	cell	NOUN
gs-3214	225	12	,	,	PUNCT
gs-3214	225	13	disrupting	disrupt	VERB
gs-3214	225	14	the	the	DET
gs-3214	225	15	integrity	integrity	NOUN
gs-3214	225	16	of	of	ADP
gs-3214	225	17	the	the	DET
gs-3214	225	18	vascular	vascular	ADJ
gs-3214	225	19	endothelium	endothelium	NOUN
gs-3214	225	20	.	.	PUNCT
gs-3214	226	1	capillary	capillary	ADJ
gs-3214	226	2	leak	leak	NOUN
gs-3214	226	3	syndrome	syndrome	NOUN
gs-3214	226	4	ensues	ensue	NOUN
gs-3214	226	5	,	,	PUNCT
gs-3214	226	6	causing	cause	VERB
gs-3214	226	7	increased	increase	VERB
gs-3214	226	8	permeability	permeability	NOUN
gs-3214	226	9	and	and	CCONJ
gs-3214	226	10	fluid	fluid	NOUN
gs-3214	226	11	extravasation	extravasation	NOUN
gs-3214	226	12	into	into	ADP
gs-3214	226	13	tissues	tissue	NOUN
gs-3214	226	14	,	,	PUNCT
gs-3214	226	15	contributing	contribute	VERB
gs-3214	226	16	to	to	ADP
gs-3214	226	17	hypotension	hypotension	NOUN
gs-3214	226	18	and	and	CCONJ
gs-3214	226	19	edema	edema	NOUN
gs-3214	226	20	observed	observe	VERB
gs-3214	226	21	in	in	ADP
gs-3214	226	22	crs	crs	PROPN
gs-3214	226	23	[	[	X
gs-3214	226	24	62	62	NUM
gs-3214	226	25	-	-	SYM
gs-3214	226	26	63	63	NUM
gs-3214	226	27	]	]	PUNCT
gs-3214	226	28	.	.	PUNCT
gs-3214	227	1	the	the	DET
gs-3214	227	2	systemic	systemic	ADJ
gs-3214	227	3	spread	spread	NOUN
gs-3214	227	4	of	of	ADP
gs-3214	227	5	pro	pro	ADJ
gs-3214	227	6	-	-	ADJ
gs-3214	227	7	inflammatory	inflammatory	ADJ
gs-3214	227	8	cytokines	cytokine	NOUN
gs-3214	227	9	results	result	VERB
gs-3214	227	10	in	in	ADP
gs-3214	227	11	a	a	DET
gs-3214	227	12	widespread	widespread	ADJ
gs-3214	227	13	inflammatory	inflammatory	ADJ
gs-3214	227	14	response	response	NOUN
gs-3214	227	15	,	,	PUNCT
gs-3214	227	16	affecting	affect	VERB
gs-3214	227	17	multiple	multiple	ADJ
gs-3214	227	18	organ	organ	NOUN
gs-3214	227	19	systems	system	NOUN
gs-3214	227	20	.	.	PUNCT
gs-3214	228	1	this	this	PRON
gs-3214	228	2	can	can	AUX
gs-3214	228	3	lead	lead	VERB
gs-3214	228	4	to	to	ADP
gs-3214	228	5	fever	fever	NOUN
gs-3214	228	6	,	,	PUNCT
gs-3214	228	7	hypotension	hypotension	NOUN
gs-3214	228	8	,	,	PUNCT
gs-3214	228	9	tachycardia	tachycardia	NOUN
gs-3214	228	10	,	,	PUNCT
gs-3214	228	11	and	and	CCONJ
gs-3214	228	12	,	,	PUNCT
gs-3214	228	13	in	in	ADP
gs-3214	228	14	severe	severe	ADJ
gs-3214	228	15	cases	case	NOUN
gs-3214	228	16	,	,	PUNCT
gs-3214	228	17	organ	organ	NOUN
gs-3214	228	18	dysfunction	dysfunction	NOUN
gs-3214	228	19	.	.	PUNCT
gs-3214	229	1	crs	crs	PROPN
gs-3214	229	2	exhibits	exhibit	VERB
gs-3214	229	3	a	a	DET
gs-3214	229	4	spectrum	spectrum	NOUN
gs-3214	229	5	of	of	ADP
gs-3214	229	6	clinical	clinical	ADJ
gs-3214	229	7	manifestations	manifestation	NOUN
gs-3214	229	8	,	,	PUNCT
gs-3214	229	9	ranging	range	VERB
gs-3214	229	10	from	from	ADP
gs-3214	229	11	mild	mild	ADJ
gs-3214	229	12	to	to	ADP
gs-3214	229	13	severe	severe	ADJ
gs-3214	229	14	.	.	PUNCT
gs-3214	230	1	fever	fever	NOUN
gs-3214	230	2	,	,	PUNCT
gs-3214	230	3	a	a	DET
gs-3214	230	4	hallmark	hallmark	ADJ
gs-3214	230	5	symptom	symptom	NOUN
gs-3214	230	6	,	,	PUNCT
gs-3214	230	7	is	be	AUX
gs-3214	230	8	often	often	ADV
gs-3214	230	9	accompanied	accompany	VERB
gs-3214	230	10	by	by	ADP
gs-3214	230	11	hypotension	hypotension	NOUN
gs-3214	230	12	,	,	PUNCT
gs-3214	230	13	tachycardia	tachycardia	NOUN
gs-3214	230	14	,	,	PUNCT
gs-3214	230	15	and	and	CCONJ
gs-3214	230	16	respiratory	respiratory	ADJ
gs-3214	230	17	distress	distress	NOUN
gs-3214	230	18	.	.	PUNCT
gs-3214	231	1	severe	severe	ADJ
gs-3214	231	2	crs	crs	PROPN
gs-3214	231	3	may	may	AUX
gs-3214	231	4	progress	progress	VERB
gs-3214	231	5	to	to	PART
gs-3214	231	6	multi	multi	ADJ
gs-3214	231	7	-	-	ADJ
gs-3214	231	8	organ	organ	ADJ
gs-3214	231	9	dysfunction	dysfunction	NOUN
gs-3214	231	10	,	,	PUNCT
gs-3214	231	11	necessitating	necessitate	VERB
gs-3214	231	12	prompt	prompt	ADJ
gs-3214	231	13	intervention	intervention	NOUN
gs-3214	231	14	.	.	PUNCT
gs-3214	232	1	on	on	ADP
gs-3214	232	2	-	-	PUNCT
gs-3214	232	3	target	target	NOUN
gs-3214	232	4	,	,	PUNCT
gs-3214	232	5	off	off	ADP
gs-3214	232	6	-	-	PUNCT
gs-3214	232	7	tumor	tumor	NOUN
gs-3214	232	8	toxicities	toxicity	NOUN
gs-3214	232	9	occur	occur	VERB
gs-3214	232	10	when	when	SCONJ
gs-3214	232	11	car	car	NOUN
gs-3214	232	12	-	-	PUNCT
gs-3214	232	13	t	t	NOUN
gs-3214	232	14	cells	cell	NOUN
gs-3214	232	15	recognize	recognize	VERB
gs-3214	232	16	and	and	CCONJ
gs-3214	232	17	attack	attack	NOUN
gs-3214	232	18	target	target	NOUN
gs-3214	232	19	antigens	antigen	NOUN
gs-3214	232	20	expressed	express	VERB
gs-3214	232	21	on	on	ADP
gs-3214	232	22	normal	normal	ADJ
gs-3214	232	23	tissues	tissue	NOUN
gs-3214	232	24	,	,	PUNCT
gs-3214	232	25	leading	lead	VERB
gs-3214	232	26	to	to	ADP
gs-3214	232	27	unintended	unintended	ADJ
gs-3214	232	28	adverse	adverse	ADJ
gs-3214	232	29	effects	effect	NOUN
gs-3214	232	30	.	.	PUNCT
gs-3214	233	1	understanding	understand	VERB
gs-3214	233	2	the	the	DET
gs-3214	233	3	underlying	underlie	VERB
gs-3214	233	4	mechanisms	mechanism	NOUN
gs-3214	233	5	is	be	AUX
gs-3214	233	6	crucial	crucial	ADJ
gs-3214	233	7	for	for	ADP
gs-3214	233	8	mitigating	mitigate	VERB
gs-3214	233	9	these	these	DET
gs-3214	233	10	toxicities	toxicity	NOUN
gs-3214	233	11	.	.	PUNCT
gs-3214	234	1	the	the	DET
gs-3214	234	2	expression	expression	NOUN
gs-3214	234	3	patterns	pattern	NOUN
gs-3214	234	4	of	of	ADP
gs-3214	234	5	target	target	NOUN
gs-3214	234	6	antigens	antigen	NOUN
gs-3214	234	7	play	play	VERB
gs-3214	234	8	a	a	DET
gs-3214	234	9	pivotal	pivotal	ADJ
gs-3214	234	10	role	role	NOUN
gs-3214	234	11	in	in	ADP
gs-3214	234	12	determining	determine	VERB
gs-3214	234	13	the	the	DET
gs-3214	234	14	occurrence	occurrence	NOUN
gs-3214	234	15	of	of	ADP
gs-3214	234	16	on	on	ADP
gs-3214	234	17	-	-	PUNCT
gs-3214	234	18	target	target	NOUN
gs-3214	234	19	,	,	PUNCT
gs-3214	234	20	off	off	ADP
gs-3214	234	21	-	-	PUNCT
gs-3214	234	22	tumor	tumor	NOUN
gs-3214	234	23	toxicities	toxicity	NOUN
gs-3214	234	24	.	.	PUNCT
gs-3214	235	1	antigens	antigen	NOUN
gs-3214	235	2	with	with	ADP
gs-3214	235	3	low	low	ADJ
gs-3214	235	4	or	or	CCONJ
gs-3214	235	5	restricted	restricted	ADJ
gs-3214	235	6	expression	expression	NOUN
gs-3214	235	7	on	on	ADP
gs-3214	235	8	normal	normal	ADJ
gs-3214	235	9	tissues	tissue	NOUN
gs-3214	235	10	are	be	AUX
gs-3214	235	11	less	less	ADV
gs-3214	235	12	likely	likely	ADJ
gs-3214	235	13	to	to	PART
gs-3214	235	14	induce	induce	VERB
gs-3214	235	15	off	off	ADP
gs-3214	235	16	-	-	PUNCT
gs-3214	235	17	tumor	tumor	NOUN
gs-3214	235	18	effects	effect	NOUN
gs-3214	235	19	.	.	PUNCT
gs-3214	236	1	the	the	DET
gs-3214	236	2	distribution	distribution	NOUN
gs-3214	236	3	of	of	ADP
gs-3214	236	4	car	car	NOUN
gs-3214	236	5	-	-	PUNCT
gs-3214	236	6	t	t	NOUN
gs-3214	236	7	cells	cell	NOUN
gs-3214	236	8	within	within	ADP
gs-3214	236	9	the	the	DET
gs-3214	236	10	body	body	NOUN
gs-3214	236	11	influences	influence	VERB
gs-3214	236	12	the	the	DET
gs-3214	236	13	likelihood	likelihood	NOUN
gs-3214	236	14	of	of	ADP
gs-3214	236	15	encountering	encounter	VERB
gs-3214	236	16	normal	normal	ADJ
gs-3214	236	17	tissues	tissue	NOUN
gs-3214	236	18	expressing	express	VERB
gs-3214	236	19	target	target	NOUN
gs-3214	236	20	antigens	antigen	NOUN
gs-3214	236	21	.	.	PUNCT
gs-3214	237	1	factors	factor	NOUN
gs-3214	237	2	such	such	ADJ
gs-3214	237	3	as	as	ADP
gs-3214	237	4	car	car	NOUN
gs-3214	237	5	-	-	PUNCT
gs-3214	237	6	t	t	NOUN
gs-3214	237	7	cell	cell	NOUN
gs-3214	237	8	trafficking	trafficking	NOUN
gs-3214	237	9	and	and	CCONJ
gs-3214	237	10	persistence	persistence	NOUN
gs-3214	237	11	contribute	contribute	VERB
gs-3214	237	12	to	to	ADP
gs-3214	237	13	the	the	DET
gs-3214	237	14	risk	risk	NOUN
gs-3214	237	15	of	of	ADP
gs-3214	237	16	off	off	ADP
gs-3214	237	17	-	-	PUNCT
gs-3214	237	18	tumor	tumor	NOUN
gs-3214	237	19	toxicities	toxicity	NOUN
gs-3214	237	20	[	[	X
gs-3214	237	21	64	64	NUM
gs-3214	237	22	-	-	SYM
gs-3214	237	23	65	65	NUM
gs-3214	237	24	]	]	PUNCT
gs-3214	237	25	.	.	PUNCT
gs-3214	238	1	georgian	georgian	PROPN
gs-3214	238	2	scientists/	scientists/	NUM
gs-3214	238	3	.	.	PUNCT
gs-3214	239	1	6	6	NUM
gs-3214	239	2	n	n	NUM
gs-3214	239	3	3	3	NUM
gs-3214	239	4	,	,	PUNCT
gs-3214	239	5	2024	2024	NUM
gs-3214	239	6	275	275	NUM
gs-3214	239	7	immunological	immunological	ADJ
gs-3214	239	8	cross	cross	NOUN
gs-3214	239	9	-	-	NOUN
gs-3214	239	10	reactivity	reactivity	NOUN
gs-3214	239	11	between	between	ADP
gs-3214	239	12	target	target	NOUN
gs-3214	239	13	antigens	antigen	NOUN
gs-3214	239	14	on	on	ADP
gs-3214	239	15	tumor	tumor	NOUN
gs-3214	239	16	cells	cell	NOUN
gs-3214	239	17	and	and	CCONJ
gs-3214	239	18	similar	similar	ADJ
gs-3214	239	19	antigens	antigen	NOUN
gs-3214	239	20	expressed	express	VERB
gs-3214	239	21	on	on	ADP
gs-3214	239	22	normal	normal	ADJ
gs-3214	239	23	tissues	tissue	NOUN
gs-3214	239	24	can	can	AUX
gs-3214	239	25	result	result	VERB
gs-3214	239	26	in	in	ADP
gs-3214	239	27	unintended	unintended	ADJ
gs-3214	239	28	recognition	recognition	NOUN
gs-3214	239	29	and	and	CCONJ
gs-3214	239	30	subsequent	subsequent	ADJ
gs-3214	239	31	toxicity	toxicity	NOUN
gs-3214	239	32	.	.	PUNCT
gs-3214	240	1	this	this	DET
gs-3214	240	2	phenomenon	phenomenon	NOUN
gs-3214	240	3	underscores	underscore	VERB
gs-3214	240	4	the	the	DET
gs-3214	240	5	importance	importance	NOUN
gs-3214	240	6	of	of	ADP
gs-3214	240	7	antigen	antigen	ADJ
gs-3214	240	8	selection	selection	NOUN
gs-3214	240	9	in	in	ADP
gs-3214	240	10	car	car	NOUN
gs-3214	240	11	-	-	PUNCT
gs-3214	240	12	t	t	NOUN
gs-3214	240	13	cell	cell	NOUN
gs-3214	240	14	therapy	therapy	NOUN
gs-3214	240	15	.	.	PUNCT
gs-3214	241	1	on	on	ADP
gs-3214	241	2	-	-	PUNCT
gs-3214	241	3	target	target	NOUN
gs-3214	241	4	,	,	PUNCT
gs-3214	241	5	off	off	ADP
gs-3214	241	6	-	-	PUNCT
gs-3214	241	7	tumor	tumor	NOUN
gs-3214	241	8	toxicities	toxicity	NOUN
gs-3214	241	9	manifest	manifest	VERB
gs-3214	241	10	as	as	ADP
gs-3214	241	11	a	a	DET
gs-3214	241	12	spectrum	spectrum	NOUN
gs-3214	241	13	of	of	ADP
gs-3214	241	14	adverse	adverse	ADJ
gs-3214	241	15	events	event	NOUN
gs-3214	241	16	,	,	PUNCT
gs-3214	241	17	ranging	range	VERB
gs-3214	241	18	from	from	ADP
gs-3214	241	19	mild	mild	ADJ
gs-3214	241	20	to	to	ADP
gs-3214	241	21	severe	severe	ADJ
gs-3214	241	22	.	.	PUNCT
gs-3214	242	1	prompt	prompt	ADJ
gs-3214	242	2	recognition	recognition	NOUN
gs-3214	242	3	and	and	CCONJ
gs-3214	242	4	targeted	target	VERB
gs-3214	242	5	management	management	NOUN
gs-3214	242	6	are	be	AUX
gs-3214	242	7	essential	essential	ADJ
gs-3214	242	8	for	for	ADP
gs-3214	242	9	minimizing	minimize	VERB
gs-3214	242	10	patient	patient	ADJ
gs-3214	242	11	morbidity	morbidity	NOUN
gs-3214	242	12	and	and	CCONJ
gs-3214	242	13	optimizing	optimize	VERB
gs-3214	242	14	treatment	treatment	NOUN
gs-3214	242	15	outcomes	outcome	NOUN
gs-3214	242	16	[	[	X
gs-3214	242	17	6667	6667	NUM
gs-3214	242	18	]	]	PUNCT
gs-3214	242	19	.	.	PUNCT
gs-3214	243	1	dermatologic	dermatologic	ADJ
gs-3214	243	2	toxicities	toxicity	NOUN
gs-3214	243	3	,	,	PUNCT
gs-3214	243	4	such	such	ADJ
gs-3214	243	5	as	as	ADP
gs-3214	243	6	rash	rash	ADJ
gs-3214	243	7	and	and	CCONJ
gs-3214	243	8	pruritus	pruritus	PROPN
gs-3214	243	9	,	,	PUNCT
gs-3214	243	10	may	may	AUX
gs-3214	243	11	occur	occur	VERB
gs-3214	243	12	due	due	ADJ
gs-3214	243	13	to	to	ADP
gs-3214	243	14	car	car	NOUN
gs-3214	243	15	-	-	PUNCT
gs-3214	243	16	t	t	NOUN
gs-3214	243	17	cell	cell	NOUN
gs-3214	243	18	recognition	recognition	NOUN
gs-3214	243	19	of	of	ADP
gs-3214	243	20	skinassociated	skinassociate	VERB
gs-3214	243	21	antigens	antigen	NOUN
gs-3214	243	22	.	.	PUNCT
gs-3214	244	1	topical	topical	ADJ
gs-3214	244	2	therapies	therapy	NOUN
gs-3214	244	3	and	and	CCONJ
gs-3214	244	4	systemic	systemic	ADJ
gs-3214	244	5	corticosteroids	corticosteroid	NOUN
gs-3214	244	6	are	be	AUX
gs-3214	244	7	commonly	commonly	ADV
gs-3214	244	8	employed	employ	VERB
gs-3214	244	9	to	to	PART
gs-3214	244	10	alleviate	alleviate	VERB
gs-3214	244	11	symptoms	symptom	NOUN
gs-3214	244	12	.	.	PUNCT
gs-3214	245	1	neurological	neurological	ADJ
gs-3214	245	2	toxicities	toxicity	NOUN
gs-3214	245	3	,	,	PUNCT
gs-3214	245	4	including	include	VERB
gs-3214	245	5	cognitive	cognitive	ADJ
gs-3214	245	6	impairment	impairment	NOUN
gs-3214	245	7	and	and	CCONJ
gs-3214	245	8	seizures	seizure	NOUN
gs-3214	245	9	,	,	PUNCT
gs-3214	245	10	can	can	AUX
gs-3214	245	11	result	result	VERB
gs-3214	245	12	from	from	ADP
gs-3214	245	13	cart	cart	NOUN
gs-3214	245	14	cell	cell	NOUN
gs-3214	245	15	infiltration	infiltration	NOUN
gs-3214	245	16	into	into	ADP
gs-3214	245	17	the	the	DET
gs-3214	245	18	central	central	ADJ
gs-3214	245	19	nervous	nervous	ADJ
gs-3214	245	20	system	system	NOUN
gs-3214	245	21	.	.	PUNCT
gs-3214	246	1	management	management	NOUN
gs-3214	246	2	strategies	strategy	NOUN
gs-3214	246	3	often	often	ADV
gs-3214	246	4	involve	involve	VERB
gs-3214	246	5	supportive	supportive	ADJ
gs-3214	246	6	care	care	NOUN
gs-3214	246	7	,	,	PUNCT
gs-3214	246	8	immunosuppression	immunosuppression	NOUN
gs-3214	246	9	,	,	PUNCT
gs-3214	246	10	and	and	CCONJ
gs-3214	246	11	neuro	neuro	VERB
gs-3214	246	12	protective	protective	ADJ
gs-3214	246	13	measures	measure	NOUN
gs-3214	246	14	.	.	PUNCT
gs-3214	247	1	gastrointestinal	gastrointestinal	ADJ
gs-3214	247	2	toxicities	toxicity	NOUN
gs-3214	247	3	,	,	PUNCT
gs-3214	247	4	such	such	ADJ
gs-3214	247	5	as	as	ADP
gs-3214	247	6	diarrhea	diarrhea	NOUN
gs-3214	247	7	and	and	CCONJ
gs-3214	247	8	colitis	colitis	NOUN
gs-3214	247	9	,	,	PUNCT
gs-3214	247	10	may	may	AUX
gs-3214	247	11	arise	arise	VERB
gs-3214	247	12	from	from	ADP
gs-3214	247	13	car	car	NOUN
gs-3214	247	14	-	-	PUNCT
gs-3214	247	15	t	t	NOUN
gs-3214	247	16	cell	cell	NOUN
gs-3214	247	17	-	-	PUNCT
gs-3214	247	18	mediated	mediate	VERB
gs-3214	247	19	inflammation	inflammation	NOUN
gs-3214	247	20	of	of	ADP
gs-3214	247	21	the	the	DET
gs-3214	247	22	gastrointestinal	gastrointestinal	ADJ
gs-3214	247	23	tract	tract	NOUN
gs-3214	247	24	.	.	PUNCT
gs-3214	248	1	symptomatic	symptomatic	ADJ
gs-3214	248	2	management	management	NOUN
gs-3214	248	3	and	and	CCONJ
gs-3214	248	4	,	,	PUNCT
gs-3214	248	5	in	in	ADP
gs-3214	248	6	severe	severe	ADJ
gs-3214	248	7	cases	case	NOUN
gs-3214	248	8	,	,	PUNCT
gs-3214	248	9	immunosuppressive	immunosuppressive	ADJ
gs-3214	248	10	agents	agent	NOUN
gs-3214	248	11	are	be	AUX
gs-3214	248	12	utilized	utilize	VERB
gs-3214	248	13	to	to	PART
gs-3214	248	14	mitigate	mitigate	VERB
gs-3214	248	15	gastrointestinal	gastrointestinal	ADJ
gs-3214	248	16	adverse	adverse	ADJ
gs-3214	248	17	events	event	NOUN
gs-3214	248	18	.	.	PUNCT
gs-3214	249	1	long	long	ADJ
gs-3214	249	2	-	-	PUNCT
gs-3214	249	3	term	term	NOUN
gs-3214	249	4	safety	safety	NOUN
gs-3214	249	5	monitoring	monitoring	NOUN
gs-3214	249	6	aims	aim	VERB
gs-3214	249	7	to	to	PART
gs-3214	249	8	identify	identify	VERB
gs-3214	249	9	and	and	CCONJ
gs-3214	249	10	manage	manage	VERB
gs-3214	249	11	late	late	ADJ
gs-3214	249	12	-	-	PUNCT
gs-3214	249	13	onset	onset	NOUN
gs-3214	249	14	toxicities	toxicity	NOUN
gs-3214	249	15	associated	associate	VERB
gs-3214	249	16	with	with	ADP
gs-3214	249	17	car	car	NOUN
gs-3214	249	18	-	-	PUNCT
gs-3214	249	19	t	t	NOUN
gs-3214	249	20	cell	cell	NOUN
gs-3214	249	21	therapy	therapy	NOUN
gs-3214	249	22	.	.	PUNCT
gs-3214	250	1	vigilant	vigilant	ADJ
gs-3214	250	2	surveillance	surveillance	NOUN
gs-3214	250	3	allows	allow	VERB
gs-3214	250	4	for	for	ADP
gs-3214	250	5	early	early	ADJ
gs-3214	250	6	intervention	intervention	NOUN
gs-3214	250	7	and	and	CCONJ
gs-3214	250	8	mitigation	mitigation	NOUN
gs-3214	250	9	of	of	ADP
gs-3214	250	10	potential	potential	ADJ
gs-3214	250	11	long	long	ADJ
gs-3214	250	12	-	-	PUNCT
gs-3214	250	13	term	term	NOUN
gs-3214	250	14	adverse	adverse	ADJ
gs-3214	250	15	effects	effect	NOUN
gs-3214	250	16	[	[	X
gs-3214	250	17	68	68	NUM
gs-3214	250	18	-	-	SYM
gs-3214	250	19	69	69	NUM
gs-3214	250	20	]	]	PUNCT
gs-3214	250	21	.	.	PUNCT
gs-3214	251	1	secondary	secondary	ADJ
gs-3214	251	2	malignancies	malignancy	NOUN
gs-3214	251	3	,	,	PUNCT
gs-3214	251	4	such	such	ADJ
gs-3214	251	5	as	as	ADP
gs-3214	251	6	lymphoproliferative	lymphoproliferative	ADJ
gs-3214	251	7	disorders	disorder	NOUN
gs-3214	251	8	and	and	CCONJ
gs-3214	251	9	myelodysplastic	myelodysplastic	ADJ
gs-3214	251	10	syndromes	syndrome	NOUN
gs-3214	251	11	,	,	PUNCT
gs-3214	251	12	represent	represent	VERB
gs-3214	251	13	rare	rare	ADJ
gs-3214	251	14	but	but	CCONJ
gs-3214	251	15	serious	serious	ADJ
gs-3214	251	16	long	long	ADJ
gs-3214	251	17	-	-	PUNCT
gs-3214	251	18	term	term	NOUN
gs-3214	251	19	complications	complication	NOUN
gs-3214	251	20	of	of	ADP
gs-3214	251	21	car	car	NOUN
gs-3214	251	22	-	-	PUNCT
gs-3214	251	23	t	t	NOUN
gs-3214	251	24	cell	cell	NOUN
gs-3214	251	25	therapy	therapy	NOUN
gs-3214	251	26	.	.	PUNCT
gs-3214	252	1	close	close	ADJ
gs-3214	252	2	surveillance	surveillance	NOUN
gs-3214	252	3	and	and	CCONJ
gs-3214	252	4	early	early	ADJ
gs-3214	252	5	intervention	intervention	NOUN
gs-3214	252	6	are	be	AUX
gs-3214	252	7	critical	critical	ADJ
gs-3214	252	8	for	for	ADP
gs-3214	252	9	optimizing	optimize	VERB
gs-3214	252	10	patient	patient	ADJ
gs-3214	252	11	outcomes	outcome	NOUN
gs-3214	252	12	.	.	PUNCT
gs-3214	253	1	cell	cell	NOUN
gs-3214	253	2	harvesting	harvesting	NOUN
gs-3214	253	3	for	for	ADP
gs-3214	253	4	car	car	NOUN
gs-3214	253	5	-	-	PUNCT
gs-3214	253	6	t	t	NOUN
gs-3214	253	7	cell	cell	NOUN
gs-3214	253	8	therapy	therapy	NOUN
gs-3214	253	9	usually	usually	ADV
gs-3214	253	10	entails	entail	VERB
gs-3214	253	11	apheresis	apheresis	NOUN
gs-3214	253	12	or	or	CCONJ
gs-3214	253	13	leukapheresis	leukapheresis	NOUN
gs-3214	253	14	methods	method	NOUN
gs-3214	253	15	aimed	aim	VERB
gs-3214	253	16	at	at	ADP
gs-3214	253	17	extracting	extract	VERB
gs-3214	253	18	peripheral	peripheral	ADJ
gs-3214	253	19	blood	blood	NOUN
gs-3214	253	20	mononuclear	mononuclear	ADJ
gs-3214	253	21	cells	cell	NOUN
gs-3214	253	22	(	(	PUNCT
gs-3214	253	23	pbmcs	pbmcs	NOUN
gs-3214	253	24	)	)	PUNCT
gs-3214	253	25	from	from	ADP
gs-3214	253	26	individuals	individual	NOUN
gs-3214	253	27	.	.	PUNCT
gs-3214	254	1	the	the	DET
gs-3214	254	2	optimization	optimization	NOUN
gs-3214	254	3	of	of	ADP
gs-3214	254	4	apheresis	apheresis	NOUN
gs-3214	254	5	variables	variable	NOUN
gs-3214	254	6	,	,	PUNCT
gs-3214	254	7	including	include	VERB
gs-3214	254	8	flow	flow	NOUN
gs-3214	254	9	rate	rate	NOUN
gs-3214	254	10	and	and	CCONJ
gs-3214	254	11	volume	volume	NOUN
gs-3214	254	12	,	,	PUNCT
gs-3214	254	13	is	be	AUX
gs-3214	254	14	essential	essential	ADJ
gs-3214	254	15	to	to	PART
gs-3214	254	16	enhance	enhance	VERB
gs-3214	254	17	cell	cell	NOUN
gs-3214	254	18	production	production	NOUN
gs-3214	254	19	while	while	SCONJ
gs-3214	254	20	minimizing	minimize	VERB
gs-3214	254	21	patient	patient	ADJ
gs-3214	254	22	discomfort	discomfort	NOUN
gs-3214	254	23	and	and	CCONJ
gs-3214	254	24	potential	potential	ADJ
gs-3214	254	25	adverse	adverse	ADJ
gs-3214	254	26	effects	effect	NOUN
gs-3214	254	27	[	[	X
gs-3214	254	28	70	70	NUM
gs-3214	254	29	-	-	SYM
gs-3214	254	30	71	71	NUM
gs-3214	254	31	]	]	PUNCT
gs-3214	254	32	.	.	PUNCT
gs-3214	255	1	after	after	ADP
gs-3214	255	2	collection	collection	NOUN
gs-3214	255	3	,	,	PUNCT
gs-3214	255	4	pbmcs	pbmc	NOUN
gs-3214	255	5	undergo	undergo	VERB
gs-3214	255	6	processing	processing	NOUN
gs-3214	255	7	to	to	PART
gs-3214	255	8	isolate	isolate	VERB
gs-3214	255	9	t	t	PROPN
gs-3214	255	10	cells	cell	NOUN
gs-3214	255	11	,	,	PUNCT
gs-3214	255	12	which	which	PRON
gs-3214	255	13	are	be	AUX
gs-3214	255	14	subsequently	subsequently	ADV
gs-3214	255	15	engineered	engineer	VERB
gs-3214	255	16	to	to	PART
gs-3214	255	17	express	express	VERB
gs-3214	255	18	cars	car	NOUN
gs-3214	255	19	.	.	PUNCT
gs-3214	256	1	this	this	DET
gs-3214	256	2	process	process	NOUN
gs-3214	256	3	includes	include	VERB
gs-3214	256	4	cell	cell	NOUN
gs-3214	256	5	enrichment	enrichment	NOUN
gs-3214	256	6	,	,	PUNCT
gs-3214	256	7	activation	activation	NOUN
gs-3214	256	8	,	,	PUNCT
gs-3214	256	9	and	and	CCONJ
gs-3214	256	10	transduction	transduction	NOUN
gs-3214	256	11	using	use	VERB
gs-3214	256	12	viral	viral	ADJ
gs-3214	256	13	vectors	vector	NOUN
gs-3214	256	14	containing	contain	VERB
gs-3214	256	15	car	car	NOUN
gs-3214	256	16	constructs	construct	NOUN
gs-3214	256	17	.	.	PUNCT
gs-3214	257	1	closed	close	VERB
gs-3214	257	2	-	-	PUNCT
gs-3214	257	3	system	system	NOUN
gs-3214	257	4	processing	processing	NOUN
gs-3214	257	5	platforms	platform	NOUN
gs-3214	257	6	and	and	CCONJ
gs-3214	257	7	automated	automate	VERB
gs-3214	257	8	cell	cell	NOUN
gs-3214	257	9	isolation	isolation	NOUN
gs-3214	257	10	techniques	technique	NOUN
gs-3214	257	11	are	be	AUX
gs-3214	257	12	utilized	utilize	VERB
gs-3214	257	13	to	to	PART
gs-3214	257	14	uphold	uphold	VERB
gs-3214	257	15	cell	cell	NOUN
gs-3214	257	16	viability	viability	NOUN
gs-3214	257	17	and	and	CCONJ
gs-3214	257	18	sterility	sterility	NOUN
gs-3214	257	19	throughout	throughout	ADP
gs-3214	257	20	this	this	DET
gs-3214	257	21	phase	phase	NOUN
gs-3214	257	22	[	[	X
gs-3214	257	23	72	72	NUM
gs-3214	257	24	-	-	SYM
gs-3214	257	25	73	73	NUM
gs-3214	257	26	]	]	PUNCT
gs-3214	257	27	.	.	PUNCT
gs-3214	258	1	the	the	DET
gs-3214	258	2	genetic	genetic	ADJ
gs-3214	258	3	modification	modification	NOUN
gs-3214	258	4	of	of	ADP
gs-3214	258	5	t	t	NOUN
gs-3214	258	6	cells	cell	NOUN
gs-3214	258	7	entails	entail	VERB
gs-3214	258	8	designing	design	VERB
gs-3214	258	9	and	and	CCONJ
gs-3214	258	10	refining	refining	NOUN
gs-3214	258	11	car	car	NOUN
gs-3214	258	12	constructs	construct	NOUN
gs-3214	258	13	to	to	PART
gs-3214	258	14	boost	boost	VERB
gs-3214	258	15	their	their	PRON
gs-3214	258	16	effectiveness	effectiveness	NOUN
gs-3214	258	17	against	against	ADP
gs-3214	258	18	tumors	tumor	NOUN
gs-3214	258	19	while	while	SCONJ
gs-3214	258	20	reducing	reduce	VERB
gs-3214	258	21	unintended	unintended	ADJ
gs-3214	258	22	harm	harm	NOUN
gs-3214	258	23	to	to	ADP
gs-3214	258	24	healthy	healthy	ADJ
gs-3214	258	25	tissues	tissue	NOUN
gs-3214	258	26	.	.	PUNCT
gs-3214	259	1	methods	method	NOUN
gs-3214	259	2	include	include	VERB
gs-3214	259	3	enhancing	enhance	VERB
gs-3214	259	4	car	car	NOUN
gs-3214	259	5	architecture	architecture	NOUN
gs-3214	259	6	,	,	PUNCT
gs-3214	259	7	carefully	carefully	ADV
gs-3214	259	8	choosing	choose	VERB
gs-3214	259	9	target	target	NOUN
gs-3214	259	10	antigens	antigen	NOUN
gs-3214	259	11	,	,	PUNCT
gs-3214	259	12	integrating	integrate	VERB
gs-3214	259	13	costimulatory	costimulatory	NOUN
gs-3214	259	14	domains	domain	NOUN
gs-3214	259	15	,	,	PUNCT
gs-3214	259	16	and	and	CCONJ
gs-3214	259	17	incorporating	incorporate	VERB
gs-3214	259	18	safety	safety	NOUN
gs-3214	259	19	mechanisms	mechanism	NOUN
gs-3214	259	20	to	to	PART
gs-3214	259	21	control	control	VERB
gs-3214	259	22	the	the	DET
gs-3214	259	23	activity	activity	NOUN
gs-3214	259	24	of	of	ADP
gs-3214	259	25	car	car	NOUN
gs-3214	259	26	-	-	PUNCT
gs-3214	259	27	t	t	NOUN
gs-3214	259	28	cells	cell	NOUN
gs-3214	259	29	.	.	PUNCT
gs-3214	260	1	choosing	choose	VERB
gs-3214	260	2	viral	viral	ADJ
gs-3214	260	3	vectors	vector	NOUN
gs-3214	260	4	for	for	ADP
gs-3214	260	5	car	car	NOUN
gs-3214	260	6	delivery	delivery	NOUN
gs-3214	260	7	,	,	PUNCT
gs-3214	260	8	such	such	ADJ
gs-3214	260	9	as	as	ADP
gs-3214	260	10	lentiviral	lentiviral	ADJ
gs-3214	260	11	or	or	CCONJ
gs-3214	260	12	retroviral	retroviral	ADJ
gs-3214	260	13	vectors	vector	NOUN
gs-3214	260	14	,	,	PUNCT
gs-3214	260	15	impacts	impact	VERB
gs-3214	260	16	transduction	transduction	NOUN
gs-3214	260	17	efficiency	efficiency	NOUN
gs-3214	260	18	and	and	CCONJ
gs-3214	260	19	the	the	DET
gs-3214	260	20	levels	level	NOUN
gs-3214	260	21	of	of	ADP
gs-3214	260	22	car	car	NOUN
gs-3214	260	23	expression	expression	NOUN
gs-3214	260	24	.	.	PUNCT
gs-3214	261	1	factors	factor	NOUN
gs-3214	261	2	in	in	ADP
gs-3214	261	3	vector	vector	NOUN
gs-3214	261	4	design	design	NOUN
gs-3214	261	5	,	,	PUNCT
gs-3214	261	6	such	such	ADJ
gs-3214	261	7	as	as	ADP
gs-3214	261	8	promoter	promoter	NOUN
gs-3214	261	9	strength	strength	NOUN
gs-3214	261	10	,	,	PUNCT
gs-3214	261	11	transgenes	transgene	NOUN
gs-3214	261	12	size	size	NOUN
gs-3214	261	13	,	,	PUNCT
gs-3214	261	14	and	and	CCONJ
gs-3214	261	15	preferences	preference	NOUN
gs-3214	261	16	for	for	ADP
gs-3214	261	17	integration	integration	NOUN
gs-3214	261	18	sites	site	NOUN
gs-3214	261	19	,	,	PUNCT
gs-3214	261	20	are	be	AUX
gs-3214	261	21	carefully	carefully	ADV
gs-3214	261	22	considered	consider	VERB
gs-3214	261	23	to	to	PART
gs-3214	261	24	maintain	maintain	VERB
gs-3214	261	25	stable	stable	ADJ
gs-3214	261	26	car	car	NOUN
gs-3214	261	27	expression	expression	NOUN
gs-3214	261	28	and	and	CCONJ
gs-3214	261	29	reduce	reduce	VERB
gs-3214	261	30	the	the	DET
gs-3214	261	31	risks	risk	NOUN
gs-3214	261	32	of	of	ADP
gs-3214	261	33	genotoxicity	genotoxicity	NOUN
gs-3214	261	34	[	[	X
gs-3214	261	35	74	74	NUM
gs-3214	261	36	-	-	SYM
gs-3214	261	37	75	75	NUM
gs-3214	261	38	]	]	PUNCT
gs-3214	261	39	.	.	PUNCT
gs-3214	262	1	after	after	ADP
gs-3214	262	2	genetic	genetic	ADJ
gs-3214	262	3	modification	modification	NOUN
gs-3214	262	4	,	,	PUNCT
gs-3214	262	5	car	car	NOUN
gs-3214	262	6	-	-	PUNCT
gs-3214	262	7	t	t	NOUN
gs-3214	262	8	cells	cell	NOUN
gs-3214	262	9	undergo	undergo	VERB
gs-3214	262	10	ex	ex	PRON
gs-3214	262	11	vivo	vivo	ADJ
gs-3214	262	12	expansion	expansion	NOUN
gs-3214	262	13	to	to	PART
gs-3214	262	14	produce	produce	VERB
gs-3214	262	15	clinically	clinically	ADV
gs-3214	262	16	significant	significant	ADJ
gs-3214	262	17	cell	cell	NOUN
gs-3214	262	18	quantities	quantity	NOUN
gs-3214	262	19	.	.	PUNCT
gs-3214	263	1	expansion	expansion	NOUN
gs-3214	263	2	techniques	technique	NOUN
gs-3214	263	3	involve	involve	VERB
gs-3214	263	4	culturing	culture	VERB
gs-3214	263	5	with	with	ADP
gs-3214	263	6	artificial	artificial	ADJ
gs-3214	263	7	antigen	antigen	NOUN
gs-3214	263	8	-	-	PUNCT
gs-3214	263	9	presenting	present	VERB
gs-3214	263	10	cells	cell	NOUN
gs-3214	263	11	(	(	PUNCT
gs-3214	263	12	aapcs	aapc	NOUN
gs-3214	263	13	)	)	PUNCT
gs-3214	263	14	,	,	PUNCT
gs-3214	263	15	georgian	georgian	NOUN
gs-3214	263	16	scientists/	scientists/	NUM
gs-3214	263	17	.	.	PUNCT
gs-3214	264	1	6	6	NUM
gs-3214	264	2	n	n	NUM
gs-3214	264	3	3	3	NUM
gs-3214	264	4	,	,	PUNCT
gs-3214	264	5	2024	2024	NUM
gs-3214	264	6	276	276	NUM
gs-3214	264	7	stimulating	stimulate	VERB
gs-3214	264	8	with	with	ADP
gs-3214	264	9	cytokines	cytokine	NOUN
gs-3214	264	10	like	like	ADP
gs-3214	264	11	interleukin-2	interleukin-2	NOUN
gs-3214	264	12	(	(	PUNCT
gs-3214	264	13	il-2	il-2	NUM
gs-3214	264	14	)	)	PUNCT
gs-3214	264	15	or	or	CCONJ
gs-3214	264	16	interleukin-7	interleukin-7	PROPN
gs-3214	264	17	(	(	PUNCT
gs-3214	264	18	il-7	il-7	NOUN
gs-3214	264	19	)	)	PUNCT
gs-3214	264	20	,	,	PUNCT
gs-3214	264	21	and	and	CCONJ
gs-3214	264	22	refining	refining	NOUN
gs-3214	264	23	culture	culture	NOUN
gs-3214	264	24	conditions	condition	NOUN
gs-3214	264	25	to	to	PART
gs-3214	264	26	encourage	encourage	VERB
gs-3214	264	27	t	t	NOUN
gs-3214	264	28	cell	cell	NOUN
gs-3214	264	29	proliferation	proliferation	NOUN
gs-3214	264	30	and	and	CCONJ
gs-3214	264	31	longevity	longevity	NOUN
gs-3214	264	32	.	.	PUNCT
gs-3214	265	1	ensuring	ensure	VERB
gs-3214	265	2	effective	effective	ADJ
gs-3214	265	3	activation	activation	NOUN
gs-3214	265	4	of	of	ADP
gs-3214	265	5	car	car	NOUN
gs-3214	265	6	-	-	PUNCT
gs-3214	265	7	t	t	NOUN
gs-3214	265	8	cells	cell	NOUN
gs-3214	265	9	and	and	CCONJ
gs-3214	265	10	the	the	DET
gs-3214	265	11	development	development	NOUN
gs-3214	265	12	of	of	ADP
gs-3214	265	13	a	a	DET
gs-3214	265	14	memory	memory	NOUN
gs-3214	265	15	phenotype	phenotype	NOUN
gs-3214	265	16	are	be	AUX
gs-3214	265	17	crucial	crucial	ADJ
gs-3214	265	18	for	for	ADP
gs-3214	265	19	sustaining	sustain	VERB
gs-3214	265	20	long	long	ADV
gs-3214	265	21	-	-	PUNCT
gs-3214	265	22	lasting	last	VERB
gs-3214	265	23	antitumor	antitumor	NOUN
gs-3214	265	24	responses	response	NOUN
gs-3214	265	25	.	.	PUNCT
gs-3214	266	1	techniques	technique	NOUN
gs-3214	266	2	to	to	PART
gs-3214	266	3	boost	boost	VERB
gs-3214	266	4	memory	memory	NOUN
gs-3214	266	5	formation	formation	NOUN
gs-3214	266	6	encompass	encompass	NOUN
gs-3214	266	7	adjusting	adjust	VERB
gs-3214	266	8	culture	culture	NOUN
gs-3214	266	9	media	medium	NOUN
gs-3214	266	10	constituents	constituent	NOUN
gs-3214	266	11	,	,	PUNCT
gs-3214	266	12	manipulating	manipulate	VERB
gs-3214	266	13	cytokine	cytokine	NOUN
gs-3214	266	14	signaling	signal	VERB
gs-3214	266	15	pathways	pathway	NOUN
gs-3214	266	16	,	,	PUNCT
gs-3214	266	17	and	and	CCONJ
gs-3214	266	18	optimizing	optimize	VERB
gs-3214	266	19	metabolic	metabolic	NOUN
gs-3214	266	20	programming	programming	NOUN
gs-3214	266	21	to	to	PART
gs-3214	266	22	support	support	VERB
gs-3214	266	23	prolonged	prolonged	ADJ
gs-3214	266	24	car	car	NOUN
gs-3214	266	25	-	-	PUNCT
gs-3214	266	26	t	t	NOUN
gs-3214	266	27	cell	cell	NOUN
gs-3214	266	28	persistence	persistence	NOUN
gs-3214	266	29	and	and	CCONJ
gs-3214	266	30	activity.[66	activity.[66	PROPN
gs-3214	266	31	]	]	PUNCT
gs-3214	266	32	quality	quality	NOUN
gs-3214	266	33	control	control	NOUN
gs-3214	266	34	measures	measure	NOUN
gs-3214	266	35	are	be	AUX
gs-3214	266	36	vital	vital	ADJ
gs-3214	266	37	to	to	PART
gs-3214	266	38	guarantee	guarantee	VERB
gs-3214	266	39	the	the	DET
gs-3214	266	40	safety	safety	NOUN
gs-3214	266	41	,	,	PUNCT
gs-3214	266	42	effectiveness	effectiveness	NOUN
gs-3214	266	43	,	,	PUNCT
gs-3214	266	44	and	and	CCONJ
gs-3214	266	45	uniformity	uniformity	NOUN
gs-3214	266	46	of	of	ADP
gs-3214	266	47	car	car	NOUN
gs-3214	266	48	-	-	PUNCT
gs-3214	266	49	t	t	NOUN
gs-3214	266	50	cell	cell	NOUN
gs-3214	266	51	products	product	NOUN
gs-3214	266	52	.	.	PUNCT
gs-3214	267	1	release	release	NOUN
gs-3214	267	2	testing	testing	NOUN
gs-3214	267	3	evaluates	evaluate	VERB
gs-3214	267	4	product	product	NOUN
gs-3214	267	5	identity	identity	NOUN
gs-3214	267	6	,	,	PUNCT
gs-3214	267	7	purity	purity	NOUN
gs-3214	267	8	,	,	PUNCT
gs-3214	267	9	viability	viability	NOUN
gs-3214	267	10	,	,	PUNCT
gs-3214	267	11	and	and	CCONJ
gs-3214	267	12	functional	functional	ADJ
gs-3214	267	13	activity	activity	NOUN
gs-3214	267	14	based	base	VERB
gs-3214	267	15	on	on	ADP
gs-3214	267	16	predetermined	predetermine	VERB
gs-3214	267	17	criteria	criterion	NOUN
gs-3214	267	18	.	.	PUNCT
gs-3214	268	1	it	it	PRON
gs-3214	268	2	's	be	AUX
gs-3214	268	3	crucial	crucial	ADJ
gs-3214	268	4	to	to	PART
gs-3214	268	5	validate	validate	VERB
gs-3214	268	6	manufacturing	manufacturing	NOUN
gs-3214	268	7	processes	process	NOUN
gs-3214	268	8	and	and	CCONJ
gs-3214	268	9	analytical	analytical	ADJ
gs-3214	268	10	methods	method	NOUN
gs-3214	268	11	to	to	PART
gs-3214	268	12	ensure	ensure	VERB
gs-3214	268	13	consistency	consistency	NOUN
gs-3214	268	14	and	and	CCONJ
gs-3214	268	15	adherence	adherence	NOUN
gs-3214	268	16	to	to	ADP
gs-3214	268	17	regulatory	regulatory	ADJ
gs-3214	268	18	standards	standard	NOUN
gs-3214	268	19	.	.	PUNCT
gs-3214	269	1	the	the	DET
gs-3214	269	2	characterization	characterization	NOUN
gs-3214	269	3	of	of	ADP
gs-3214	269	4	car	car	NOUN
gs-3214	269	5	-	-	PUNCT
gs-3214	269	6	t	t	NOUN
gs-3214	269	7	cell	cell	NOUN
gs-3214	269	8	products	product	NOUN
gs-3214	269	9	involves	involve	VERB
gs-3214	269	10	evaluating	evaluate	VERB
gs-3214	269	11	their	their	PRON
gs-3214	269	12	phenotype	phenotype	NOUN
gs-3214	269	13	,	,	PUNCT
gs-3214	269	14	genotype	genotype	NOUN
gs-3214	269	15	,	,	PUNCT
gs-3214	269	16	and	and	CCONJ
gs-3214	269	17	functional	functional	ADJ
gs-3214	269	18	attributes	attribute	NOUN
gs-3214	269	19	using	use	VERB
gs-3214	269	20	techniques	technique	NOUN
gs-3214	269	21	such	such	ADJ
gs-3214	269	22	as	as	ADP
gs-3214	269	23	flow	flow	NOUN
gs-3214	269	24	cytometry	cytometry	NOUN
gs-3214	269	25	,	,	PUNCT
gs-3214	269	26	pcr	pcr	NOUN
gs-3214	269	27	-	-	PUNCT
gs-3214	269	28	based	base	VERB
gs-3214	269	29	assays	assay	NOUN
gs-3214	269	30	,	,	PUNCT
gs-3214	269	31	and	and	CCONJ
gs-3214	269	32	cytotoxicity	cytotoxicity	NOUN
gs-3214	269	33	assays	assay	NOUN
gs-3214	269	34	.	.	PUNCT
gs-3214	270	1	long	long	ADJ
gs-3214	270	2	-	-	PUNCT
gs-3214	270	3	term	term	NOUN
gs-3214	270	4	stability	stability	NOUN
gs-3214	270	5	studies	study	NOUN
gs-3214	270	6	assess	assess	VERB
gs-3214	270	7	product	product	NOUN
gs-3214	270	8	viability	viability	NOUN
gs-3214	270	9	,	,	PUNCT
gs-3214	270	10	potency	potency	NOUN
gs-3214	270	11	,	,	PUNCT
gs-3214	270	12	and	and	CCONJ
gs-3214	270	13	cytokine	cytokine	VERB
gs-3214	270	14	secretion	secretion	NOUN
gs-3214	270	15	profiles	profile	NOUN
gs-3214	270	16	across	across	ADP
gs-3214	270	17	different	different	ADJ
gs-3214	270	18	storage	storage	NOUN
gs-3214	270	19	conditions	condition	NOUN
gs-3214	270	20	to	to	PART
gs-3214	270	21	determine	determine	VERB
gs-3214	270	22	shelf	shelf	NOUN
gs-3214	270	23	-	-	PUNCT
gs-3214	270	24	life	life	NOUN
gs-3214	270	25	and	and	CCONJ
gs-3214	270	26	facilitate	facilitate	NOUN
gs-3214	270	27	product	product	NOUN
gs-3214	270	28	logistics	logistic	NOUN
gs-3214	270	29	[	[	X
gs-3214	270	30	76	76	NUM
gs-3214	270	31	-	-	SYM
gs-3214	270	32	77	77	NUM
gs-3214	270	33	]	]	PUNCT
gs-3214	270	34	.	.	PUNCT
gs-3214	271	1	biomarkers	biomarker	NOUN
gs-3214	271	2	serve	serve	VERB
gs-3214	271	3	as	as	ADP
gs-3214	271	4	crucial	crucial	ADJ
gs-3214	271	5	tools	tool	NOUN
gs-3214	271	6	in	in	ADP
gs-3214	271	7	the	the	DET
gs-3214	271	8	field	field	NOUN
gs-3214	271	9	of	of	ADP
gs-3214	271	10	cancer	cancer	NOUN
gs-3214	271	11	immunotherapy	immunotherapy	NOUN
gs-3214	271	12	,	,	PUNCT
gs-3214	271	13	aiding	aid	VERB
gs-3214	271	14	in	in	ADP
gs-3214	271	15	patient	patient	ADJ
gs-3214	271	16	selection	selection	NOUN
gs-3214	271	17	and	and	CCONJ
gs-3214	271	18	treatment	treatment	NOUN
gs-3214	271	19	optimization	optimization	NOUN
gs-3214	271	20	.	.	PUNCT
gs-3214	272	1	in	in	ADP
gs-3214	272	2	the	the	DET
gs-3214	272	3	context	context	NOUN
gs-3214	272	4	of	of	ADP
gs-3214	272	5	chimeric	chimeric	ADJ
gs-3214	272	6	antigen	antigen	ADJ
gs-3214	272	7	receptor	receptor	NOUN
gs-3214	272	8	(	(	PUNCT
gs-3214	272	9	car	car	NOUN
gs-3214	272	10	)	)	PUNCT
gs-3214	272	11	t	t	NOUN
gs-3214	272	12	cell	cell	NOUN
gs-3214	272	13	therapy	therapy	NOUN
gs-3214	272	14	,	,	PUNCT
gs-3214	272	15	biomarkers	biomarker	NOUN
gs-3214	272	16	play	play	VERB
gs-3214	272	17	a	a	DET
gs-3214	272	18	significant	significant	ADJ
gs-3214	272	19	role	role	NOUN
gs-3214	272	20	in	in	ADP
gs-3214	272	21	predicting	predict	VERB
gs-3214	272	22	treatment	treatment	NOUN
gs-3214	272	23	response	response	NOUN
gs-3214	272	24	,	,	PUNCT
gs-3214	272	25	identifying	identify	VERB
gs-3214	272	26	potential	potential	ADJ
gs-3214	272	27	toxicities	toxicity	NOUN
gs-3214	272	28	,	,	PUNCT
gs-3214	272	29	and	and	CCONJ
gs-3214	272	30	guiding	guide	VERB
gs-3214	272	31	personalized	personalize	VERB
gs-3214	272	32	treatment	treatment	NOUN
gs-3214	272	33	approaches	approach	NOUN
gs-3214	272	34	.	.	PUNCT
gs-3214	273	1	predictive	predictive	ADJ
gs-3214	273	2	biomarkers	biomarker	NOUN
gs-3214	273	3	in	in	ADP
gs-3214	273	4	car	car	NOUN
gs-3214	273	5	-	-	PUNCT
gs-3214	273	6	t	t	NOUN
gs-3214	273	7	cell	cell	NOUN
gs-3214	273	8	therapy	therapy	NOUN
gs-3214	273	9	commonly	commonly	ADV
gs-3214	273	10	center	center	NOUN
gs-3214	273	11	on	on	ADP
gs-3214	273	12	the	the	DET
gs-3214	273	13	profiles	profile	NOUN
gs-3214	273	14	of	of	ADP
gs-3214	273	15	tumor	tumor	NOUN
gs-3214	273	16	antigen	antigen	ADJ
gs-3214	273	17	expression	expression	NOUN
gs-3214	273	18	.	.	PUNCT
gs-3214	274	1	the	the	DET
gs-3214	274	2	selection	selection	NOUN
gs-3214	274	3	of	of	ADP
gs-3214	274	4	target	target	NOUN
gs-3214	274	5	antigens	antigen	NOUN
gs-3214	274	6	plays	play	VERB
gs-3214	274	7	a	a	DET
gs-3214	274	8	crucial	crucial	ADJ
gs-3214	274	9	role	role	NOUN
gs-3214	274	10	in	in	ADP
gs-3214	274	11	treatment	treatment	NOUN
gs-3214	274	12	outcomes	outcome	NOUN
gs-3214	274	13	,	,	PUNCT
gs-3214	274	14	with	with	ADP
gs-3214	274	15	higher	high	ADJ
gs-3214	274	16	and	and	CCONJ
gs-3214	274	17	more	more	ADV
gs-3214	274	18	consistent	consistent	ADJ
gs-3214	274	19	expression	expression	NOUN
gs-3214	274	20	levels	level	NOUN
gs-3214	274	21	correlating	correlate	VERB
gs-3214	274	22	with	with	ADP
gs-3214	274	23	better	well	ADJ
gs-3214	274	24	response	response	NOUN
gs-3214	274	25	rates	rate	NOUN
gs-3214	274	26	.	.	PUNCT
gs-3214	275	1	various	various	ADJ
gs-3214	275	2	techniques	technique	NOUN
gs-3214	275	3	,	,	PUNCT
gs-3214	275	4	including	include	VERB
gs-3214	275	5	immunohistochemistry	immunohistochemistry	NOUN
gs-3214	275	6	,	,	PUNCT
gs-3214	275	7	flow	flow	NOUN
gs-3214	275	8	cytometry	cytometry	NOUN
gs-3214	275	9	,	,	PUNCT
gs-3214	275	10	and	and	CCONJ
gs-3214	275	11	molecular	molecular	ADJ
gs-3214	275	12	profiling	profiling	NOUN
gs-3214	275	13	,	,	PUNCT
gs-3214	275	14	are	be	AUX
gs-3214	275	15	utilized	utilize	VERB
gs-3214	275	16	to	to	PART
gs-3214	275	17	evaluate	evaluate	VERB
gs-3214	275	18	antigen	antigen	ADJ
gs-3214	275	19	expression	expression	NOUN
gs-3214	275	20	on	on	ADP
gs-3214	275	21	tumor	tumor	NOUN
gs-3214	275	22	cells	cell	NOUN
gs-3214	275	23	.	.	PUNCT
gs-3214	276	1	for	for	ADP
gs-3214	276	2	instance	instance	NOUN
gs-3214	276	3	,	,	PUNCT
gs-3214	276	4	in	in	ADP
gs-3214	276	5	b	b	NOUN
gs-3214	276	6	-	-	PUNCT
gs-3214	276	7	cell	cell	NOUN
gs-3214	276	8	malignancies	malignancy	NOUN
gs-3214	276	9	,	,	PUNCT
gs-3214	276	10	cd19	cd19	PROPN
gs-3214	276	11	has	have	AUX
gs-3214	276	12	been	be	AUX
gs-3214	276	13	a	a	DET
gs-3214	276	14	prime	prime	ADJ
gs-3214	276	15	target	target	NOUN
gs-3214	276	16	due	due	ADP
gs-3214	276	17	to	to	ADP
gs-3214	276	18	its	its	PRON
gs-3214	276	19	consistent	consistent	ADJ
gs-3214	276	20	expression	expression	NOUN
gs-3214	276	21	on	on	ADP
gs-3214	276	22	malignant	malignant	ADJ
gs-3214	276	23	b	b	NOUN
gs-3214	276	24	cells	cell	NOUN
gs-3214	276	25	,	,	PUNCT
gs-3214	276	26	leading	lead	VERB
gs-3214	276	27	to	to	ADP
gs-3214	276	28	notable	notable	ADJ
gs-3214	276	29	clinical	clinical	ADJ
gs-3214	276	30	responses	response	NOUN
gs-3214	276	31	[	[	X
gs-3214	276	32	78	78	NUM
gs-3214	276	33	-	-	SYM
gs-3214	276	34	79	79	NUM
gs-3214	276	35	]	]	PUNCT
gs-3214	276	36	.	.	PUNCT
gs-3214	277	1	the	the	PRON
gs-3214	277	2	tumor	tumor	NOUN
gs-3214	277	3	microenvironment	microenvironment	NOUN
gs-3214	277	4	(	(	PUNCT
gs-3214	277	5	tme	tme	NOUN
gs-3214	277	6	)	)	PUNCT
gs-3214	277	7	significantly	significantly	ADV
gs-3214	277	8	influences	influence	VERB
gs-3214	277	9	car	car	NOUN
gs-3214	277	10	-	-	PUNCT
gs-3214	277	11	t	t	NOUN
gs-3214	277	12	cell	cell	NOUN
gs-3214	277	13	activity	activity	NOUN
gs-3214	277	14	.	.	PUNCT
gs-3214	278	1	biomarkers	biomarker	NOUN
gs-3214	278	2	reflecting	reflect	VERB
gs-3214	278	3	tme	tme	NOUN
gs-3214	278	4	features	feature	NOUN
gs-3214	278	5	,	,	PUNCT
gs-3214	278	6	such	such	ADJ
gs-3214	278	7	as	as	ADP
gs-3214	278	8	immune	immune	ADJ
gs-3214	278	9	cell	cell	NOUN
gs-3214	278	10	infiltration	infiltration	NOUN
gs-3214	278	11	,	,	PUNCT
gs-3214	278	12	cytokine	cytokine	ADJ
gs-3214	278	13	profiles	profile	NOUN
gs-3214	278	14	,	,	PUNCT
gs-3214	278	15	and	and	CCONJ
gs-3214	278	16	expression	expression	NOUN
gs-3214	278	17	of	of	ADP
gs-3214	278	18	inhibitory	inhibitory	ADJ
gs-3214	278	19	molecules	molecule	NOUN
gs-3214	278	20	,	,	PUNCT
gs-3214	278	21	offer	offer	VERB
gs-3214	278	22	insights	insight	NOUN
gs-3214	278	23	into	into	ADP
gs-3214	278	24	the	the	DET
gs-3214	278	25	immunosuppressive	immunosuppressive	ADJ
gs-3214	278	26	nature	nature	NOUN
gs-3214	278	27	of	of	ADP
gs-3214	278	28	the	the	DET
gs-3214	278	29	tme	tme	NOUN
gs-3214	278	30	and	and	CCONJ
gs-3214	278	31	its	its	PRON
gs-3214	278	32	effects	effect	NOUN
gs-3214	278	33	on	on	ADP
gs-3214	278	34	car	car	NOUN
gs-3214	278	35	-	-	PUNCT
gs-3214	278	36	t	t	NOUN
gs-3214	278	37	cell	cell	NOUN
gs-3214	278	38	effectiveness	effectiveness	NOUN
gs-3214	278	39	.	.	PUNCT
gs-3214	279	1	patients	patient	NOUN
gs-3214	279	2	with	with	ADP
gs-3214	279	3	an	an	DET
gs-3214	279	4	inflamed	inflame	VERB
gs-3214	279	5	tme	tme	NOUN
gs-3214	279	6	,	,	PUNCT
gs-3214	279	7	marked	mark	VERB
gs-3214	279	8	by	by	ADP
gs-3214	279	9	abundant	abundant	ADJ
gs-3214	279	10	effector	effector	NOUN
gs-3214	279	11	t	t	NOUN
gs-3214	279	12	cells	cell	NOUN
gs-3214	279	13	and	and	CCONJ
gs-3214	279	14	low	low	ADJ
gs-3214	279	15	expression	expression	NOUN
gs-3214	279	16	of	of	ADP
gs-3214	279	17	inhibitory	inhibitory	ADJ
gs-3214	279	18	molecules	molecule	NOUN
gs-3214	279	19	like	like	ADP
gs-3214	279	20	pd	pd	NOUN
gs-3214	279	21	-	-	PUNCT
gs-3214	279	22	l1	l1	PROPN
gs-3214	279	23	,	,	PUNCT
gs-3214	279	24	tend	tend	VERB
gs-3214	279	25	to	to	PART
gs-3214	279	26	respond	respond	VERB
gs-3214	279	27	better	well	ADV
gs-3214	279	28	to	to	ADP
gs-3214	279	29	car	car	NOUN
gs-3214	279	30	-	-	PUNCT
gs-3214	279	31	t	t	NOUN
gs-3214	279	32	cell	cell	NOUN
gs-3214	279	33	therapy	therapy	NOUN
gs-3214	279	34	.	.	PUNCT
gs-3214	280	1	conversely	conversely	ADV
gs-3214	280	2	,	,	PUNCT
gs-3214	280	3	an	an	DET
gs-3214	280	4	immunosuppressive	immunosuppressive	ADJ
gs-3214	280	5	tme	tme	NOUN
gs-3214	280	6	may	may	AUX
gs-3214	280	7	impair	impair	VERB
gs-3214	280	8	car	car	NOUN
gs-3214	280	9	-	-	PUNCT
gs-3214	280	10	t	t	NOUN
gs-3214	280	11	cell	cell	NOUN
gs-3214	280	12	function	function	NOUN
gs-3214	280	13	and	and	CCONJ
gs-3214	280	14	result	result	VERB
gs-3214	280	15	in	in	ADP
gs-3214	280	16	treatment	treatment	NOUN
gs-3214	280	17	resistance	resistance	NOUN
gs-3214	281	1	[	[	X
gs-3214	281	2	80	80	NUM
gs-3214	281	3	-	-	SYM
gs-3214	281	4	81	81	NUM
gs-3214	281	5	]	]	PUNCT
gs-3214	281	6	.	.	PUNCT
gs-3214	282	1	immuno	immuno	PROPN
gs-3214	282	2	phenotyping	phenotyping	NOUN
gs-3214	282	3	of	of	ADP
gs-3214	282	4	peripheral	peripheral	ADJ
gs-3214	282	5	blood	blood	NOUN
gs-3214	282	6	samples	sample	NOUN
gs-3214	282	7	facilitates	facilitate	VERB
gs-3214	282	8	the	the	DET
gs-3214	282	9	examination	examination	NOUN
gs-3214	282	10	of	of	ADP
gs-3214	282	11	immune	immune	ADJ
gs-3214	282	12	cell	cell	NOUN
gs-3214	282	13	subsets	subset	NOUN
gs-3214	282	14	and	and	CCONJ
gs-3214	282	15	the	the	DET
gs-3214	282	16	tracking	tracking	NOUN
gs-3214	282	17	of	of	ADP
gs-3214	282	18	alterations	alteration	NOUN
gs-3214	282	19	post	post	ADJ
gs-3214	282	20	-	-	ADJ
gs-3214	282	21	car	car	NOUN
gs-3214	282	22	-	-	PUNCT
gs-3214	282	23	t	t	NOUN
gs-3214	282	24	cell	cell	NOUN
gs-3214	282	25	infusion	infusion	NOUN
gs-3214	282	26	.	.	PUNCT
gs-3214	283	1	flow	flow	NOUN
gs-3214	283	2	cytometry	cytometry	NOUN
gs-3214	283	3	analysis	analysis	NOUN
gs-3214	283	4	permits	permit	VERB
gs-3214	283	5	the	the	DET
gs-3214	283	6	evaluation	evaluation	NOUN
gs-3214	283	7	of	of	ADP
gs-3214	283	8	t	t	PROPN
gs-3214	283	9	cell	cell	NOUN
gs-3214	283	10	subsets	subset	NOUN
gs-3214	283	11	,	,	PUNCT
gs-3214	283	12	such	such	ADJ
gs-3214	283	13	as	as	ADP
gs-3214	283	14	central	central	ADJ
gs-3214	283	15	memory	memory	NOUN
gs-3214	283	16	,	,	PUNCT
gs-3214	283	17	effector	effector	NOUN
gs-3214	283	18	memory	memory	NOUN
gs-3214	283	19	,	,	PUNCT
gs-3214	283	20	and	and	CCONJ
gs-3214	283	21	regulatory	regulatory	ADJ
gs-3214	283	22	t	t	NOUN
gs-3214	283	23	cells	cell	NOUN
gs-3214	283	24	,	,	PUNCT
gs-3214	283	25	offering	offer	VERB
gs-3214	283	26	insights	insight	NOUN
gs-3214	283	27	into	into	ADP
gs-3214	283	28	car	car	NOUN
gs-3214	283	29	-	-	PUNCT
gs-3214	283	30	t	t	NOUN
gs-3214	283	31	cell	cell	NOUN
gs-3214	283	32	persistence	persistence	NOUN
gs-3214	283	33	and	and	CCONJ
gs-3214	283	34	functionality	functionality	NOUN
gs-3214	283	35	.	.	PUNCT
gs-3214	284	1	moreover	moreover	ADV
gs-3214	284	2	,	,	PUNCT
gs-3214	284	3	monitoring	monitor	VERB
gs-3214	284	4	cytokine	cytokine	ADJ
gs-3214	284	5	levels	level	NOUN
gs-3214	284	6	in	in	ADP
gs-3214	284	7	peripheral	peripheral	ADJ
gs-3214	284	8	blood	blood	NOUN
gs-3214	284	9	serves	serve	VERB
gs-3214	284	10	as	as	ADP
gs-3214	284	11	a	a	DET
gs-3214	284	12	biomarker	biomarker	NOUN
gs-3214	284	13	for	for	ADP
gs-3214	284	14	gauging	gauge	VERB
gs-3214	284	15	treatment	treatment	NOUN
gs-3214	284	16	response	response	NOUN
gs-3214	284	17	and	and	CCONJ
gs-3214	284	18	detecting	detect	VERB
gs-3214	284	19	cytokine	cytokine	NOUN
gs-3214	284	20	release	release	NOUN
gs-3214	284	21	syndrome	syndrome	NOUN
gs-3214	284	22	(	(	PUNCT
gs-3214	284	23	crs	crs	PROPN
gs-3214	284	24	)	)	PUNCT
gs-3214	285	1	[	[	X
gs-3214	285	2	98	98	NUM
gs-3214	285	3	-	-	SYM
gs-3214	285	4	99	99	NUM
gs-3214	285	5	]	]	PUNCT
gs-3214	285	6	.	.	PUNCT
gs-3214	286	1	georgian	georgian	PROPN
gs-3214	286	2	scientists/	scientists/	NUM
gs-3214	286	3	.	.	PUNCT
gs-3214	287	1	6	6	NUM
gs-3214	287	2	n	n	NUM
gs-3214	287	3	3	3	NUM
gs-3214	287	4	,	,	PUNCT
gs-3214	287	5	2024	2024	NUM
gs-3214	287	6	277	277	NUM
gs-3214	287	7	tumor	tumor	NOUN
gs-3214	287	8	tissue	tissue	NOUN
gs-3214	287	9	profiling	profiling	NOUN
gs-3214	287	10	encompasses	encompass	VERB
gs-3214	287	11	analyzing	analyze	VERB
gs-3214	287	12	biopsy	biopsy	ADJ
gs-3214	287	13	specimens	specimen	NOUN
gs-3214	287	14	to	to	PART
gs-3214	287	15	assess	assess	VERB
gs-3214	287	16	tumor	tumor	NOUN
gs-3214	287	17	heterogeneity	heterogeneity	NOUN
gs-3214	287	18	,	,	PUNCT
gs-3214	287	19	antigen	antigen	ADJ
gs-3214	287	20	expression	expression	NOUN
gs-3214	287	21	patterns	pattern	NOUN
gs-3214	287	22	,	,	PUNCT
gs-3214	287	23	and	and	CCONJ
gs-3214	287	24	immune	immune	ADJ
gs-3214	287	25	cell	cell	NOUN
gs-3214	287	26	infiltration	infiltration	NOUN
gs-3214	287	27	within	within	ADP
gs-3214	287	28	the	the	DET
gs-3214	287	29	tumor	tumor	NOUN
gs-3214	287	30	microenvironment	microenvironment	NOUN
gs-3214	287	31	(	(	PUNCT
gs-3214	287	32	tme	tme	NOUN
gs-3214	287	33	)	)	PUNCT
gs-3214	287	34	.	.	PUNCT
gs-3214	288	1	techniques	technique	NOUN
gs-3214	288	2	such	such	ADJ
gs-3214	288	3	as	as	ADP
gs-3214	288	4	next	next	ADJ
gs-3214	288	5	-	-	PUNCT
gs-3214	288	6	generation	generation	NOUN
gs-3214	288	7	sequencing	sequencing	NOUN
gs-3214	288	8	(	(	PUNCT
gs-3214	288	9	ngs	ng	NOUN
gs-3214	288	10	)	)	PUNCT
gs-3214	288	11	and	and	CCONJ
gs-3214	288	12	single	single	ADJ
gs-3214	288	13	-	-	PUNCT
gs-3214	288	14	cell	cell	NOUN
gs-3214	288	15	rna	rna	NOUN
gs-3214	288	16	sequencing	sequence	VERB
gs-3214	288	17	(	(	PUNCT
gs-3214	288	18	scrna	scrna	NOUN
gs-3214	288	19	-	-	PUNCT
gs-3214	288	20	seq	seq	NOUN
gs-3214	288	21	)	)	PUNCT
gs-3214	288	22	offer	offer	VERB
gs-3214	288	23	comprehensive	comprehensive	ADJ
gs-3214	288	24	insights	insight	NOUN
gs-3214	288	25	into	into	ADP
gs-3214	288	26	genetic	genetic	ADJ
gs-3214	288	27	alterations	alteration	NOUN
gs-3214	288	28	,	,	PUNCT
gs-3214	288	29	tumor	tumor	NOUN
gs-3214	288	30	neoantigens	neoantigen	NOUN
gs-3214	288	31	,	,	PUNCT
gs-3214	288	32	and	and	CCONJ
gs-3214	288	33	immune	immune	ADJ
gs-3214	288	34	cell	cell	NOUN
gs-3214	288	35	composition	composition	NOUN
gs-3214	288	36	.	.	PUNCT
gs-3214	289	1	by	by	ADP
gs-3214	289	2	integrating	integrate	VERB
gs-3214	289	3	tumor	tumor	NOUN
gs-3214	289	4	tissue	tissue	NOUN
gs-3214	289	5	profiling	profiling	NOUN
gs-3214	289	6	with	with	ADP
gs-3214	289	7	peripheral	peripheral	ADJ
gs-3214	289	8	blood	blood	NOUN
gs-3214	289	9	immune	immune	ADJ
gs-3214	289	10	phenotyping	phenotyping	NOUN
gs-3214	289	11	,	,	PUNCT
gs-3214	289	12	patient	patient	ADJ
gs-3214	289	13	stratification	stratification	NOUN
gs-3214	289	14	and	and	CCONJ
gs-3214	289	15	prediction	prediction	NOUN
gs-3214	289	16	of	of	ADP
gs-3214	289	17	treatment	treatment	NOUN
gs-3214	289	18	response	response	NOUN
gs-3214	289	19	can	can	AUX
gs-3214	289	20	be	be	AUX
gs-3214	289	21	improved	improve	VERB
gs-3214	289	22	[	[	X
gs-3214	289	23	27,36,55	27,36,55	X
gs-3214	289	24	]	]	X
gs-3214	289	25	.	.	PUNCT
gs-3214	290	1	personalized	personalized	ADJ
gs-3214	290	2	medicine	medicine	NOUN
gs-3214	290	3	approaches	approach	NOUN
gs-3214	290	4	aim	aim	VERB
gs-3214	290	5	to	to	PART
gs-3214	290	6	optimize	optimize	VERB
gs-3214	290	7	car	car	NOUN
gs-3214	290	8	-	-	PUNCT
gs-3214	290	9	t	t	NOUN
gs-3214	290	10	cell	cell	NOUN
gs-3214	290	11	therapy	therapy	NOUN
gs-3214	290	12	outcomes	outcome	NOUN
gs-3214	290	13	by	by	ADP
gs-3214	290	14	considering	consider	VERB
gs-3214	290	15	patient	patient	ADJ
gs-3214	290	16	-	-	PUNCT
gs-3214	290	17	specific	specific	ADJ
gs-3214	290	18	factors	factor	NOUN
gs-3214	290	19	.	.	PUNCT
gs-3214	291	1	human	human	ADJ
gs-3214	291	2	leukocyte	leukocyte	NOUN
gs-3214	291	3	antigen	antigen	NOUN
gs-3214	291	4	(	(	PUNCT
gs-3214	291	5	hla	hla	NOUN
gs-3214	291	6	)	)	PUNCT
gs-3214	291	7	typing	typing	NOUN
gs-3214	291	8	facilitates	facilitate	VERB
gs-3214	291	9	donor	donor	NOUN
gs-3214	291	10	selection	selection	NOUN
gs-3214	291	11	for	for	ADP
gs-3214	291	12	allogeneic	allogeneic	ADJ
gs-3214	291	13	car	car	NOUN
gs-3214	291	14	-	-	PUNCT
gs-3214	291	15	t	t	NOUN
gs-3214	291	16	cell	cell	NOUN
gs-3214	291	17	therapy	therapy	NOUN
gs-3214	291	18	,	,	PUNCT
gs-3214	291	19	reducing	reduce	VERB
gs-3214	291	20	the	the	DET
gs-3214	291	21	risk	risk	NOUN
gs-3214	291	22	of	of	ADP
gs-3214	291	23	graft	graft	NOUN
gs-3214	291	24	-	-	PUNCT
gs-3214	291	25	versus	versus	ADP
gs-3214	291	26	-	-	PUNCT
gs-3214	291	27	host	host	NOUN
gs-3214	291	28	disease	disease	NOUN
gs-3214	291	29	(	(	PUNCT
gs-3214	291	30	gvhd	gvhd	PROPN
gs-3214	291	31	)	)	PUNCT
gs-3214	291	32	and	and	CCONJ
gs-3214	291	33	enhancing	enhance	VERB
gs-3214	291	34	treatment	treatment	NOUN
gs-3214	291	35	efficacy	efficacy	NOUN
gs-3214	291	36	.	.	PUNCT
gs-3214	292	1	antigen	antigen	ADJ
gs-3214	292	2	matching	matching	NOUN
gs-3214	292	3	ensures	ensure	VERB
gs-3214	292	4	the	the	DET
gs-3214	292	5	specificity	specificity	NOUN
gs-3214	292	6	of	of	ADP
gs-3214	292	7	car	car	NOUN
gs-3214	292	8	-	-	PUNCT
gs-3214	292	9	t	t	NOUN
gs-3214	292	10	cells	cell	NOUN
gs-3214	292	11	towards	towards	ADP
gs-3214	292	12	tumor	tumor	NOUN
gs-3214	292	13	cells	cell	NOUN
gs-3214	292	14	while	while	SCONJ
gs-3214	292	15	minimizing	minimize	VERB
gs-3214	292	16	off	off	ADP
gs-3214	292	17	-	-	PUNCT
gs-3214	292	18	target	target	NOUN
gs-3214	292	19	toxicities	toxicity	NOUN
gs-3214	292	20	.	.	PUNCT
gs-3214	293	1	additionally	additionally	ADV
gs-3214	293	2	,	,	PUNCT
gs-3214	293	3	selecting	select	VERB
gs-3214	293	4	target	target	NOUN
gs-3214	293	5	antigens	antigen	NOUN
gs-3214	293	6	based	base	VERB
gs-3214	293	7	on	on	ADP
gs-3214	293	8	patient	patient	NOUN
gs-3214	293	9	-	-	PUNCT
gs-3214	293	10	specific	specific	ADJ
gs-3214	293	11	tumor	tumor	NOUN
gs-3214	293	12	characteristics	characteristic	NOUN
gs-3214	293	13	improves	improve	VERB
gs-3214	293	14	treatment	treatment	NOUN
gs-3214	293	15	specificity	specificity	NOUN
gs-3214	293	16	and	and	CCONJ
gs-3214	293	17	efficacy	efficacy	NOUN
gs-3214	293	18	.	.	PUNCT
gs-3214	294	1	biomarker	biomarker	NOUN
gs-3214	294	2	-	-	PUNCT
gs-3214	294	3	guided	guide	VERB
gs-3214	294	4	treatment	treatment	NOUN
gs-3214	294	5	algorithms	algorithm	NOUN
gs-3214	294	6	combine	combine	VERB
gs-3214	294	7	molecular	molecular	ADJ
gs-3214	294	8	profiling	profiling	NOUN
gs-3214	294	9	,	,	PUNCT
gs-3214	294	10	imaging	imaging	NOUN
gs-3214	294	11	techniques	technique	NOUN
gs-3214	294	12	,	,	PUNCT
gs-3214	294	13	and	and	CCONJ
gs-3214	294	14	clinical	clinical	ADJ
gs-3214	294	15	indicators	indicator	NOUN
gs-3214	294	16	to	to	PART
gs-3214	294	17	customize	customize	VERB
gs-3214	294	18	car	car	NOUN
gs-3214	294	19	-	-	PUNCT
gs-3214	294	20	t	t	NOUN
gs-3214	294	21	cell	cell	NOUN
gs-3214	294	22	therapy	therapy	NOUN
gs-3214	294	23	plans	plan	VERB
gs-3214	294	24	for	for	ADP
gs-3214	294	25	each	each	DET
gs-3214	294	26	patient	patient	NOUN
gs-3214	294	27	.	.	PUNCT
gs-3214	295	1	by	by	ADP
gs-3214	295	2	utilizing	utilize	VERB
gs-3214	295	3	predictive	predictive	ADJ
gs-3214	295	4	biomarkers	biomarker	NOUN
gs-3214	295	5	such	such	ADJ
gs-3214	295	6	as	as	ADP
gs-3214	295	7	tumor	tumor	NOUN
gs-3214	295	8	antigen	antigen	NOUN
gs-3214	295	9	expression	expression	NOUN
gs-3214	295	10	and	and	CCONJ
gs-3214	295	11	characteristics	characteristic	NOUN
gs-3214	295	12	of	of	ADP
gs-3214	295	13	the	the	DET
gs-3214	295	14	tumor	tumor	NOUN
gs-3214	295	15	microenvironment	microenvironment	NOUN
gs-3214	295	16	(	(	PUNCT
gs-3214	295	17	tme	tme	PROPN
gs-3214	295	18	)	)	PUNCT
gs-3214	295	19	,	,	PUNCT
gs-3214	295	20	these	these	DET
gs-3214	295	21	algorithms	algorithm	NOUN
gs-3214	295	22	categories	category	NOUN
gs-3214	295	23	patients	patient	NOUN
gs-3214	295	24	into	into	ADP
gs-3214	295	25	groups	group	NOUN
gs-3214	295	26	with	with	ADP
gs-3214	295	27	varying	vary	VERB
gs-3214	295	28	probabilities	probability	NOUN
gs-3214	295	29	of	of	ADP
gs-3214	295	30	response	response	NOUN
gs-3214	295	31	and	and	CCONJ
gs-3214	295	32	risk	risk	NOUN
gs-3214	295	33	of	of	ADP
gs-3214	295	34	adverse	adverse	ADJ
gs-3214	295	35	effects	effect	NOUN
gs-3214	295	36	.	.	PUNCT
gs-3214	296	1	this	this	DET
gs-3214	296	2	personalized	personalize	VERB
gs-3214	296	3	strategy	strategy	NOUN
gs-3214	296	4	enhances	enhance	VERB
gs-3214	296	5	treatment	treatment	NOUN
gs-3214	296	6	effectiveness	effectiveness	NOUN
gs-3214	296	7	and	and	CCONJ
gs-3214	296	8	reduces	reduce	VERB
gs-3214	296	9	the	the	DET
gs-3214	296	10	occurrence	occurrence	NOUN
gs-3214	296	11	of	of	ADP
gs-3214	296	12	unwanted	unwanted	ADJ
gs-3214	296	13	events	event	NOUN
gs-3214	296	14	[	[	X
gs-3214	296	15	12	12	NUM
gs-3214	296	16	,	,	PUNCT
gs-3214	296	17	45	45	NUM
gs-3214	296	18	,	,	PUNCT
gs-3214	296	19	68	68	NUM
gs-3214	296	20	,	,	PUNCT
gs-3214	296	21	97	97	NUM
gs-3214	296	22	]	]	PUNCT
gs-3214	296	23	.	.	PUNCT
gs-3214	297	1	the	the	DET
gs-3214	297	2	regulatory	regulatory	ADJ
gs-3214	297	3	landscape	landscape	NOUN
gs-3214	297	4	and	and	CCONJ
gs-3214	297	5	market	market	NOUN
gs-3214	297	6	access	access	NOUN
gs-3214	297	7	for	for	ADP
gs-3214	297	8	chimeric	chimeric	ADJ
gs-3214	297	9	antigen	antigen	ADJ
gs-3214	297	10	receptor	receptor	NOUN
gs-3214	297	11	(	(	PUNCT
gs-3214	297	12	car	car	NOUN
gs-3214	297	13	)	)	PUNCT
gs-3214	297	14	t	t	NOUN
gs-3214	297	15	cell	cell	NOUN
gs-3214	297	16	therapy	therapy	NOUN
gs-3214	297	17	are	be	AUX
gs-3214	297	18	critical	critical	ADJ
gs-3214	297	19	aspects	aspect	NOUN
gs-3214	297	20	that	that	PRON
gs-3214	297	21	shape	shape	VERB
gs-3214	297	22	the	the	DET
gs-3214	297	23	development	development	NOUN
gs-3214	297	24	,	,	PUNCT
gs-3214	297	25	approval	approval	NOUN
gs-3214	297	26	,	,	PUNCT
gs-3214	297	27	and	and	CCONJ
gs-3214	297	28	commercialization	commercialization	NOUN
gs-3214	297	29	of	of	ADP
gs-3214	297	30	these	these	DET
gs-3214	297	31	innovative	innovative	ADJ
gs-3214	297	32	treatments	treatment	NOUN
gs-3214	297	33	.	.	PUNCT
gs-3214	298	1	this	this	DET
gs-3214	298	2	chapter	chapter	NOUN
gs-3214	298	3	provides	provide	VERB
gs-3214	298	4	an	an	DET
gs-3214	298	5	overview	overview	NOUN
gs-3214	298	6	of	of	ADP
gs-3214	298	7	the	the	DET
gs-3214	298	8	regulatory	regulatory	ADJ
gs-3214	298	9	pathways	pathway	NOUN
gs-3214	298	10	,	,	PUNCT
gs-3214	298	11	challenges	challenge	NOUN
gs-3214	298	12	in	in	ADP
gs-3214	298	13	market	market	NOUN
gs-3214	298	14	access	access	NOUN
gs-3214	298	15	,	,	PUNCT
gs-3214	298	16	and	and	CCONJ
gs-3214	298	17	considerations	consideration	NOUN
gs-3214	298	18	for	for	ADP
gs-3214	298	19	global	global	ADJ
gs-3214	298	20	disparities	disparity	NOUN
gs-3214	298	21	in	in	ADP
gs-3214	298	22	accessing	access	VERB
gs-3214	298	23	car	car	NOUN
gs-3214	298	24	-	-	PUNCT
gs-3214	298	25	t	t	NOUN
gs-3214	298	26	cell	cell	NOUN
gs-3214	298	27	therapy	therapy	NOUN
gs-3214	298	28	.	.	PUNCT
gs-3214	299	1	despite	despite	SCONJ
gs-3214	299	2	regulatory	regulatory	ADJ
gs-3214	299	3	approval	approval	NOUN
gs-3214	299	4	,	,	PUNCT
gs-3214	299	5	reimbursement	reimbursement	NOUN
gs-3214	299	6	challenges	challenge	NOUN
gs-3214	299	7	pose	pose	VERB
gs-3214	299	8	significant	significant	ADJ
gs-3214	299	9	barriers	barrier	NOUN
gs-3214	299	10	to	to	PART
gs-3214	299	11	patient	patient	VERB
gs-3214	299	12	access	access	NOUN
gs-3214	299	13	to	to	ADP
gs-3214	299	14	car	car	NOUN
gs-3214	299	15	-	-	PUNCT
gs-3214	299	16	t	t	NOUN
gs-3214	299	17	cell	cell	NOUN
gs-3214	299	18	therapy	therapy	NOUN
gs-3214	299	19	.	.	PUNCT
gs-3214	300	1	the	the	DET
gs-3214	300	2	high	high	ADJ
gs-3214	300	3	cost	cost	NOUN
gs-3214	300	4	of	of	ADP
gs-3214	300	5	manufacturing	manufacturing	NOUN
gs-3214	300	6	,	,	PUNCT
gs-3214	300	7	limited	limit	VERB
gs-3214	300	8	clinical	clinical	ADJ
gs-3214	300	9	evidence	evidence	NOUN
gs-3214	300	10	,	,	PUNCT
gs-3214	300	11	and	and	CCONJ
gs-3214	300	12	uncertainty	uncertainty	NOUN
gs-3214	300	13	regarding	regard	VERB
gs-3214	300	14	long	long	ADJ
gs-3214	300	15	-	-	PUNCT
gs-3214	300	16	term	term	NOUN
gs-3214	300	17	outcomes	outcome	NOUN
gs-3214	300	18	contribute	contribute	VERB
gs-3214	300	19	to	to	ADP
gs-3214	300	20	reimbursement	reimbursement	NOUN
gs-3214	300	21	hurdles	hurdle	NOUN
gs-3214	300	22	faced	face	VERB
gs-3214	300	23	by	by	ADP
gs-3214	300	24	healthcare	healthcare	NOUN
gs-3214	300	25	payers	payer	NOUN
gs-3214	300	26	.	.	PUNCT
gs-3214	301	1	reimbursement	reimbursement	NOUN
gs-3214	301	2	decisions	decision	NOUN
gs-3214	301	3	often	often	ADV
gs-3214	301	4	involve	involve	VERB
gs-3214	301	5	complex	complex	ADJ
gs-3214	301	6	assessments	assessment	NOUN
gs-3214	301	7	of	of	ADP
gs-3214	301	8	cost	cost	NOUN
gs-3214	301	9	-	-	PUNCT
gs-3214	301	10	effectiveness	effectiveness	NOUN
gs-3214	301	11	,	,	PUNCT
gs-3214	301	12	budget	budget	NOUN
gs-3214	301	13	impact	impact	NOUN
gs-3214	301	14	,	,	PUNCT
gs-3214	301	15	and	and	CCONJ
gs-3214	301	16	societal	societal	ADJ
gs-3214	301	17	value	value	NOUN
gs-3214	301	18	.	.	PUNCT
gs-3214	302	1	to	to	PART
gs-3214	302	2	address	address	VERB
gs-3214	302	3	these	these	DET
gs-3214	302	4	challenges	challenge	NOUN
gs-3214	302	5	,	,	PUNCT
gs-3214	302	6	manufacturers	manufacturer	NOUN
gs-3214	302	7	may	may	AUX
gs-3214	302	8	engage	engage	VERB
gs-3214	302	9	in	in	ADP
gs-3214	302	10	value	value	NOUN
gs-3214	302	11	-	-	PUNCT
gs-3214	302	12	based	base	VERB
gs-3214	302	13	pricing	pricing	NOUN
gs-3214	302	14	agreements	agreement	NOUN
gs-3214	302	15	,	,	PUNCT
gs-3214	302	16	outcome	outcome	NOUN
gs-3214	302	17	-	-	PUNCT
gs-3214	302	18	based	base	VERB
gs-3214	302	19	reimbursement	reimbursement	NOUN
gs-3214	302	20	models	model	NOUN
gs-3214	302	21	,	,	PUNCT
gs-3214	302	22	and	and	CCONJ
gs-3214	302	23	negotiations	negotiation	NOUN
gs-3214	302	24	with	with	ADP
gs-3214	302	25	payers	payer	NOUN
gs-3214	302	26	to	to	PART
gs-3214	302	27	ensure	ensure	VERB
gs-3214	302	28	adequate	adequate	ADJ
gs-3214	302	29	reimbursement	reimbursement	NOUN
gs-3214	302	30	for	for	ADP
gs-3214	302	31	car	car	NOUN
gs-3214	302	32	-	-	PUNCT
gs-3214	302	33	t	t	NOUN
gs-3214	302	34	cell	cell	NOUN
gs-3214	302	35	therapies	therapy	NOUN
gs-3214	302	36	.	.	PUNCT
gs-3214	303	1	despite	despite	SCONJ
gs-3214	303	2	regulatory	regulatory	ADJ
gs-3214	303	3	approval	approval	NOUN
gs-3214	303	4	,	,	PUNCT
gs-3214	303	5	reimbursement	reimbursement	NOUN
gs-3214	303	6	challenges	challenge	NOUN
gs-3214	303	7	pose	pose	VERB
gs-3214	303	8	significant	significant	ADJ
gs-3214	303	9	barriers	barrier	NOUN
gs-3214	303	10	to	to	PART
gs-3214	303	11	patient	patient	VERB
gs-3214	303	12	access	access	NOUN
gs-3214	303	13	to	to	ADP
gs-3214	303	14	car	car	NOUN
gs-3214	303	15	-	-	PUNCT
gs-3214	303	16	t	t	NOUN
gs-3214	303	17	cell	cell	NOUN
gs-3214	303	18	therapy	therapy	NOUN
gs-3214	303	19	.	.	PUNCT
gs-3214	304	1	the	the	DET
gs-3214	304	2	high	high	ADJ
gs-3214	304	3	cost	cost	NOUN
gs-3214	304	4	of	of	ADP
gs-3214	304	5	manufacturing	manufacturing	NOUN
gs-3214	304	6	,	,	PUNCT
gs-3214	304	7	limited	limit	VERB
gs-3214	304	8	clinical	clinical	ADJ
gs-3214	304	9	evidence	evidence	NOUN
gs-3214	304	10	,	,	PUNCT
gs-3214	304	11	and	and	CCONJ
gs-3214	304	12	uncertainty	uncertainty	NOUN
gs-3214	304	13	regarding	regard	VERB
gs-3214	304	14	long	long	ADJ
gs-3214	304	15	-	-	PUNCT
gs-3214	304	16	term	term	NOUN
gs-3214	304	17	outcomes	outcome	NOUN
gs-3214	304	18	contribute	contribute	VERB
gs-3214	304	19	to	to	ADP
gs-3214	304	20	reimbursement	reimbursement	NOUN
gs-3214	304	21	hurdles	hurdle	NOUN
gs-3214	304	22	faced	face	VERB
gs-3214	304	23	by	by	ADP
gs-3214	304	24	healthcare	healthcare	NOUN
gs-3214	304	25	payers	payer	NOUN
gs-3214	304	26	.	.	PUNCT
gs-3214	305	1	reimbursement	reimbursement	NOUN
gs-3214	305	2	decisions	decision	NOUN
gs-3214	305	3	often	often	ADV
gs-3214	305	4	involve	involve	VERB
gs-3214	305	5	complex	complex	ADJ
gs-3214	305	6	assessments	assessment	NOUN
gs-3214	305	7	of	of	ADP
gs-3214	305	8	cost	cost	NOUN
gs-3214	305	9	-	-	PUNCT
gs-3214	305	10	effectiveness	effectiveness	NOUN
gs-3214	305	11	,	,	PUNCT
gs-3214	305	12	budget	budget	NOUN
gs-3214	305	13	impact	impact	NOUN
gs-3214	305	14	,	,	PUNCT
gs-3214	305	15	and	and	CCONJ
gs-3214	305	16	societal	societal	ADJ
gs-3214	305	17	value	value	NOUN
gs-3214	305	18	.	.	PUNCT
gs-3214	306	1	to	to	PART
gs-3214	306	2	address	address	VERB
gs-3214	306	3	these	these	DET
gs-3214	306	4	challenges	challenge	NOUN
gs-3214	306	5	,	,	PUNCT
gs-3214	306	6	manufacturers	manufacturer	NOUN
gs-3214	306	7	may	may	AUX
gs-3214	306	8	engage	engage	VERB
gs-3214	306	9	in	in	ADP
gs-3214	306	10	value	value	NOUN
gs-3214	306	11	-	-	PUNCT
gs-3214	306	12	based	base	VERB
gs-3214	306	13	pricing	pricing	NOUN
gs-3214	306	14	agreements	agreement	NOUN
gs-3214	306	15	,	,	PUNCT
gs-3214	306	16	outcome	outcome	NOUN
gs-3214	306	17	-	-	PUNCT
gs-3214	306	18	based	base	VERB
gs-3214	306	19	reimbursement	reimbursement	NOUN
gs-3214	306	20	models	model	NOUN
gs-3214	306	21	,	,	PUNCT
gs-3214	306	22	and	and	CCONJ
gs-3214	306	23	negotiations	negotiation	NOUN
gs-3214	306	24	with	with	ADP
gs-3214	306	25	payers	payer	NOUN
gs-3214	306	26	to	to	PART
gs-3214	306	27	ensure	ensure	VERB
gs-3214	306	28	adequate	adequate	ADJ
gs-3214	306	29	reimbursement	reimbursement	NOUN
gs-3214	306	30	for	for	ADP
gs-3214	306	31	car	car	NOUN
gs-3214	306	32	-	-	PUNCT
gs-3214	306	33	t	t	NOUN
gs-3214	306	34	cell	cell	NOUN
gs-3214	306	35	therapies	therapy	NOUN
gs-3214	306	36	[	[	X
gs-3214	306	37	42,64,69	42,64,69	NUM
gs-3214	306	38	]	]	PUNCT
gs-3214	306	39	.	.	PUNCT
gs-3214	307	1	global	global	ADJ
gs-3214	307	2	disparities	disparity	NOUN
gs-3214	307	3	in	in	ADP
gs-3214	307	4	access	access	NOUN
gs-3214	307	5	to	to	ADP
gs-3214	307	6	car	car	NOUN
gs-3214	307	7	-	-	PUNCT
gs-3214	307	8	t	t	NOUN
gs-3214	307	9	cell	cell	NOUN
gs-3214	307	10	therapy	therapy	NOUN
gs-3214	307	11	highlight	highlight	VERB
gs-3214	307	12	broader	broad	ADJ
gs-3214	307	13	issues	issue	NOUN
gs-3214	307	14	related	relate	VERB
gs-3214	307	15	to	to	ADP
gs-3214	307	16	healthcare	healthcare	PROPN
gs-3214	307	17	equity	equity	NOUN
gs-3214	307	18	and	and	CCONJ
gs-3214	307	19	affordability	affordability	NOUN
gs-3214	307	20	.	.	PUNCT
gs-3214	308	1	while	while	SCONJ
gs-3214	308	2	car	car	NOUN
gs-3214	308	3	-	-	PUNCT
gs-3214	308	4	t	t	NOUN
gs-3214	308	5	cell	cell	NOUN
gs-3214	308	6	therapies	therapy	NOUN
gs-3214	308	7	have	have	AUX
gs-3214	308	8	received	receive	VERB
gs-3214	308	9	regulatory	regulatory	ADJ
gs-3214	308	10	approval	approval	NOUN
gs-3214	308	11	in	in	ADP
gs-3214	308	12	regions	region	NOUN
gs-3214	308	13	like	like	ADP
gs-3214	308	14	north	north	PROPN
gs-3214	308	15	america	america	PROPN
gs-3214	308	16	and	and	CCONJ
gs-3214	308	17	europe	europe	PROPN
gs-3214	308	18	,	,	PUNCT
gs-3214	308	19	access	access	NOUN
gs-3214	308	20	remains	remain	VERB
gs-3214	308	21	limited	limited	ADJ
gs-3214	308	22	in	in	ADP
gs-3214	308	23	many	many	ADJ
gs-3214	308	24	lowand	lowand	ADJ
gs-3214	308	25	middle	middle	ADJ
gs-3214	308	26	-	-	PUNCT
gs-3214	308	27	income	income	NOUN
gs-3214	308	28	countries	country	NOUN
gs-3214	308	29	(	(	PUNCT
gs-3214	308	30	lmics	lmics	PROPN
gs-3214	308	31	)	)	PUNCT
gs-3214	308	32	due	due	ADJ
gs-3214	308	33	georgian	georgian	NOUN
gs-3214	308	34	scientists/	scientists/	NUM
gs-3214	308	35	.	.	PUNCT
gs-3214	309	1	6	6	NUM
gs-3214	309	2	n	n	NUM
gs-3214	309	3	3	3	NUM
gs-3214	309	4	,	,	PUNCT
gs-3214	309	5	2024	2024	NUM
gs-3214	309	6	278	278	NUM
gs-3214	309	7	to	to	ADP
gs-3214	309	8	factors	factor	NOUN
gs-3214	309	9	such	such	ADJ
gs-3214	309	10	as	as	ADP
gs-3214	309	11	cost	cost	NOUN
gs-3214	309	12	,	,	PUNCT
gs-3214	309	13	infrastructure	infrastructure	NOUN
gs-3214	309	14	limitations	limitation	NOUN
gs-3214	309	15	,	,	PUNCT
gs-3214	309	16	and	and	CCONJ
gs-3214	309	17	regulatory	regulatory	ADJ
gs-3214	309	18	barriers	barrier	NOUN
gs-3214	309	19	.	.	PUNCT
gs-3214	310	1	addressing	address	VERB
gs-3214	310	2	these	these	DET
gs-3214	310	3	disparities	disparity	NOUN
gs-3214	310	4	requires	require	VERB
gs-3214	310	5	collaborative	collaborative	ADJ
gs-3214	310	6	efforts	effort	NOUN
gs-3214	310	7	among	among	ADP
gs-3214	310	8	stakeholders	stakeholder	NOUN
gs-3214	310	9	,	,	PUNCT
gs-3214	310	10	including	include	VERB
gs-3214	310	11	governments	government	NOUN
gs-3214	310	12	,	,	PUNCT
gs-3214	310	13	pharmaceutical	pharmaceutical	ADJ
gs-3214	310	14	companies	company	NOUN
gs-3214	310	15	,	,	PUNCT
gs-3214	310	16	non	non	ADJ
gs-3214	310	17	-	-	ADJ
gs-3214	310	18	governmental	governmental	ADJ
gs-3214	310	19	organizations	organization	NOUN
gs-3214	310	20	(	(	PUNCT
gs-3214	310	21	ngos	ngo	NOUN
gs-3214	310	22	)	)	PUNCT
gs-3214	310	23	,	,	PUNCT
gs-3214	310	24	and	and	CCONJ
gs-3214	310	25	international	international	ADJ
gs-3214	310	26	agencies	agency	NOUN
gs-3214	310	27	,	,	PUNCT
gs-3214	310	28	to	to	PART
gs-3214	310	29	facilitate	facilitate	VERB
gs-3214	310	30	technology	technology	NOUN
gs-3214	310	31	transfer	transfer	NOUN
gs-3214	310	32	,	,	PUNCT
gs-3214	310	33	capacity	capacity	NOUN
gs-3214	310	34	building	building	NOUN
gs-3214	310	35	,	,	PUNCT
gs-3214	310	36	and	and	CCONJ
gs-3214	310	37	financial	financial	ADJ
gs-3214	310	38	assistance	assistance	NOUN
gs-3214	310	39	programs	program	NOUN
gs-3214	310	40	[	[	X
gs-3214	310	41	3,17,49,58	3,17,49,58	NOUN
gs-3214	310	42	]	]	PUNCT
gs-3214	310	43	.	.	PUNCT
gs-3214	311	1	while	while	SCONJ
gs-3214	311	2	regulatory	regulatory	ADJ
gs-3214	311	3	agencies	agency	NOUN
gs-3214	311	4	such	such	ADJ
gs-3214	311	5	as	as	ADP
gs-3214	311	6	the	the	DET
gs-3214	311	7	fda	fda	PROPN
gs-3214	311	8	and	and	CCONJ
gs-3214	311	9	ema	ema	PROPN
gs-3214	311	10	play	play	VERB
gs-3214	311	11	pivotal	pivotal	ADJ
gs-3214	311	12	roles	role	NOUN
gs-3214	311	13	in	in	ADP
gs-3214	311	14	evaluating	evaluate	VERB
gs-3214	311	15	safety	safety	NOUN
gs-3214	311	16	and	and	CCONJ
gs-3214	311	17	efficacy	efficacy	NOUN
gs-3214	311	18	,	,	PUNCT
gs-3214	311	19	reimbursement	reimbursement	NOUN
gs-3214	311	20	challenges	challenge	NOUN
gs-3214	311	21	and	and	CCONJ
gs-3214	311	22	global	global	ADJ
gs-3214	311	23	disparities	disparity	NOUN
gs-3214	311	24	in	in	ADP
gs-3214	311	25	access	access	NOUN
gs-3214	311	26	pose	pose	VERB
gs-3214	311	27	significant	significant	ADJ
gs-3214	311	28	hurdles	hurdle	NOUN
gs-3214	311	29	.	.	PUNCT
gs-3214	312	1	addressing	address	VERB
gs-3214	312	2	these	these	DET
gs-3214	312	3	challenges	challenge	NOUN
gs-3214	312	4	requires	require	VERB
gs-3214	312	5	collaborative	collaborative	ADJ
gs-3214	312	6	efforts	effort	NOUN
gs-3214	312	7	among	among	ADP
gs-3214	312	8	stakeholders	stakeholder	NOUN
gs-3214	312	9	to	to	PART
gs-3214	312	10	ensure	ensure	VERB
gs-3214	312	11	equitable	equitable	ADJ
gs-3214	312	12	access	access	NOUN
gs-3214	312	13	to	to	ADP
gs-3214	312	14	these	these	DET
gs-3214	312	15	lifesaving	lifesaving	NOUN
gs-3214	312	16	therapies	therapy	NOUN
gs-3214	312	17	for	for	ADP
gs-3214	312	18	patients	patient	NOUN
gs-3214	312	19	worldwide	worldwide	ADV
gs-3214	312	20	.	.	PUNCT
gs-3214	313	1	ethical	ethical	ADJ
gs-3214	313	2	considerations	consideration	NOUN
gs-3214	313	3	and	and	CCONJ
gs-3214	313	4	societal	societal	ADJ
gs-3214	313	5	implications	implication	NOUN
gs-3214	313	6	surrounding	surround	VERB
gs-3214	313	7	chimeric	chimeric	ADJ
gs-3214	313	8	antigen	antigen	ADJ
gs-3214	313	9	receptor	receptor	NOUN
gs-3214	313	10	(	(	PUNCT
gs-3214	313	11	car	car	NOUN
gs-3214	313	12	)	)	PUNCT
gs-3214	313	13	t	t	NOUN
gs-3214	313	14	cell	cell	NOUN
gs-3214	313	15	therapy	therapy	NOUN
gs-3214	313	16	are	be	AUX
gs-3214	313	17	paramount	paramount	ADJ
gs-3214	313	18	in	in	ADP
gs-3214	313	19	shaping	shape	VERB
gs-3214	313	20	the	the	DET
gs-3214	313	21	discourse	discourse	NOUN
gs-3214	313	22	on	on	ADP
gs-3214	313	23	access	access	NOUN
gs-3214	313	24	,	,	PUNCT
gs-3214	313	25	equity	equity	NOUN
gs-3214	313	26	,	,	PUNCT
gs-3214	313	27	and	and	CCONJ
gs-3214	313	28	patient	patient	ADJ
gs-3214	313	29	autonomy	autonomy	NOUN
gs-3214	313	30	.	.	PUNCT
gs-3214	314	1	this	this	DET
gs-3214	314	2	chapter	chapter	NOUN
gs-3214	314	3	delves	delve	VERB
gs-3214	314	4	into	into	ADP
gs-3214	314	5	the	the	DET
gs-3214	314	6	ethical	ethical	ADJ
gs-3214	314	7	dilemmas	dilemma	NOUN
gs-3214	314	8	,	,	PUNCT
gs-3214	314	9	financial	financial	ADJ
gs-3214	314	10	toxicity	toxicity	NOUN
gs-3214	314	11	,	,	PUNCT
gs-3214	314	12	informed	informed	ADJ
gs-3214	314	13	consent	consent	NOUN
gs-3214	314	14	,	,	PUNCT
gs-3214	314	15	and	and	CCONJ
gs-3214	314	16	equity	equity	NOUN
gs-3214	314	17	issues	issue	NOUN
gs-3214	314	18	associated	associate	VERB
gs-3214	314	19	with	with	ADP
gs-3214	314	20	car	car	NOUN
gs-3214	314	21	-	-	PUNCT
gs-3214	314	22	t	t	NOUN
gs-3214	314	23	cell	cell	NOUN
gs-3214	314	24	therapy	therapy	NOUN
gs-3214	314	25	.	.	PUNCT
gs-3214	315	1	ensuring	ensure	VERB
gs-3214	315	2	equitable	equitable	ADJ
gs-3214	315	3	access	access	NOUN
gs-3214	315	4	to	to	ADP
gs-3214	315	5	car	car	NOUN
gs-3214	315	6	-	-	PUNCT
gs-3214	315	7	t	t	NOUN
gs-3214	315	8	cell	cell	NOUN
gs-3214	315	9	therapy	therapy	NOUN
gs-3214	315	10	remains	remain	VERB
gs-3214	315	11	a	a	DET
gs-3214	315	12	significant	significant	ADJ
gs-3214	315	13	challenge	challenge	NOUN
gs-3214	315	14	,	,	PUNCT
gs-3214	315	15	particularly	particularly	ADV
gs-3214	315	16	in	in	ADP
gs-3214	315	17	lowand	lowand	ADJ
gs-3214	315	18	middle	middle	ADJ
gs-3214	315	19	-	-	PUNCT
gs-3214	315	20	income	income	NOUN
gs-3214	315	21	countries	country	NOUN
gs-3214	315	22	(	(	PUNCT
gs-3214	315	23	lmics	lmic	NOUN
gs-3214	315	24	)	)	PUNCT
gs-3214	315	25	where	where	SCONJ
gs-3214	315	26	healthcare	healthcare	NOUN
gs-3214	315	27	resources	resource	NOUN
gs-3214	315	28	are	be	AUX
gs-3214	315	29	limited	limited	ADJ
gs-3214	315	30	.	.	PUNCT
gs-3214	316	1	disparities	disparity	NOUN
gs-3214	316	2	in	in	ADP
gs-3214	316	3	access	access	NOUN
gs-3214	316	4	stem	stem	NOUN
gs-3214	316	5	from	from	ADP
gs-3214	316	6	various	various	ADJ
gs-3214	316	7	factors	factor	NOUN
gs-3214	316	8	,	,	PUNCT
gs-3214	316	9	including	include	VERB
gs-3214	316	10	high	high	ADJ
gs-3214	316	11	treatment	treatment	NOUN
gs-3214	316	12	costs	cost	NOUN
gs-3214	316	13	,	,	PUNCT
gs-3214	316	14	infrastructure	infrastructure	NOUN
gs-3214	316	15	limitations	limitation	NOUN
gs-3214	316	16	,	,	PUNCT
gs-3214	316	17	and	and	CCONJ
gs-3214	316	18	regulatory	regulatory	ADJ
gs-3214	316	19	barriers	barrier	NOUN
gs-3214	316	20	.	.	PUNCT
gs-3214	317	1	addressing	address	VERB
gs-3214	317	2	these	these	DET
gs-3214	317	3	disparities	disparity	NOUN
gs-3214	317	4	requires	require	VERB
gs-3214	317	5	collaborative	collaborative	ADJ
gs-3214	317	6	efforts	effort	NOUN
gs-3214	317	7	among	among	ADP
gs-3214	317	8	governments	government	NOUN
gs-3214	317	9	,	,	PUNCT
gs-3214	317	10	pharmaceutical	pharmaceutical	ADJ
gs-3214	317	11	companies	company	NOUN
gs-3214	317	12	,	,	PUNCT
gs-3214	317	13	and	and	CCONJ
gs-3214	317	14	international	international	ADJ
gs-3214	317	15	organizations	organization	NOUN
gs-3214	317	16	to	to	PART
gs-3214	317	17	implement	implement	VERB
gs-3214	317	18	financial	financial	ADJ
gs-3214	317	19	assistance	assistance	NOUN
gs-3214	317	20	programs	program	NOUN
gs-3214	317	21	,	,	PUNCT
gs-3214	317	22	technology	technology	NOUN
gs-3214	317	23	transfer	transfer	NOUN
gs-3214	317	24	initiatives	initiative	NOUN
gs-3214	317	25	,	,	PUNCT
gs-3214	317	26	and	and	CCONJ
gs-3214	317	27	capacity	capacity	NOUN
gs-3214	317	28	-	-	PUNCT
gs-3214	317	29	building	building	NOUN
gs-3214	317	30	efforts	effort	NOUN
gs-3214	317	31	in	in	ADP
gs-3214	317	32	lmics	lmic	NOUN
gs-3214	317	33	[	[	X
gs-3214	317	34	29,36,42,75	29,36,42,75	NUM
gs-3214	317	35	]	]	PUNCT
gs-3214	317	36	.	.	PUNCT
gs-3214	318	1	informed	informed	ADJ
gs-3214	318	2	consent	consent	NOUN
gs-3214	318	3	is	be	AUX
gs-3214	318	4	a	a	DET
gs-3214	318	5	cornerstone	cornerstone	NOUN
gs-3214	318	6	of	of	ADP
gs-3214	318	7	ethical	ethical	ADJ
gs-3214	318	8	medical	medical	ADJ
gs-3214	318	9	practice	practice	NOUN
gs-3214	318	10	and	and	CCONJ
gs-3214	318	11	is	be	AUX
gs-3214	318	12	particularly	particularly	ADV
gs-3214	318	13	pertinent	pertinent	ADJ
gs-3214	318	14	in	in	ADP
gs-3214	318	15	the	the	DET
gs-3214	318	16	context	context	NOUN
gs-3214	318	17	of	of	ADP
gs-3214	318	18	car	car	NOUN
gs-3214	318	19	-	-	PUNCT
gs-3214	318	20	t	t	NOUN
gs-3214	318	21	cell	cell	NOUN
gs-3214	318	22	therapy	therapy	NOUN
gs-3214	318	23	,	,	PUNCT
gs-3214	318	24	given	give	VERB
gs-3214	318	25	its	its	PRON
gs-3214	318	26	novel	novel	NOUN
gs-3214	318	27	and	and	CCONJ
gs-3214	318	28	potentially	potentially	ADV
gs-3214	318	29	risky	risky	ADJ
gs-3214	318	30	nature	nature	NOUN
gs-3214	318	31	.	.	PUNCT
gs-3214	319	1	patients	patient	NOUN
gs-3214	319	2	must	must	AUX
gs-3214	319	3	be	be	AUX
gs-3214	319	4	adequately	adequately	ADV
gs-3214	319	5	informed	inform	VERB
gs-3214	319	6	about	about	ADP
gs-3214	319	7	the	the	DET
gs-3214	319	8	benefits	benefit	NOUN
gs-3214	319	9	,	,	PUNCT
gs-3214	319	10	risks	risk	NOUN
gs-3214	319	11	,	,	PUNCT
gs-3214	319	12	and	and	CCONJ
gs-3214	319	13	uncertainties	uncertainty	NOUN
gs-3214	319	14	associated	associate	VERB
gs-3214	319	15	with	with	ADP
gs-3214	319	16	car	car	NOUN
gs-3214	319	17	-	-	PUNCT
gs-3214	319	18	t	t	NOUN
gs-3214	319	19	cell	cell	NOUN
gs-3214	319	20	therapy	therapy	NOUN
gs-3214	319	21	to	to	PART
gs-3214	319	22	make	make	VERB
gs-3214	319	23	autonomous	autonomous	ADJ
gs-3214	319	24	decisions	decision	NOUN
gs-3214	319	25	about	about	ADP
gs-3214	319	26	treatment	treatment	NOUN
gs-3214	319	27	.	.	PUNCT
gs-3214	320	1	moreover	moreover	ADV
gs-3214	320	2	,	,	PUNCT
gs-3214	320	3	the	the	DET
gs-3214	320	4	dynamic	dynamic	ADJ
gs-3214	320	5	nature	nature	NOUN
gs-3214	320	6	of	of	ADP
gs-3214	320	7	informed	informed	ADJ
gs-3214	320	8	consent	consent	NOUN
gs-3214	320	9	necessitates	necessitate	VERB
gs-3214	320	10	ongoing	ongoing	ADJ
gs-3214	320	11	communication	communication	NOUN
gs-3214	320	12	between	between	ADP
gs-3214	320	13	healthcare	healthcare	NOUN
gs-3214	320	14	providers	provider	NOUN
gs-3214	320	15	,	,	PUNCT
gs-3214	320	16	patients	patient	NOUN
gs-3214	320	17	,	,	PUNCT
gs-3214	320	18	and	and	CCONJ
gs-3214	320	19	caregivers	caregiver	NOUN
gs-3214	320	20	throughout	throughout	ADP
gs-3214	320	21	the	the	DET
gs-3214	320	22	treatment	treatment	NOUN
gs-3214	320	23	process	process	NOUN
gs-3214	320	24	,	,	PUNCT
gs-3214	320	25	including	include	VERB
gs-3214	320	26	discussions	discussion	NOUN
gs-3214	320	27	about	about	ADP
gs-3214	320	28	potential	potential	ADJ
gs-3214	320	29	adverse	adverse	ADJ
gs-3214	320	30	events	event	NOUN
gs-3214	320	31	,	,	PUNCT
gs-3214	320	32	treatment	treatment	NOUN
gs-3214	320	33	response	response	NOUN
gs-3214	320	34	,	,	PUNCT
gs-3214	320	35	and	and	CCONJ
gs-3214	320	36	long	long	ADJ
gs-3214	320	37	-	-	PUNCT
gs-3214	320	38	term	term	NOUN
gs-3214	320	39	effects	effect	NOUN
gs-3214	320	40	[	[	X
gs-3214	320	41	100	100	NUM
gs-3214	320	42	]	]	PUNCT
gs-3214	320	43	.	.	PUNCT
gs-3214	321	1	the	the	DET
gs-3214	321	2	high	high	ADJ
gs-3214	321	3	cost	cost	NOUN
gs-3214	321	4	of	of	ADP
gs-3214	321	5	car	car	NOUN
gs-3214	321	6	-	-	PUNCT
gs-3214	321	7	t	t	NOUN
gs-3214	321	8	cell	cell	NOUN
gs-3214	321	9	therapy	therapy	NOUN
gs-3214	321	10	poses	pose	VERB
gs-3214	321	11	significant	significant	ADJ
gs-3214	321	12	financial	financial	ADJ
gs-3214	321	13	burdens	burden	NOUN
gs-3214	321	14	on	on	ADP
gs-3214	321	15	patients	patient	NOUN
gs-3214	321	16	,	,	PUNCT
gs-3214	321	17	healthcare	healthcare	NOUN
gs-3214	321	18	systems	system	NOUN
gs-3214	321	19	,	,	PUNCT
gs-3214	321	20	and	and	CCONJ
gs-3214	321	21	payers	payer	NOUN
gs-3214	321	22	.	.	PUNCT
gs-3214	322	1	financial	financial	ADJ
gs-3214	322	2	toxicity	toxicity	NOUN
gs-3214	322	3	,	,	PUNCT
gs-3214	322	4	characterized	characterize	VERB
gs-3214	322	5	by	by	ADP
gs-3214	322	6	the	the	DET
gs-3214	322	7	economic	economic	ADJ
gs-3214	322	8	hardship	hardship	NOUN
gs-3214	322	9	experienced	experience	VERB
gs-3214	322	10	by	by	ADP
gs-3214	322	11	patients	patient	NOUN
gs-3214	322	12	and	and	CCONJ
gs-3214	322	13	families	family	NOUN
gs-3214	322	14	due	due	ADP
gs-3214	322	15	to	to	ADP
gs-3214	322	16	healthcare	healthcare	NOUN
gs-3214	322	17	expenses	expense	NOUN
gs-3214	322	18	,	,	PUNCT
gs-3214	322	19	may	may	AUX
gs-3214	322	20	lead	lead	VERB
gs-3214	322	21	to	to	ADP
gs-3214	322	22	treatment	treatment	NOUN
gs-3214	322	23	non	non	NOUN
gs-3214	322	24	-	-	NOUN
gs-3214	322	25	adherence	adherence	ADJ
gs-3214	322	26	,	,	PUNCT
gs-3214	322	27	bankruptcy	bankruptcy	NOUN
gs-3214	322	28	,	,	PUNCT
gs-3214	322	29	and	and	CCONJ
gs-3214	322	30	decreased	decrease	VERB
gs-3214	322	31	quality	quality	NOUN
gs-3214	322	32	of	of	ADP
gs-3214	322	33	life	life	NOUN
gs-3214	322	34	.	.	PUNCT
gs-3214	323	1	addressing	address	VERB
gs-3214	323	2	financial	financial	ADJ
gs-3214	323	3	toxicity	toxicity	NOUN
gs-3214	323	4	requires	require	VERB
gs-3214	323	5	innovative	innovative	ADJ
gs-3214	323	6	reimbursement	reimbursement	NOUN
gs-3214	323	7	models	model	NOUN
gs-3214	323	8	,	,	PUNCT
gs-3214	323	9	value	value	NOUN
gs-3214	323	10	-	-	PUNCT
gs-3214	323	11	based	base	VERB
gs-3214	323	12	pricing	pricing	NOUN
gs-3214	323	13	agreements	agreement	NOUN
gs-3214	323	14	,	,	PUNCT
gs-3214	323	15	and	and	CCONJ
gs-3214	323	16	advocacy	advocacy	NOUN
gs-3214	323	17	for	for	ADP
gs-3214	323	18	insurance	insurance	NOUN
gs-3214	323	19	coverage	coverage	NOUN
gs-3214	323	20	and	and	CCONJ
gs-3214	323	21	government	government	NOUN
gs-3214	323	22	subsidies	subsidy	NOUN
gs-3214	323	23	to	to	PART
gs-3214	323	24	ensure	ensure	VERB
gs-3214	323	25	that	that	SCONJ
gs-3214	323	26	all	all	DET
gs-3214	323	27	eligible	eligible	ADJ
gs-3214	323	28	patients	patient	NOUN
gs-3214	323	29	have	have	VERB
gs-3214	323	30	access	access	NOUN
gs-3214	323	31	to	to	ADP
gs-3214	323	32	car	car	NOUN
gs-3214	323	33	-	-	PUNCT
gs-3214	323	34	t	t	NOUN
gs-3214	323	35	cell	cell	NOUN
gs-3214	323	36	therapy	therapy	NOUN
gs-3214	323	37	without	without	ADP
gs-3214	323	38	facing	face	VERB
gs-3214	323	39	financial	financial	ADJ
gs-3214	323	40	ruin	ruin	NOUN
gs-3214	324	1	[	[	X
gs-3214	324	2	8,34	8,34	NUM
gs-3214	324	3	,	,	PUNCT
gs-3214	324	4	96	96	NUM
gs-3214	324	5	]	]	PUNCT
gs-3214	324	6	.	.	PUNCT
gs-3214	325	1	equity	equity	NOUN
gs-3214	325	2	in	in	ADP
gs-3214	325	3	clinical	clinical	ADJ
gs-3214	325	4	trial	trial	NOUN
gs-3214	325	5	participation	participation	NOUN
gs-3214	325	6	is	be	AUX
gs-3214	325	7	essential	essential	ADJ
gs-3214	325	8	to	to	PART
gs-3214	325	9	ensure	ensure	VERB
gs-3214	325	10	that	that	SCONJ
gs-3214	325	11	diverse	diverse	ADJ
gs-3214	325	12	patient	patient	NOUN
gs-3214	325	13	populations	population	NOUN
gs-3214	325	14	are	be	AUX
gs-3214	325	15	represented	represent	VERB
gs-3214	325	16	in	in	ADP
gs-3214	325	17	car	car	NOUN
gs-3214	325	18	-	-	PUNCT
gs-3214	325	19	t	t	NOUN
gs-3214	325	20	cell	cell	NOUN
gs-3214	325	21	therapy	therapy	NOUN
gs-3214	325	22	research	research	NOUN
gs-3214	325	23	.	.	PUNCT
gs-3214	326	1	however	however	ADV
gs-3214	326	2	,	,	PUNCT
gs-3214	326	3	disparities	disparity	NOUN
gs-3214	326	4	in	in	ADP
gs-3214	326	5	trial	trial	NOUN
gs-3214	326	6	participation	participation	NOUN
gs-3214	326	7	based	base	VERB
gs-3214	326	8	on	on	ADP
gs-3214	326	9	factors	factor	NOUN
gs-3214	326	10	such	such	ADJ
gs-3214	326	11	as	as	ADP
gs-3214	326	12	race	race	NOUN
gs-3214	326	13	,	,	PUNCT
gs-3214	326	14	ethnicity	ethnicity	NOUN
gs-3214	326	15	,	,	PUNCT
gs-3214	326	16	socioeconomic	socioeconomic	ADJ
gs-3214	326	17	status	status	NOUN
gs-3214	326	18	,	,	PUNCT
gs-3214	326	19	and	and	CCONJ
gs-3214	326	20	geographic	geographic	ADJ
gs-3214	326	21	location	location	NOUN
gs-3214	326	22	persist	persist	NOUN
gs-3214	326	23	.	.	PUNCT
gs-3214	327	1	barriers	barrier	NOUN
gs-3214	327	2	to	to	ADP
gs-3214	327	3	participation	participation	NOUN
gs-3214	327	4	include	include	VERB
gs-3214	327	5	lack	lack	NOUN
gs-3214	327	6	of	of	ADP
gs-3214	327	7	awareness	awareness	NOUN
gs-3214	327	8	,	,	PUNCT
gs-3214	327	9	language	language	NOUN
gs-3214	327	10	barriers	barrier	NOUN
gs-3214	327	11	,	,	PUNCT
gs-3214	327	12	mistrust	mistrust	NOUN
gs-3214	327	13	of	of	ADP
gs-3214	327	14	the	the	DET
gs-3214	327	15	medical	medical	ADJ
gs-3214	327	16	system	system	NOUN
gs-3214	327	17	,	,	PUNCT
gs-3214	327	18	and	and	CCONJ
gs-3214	327	19	logistical	logistical	ADJ
gs-3214	327	20	challenges	challenge	NOUN
gs-3214	327	21	.	.	PUNCT
gs-3214	328	1	increasing	increase	VERB
gs-3214	328	2	diversity	diversity	NOUN
gs-3214	328	3	in	in	ADP
gs-3214	328	4	clinical	clinical	ADJ
gs-3214	328	5	trials	trial	NOUN
gs-3214	328	6	requires	require	VERB
gs-3214	328	7	proactive	proactive	ADJ
gs-3214	328	8	recruitment	recruitment	NOUN
gs-3214	328	9	strategies	strategy	NOUN
gs-3214	328	10	,	,	PUNCT
gs-3214	328	11	community	community	NOUN
gs-3214	328	12	engagement	engagement	NOUN
gs-3214	328	13	initiatives	initiative	NOUN
gs-3214	328	14	,	,	PUNCT
gs-3214	328	15	and	and	CCONJ
gs-3214	328	16	culturally	culturally	ADV
gs-3214	328	17	sensitive	sensitive	ADJ
gs-3214	328	18	approaches	approach	NOUN
gs-3214	328	19	to	to	PART
gs-3214	328	20	address	address	VERB
gs-3214	328	21	barriers	barrier	NOUN
gs-3214	328	22	and	and	CCONJ
gs-3214	328	23	promote	promote	VERB
gs-3214	328	24	inclusivity	inclusivity	NOUN
gs-3214	329	1	[	[	X
gs-3214	329	2	2,29,46,95	2,29,46,95	NUM
gs-3214	329	3	]	]	X
gs-3214	329	4	georgian	georgian	NOUN
gs-3214	329	5	scientists/	scientists/	NUM
gs-3214	329	6	.	.	PUNCT
gs-3214	330	1	6	6	NUM
gs-3214	330	2	n	n	NUM
gs-3214	330	3	3	3	NUM
gs-3214	330	4	,	,	PUNCT
gs-3214	330	5	2024	2024	NUM
gs-3214	330	6	279	279	NUM
gs-3214	330	7	as	as	ADP
gs-3214	330	8	chimeric	chimeric	ADJ
gs-3214	330	9	antigen	antigen	ADJ
gs-3214	330	10	receptor	receptor	NOUN
gs-3214	330	11	(	(	PUNCT
gs-3214	330	12	car	car	NOUN
gs-3214	330	13	)	)	PUNCT
gs-3214	330	14	t	t	NOUN
gs-3214	330	15	cell	cell	NOUN
gs-3214	330	16	therapy	therapy	NOUN
gs-3214	330	17	continues	continue	VERB
gs-3214	330	18	to	to	PART
gs-3214	330	19	evolve	evolve	VERB
gs-3214	330	20	,	,	PUNCT
gs-3214	330	21	future	future	ADJ
gs-3214	330	22	directions	direction	NOUN
gs-3214	330	23	and	and	CCONJ
gs-3214	330	24	emerging	emerge	VERB
gs-3214	330	25	technologies	technology	NOUN
gs-3214	330	26	hold	hold	VERB
gs-3214	330	27	the	the	DET
gs-3214	330	28	promise	promise	NOUN
gs-3214	330	29	of	of	ADP
gs-3214	330	30	further	further	ADJ
gs-3214	330	31	enhancing	enhance	VERB
gs-3214	330	32	efficacy	efficacy	NOUN
gs-3214	330	33	,	,	PUNCT
gs-3214	330	34	safety	safety	NOUN
gs-3214	330	35	,	,	PUNCT
gs-3214	330	36	and	and	CCONJ
gs-3214	330	37	accessibility	accessibility	NOUN
gs-3214	330	38	.	.	PUNCT
gs-3214	331	1	this	this	DET
gs-3214	331	2	chapter	chapter	NOUN
gs-3214	331	3	explores	explore	VERB
gs-3214	331	4	the	the	DET
gs-3214	331	5	potential	potential	NOUN
gs-3214	331	6	of	of	ADP
gs-3214	331	7	next	next	ADJ
gs-3214	331	8	-	-	PUNCT
gs-3214	331	9	generation	generation	NOUN
gs-3214	331	10	car	car	NOUN
gs-3214	331	11	-	-	PUNCT
gs-3214	331	12	t	t	NOUN
gs-3214	331	13	cell	cell	NOUN
gs-3214	331	14	therapies	therapy	NOUN
gs-3214	331	15	,	,	PUNCT
gs-3214	331	16	combination	combination	NOUN
gs-3214	331	17	approaches	approach	NOUN
gs-3214	331	18	,	,	PUNCT
gs-3214	331	19	gene	gene	NOUN
gs-3214	331	20	editing	editing	NOUN
gs-3214	331	21	technologies	technology	NOUN
gs-3214	331	22	,	,	PUNCT
gs-3214	331	23	and	and	CCONJ
gs-3214	331	24	the	the	DET
gs-3214	331	25	integration	integration	NOUN
gs-3214	331	26	of	of	ADP
gs-3214	331	27	predictive	predictive	ADJ
gs-3214	331	28	modelling	modelling	NOUN
gs-3214	331	29	and	and	CCONJ
gs-3214	331	30	artificial	artificial	ADJ
gs-3214	331	31	intelligence	intelligence	NOUN
gs-3214	331	32	(	(	PUNCT
gs-3214	331	33	ai	ai	NOUN
gs-3214	331	34	)	)	PUNCT
gs-3214	331	35	in	in	ADP
gs-3214	331	36	advancing	advance	VERB
gs-3214	331	37	the	the	DET
gs-3214	331	38	field	field	NOUN
gs-3214	331	39	[	[	X
gs-3214	331	40	15,48,67	15,48,67	NUM
gs-3214	331	41	]	]	PUNCT
gs-3214	331	42	.	.	PUNCT
gs-3214	332	1	next	next	ADJ
gs-3214	332	2	-	-	PUNCT
gs-3214	332	3	generation	generation	NOUN
gs-3214	332	4	car	car	NOUN
gs-3214	332	5	-	-	PUNCT
gs-3214	332	6	t	t	NOUN
gs-3214	332	7	cell	cell	NOUN
gs-3214	332	8	therapies	therapy	NOUN
gs-3214	332	9	aim	aim	VERB
gs-3214	332	10	to	to	PART
gs-3214	332	11	overcome	overcome	VERB
gs-3214	332	12	existing	exist	VERB
gs-3214	332	13	limitations	limitation	NOUN
gs-3214	332	14	by	by	ADP
gs-3214	332	15	incorporating	incorporate	VERB
gs-3214	332	16	novel	novel	ADJ
gs-3214	332	17	designs	design	NOUN
gs-3214	332	18	,	,	PUNCT
gs-3214	332	19	engineering	engineering	NOUN
gs-3214	332	20	strategies	strategy	NOUN
gs-3214	332	21	,	,	PUNCT
gs-3214	332	22	and	and	CCONJ
gs-3214	332	23	targeting	target	VERB
gs-3214	332	24	mechanisms	mechanism	NOUN
gs-3214	332	25	.	.	PUNCT
gs-3214	333	1	advances	advance	NOUN
gs-3214	333	2	in	in	ADP
gs-3214	333	3	car	car	NOUN
gs-3214	333	4	construct	construct	NOUN
gs-3214	333	5	design	design	NOUN
gs-3214	333	6	,	,	PUNCT
gs-3214	333	7	such	such	ADJ
gs-3214	333	8	as	as	ADP
gs-3214	333	9	the	the	DET
gs-3214	333	10	incorporation	incorporation	NOUN
gs-3214	333	11	of	of	ADP
gs-3214	333	12	additional	additional	ADJ
gs-3214	333	13	costimulatory	costimulatory	NOUN
gs-3214	333	14	domains	domain	NOUN
gs-3214	333	15	or	or	CCONJ
gs-3214	333	16	switchable	switchable	ADJ
gs-3214	333	17	receptors	receptor	NOUN
gs-3214	333	18	,	,	PUNCT
gs-3214	333	19	offer	offer	VERB
gs-3214	333	20	enhanced	enhance	VERB
gs-3214	333	21	t	t	NOUN
gs-3214	333	22	cell	cell	NOUN
gs-3214	333	23	activation	activation	NOUN
gs-3214	333	24	,	,	PUNCT
gs-3214	333	25	persistence	persistence	NOUN
gs-3214	333	26	,	,	PUNCT
gs-3214	333	27	and	and	CCONJ
gs-3214	333	28	tumor	tumor	NOUN
gs-3214	333	29	targeting	target	VERB
gs-3214	333	30	.	.	PUNCT
gs-3214	334	1	furthermore	furthermore	ADV
gs-3214	334	2	,	,	PUNCT
gs-3214	334	3	the	the	DET
gs-3214	334	4	development	development	NOUN
gs-3214	334	5	of	of	ADP
gs-3214	334	6	universal	universal	ADJ
gs-3214	334	7	car	car	NOUN
gs-3214	334	8	-	-	PUNCT
gs-3214	334	9	t	t	NOUN
gs-3214	334	10	cells	cell	NOUN
gs-3214	334	11	,	,	PUNCT
gs-3214	334	12	engineered	engineer	VERB
gs-3214	334	13	to	to	PART
gs-3214	334	14	evade	evade	VERB
gs-3214	334	15	immune	immune	ADJ
gs-3214	334	16	rejection	rejection	NOUN
gs-3214	334	17	and	and	CCONJ
gs-3214	334	18	exhibit	exhibit	VERB
gs-3214	334	19	broad	broad	ADJ
gs-3214	334	20	antigen	antigen	ADJ
gs-3214	334	21	specificity	specificity	NOUN
gs-3214	334	22	,	,	PUNCT
gs-3214	334	23	holds	hold	VERB
gs-3214	334	24	promise	promise	NOUN
gs-3214	334	25	for	for	ADP
gs-3214	334	26	off	off	ADP
gs-3214	334	27	-	-	PUNCT
gs-3214	334	28	theshelf	theshelf	PRON
gs-3214	334	29	therapies	therapy	NOUN
gs-3214	334	30	with	with	ADP
gs-3214	334	31	improved	improved	ADJ
gs-3214	334	32	accessibility	accessibility	NOUN
gs-3214	334	33	and	and	CCONJ
gs-3214	334	34	scalability	scalability	NOUN
gs-3214	334	35	.	.	PUNCT
gs-3214	335	1	combination	combination	NOUN
gs-3214	335	2	therapies	therapy	NOUN
gs-3214	335	3	involving	involve	VERB
gs-3214	335	4	car	car	NOUN
gs-3214	335	5	-	-	PUNCT
gs-3214	335	6	t	t	NOUN
gs-3214	335	7	cell	cell	NOUN
gs-3214	335	8	therapy	therapy	NOUN
gs-3214	335	9	and	and	CCONJ
gs-3214	335	10	other	other	ADJ
gs-3214	335	11	treatment	treatment	NOUN
gs-3214	335	12	modalities	modality	NOUN
gs-3214	335	13	,	,	PUNCT
gs-3214	335	14	such	such	ADJ
gs-3214	335	15	as	as	ADP
gs-3214	335	16	checkpoint	checkpoint	NOUN
gs-3214	335	17	inhibitors	inhibitor	NOUN
gs-3214	335	18	,	,	PUNCT
gs-3214	335	19	targeted	target	VERB
gs-3214	335	20	therapies	therapy	NOUN
gs-3214	335	21	,	,	PUNCT
gs-3214	335	22	and	and	CCONJ
gs-3214	335	23	conventional	conventional	ADJ
gs-3214	335	24	cytotoxic	cytotoxic	ADJ
gs-3214	335	25	agents	agent	NOUN
gs-3214	335	26	,	,	PUNCT
gs-3214	335	27	offer	offer	VERB
gs-3214	335	28	synergistic	synergistic	ADJ
gs-3214	335	29	effects	effect	NOUN
gs-3214	335	30	and	and	CCONJ
gs-3214	335	31	complementary	complementary	ADJ
gs-3214	335	32	mechanisms	mechanism	NOUN
gs-3214	335	33	of	of	ADP
gs-3214	335	34	action	action	NOUN
gs-3214	335	35	.	.	PUNCT
gs-3214	336	1	by	by	ADP
gs-3214	336	2	leveraging	leverage	VERB
gs-3214	336	3	the	the	DET
gs-3214	336	4	immune	immune	ADJ
gs-3214	336	5	modulatory	modulatory	NOUN
gs-3214	336	6	properties	property	NOUN
gs-3214	336	7	of	of	ADP
gs-3214	336	8	checkpoint	checkpoint	NOUN
gs-3214	336	9	inhibitors	inhibitor	NOUN
gs-3214	336	10	or	or	CCONJ
gs-3214	336	11	the	the	DET
gs-3214	336	12	targeted	target	VERB
gs-3214	336	13	cytotoxicity	cytotoxicity	NOUN
gs-3214	336	14	of	of	ADP
gs-3214	336	15	small	small	ADJ
gs-3214	336	16	molecule	molecule	NOUN
gs-3214	336	17	inhibitors	inhibitor	NOUN
gs-3214	336	18	,	,	PUNCT
gs-3214	336	19	combination	combination	NOUN
gs-3214	336	20	approaches	approach	NOUN
gs-3214	336	21	aim	aim	VERB
gs-3214	336	22	to	to	PART
gs-3214	336	23	overcome	overcome	VERB
gs-3214	336	24	tumor	tumor	NOUN
gs-3214	336	25	immune	immune	ADJ
gs-3214	336	26	evasion	evasion	NOUN
gs-3214	336	27	mechanisms	mechanism	NOUN
gs-3214	336	28	,	,	PUNCT
gs-3214	336	29	enhance	enhance	VERB
gs-3214	336	30	car	car	NOUN
gs-3214	336	31	-	-	PUNCT
gs-3214	336	32	t	t	NOUN
gs-3214	336	33	cell	cell	NOUN
gs-3214	336	34	trafficking	trafficking	NOUN
gs-3214	336	35	and	and	CCONJ
gs-3214	336	36	persistence	persistence	NOUN
gs-3214	336	37	,	,	PUNCT
gs-3214	336	38	and	and	CCONJ
gs-3214	336	39	broaden	broaden	VERB
gs-3214	336	40	the	the	DET
gs-3214	336	41	applicability	applicability	NOUN
gs-3214	336	42	of	of	ADP
gs-3214	336	43	car	car	NOUN
gs-3214	336	44	-	-	PUNCT
gs-3214	336	45	t	t	NOUN
gs-3214	336	46	cell	cell	NOUN
gs-3214	336	47	therapy	therapy	NOUN
gs-3214	336	48	across	across	ADP
gs-3214	336	49	diverse	diverse	ADJ
gs-3214	336	50	cancer	cancer	NOUN
gs-3214	336	51	types	type	NOUN
gs-3214	336	52	and	and	CCONJ
gs-3214	336	53	disease	disease	NOUN
gs-3214	336	54	stages	stage	NOUN
gs-3214	336	55	[	[	X
gs-3214	336	56	4.33,38	4.33,38	NUM
gs-3214	336	57	,	,	PUNCT
gs-3214	336	58	69	69	NUM
gs-3214	336	59	]	]	PUNCT
gs-3214	336	60	.	.	PUNCT
gs-3214	337	1	advancements	advancement	NOUN
gs-3214	337	2	in	in	ADP
gs-3214	337	3	gene	gene	NOUN
gs-3214	337	4	editing	edit	VERB
gs-3214	337	5	technologies	technology	NOUN
gs-3214	337	6	,	,	PUNCT
gs-3214	337	7	particularly	particularly	ADV
gs-3214	337	8	crispr	crispr	ADJ
gs-3214	337	9	-	-	PUNCT
gs-3214	337	10	cas9	cas9	NOUN
gs-3214	337	11	,	,	PUNCT
gs-3214	337	12	present	present	ADJ
gs-3214	337	13	new	new	ADJ
gs-3214	337	14	opportunities	opportunity	NOUN
gs-3214	337	15	for	for	ADP
gs-3214	337	16	precision	precision	NOUN
gs-3214	337	17	genome	genome	NOUN
gs-3214	337	18	engineering	engineering	NOUN
gs-3214	337	19	in	in	ADP
gs-3214	337	20	car	car	NOUN
gs-3214	337	21	-	-	PUNCT
gs-3214	337	22	t	t	NOUN
gs-3214	337	23	cell	cell	NOUN
gs-3214	337	24	therapy	therapy	NOUN
gs-3214	337	25	.	.	PUNCT
gs-3214	338	1	crispr	crispr	NOUN
gs-3214	338	2	-	-	PUNCT
gs-3214	338	3	based	base	VERB
gs-3214	338	4	approaches	approach	NOUN
gs-3214	338	5	enable	enable	VERB
gs-3214	338	6	precise	precise	ADJ
gs-3214	338	7	modification	modification	NOUN
gs-3214	338	8	of	of	ADP
gs-3214	338	9	t	t	PROPN
gs-3214	338	10	cell	cell	NOUN
gs-3214	338	11	genomes	genome	VERB
gs-3214	338	12	to	to	PART
gs-3214	338	13	enhance	enhance	VERB
gs-3214	338	14	car	car	NOUN
gs-3214	338	15	expression	expression	NOUN
gs-3214	338	16	,	,	PUNCT
gs-3214	338	17	disrupt	disrupt	VERB
gs-3214	338	18	inhibitory	inhibitory	ADJ
gs-3214	338	19	signaling	signal	VERB
gs-3214	338	20	pathways	pathway	NOUN
gs-3214	338	21	,	,	PUNCT
gs-3214	338	22	or	or	CCONJ
gs-3214	338	23	introduce	introduce	VERB
gs-3214	338	24	safety	safety	NOUN
gs-3214	338	25	switches	switch	NOUN
gs-3214	338	26	for	for	ADP
gs-3214	338	27	controlled	control	VERB
gs-3214	338	28	cell	cell	NOUN
gs-3214	338	29	elimination	elimination	NOUN
gs-3214	338	30	.	.	PUNCT
gs-3214	339	1	additionally	additionally	ADV
gs-3214	339	2	,	,	PUNCT
gs-3214	339	3	gene	gene	NOUN
gs-3214	339	4	editing	edit	VERB
gs-3214	339	5	techniques	technique	NOUN
gs-3214	339	6	facilitate	facilitate	VERB
gs-3214	339	7	the	the	DET
gs-3214	339	8	generation	generation	NOUN
gs-3214	339	9	of	of	ADP
gs-3214	339	10	allogeneic	allogeneic	ADJ
gs-3214	339	11	car	car	NOUN
gs-3214	339	12	-	-	PUNCT
gs-3214	339	13	t	t	NOUN
gs-3214	339	14	cells	cell	NOUN
gs-3214	339	15	with	with	ADP
gs-3214	339	16	improved	improved	ADJ
gs-3214	339	17	safety	safety	NOUN
gs-3214	339	18	profiles	profile	NOUN
gs-3214	339	19	and	and	CCONJ
gs-3214	339	20	off	off	ADP
gs-3214	339	21	-	-	PUNCT
gs-3214	339	22	the	the	DET
gs-3214	339	23	-	-	PUNCT
gs-3214	339	24	shelf	shelf	NOUN
gs-3214	339	25	availability	availability	NOUN
gs-3214	339	26	by	by	ADP
gs-3214	339	27	eliminating	eliminate	VERB
gs-3214	339	28	alloreactivity	alloreactivity	NOUN
gs-3214	339	29	and	and	CCONJ
gs-3214	339	30	mitigating	mitigate	VERB
gs-3214	339	31	graft	graft	NOUN
gs-3214	339	32	-	-	PUNCT
gs-3214	339	33	versus	versus	ADP
gs-3214	339	34	-	-	PUNCT
gs-3214	339	35	host	host	NOUN
gs-3214	339	36	disease	disease	NOUN
gs-3214	339	37	(	(	PUNCT
gs-3214	339	38	gvhd	gvhd	NOUN
gs-3214	339	39	)	)	PUNCT
gs-3214	339	40	risks	risk	NOUN
gs-3214	340	1	[	[	X
gs-3214	340	2	8183	8183	NUM
gs-3214	340	3	]	]	PUNCT
gs-3214	340	4	.	.	PUNCT
gs-3214	341	1	the	the	DET
gs-3214	341	2	integration	integration	NOUN
gs-3214	341	3	of	of	ADP
gs-3214	341	4	predictive	predictive	ADJ
gs-3214	341	5	modelling	modelling	NOUN
gs-3214	341	6	and	and	CCONJ
gs-3214	341	7	artificial	artificial	ADJ
gs-3214	341	8	intelligence	intelligence	NOUN
gs-3214	341	9	(	(	PUNCT
gs-3214	341	10	ai	ai	AUX
gs-3214	341	11	)	)	PUNCT
gs-3214	341	12	holds	hold	VERB
gs-3214	341	13	tremendous	tremendous	ADJ
gs-3214	341	14	potential	potential	NOUN
gs-3214	341	15	in	in	ADP
gs-3214	341	16	optimizing	optimize	VERB
gs-3214	341	17	car	car	NOUN
gs-3214	341	18	-	-	PUNCT
gs-3214	341	19	t	t	NOUN
gs-3214	341	20	cell	cell	NOUN
gs-3214	341	21	therapy	therapy	NOUN
gs-3214	341	22	outcomes	outcome	NOUN
gs-3214	341	23	and	and	CCONJ
gs-3214	341	24	personalized	personalized	ADJ
gs-3214	341	25	treatment	treatment	NOUN
gs-3214	341	26	strategies	strategy	NOUN
gs-3214	341	27	.	.	PUNCT
gs-3214	342	1	machine	machine	NOUN
gs-3214	342	2	learning	learn	VERB
gs-3214	342	3	algorithms	algorithms	PROPN
gs-3214	342	4	analyses	analyse	VERB
gs-3214	342	5	complex	complex	ADJ
gs-3214	342	6	datasets	dataset	NOUN
gs-3214	342	7	,	,	PUNCT
gs-3214	342	8	including	include	VERB
gs-3214	342	9	patient	patient	ADJ
gs-3214	342	10	demographics	demographic	NOUN
gs-3214	342	11	,	,	PUNCT
gs-3214	342	12	genetic	genetic	ADJ
gs-3214	342	13	profiles	profile	NOUN
gs-3214	342	14	,	,	PUNCT
gs-3214	342	15	tumor	tumor	NOUN
gs-3214	342	16	characteristics	characteristic	NOUN
gs-3214	342	17	,	,	PUNCT
gs-3214	342	18	and	and	CCONJ
gs-3214	342	19	treatment	treatment	NOUN
gs-3214	342	20	responses	response	NOUN
gs-3214	342	21	,	,	PUNCT
gs-3214	342	22	to	to	PART
gs-3214	342	23	identify	identify	VERB
gs-3214	342	24	predictive	predictive	ADJ
gs-3214	342	25	biomarkers	biomarker	NOUN
gs-3214	342	26	,	,	PUNCT
gs-3214	342	27	treatment	treatment	NOUN
gs-3214	342	28	algorithms	algorithm	NOUN
gs-3214	342	29	,	,	PUNCT
gs-3214	342	30	and	and	CCONJ
gs-3214	342	31	patient	patient	NOUN
gs-3214	342	32	-	-	PUNCT
gs-3214	342	33	specific	specific	ADJ
gs-3214	342	34	dosing	dosing	ADJ
gs-3214	342	35	regimens	regimen	NOUN
gs-3214	342	36	.	.	PUNCT
gs-3214	343	1	by	by	ADP
gs-3214	343	2	leveraging	leverage	VERB
gs-3214	343	3	ai	ai	NOUN
gs-3214	343	4	-	-	PUNCT
gs-3214	343	5	driven	drive	VERB
gs-3214	343	6	predictive	predictive	ADJ
gs-3214	343	7	modelling	modelling	NOUN
gs-3214	343	8	,	,	PUNCT
gs-3214	343	9	clinicians	clinician	NOUN
gs-3214	343	10	can	can	AUX
gs-3214	343	11	enhance	enhance	VERB
gs-3214	343	12	treatment	treatment	NOUN
gs-3214	343	13	efficacy	efficacy	NOUN
gs-3214	343	14	,	,	PUNCT
gs-3214	343	15	minimize	minimize	VERB
gs-3214	343	16	adverse	adverse	ADJ
gs-3214	343	17	events	event	NOUN
gs-3214	343	18	,	,	PUNCT
gs-3214	343	19	and	and	CCONJ
gs-3214	343	20	tailor	tailor	NOUN
gs-3214	343	21	therapy	therapy	NOUN
gs-3214	343	22	to	to	ADP
gs-3214	343	23	individual	individual	ADJ
gs-3214	343	24	patient	patient	NOUN
gs-3214	343	25	needs	need	VERB
gs-3214	343	26	[	[	X
gs-3214	343	27	42,49,56	42,49,56	NUM
gs-3214	343	28	,	,	PUNCT
gs-3214	343	29	94	94	NUM
gs-3214	343	30	]	]	PUNCT
gs-3214	343	31	.	.	PUNCT
gs-3214	344	1	in	in	ADP
gs-3214	344	2	light	light	NOUN
gs-3214	344	3	of	of	ADP
gs-3214	344	4	the	the	DET
gs-3214	344	5	evolving	evolve	VERB
gs-3214	344	6	landscape	landscape	NOUN
gs-3214	344	7	of	of	ADP
gs-3214	344	8	car	car	NOUN
gs-3214	344	9	-	-	PUNCT
gs-3214	344	10	t	t	NOUN
gs-3214	344	11	cell	cell	NOUN
gs-3214	344	12	therapy	therapy	NOUN
gs-3214	344	13	,	,	PUNCT
gs-3214	344	14	are	be	AUX
gs-3214	344	15	proposed	propose	VERB
gs-3214	344	16	to	to	PART
gs-3214	344	17	optimize	optimize	VERB
gs-3214	344	18	clinical	clinical	ADJ
gs-3214	344	19	practice	practice	NOUN
gs-3214	344	20	and	and	CCONJ
gs-3214	344	21	policy	policy	NOUN
gs-3214	344	22	:	:	PUNCT
gs-3214	344	23	enhanced	enhance	VERB
gs-3214	344	24	patient	patient	ADJ
gs-3214	344	25	selection	selection	NOUN
gs-3214	344	26	:	:	PUNCT
gs-3214	344	27	implementing	implement	VERB
gs-3214	344	28	comprehensive	comprehensive	ADJ
gs-3214	344	29	biomarker	biomarker	NOUN
gs-3214	344	30	profiling	profiling	NOUN
gs-3214	344	31	and	and	CCONJ
gs-3214	344	32	patient	patient	ADJ
gs-3214	344	33	stratification	stratification	NOUN
gs-3214	344	34	strategies	strategy	NOUN
gs-3214	344	35	is	be	AUX
gs-3214	344	36	essential	essential	ADJ
gs-3214	344	37	to	to	PART
gs-3214	344	38	identify	identify	VERB
gs-3214	344	39	the	the	DET
gs-3214	344	40	most	most	ADV
gs-3214	344	41	suitable	suitable	ADJ
gs-3214	344	42	candidates	candidate	NOUN
gs-3214	344	43	for	for	ADP
gs-3214	344	44	car	car	NOUN
gs-3214	344	45	-	-	PUNCT
gs-3214	344	46	t	t	NOUN
gs-3214	344	47	cell	cell	NOUN
gs-3214	344	48	therapy	therapy	NOUN
gs-3214	344	49	.	.	PUNCT
gs-3214	345	1	this	this	PRON
gs-3214	345	2	involves	involve	VERB
gs-3214	345	3	analyzing	analyze	VERB
gs-3214	345	4	various	various	ADJ
gs-3214	345	5	biomarkers	biomarker	NOUN
gs-3214	345	6	related	relate	VERB
gs-3214	345	7	to	to	ADP
gs-3214	345	8	tumor	tumor	NOUN
gs-3214	345	9	biology	biology	NOUN
gs-3214	345	10	,	,	PUNCT
gs-3214	345	11	immune	immune	ADJ
gs-3214	345	12	status	status	NOUN
gs-3214	345	13	,	,	PUNCT
gs-3214	345	14	and	and	CCONJ
gs-3214	345	15	treatment	treatment	NOUN
gs-3214	345	16	history	history	NOUN
gs-3214	345	17	to	to	PART
gs-3214	345	18	determine	determine	VERB
gs-3214	345	19	which	which	PRON
gs-3214	345	20	patients	patient	NOUN
gs-3214	345	21	are	be	AUX
gs-3214	345	22	most	most	ADV
gs-3214	345	23	likely	likely	ADJ
gs-3214	345	24	to	to	PART
gs-3214	345	25	benefit	benefit	VERB
gs-3214	345	26	from	from	ADP
gs-3214	345	27	this	this	DET
gs-3214	345	28	innovative	innovative	ADJ
gs-3214	345	29	treatment	treatment	NOUN
gs-3214	345	30	approach	approach	NOUN
gs-3214	345	31	.	.	PUNCT
gs-3214	346	1	by	by	ADP
gs-3214	346	2	employing	employ	VERB
gs-3214	346	3	advanced	advanced	ADJ
gs-3214	346	4	molecular	molecular	ADJ
gs-3214	346	5	and	and	CCONJ
gs-3214	346	6	immunological	immunological	ADJ
gs-3214	346	7	techniques	technique	NOUN
gs-3214	346	8	,	,	PUNCT
gs-3214	346	9	healthcare	healthcare	NOUN
gs-3214	346	10	providers	provider	NOUN
gs-3214	346	11	can	can	AUX
gs-3214	346	12	tailor	tailor	VERB
gs-3214	346	13	car	car	NOUN
gs-3214	346	14	-	-	PUNCT
gs-3214	346	15	t	t	NOUN
gs-3214	346	16	cell	cell	NOUN
gs-3214	346	17	therapy	therapy	NOUN
gs-3214	346	18	to	to	ADP
gs-3214	346	19	individual	individual	ADJ
gs-3214	346	20	patients	patient	NOUN
gs-3214	346	21	,	,	PUNCT
gs-3214	346	22	optimizing	optimize	VERB
gs-3214	346	23	treatment	treatment	NOUN
gs-3214	346	24	outcomes	outcome	NOUN
gs-3214	346	25	and	and	CCONJ
gs-3214	346	26	minimizing	minimize	VERB
gs-3214	346	27	potential	potential	ADJ
gs-3214	346	28	risks	risk	NOUN
gs-3214	346	29	.	.	PUNCT
gs-3214	347	1	this	this	DET
gs-3214	347	2	georgian	georgian	NOUN
gs-3214	347	3	scientists/	scientists/	NUM
gs-3214	347	4	.	.	PUNCT
gs-3214	348	1	6	6	NUM
gs-3214	348	2	n	n	NUM
gs-3214	348	3	3	3	NUM
gs-3214	348	4	,	,	PUNCT
gs-3214	348	5	2024	2024	NUM
gs-3214	348	6	280	280	NUM
gs-3214	348	7	personalized	personalized	ADJ
gs-3214	348	8	approach	approach	NOUN
gs-3214	348	9	ensures	ensure	VERB
gs-3214	348	10	that	that	SCONJ
gs-3214	348	11	resources	resource	NOUN
gs-3214	348	12	are	be	AUX
gs-3214	348	13	allocated	allocate	VERB
gs-3214	348	14	efficiently	efficiently	ADV
gs-3214	348	15	and	and	CCONJ
gs-3214	348	16	that	that	SCONJ
gs-3214	348	17	patients	patient	NOUN
gs-3214	348	18	receive	receive	VERB
gs-3214	348	19	the	the	DET
gs-3214	348	20	most	most	ADV
gs-3214	348	21	appropriate	appropriate	ADJ
gs-3214	348	22	and	and	CCONJ
gs-3214	348	23	effective	effective	ADJ
gs-3214	348	24	care	care	NOUN
gs-3214	348	25	for	for	ADP
gs-3214	348	26	their	their	PRON
gs-3214	348	27	specific	specific	ADJ
gs-3214	348	28	circumstances	circumstance	NOUN
gs-3214	348	29	.	.	PUNCT
gs-3214	349	1	multidisciplinary	multidisciplinary	ADJ
gs-3214	349	2	care	care	NOUN
gs-3214	349	3	:	:	PUNCT
gs-3214	349	4	forming	form	VERB
gs-3214	349	5	multidisciplinary	multidisciplinary	ADJ
gs-3214	349	6	teams	team	NOUN
gs-3214	349	7	composed	compose	VERB
gs-3214	349	8	of	of	ADP
gs-3214	349	9	oncologists	oncologist	NOUN
gs-3214	349	10	,	,	PUNCT
gs-3214	349	11	immunologists	immunologist	NOUN
gs-3214	349	12	,	,	PUNCT
gs-3214	349	13	hematologists	hematologist	NOUN
gs-3214	349	14	,	,	PUNCT
gs-3214	349	15	and	and	CCONJ
gs-3214	349	16	supportive	supportive	ADJ
gs-3214	349	17	care	care	NOUN
gs-3214	349	18	specialists	specialist	NOUN
gs-3214	349	19	is	be	AUX
gs-3214	349	20	crucial	crucial	ADJ
gs-3214	349	21	for	for	ADP
gs-3214	349	22	delivering	deliver	VERB
gs-3214	349	23	comprehensive	comprehensive	ADJ
gs-3214	349	24	patient	patient	NOUN
gs-3214	349	25	care	care	NOUN
gs-3214	349	26	throughout	throughout	ADP
gs-3214	349	27	the	the	DET
gs-3214	349	28	car	car	NOUN
gs-3214	349	29	-	-	PUNCT
gs-3214	349	30	t	t	NOUN
gs-3214	349	31	cell	cell	NOUN
gs-3214	349	32	therapy	therapy	NOUN
gs-3214	349	33	journey	journey	NOUN
gs-3214	349	34	.	.	PUNCT
gs-3214	350	1	these	these	DET
gs-3214	350	2	teams	team	NOUN
gs-3214	350	3	collaborate	collaborate	VERB
gs-3214	350	4	to	to	PART
gs-3214	350	5	provide	provide	VERB
gs-3214	350	6	holistic	holistic	ADJ
gs-3214	350	7	care	care	NOUN
gs-3214	350	8	,	,	PUNCT
gs-3214	350	9	including	include	VERB
gs-3214	350	10	preand	preand	VERB
gs-3214	350	11	post	post	ADJ
gs-3214	350	12	-	-	ADJ
gs-3214	350	13	treatment	treatment	ADJ
gs-3214	350	14	monitoring	monitoring	NOUN
gs-3214	350	15	,	,	PUNCT
gs-3214	350	16	management	management	NOUN
gs-3214	350	17	of	of	ADP
gs-3214	350	18	adverse	adverse	ADJ
gs-3214	350	19	events	event	NOUN
gs-3214	350	20	,	,	PUNCT
gs-3214	350	21	and	and	CCONJ
gs-3214	350	22	supportive	supportive	ADJ
gs-3214	350	23	care	care	NOUN
gs-3214	350	24	interventions	intervention	NOUN
gs-3214	350	25	.	.	PUNCT
gs-3214	351	1	by	by	ADP
gs-3214	351	2	leveraging	leverage	VERB
gs-3214	351	3	the	the	DET
gs-3214	351	4	expertise	expertise	NOUN
gs-3214	351	5	of	of	ADP
gs-3214	351	6	various	various	ADJ
gs-3214	351	7	healthcare	healthcare	NOUN
gs-3214	351	8	professionals	professional	NOUN
gs-3214	351	9	,	,	PUNCT
gs-3214	351	10	patients	patient	NOUN
gs-3214	351	11	can	can	AUX
gs-3214	351	12	receive	receive	VERB
gs-3214	351	13	personalized	personalized	ADJ
gs-3214	351	14	and	and	CCONJ
gs-3214	351	15	integrated	integrate	VERB
gs-3214	351	16	care	care	NOUN
gs-3214	351	17	that	that	PRON
gs-3214	351	18	addresses	address	VERB
gs-3214	351	19	their	their	PRON
gs-3214	351	20	unique	unique	ADJ
gs-3214	351	21	needs	need	NOUN
gs-3214	351	22	and	and	CCONJ
gs-3214	351	23	maximizes	maximize	VERB
gs-3214	351	24	treatment	treatment	NOUN
gs-3214	351	25	outcomes	outcome	NOUN
gs-3214	351	26	while	while	SCONJ
gs-3214	351	27	minimizing	minimize	VERB
gs-3214	351	28	complications	complication	NOUN
gs-3214	351	29	.	.	PUNCT
gs-3214	352	1	continued	continue	VERB
gs-3214	352	2	surveillance	surveillance	NOUN
gs-3214	352	3	:	:	PUNCT
gs-3214	352	4	establishing	establish	VERB
gs-3214	352	5	long	long	ADJ
gs-3214	352	6	-	-	PUNCT
gs-3214	352	7	term	term	NOUN
gs-3214	352	8	surveillance	surveillance	NOUN
gs-3214	352	9	programs	program	NOUN
gs-3214	352	10	is	be	AUX
gs-3214	352	11	essential	essential	ADJ
gs-3214	352	12	to	to	PART
gs-3214	352	13	monitor	monitor	VERB
gs-3214	352	14	treatment	treatment	NOUN
gs-3214	352	15	outcomes	outcome	NOUN
gs-3214	352	16	,	,	PUNCT
gs-3214	352	17	late	late	ADJ
gs-3214	352	18	toxicities	toxicity	NOUN
gs-3214	352	19	,	,	PUNCT
gs-3214	352	20	and	and	CCONJ
gs-3214	352	21	relapse	relapse	NOUN
gs-3214	352	22	patterns	pattern	NOUN
gs-3214	352	23	in	in	ADP
gs-3214	352	24	patients	patient	NOUN
gs-3214	352	25	receiving	receive	VERB
gs-3214	352	26	car	car	NOUN
gs-3214	352	27	-	-	PUNCT
gs-3214	352	28	t	t	NOUN
gs-3214	352	29	cell	cell	NOUN
gs-3214	352	30	therapy	therapy	NOUN
gs-3214	352	31	.	.	PUNCT
gs-3214	353	1	this	this	PRON
gs-3214	353	2	involves	involve	VERB
gs-3214	353	3	developing	develop	VERB
gs-3214	353	4	standardized	standardized	ADJ
gs-3214	353	5	monitoring	monitoring	NOUN
gs-3214	353	6	guidelines	guideline	NOUN
gs-3214	353	7	and	and	CCONJ
gs-3214	353	8	establishing	establish	VERB
gs-3214	353	9	registries	registry	NOUN
gs-3214	353	10	to	to	PART
gs-3214	353	11	systematically	systematically	ADV
gs-3214	353	12	collect	collect	VERB
gs-3214	353	13	and	and	CCONJ
gs-3214	353	14	analyses	analyse	VERB
gs-3214	353	15	data	datum	NOUN
gs-3214	353	16	over	over	ADP
gs-3214	353	17	time	time	NOUN
gs-3214	353	18	.	.	PUNCT
gs-3214	354	1	these	these	DET
gs-3214	354	2	programs	program	NOUN
gs-3214	354	3	enable	enable	VERB
gs-3214	354	4	healthcare	healthcare	NOUN
gs-3214	354	5	providers	provider	NOUN
gs-3214	354	6	to	to	PART
gs-3214	354	7	track	track	VERB
gs-3214	354	8	patient	patient	ADJ
gs-3214	354	9	progress	progress	NOUN
gs-3214	354	10	,	,	PUNCT
gs-3214	354	11	identify	identify	VERB
gs-3214	354	12	potential	potential	ADJ
gs-3214	354	13	long	long	ADJ
gs-3214	354	14	-	-	PUNCT
gs-3214	354	15	term	term	NOUN
gs-3214	354	16	effects	effect	NOUN
gs-3214	354	17	of	of	ADP
gs-3214	354	18	therapy	therapy	NOUN
gs-3214	354	19	,	,	PUNCT
gs-3214	354	20	and	and	CCONJ
gs-3214	354	21	optimize	optimize	VERB
gs-3214	354	22	patient	patient	NOUN
gs-3214	354	23	care	care	NOUN
gs-3214	354	24	strategies	strategy	NOUN
gs-3214	354	25	accordingly	accordingly	ADV
gs-3214	354	26	.	.	PUNCT
gs-3214	355	1	by	by	ADP
gs-3214	355	2	implementing	implement	VERB
gs-3214	355	3	robust	robust	ADJ
gs-3214	355	4	surveillance	surveillance	NOUN
gs-3214	355	5	initiatives	initiative	NOUN
gs-3214	355	6	,	,	PUNCT
gs-3214	355	7	we	we	PRON
gs-3214	355	8	can	can	AUX
gs-3214	355	9	ensure	ensure	VERB
gs-3214	355	10	the	the	DET
gs-3214	355	11	ongoing	ongoing	ADJ
gs-3214	355	12	safety	safety	NOUN
gs-3214	355	13	and	and	CCONJ
gs-3214	355	14	effectiveness	effectiveness	NOUN
gs-3214	355	15	of	of	ADP
gs-3214	355	16	car	car	NOUN
gs-3214	355	17	-	-	PUNCT
gs-3214	355	18	t	t	NOUN
gs-3214	355	19	cell	cell	NOUN
gs-3214	355	20	therapy	therapy	NOUN
gs-3214	355	21	and	and	CCONJ
gs-3214	355	22	improve	improve	VERB
gs-3214	355	23	patient	patient	ADJ
gs-3214	355	24	outcomes	outcome	NOUN
gs-3214	355	25	[	[	X
gs-3214	355	26	18	18	NUM
gs-3214	355	27	,	,	PUNCT
gs-3214	355	28	24	24	NUM
gs-3214	355	29	,	,	PUNCT
gs-3214	355	30	61,93	61,93	NOUN
gs-3214	355	31	]	]	X
gs-3214	355	32	.	.	PUNCT
gs-3214	356	1	ensuring	ensure	VERB
gs-3214	356	2	equitable	equitable	ADJ
gs-3214	356	3	access	access	NOUN
gs-3214	356	4	to	to	ADP
gs-3214	356	5	car	car	NOUN
gs-3214	356	6	-	-	PUNCT
gs-3214	356	7	t	t	NOUN
gs-3214	356	8	cell	cell	NOUN
gs-3214	356	9	therapy	therapy	NOUN
gs-3214	356	10	for	for	ADP
gs-3214	356	11	all	all	DET
gs-3214	356	12	eligible	eligible	ADJ
gs-3214	356	13	patients	patient	NOUN
gs-3214	356	14	,	,	PUNCT
gs-3214	356	15	regardless	regardless	ADV
gs-3214	356	16	of	of	ADP
gs-3214	356	17	socioeconomic	socioeconomic	ADJ
gs-3214	356	18	status	status	NOUN
gs-3214	356	19	or	or	CCONJ
gs-3214	356	20	geographical	geographical	ADJ
gs-3214	356	21	location	location	NOUN
gs-3214	356	22	,	,	PUNCT
gs-3214	356	23	is	be	AUX
gs-3214	356	24	crucial	crucial	ADJ
gs-3214	356	25	.	.	PUNCT
gs-3214	357	1	this	this	PRON
gs-3214	357	2	can	can	AUX
gs-3214	357	3	be	be	AUX
gs-3214	357	4	achieved	achieve	VERB
gs-3214	357	5	through	through	ADP
gs-3214	357	6	advocating	advocate	VERB
gs-3214	357	7	for	for	ADP
gs-3214	357	8	innovative	innovative	ADJ
gs-3214	357	9	reimbursement	reimbursement	NOUN
gs-3214	357	10	models	model	NOUN
gs-3214	357	11	and	and	CCONJ
gs-3214	357	12	value	value	NOUN
gs-3214	357	13	-	-	PUNCT
gs-3214	357	14	based	base	VERB
gs-3214	357	15	pricing	pricing	NOUN
gs-3214	357	16	agreements	agreement	NOUN
gs-3214	357	17	that	that	PRON
gs-3214	357	18	align	align	VERB
gs-3214	357	19	the	the	DET
gs-3214	357	20	cost	cost	NOUN
gs-3214	357	21	of	of	ADP
gs-3214	357	22	therapy	therapy	NOUN
gs-3214	357	23	with	with	ADP
gs-3214	357	24	its	its	PRON
gs-3214	357	25	clinical	clinical	ADJ
gs-3214	357	26	benefits	benefit	NOUN
gs-3214	357	27	.	.	PUNCT
gs-3214	358	1	additionally	additionally	ADV
gs-3214	358	2	,	,	PUNCT
gs-3214	358	3	fostering	foster	VERB
gs-3214	358	4	international	international	ADJ
gs-3214	358	5	collaborations	collaboration	NOUN
gs-3214	358	6	and	and	CCONJ
gs-3214	358	7	sharing	share	VERB
gs-3214	358	8	best	good	ADJ
gs-3214	358	9	practices	practice	NOUN
gs-3214	358	10	can	can	AUX
gs-3214	358	11	help	help	VERB
gs-3214	358	12	address	address	VERB
gs-3214	358	13	disparities	disparity	NOUN
gs-3214	358	14	in	in	ADP
gs-3214	358	15	access	access	NOUN
gs-3214	358	16	and	and	CCONJ
gs-3214	358	17	affordability	affordability	NOUN
gs-3214	358	18	.	.	PUNCT
gs-3214	359	1	by	by	ADP
gs-3214	359	2	prioritizing	prioritize	VERB
gs-3214	359	3	patient	patient	NOUN
gs-3214	359	4	needs	need	NOUN
gs-3214	359	5	and	and	CCONJ
gs-3214	359	6	promoting	promote	VERB
gs-3214	359	7	fair	fair	ADJ
gs-3214	359	8	distribution	distribution	NOUN
gs-3214	359	9	of	of	ADP
gs-3214	359	10	resources	resource	NOUN
gs-3214	359	11	,	,	PUNCT
gs-3214	359	12	we	we	PRON
gs-3214	359	13	can	can	AUX
gs-3214	359	14	work	work	VERB
gs-3214	359	15	towards	towards	ADP
gs-3214	359	16	making	make	VERB
gs-3214	359	17	car	car	NOUN
gs-3214	359	18	-	-	PUNCT
gs-3214	359	19	t	t	NOUN
gs-3214	359	20	cell	cell	NOUN
gs-3214	359	21	therapy	therapy	NOUN
gs-3214	359	22	accessible	accessible	ADJ
gs-3214	359	23	to	to	ADP
gs-3214	359	24	all	all	PRON
gs-3214	359	25	who	who	PRON
gs-3214	359	26	can	can	AUX
gs-3214	359	27	benefit	benefit	VERB
gs-3214	359	28	from	from	ADP
gs-3214	359	29	it	it	PRON
gs-3214	359	30	[	[	X
gs-3214	359	31	24,37,62	24,37,62	NUM
gs-3214	359	32	]	]	PUNCT
gs-3214	359	33	.	.	PUNCT
gs-3214	360	1	regulatory	regulatory	ADJ
gs-3214	360	2	harmonization	harmonization	NOUN
gs-3214	360	3	aims	aim	VERB
gs-3214	360	4	to	to	PART
gs-3214	360	5	streamline	streamline	VERB
gs-3214	360	6	and	and	CCONJ
gs-3214	360	7	unify	unify	VERB
gs-3214	360	8	approval	approval	NOUN
gs-3214	360	9	pathways	pathway	NOUN
gs-3214	360	10	for	for	ADP
gs-3214	360	11	car	car	NOUN
gs-3214	360	12	-	-	PUNCT
gs-3214	360	13	t	t	NOUN
gs-3214	360	14	cell	cell	NOUN
gs-3214	360	15	therapies	therapy	NOUN
gs-3214	360	16	worldwide	worldwide	ADV
gs-3214	360	17	,	,	PUNCT
gs-3214	360	18	facilitating	facilitate	VERB
gs-3214	360	19	their	their	PRON
gs-3214	360	20	efficient	efficient	ADJ
gs-3214	360	21	evaluation	evaluation	NOUN
gs-3214	360	22	and	and	CCONJ
gs-3214	360	23	availability	availability	NOUN
gs-3214	360	24	.	.	PUNCT
gs-3214	361	1	this	this	DET
gs-3214	361	2	process	process	NOUN
gs-3214	361	3	ensures	ensure	VERB
gs-3214	361	4	consistent	consistent	ADJ
gs-3214	361	5	standards	standard	NOUN
gs-3214	361	6	for	for	ADP
gs-3214	361	7	safety	safety	NOUN
gs-3214	361	8	monitoring	monitoring	NOUN
gs-3214	361	9	and	and	CCONJ
gs-3214	361	10	oversight	oversight	NOUN
gs-3214	361	11	to	to	PART
gs-3214	361	12	safeguard	safeguard	VERB
gs-3214	361	13	patient	patient	ADJ
gs-3214	361	14	well	well	ADV
gs-3214	361	15	-	-	PUNCT
gs-3214	361	16	being	being	NOUN
gs-3214	361	17	.	.	PUNCT
gs-3214	362	1	by	by	ADP
gs-3214	362	2	promoting	promote	VERB
gs-3214	362	3	collaboration	collaboration	NOUN
gs-3214	362	4	among	among	ADP
gs-3214	362	5	regulatory	regulatory	ADJ
gs-3214	362	6	agencies	agency	NOUN
gs-3214	362	7	and	and	CCONJ
gs-3214	362	8	adhering	adhere	VERB
gs-3214	362	9	to	to	PART
gs-3214	362	10	stringent	stringent	VERB
gs-3214	362	11	safety	safety	NOUN
gs-3214	362	12	protocols	protocol	NOUN
gs-3214	362	13	,	,	PUNCT
gs-3214	362	14	regulatory	regulatory	ADJ
gs-3214	362	15	harmonization	harmonization	NOUN
gs-3214	362	16	accelerates	accelerate	VERB
gs-3214	362	17	the	the	DET
gs-3214	362	18	delivery	delivery	NOUN
gs-3214	362	19	of	of	ADP
gs-3214	362	20	innovative	innovative	ADJ
gs-3214	362	21	therapies	therapy	NOUN
gs-3214	362	22	to	to	ADP
gs-3214	362	23	patients	patient	NOUN
gs-3214	362	24	while	while	SCONJ
gs-3214	362	25	maintaining	maintain	VERB
gs-3214	362	26	rigorous	rigorous	ADJ
gs-3214	362	27	standards	standard	NOUN
gs-3214	362	28	for	for	ADP
gs-3214	362	29	efficacy	efficacy	NOUN
gs-3214	362	30	and	and	CCONJ
gs-3214	362	31	safety	safety	NOUN
gs-3214	362	32	[	[	X
gs-3214	362	33	84	84	NUM
gs-3214	362	34	-	-	SYM
gs-3214	362	35	85	85	NUM
gs-3214	362	36	]	]	PUNCT
gs-3214	362	37	.	.	PUNCT
gs-3214	363	1	the	the	DET
gs-3214	363	2	future	future	NOUN
gs-3214	363	3	of	of	ADP
gs-3214	363	4	car	car	NOUN
gs-3214	363	5	-	-	PUNCT
gs-3214	363	6	t	t	NOUN
gs-3214	363	7	cell	cell	NOUN
gs-3214	363	8	therapy	therapy	NOUN
gs-3214	363	9	presents	present	VERB
gs-3214	363	10	exciting	exciting	ADJ
gs-3214	363	11	possibilities	possibility	NOUN
gs-3214	363	12	for	for	ADP
gs-3214	363	13	advancing	advance	VERB
gs-3214	363	14	the	the	DET
gs-3214	363	15	field	field	NOUN
gs-3214	363	16	and	and	CCONJ
gs-3214	363	17	enhancing	enhance	VERB
gs-3214	363	18	patient	patient	ADJ
gs-3214	363	19	outcomes	outcome	NOUN
gs-3214	363	20	.	.	PUNCT
gs-3214	364	1	next	next	ADJ
gs-3214	364	2	-	-	PUNCT
gs-3214	364	3	generation	generation	NOUN
gs-3214	364	4	car	car	NOUN
gs-3214	364	5	-	-	PUNCT
gs-3214	364	6	t	t	NOUN
gs-3214	364	7	cell	cell	NOUN
gs-3214	364	8	therapies	therapy	NOUN
gs-3214	364	9	,	,	PUNCT
gs-3214	364	10	combined	combined	ADJ
gs-3214	364	11	treatment	treatment	NOUN
gs-3214	364	12	strategies	strategy	NOUN
gs-3214	364	13	,	,	PUNCT
gs-3214	364	14	gene	gene	NOUN
gs-3214	364	15	editing	editing	NOUN
gs-3214	364	16	technologies	technology	NOUN
gs-3214	364	17	,	,	PUNCT
gs-3214	364	18	and	and	CCONJ
gs-3214	364	19	the	the	DET
gs-3214	364	20	integration	integration	NOUN
gs-3214	364	21	of	of	ADP
gs-3214	364	22	ai	ai	ADJ
gs-3214	364	23	-	-	PUNCT
gs-3214	364	24	driven	drive	VERB
gs-3214	364	25	predictive	predictive	NOUN
gs-3214	364	26	modelling	modelling	NOUN
gs-3214	364	27	offer	offer	VERB
gs-3214	364	28	the	the	DET
gs-3214	364	29	potential	potential	NOUN
gs-3214	364	30	to	to	PART
gs-3214	364	31	revolutionize	revolutionize	VERB
gs-3214	364	32	cancer	cancer	NOUN
gs-3214	364	33	treatment	treatment	NOUN
gs-3214	364	34	.	.	PUNCT
gs-3214	365	1	these	these	DET
gs-3214	365	2	innovations	innovation	NOUN
gs-3214	365	3	bring	bring	VERB
gs-3214	365	4	us	we	PRON
gs-3214	365	5	closer	close	ADV
gs-3214	365	6	to	to	ADP
gs-3214	365	7	the	the	DET
gs-3214	365	8	aspiration	aspiration	NOUN
gs-3214	365	9	of	of	ADP
gs-3214	365	10	achieving	achieve	VERB
gs-3214	365	11	lasting	lasting	ADJ
gs-3214	365	12	remissions	remission	NOUN
gs-3214	365	13	and	and	CCONJ
gs-3214	365	14	potential	potential	ADJ
gs-3214	365	15	cures	cure	NOUN
gs-3214	365	16	for	for	ADP
gs-3214	365	17	individuals	individual	NOUN
gs-3214	365	18	facing	face	VERB
gs-3214	365	19	refractory	refractory	NOUN
gs-3214	365	20	malignancies	malignancy	NOUN
gs-3214	365	21	[	[	X
gs-3214	365	22	86	86	NUM
gs-3214	365	23	-	-	SYM
gs-3214	365	24	88	88	NUM
gs-3214	365	25	]	]	PUNCT
gs-3214	365	26	.	.	PUNCT
gs-3214	366	1	in	in	ADP
gs-3214	366	2	the	the	DET
gs-3214	366	3	rapidly	rapidly	ADV
gs-3214	366	4	evolving	evolve	VERB
gs-3214	366	5	landscape	landscape	NOUN
gs-3214	366	6	of	of	ADP
gs-3214	366	7	chimeric	chimeric	ADJ
gs-3214	366	8	antigen	antigen	ADJ
gs-3214	366	9	receptor	receptor	NOUN
gs-3214	366	10	(	(	PUNCT
gs-3214	366	11	car	car	NOUN
gs-3214	366	12	)	)	PUNCT
gs-3214	366	13	t	t	NOUN
gs-3214	366	14	cell	cell	NOUN
gs-3214	366	15	therapy	therapy	NOUN
gs-3214	366	16	,	,	PUNCT
gs-3214	366	17	the	the	DET
gs-3214	366	18	journey	journey	NOUN
gs-3214	366	19	from	from	ADP
gs-3214	366	20	bench	bench	NOUN
gs-3214	366	21	to	to	ADP
gs-3214	366	22	bedside	bedside	NOUN
gs-3214	366	23	has	have	AUX
gs-3214	366	24	yielded	yield	VERB
gs-3214	366	25	remarkable	remarkable	ADJ
gs-3214	366	26	advancements	advancement	NOUN
gs-3214	366	27	and	and	CCONJ
gs-3214	366	28	transformative	transformative	VERB
gs-3214	366	29	outcomes	outcome	NOUN
gs-3214	366	30	for	for	ADP
gs-3214	366	31	patients	patient	NOUN
gs-3214	366	32	with	with	ADP
gs-3214	366	33	hematologic	hematologic	ADJ
gs-3214	366	34	malignancies	malignancy	NOUN
gs-3214	366	35	and	and	CCONJ
gs-3214	366	36	solid	solid	ADJ
gs-3214	366	37	tumors	tumor	NOUN
gs-3214	366	38	.	.	PUNCT
gs-3214	367	1	georgian	georgian	NOUN
gs-3214	367	2	scientists/	scientists/	NUM
gs-3214	367	3	.	.	PUNCT
gs-3214	368	1	6	6	NUM
gs-3214	368	2	n	n	NUM
gs-3214	368	3	3	3	NUM
gs-3214	368	4	,	,	PUNCT
gs-3214	368	5	2024	2024	NUM
gs-3214	368	6	281	281	NUM
gs-3214	368	7	car	car	NOUN
gs-3214	368	8	-	-	PUNCT
gs-3214	368	9	t	t	NOUN
gs-3214	368	10	cell	cell	NOUN
gs-3214	368	11	therapy	therapy	NOUN
gs-3214	368	12	has	have	AUX
gs-3214	368	13	revolutionized	revolutionize	VERB
gs-3214	368	14	cancer	cancer	NOUN
gs-3214	368	15	treatment	treatment	NOUN
gs-3214	368	16	by	by	ADP
gs-3214	368	17	harnessing	harness	VERB
gs-3214	368	18	the	the	DET
gs-3214	368	19	power	power	NOUN
gs-3214	368	20	of	of	ADP
gs-3214	368	21	the	the	DET
gs-3214	368	22	immune	immune	ADJ
gs-3214	368	23	system	system	NOUN
gs-3214	368	24	to	to	PART
gs-3214	368	25	target	target	VERB
gs-3214	368	26	and	and	CCONJ
gs-3214	368	27	eliminate	eliminate	VERB
gs-3214	368	28	tumor	tumor	NOUN
gs-3214	368	29	cells	cell	NOUN
gs-3214	368	30	.	.	PUNCT
gs-3214	369	1	clinical	clinical	ADJ
gs-3214	369	2	trials	trial	NOUN
gs-3214	369	3	have	have	AUX
gs-3214	369	4	demonstrated	demonstrate	VERB
gs-3214	369	5	unprecedented	unprecedented	ADJ
gs-3214	369	6	response	response	NOUN
gs-3214	369	7	rates	rate	NOUN
gs-3214	369	8	and	and	CCONJ
gs-3214	369	9	durable	durable	ADJ
gs-3214	369	10	remissions	remission	NOUN
gs-3214	369	11	in	in	ADP
gs-3214	369	12	patients	patient	NOUN
gs-3214	369	13	with	with	ADP
gs-3214	369	14	relapsed	relapse	VERB
gs-3214	369	15	/	/	SYM
gs-3214	369	16	refractory	refractory	NOUN
gs-3214	369	17	hematologic	hematologic	NOUN
gs-3214	369	18	malignancies	malignancy	NOUN
gs-3214	369	19	,	,	PUNCT
gs-3214	369	20	particularly	particularly	ADV
gs-3214	369	21	b	b	X
gs-3214	369	22	-	-	PUNCT
gs-3214	369	23	cell	cell	NOUN
gs-3214	369	24	acute	acute	ADJ
gs-3214	369	25	lymphoblastic	lymphoblastic	ADJ
gs-3214	369	26	leukemia	leukemia	NOUN
gs-3214	369	27	(	(	PUNCT
gs-3214	369	28	all	all	ADV
gs-3214	369	29	)	)	PUNCT
gs-3214	369	30	,	,	PUNCT
gs-3214	369	31	diffuse	diffuse	VERB
gs-3214	369	32	large	large	ADJ
gs-3214	369	33	b	b	NOUN
gs-3214	369	34	-	-	PUNCT
gs-3214	369	35	cell	cell	NOUN
gs-3214	369	36	lymphoma	lymphoma	NOUN
gs-3214	369	37	(	(	PUNCT
gs-3214	369	38	dlbcl	dlbcl	NOUN
gs-3214	369	39	)	)	PUNCT
gs-3214	369	40	,	,	PUNCT
gs-3214	369	41	and	and	CCONJ
gs-3214	369	42	multiple	multiple	ADJ
gs-3214	369	43	myeloma	myeloma	NOUN
gs-3214	369	44	.	.	PUNCT
gs-3214	370	1	additionally	additionally	ADV
gs-3214	370	2	,	,	PUNCT
gs-3214	370	3	emerging	emerge	VERB
gs-3214	370	4	data	datum	NOUN
gs-3214	370	5	from	from	ADP
gs-3214	370	6	early	early	ADJ
gs-3214	370	7	-	-	PUNCT
gs-3214	370	8	phase	phase	NOUN
gs-3214	370	9	trials	trial	NOUN
gs-3214	370	10	in	in	ADP
gs-3214	370	11	solid	solid	ADJ
gs-3214	370	12	tumors	tumor	NOUN
gs-3214	370	13	show	show	VERB
gs-3214	370	14	promising	promising	ADJ
gs-3214	370	15	signs	sign	NOUN
gs-3214	370	16	of	of	ADP
gs-3214	370	17	efficacy	efficacy	NOUN
gs-3214	370	18	,	,	PUNCT
gs-3214	370	19	although	although	SCONJ
gs-3214	370	20	challenges	challenge	NOUN
gs-3214	370	21	such	such	ADJ
gs-3214	370	22	as	as	ADP
gs-3214	370	23	tumor	tumor	NOUN
gs-3214	370	24	heterogeneity	heterogeneity	NOUN
gs-3214	370	25	,	,	PUNCT
gs-3214	370	26	antigen	antigen	ADJ
gs-3214	370	27	escape	escape	NOUN
gs-3214	370	28	,	,	PUNCT
gs-3214	370	29	and	and	CCONJ
gs-3214	370	30	immunosuppressive	immunosuppressive	ADJ
gs-3214	370	31	micro	micro	NOUN
gs-3214	370	32	-	-	NOUN
gs-3214	370	33	environments	environment	NOUN
gs-3214	370	34	persist	persist	NOUN
gs-3214	370	35	.	.	PUNCT
gs-3214	371	1	safety	safety	NOUN
gs-3214	371	2	concerns	concern	NOUN
gs-3214	371	3	,	,	PUNCT
gs-3214	371	4	including	include	VERB
gs-3214	371	5	cytokine	cytokine	ADJ
gs-3214	371	6	release	release	NOUN
gs-3214	371	7	syndrome	syndrome	NOUN
gs-3214	371	8	(	(	PUNCT
gs-3214	371	9	crs	crs	PROPN
gs-3214	371	10	)	)	PUNCT
gs-3214	371	11	,	,	PUNCT
gs-3214	371	12	neurotoxicity	neurotoxicity	NOUN
gs-3214	371	13	,	,	PUNCT
gs-3214	371	14	and	and	CCONJ
gs-3214	371	15	on	on	ADP
gs-3214	371	16	-	-	PUNCT
gs-3214	371	17	target	target	VERB
gs-3214	371	18	/	/	SYM
gs-3214	371	19	off	off	ADP
gs-3214	371	20	-	-	PUNCT
gs-3214	371	21	tumor	tumor	NOUN
gs-3214	371	22	toxicities	toxicity	NOUN
gs-3214	371	23	,	,	PUNCT
gs-3214	371	24	have	have	AUX
gs-3214	371	25	been	be	AUX
gs-3214	371	26	mitigated	mitigate	VERB
gs-3214	371	27	through	through	ADP
gs-3214	371	28	improved	improve	VERB
gs-3214	371	29	patient	patient	ADJ
gs-3214	371	30	monitoring	monitoring	NOUN
gs-3214	371	31	,	,	PUNCT
gs-3214	371	32	management	management	NOUN
gs-3214	371	33	algorithms	algorithm	NOUN
gs-3214	371	34	,	,	PUNCT
gs-3214	371	35	and	and	CCONJ
gs-3214	371	36	the	the	DET
gs-3214	371	37	development	development	NOUN
gs-3214	371	38	of	of	ADP
gs-3214	371	39	novel	novel	ADJ
gs-3214	371	40	safety	safety	NOUN
gs-3214	371	41	switches	switch	NOUN
gs-3214	371	42	.	.	PUNCT
gs-3214	372	1	despite	despite	SCONJ
gs-3214	372	2	the	the	DET
gs-3214	372	3	remarkable	remarkable	ADJ
gs-3214	372	4	successes	success	NOUN
gs-3214	372	5	of	of	ADP
gs-3214	372	6	car	car	NOUN
gs-3214	372	7	-	-	PUNCT
gs-3214	372	8	t	t	NOUN
gs-3214	372	9	cell	cell	NOUN
gs-3214	372	10	therapy	therapy	NOUN
gs-3214	372	11	,	,	PUNCT
gs-3214	372	12	several	several	ADJ
gs-3214	372	13	limitations	limitation	NOUN
gs-3214	372	14	and	and	CCONJ
gs-3214	372	15	challenges	challenge	NOUN
gs-3214	372	16	remain	remain	VERB
gs-3214	372	17	.	.	PUNCT
gs-3214	373	1	these	these	PRON
gs-3214	373	2	include	include	VERB
gs-3214	373	3	the	the	DET
gs-3214	373	4	limited	limited	ADJ
gs-3214	373	5	durability	durability	NOUN
gs-3214	373	6	of	of	ADP
gs-3214	373	7	responses	response	NOUN
gs-3214	373	8	in	in	ADP
gs-3214	373	9	some	some	DET
gs-3214	373	10	patients	patient	NOUN
gs-3214	373	11	,	,	PUNCT
gs-3214	373	12	the	the	DET
gs-3214	373	13	development	development	NOUN
gs-3214	373	14	of	of	ADP
gs-3214	373	15	resistance	resistance	NOUN
gs-3214	373	16	mechanisms	mechanism	NOUN
gs-3214	373	17	,	,	PUNCT
gs-3214	373	18	and	and	CCONJ
gs-3214	373	19	the	the	DET
gs-3214	373	20	need	need	NOUN
gs-3214	373	21	for	for	ADP
gs-3214	373	22	optimization	optimization	NOUN
gs-3214	373	23	of	of	ADP
gs-3214	373	24	manufacturing	manufacturing	NOUN
gs-3214	373	25	processes	process	NOUN
gs-3214	373	26	to	to	PART
gs-3214	373	27	ensure	ensure	VERB
gs-3214	373	28	scalability	scalability	NOUN
gs-3214	373	29	and	and	CCONJ
gs-3214	373	30	costeffectiveness	costeffectiveness	NOUN
gs-3214	373	31	.	.	PUNCT
gs-3214	374	1	future	future	ADJ
gs-3214	374	2	research	research	NOUN
gs-3214	374	3	efforts	effort	NOUN
gs-3214	374	4	should	should	AUX
gs-3214	374	5	focus	focus	VERB
gs-3214	374	6	on	on	ADP
gs-3214	374	7	refining	refine	VERB
gs-3214	374	8	car	car	NOUN
gs-3214	374	9	-	-	PUNCT
gs-3214	374	10	t	t	NOUN
gs-3214	374	11	cell	cell	NOUN
gs-3214	374	12	designs	design	NOUN
gs-3214	374	13	,	,	PUNCT
gs-3214	374	14	enhancing	enhance	VERB
gs-3214	374	15	persistence	persistence	NOUN
gs-3214	374	16	and	and	CCONJ
gs-3214	374	17	memory	memory	NOUN
gs-3214	374	18	formation	formation	NOUN
gs-3214	374	19	,	,	PUNCT
gs-3214	374	20	exploring	explore	VERB
gs-3214	374	21	combination	combination	NOUN
gs-3214	374	22	strategies	strategy	NOUN
gs-3214	374	23	with	with	ADP
gs-3214	374	24	other	other	ADJ
gs-3214	374	25	immunotherapies	immunotherapy	NOUN
gs-3214	374	26	and	and	CCONJ
gs-3214	374	27	targeted	target	VERB
gs-3214	374	28	agents	agent	NOUN
gs-3214	374	29	,	,	PUNCT
gs-3214	374	30	and	and	CCONJ
gs-3214	374	31	identifying	identify	VERB
gs-3214	374	32	predictive	predictive	ADJ
gs-3214	374	33	biomarkers	biomarker	NOUN
gs-3214	374	34	to	to	PART
gs-3214	374	35	guide	guide	VERB
gs-3214	374	36	patient	patient	ADJ
gs-3214	374	37	selection	selection	NOUN
gs-3214	374	38	and	and	CCONJ
gs-3214	374	39	treatment	treatment	NOUN
gs-3214	374	40	algorithms	algorithm	NOUN
gs-3214	374	41	[	[	X
gs-3214	374	42	89	89	NUM
gs-3214	374	43	-	-	SYM
gs-3214	374	44	92	92	NUM
gs-3214	374	45	]	]	PUNCT
gs-3214	374	46	.	.	PUNCT
gs-3214	375	1	cytokine	cytokine	ADJ
gs-3214	375	2	release	release	NOUN
gs-3214	375	3	syndrome	syndrome	NOUN
gs-3214	375	4	(	(	PUNCT
gs-3214	375	5	crs	crs	PROPN
gs-3214	375	6	)	)	PUNCT
gs-3214	375	7	is	be	AUX
gs-3214	375	8	a	a	DET
gs-3214	375	9	systemic	systemic	ADJ
gs-3214	375	10	inflammatory	inflammatory	ADJ
gs-3214	375	11	response	response	NOUN
gs-3214	375	12	initiated	initiate	VERB
gs-3214	375	13	by	by	ADP
gs-3214	375	14	the	the	DET
gs-3214	375	15	activation	activation	NOUN
gs-3214	375	16	of	of	ADP
gs-3214	375	17	car	car	NOUN
gs-3214	375	18	-	-	PUNCT
gs-3214	375	19	t	t	NOUN
gs-3214	375	20	cells	cell	NOUN
gs-3214	375	21	.	.	PUNCT
gs-3214	376	1	upon	upon	SCONJ
gs-3214	376	2	encountering	encounter	VERB
gs-3214	376	3	target	target	NOUN
gs-3214	376	4	antigens	antigen	NOUN
gs-3214	376	5	,	,	PUNCT
gs-3214	376	6	car	car	NOUN
gs-3214	376	7	-	-	PUNCT
gs-3214	376	8	t	t	NOUN
gs-3214	376	9	cells	cell	NOUN
gs-3214	376	10	rapidly	rapidly	ADV
gs-3214	376	11	proliferate	proliferate	VERB
gs-3214	376	12	,	,	PUNCT
gs-3214	376	13	releasing	release	VERB
gs-3214	376	14	a	a	DET
gs-3214	376	15	cascade	cascade	NOUN
gs-3214	376	16	of	of	ADP
gs-3214	376	17	pro	pro	ADJ
gs-3214	376	18	-	-	ADJ
gs-3214	376	19	inflammatory	inflammatory	ADJ
gs-3214	376	20	cytokines	cytokine	NOUN
gs-3214	376	21	,	,	PUNCT
gs-3214	376	22	including	include	VERB
gs-3214	376	23	interleukin-6	interleukin-6	NUM
gs-3214	376	24	(	(	PUNCT
gs-3214	376	25	il-6	il-6	NUM
gs-3214	376	26	)	)	PUNCT
gs-3214	376	27	,	,	PUNCT
gs-3214	376	28	interferon	interferon	NOUN
gs-3214	376	29	-	-	PUNCT
gs-3214	376	30	gamma	gamma	NOUN
gs-3214	376	31	(	(	PUNCT
gs-3214	376	32	ifn	ifn	PROPN
gs-3214	376	33	)	)	PUNCT
gs-3214	376	34	,	,	PUNCT
gs-3214	376	35	and	and	CCONJ
gs-3214	376	36	tumor	tumor	NOUN
gs-3214	376	37	necrosis	necrosis	NOUN
gs-3214	376	38	factor	factor	NOUN
gs-3214	376	39	-	-	PUNCT
gs-3214	376	40	alpha	alpha	NOUN
gs-3214	376	41	(	(	PUNCT
gs-3214	376	42	tnf	tnf	PROPN
gs-3214	376	43	)	)	PUNCT
gs-3214	376	44	.	.	PUNCT
gs-3214	377	1	this	this	DET
gs-3214	377	2	activation	activation	NOUN
gs-3214	377	3	sets	set	VERB
gs-3214	377	4	off	off	ADP
gs-3214	377	5	a	a	DET
gs-3214	377	6	complex	complex	ADJ
gs-3214	377	7	signaling	signal	VERB
gs-3214	377	8	network	network	NOUN
gs-3214	377	9	that	that	PRON
gs-3214	377	10	contributes	contribute	VERB
gs-3214	377	11	to	to	ADP
gs-3214	377	12	the	the	DET
gs-3214	377	13	subsequent	subsequent	ADJ
gs-3214	377	14	clinical	clinical	ADJ
gs-3214	377	15	manifestations	manifestation	NOUN
gs-3214	377	16	of	of	ADP
gs-3214	377	17	crs	crs	PROPN
gs-3214	377	18	.	.	PUNCT
gs-3214	378	1	future	future	ADJ
gs-3214	378	2	perspectives	perspective	NOUN
gs-3214	378	3	:	:	PUNCT
gs-3214	378	4	the	the	DET
gs-3214	378	5	future	future	NOUN
gs-3214	378	6	of	of	ADP
gs-3214	378	7	car	car	NOUN
gs-3214	378	8	-	-	PUNCT
gs-3214	378	9	t	t	NOUN
gs-3214	378	10	cell	cell	NOUN
gs-3214	378	11	therapy	therapy	NOUN
gs-3214	378	12	lies	lie	VERB
gs-3214	378	13	in	in	ADP
gs-3214	378	14	addressing	address	VERB
gs-3214	378	15	the	the	DET
gs-3214	378	16	current	current	ADJ
gs-3214	378	17	limitations	limitation	NOUN
gs-3214	378	18	:	:	PUNCT
gs-3214	378	19	1	1	X
gs-3214	378	20	.	.	NUM
gs-3214	378	21	improved	improved	ADJ
gs-3214	378	22	design	design	NOUN
gs-3214	378	23	:	:	PUNCT
gs-3214	378	24	fourthand	fourthand	NOUN
gs-3214	378	25	fifth	fifth	ADJ
gs-3214	378	26	-	-	PUNCT
gs-3214	378	27	generation	generation	NOUN
gs-3214	378	28	cars	car	NOUN
gs-3214	378	29	integrating	integrate	VERB
gs-3214	378	30	costimulatory	costimulatory	NOUN
gs-3214	378	31	signals	signal	NOUN
gs-3214	378	32	or	or	CCONJ
gs-3214	378	33	suicide	suicide	NOUN
gs-3214	378	34	switches	switch	NOUN
gs-3214	378	35	.	.	PUNCT
gs-3214	379	1	universal	universal	ADJ
gs-3214	379	2	car	car	NOUN
gs-3214	379	3	-	-	PUNCT
gs-3214	379	4	t	t	NOUN
gs-3214	379	5	cells	cell	NOUN
gs-3214	379	6	to	to	PART
gs-3214	379	7	target	target	VERB
gs-3214	379	8	multiple	multiple	ADJ
gs-3214	379	9	antigens	antigen	NOUN
gs-3214	379	10	.	.	PUNCT
gs-3214	380	1	2	2	X
gs-3214	380	2	.	.	NOUN
gs-3214	380	3	combination	combination	NOUN
gs-3214	380	4	strategies	strategy	NOUN
gs-3214	380	5	:	:	PUNCT
gs-3214	380	6	combining	combine	VERB
gs-3214	380	7	car	car	NOUN
gs-3214	380	8	-	-	PUNCT
gs-3214	380	9	t	t	NOUN
gs-3214	380	10	cells	cell	NOUN
gs-3214	380	11	with	with	ADP
gs-3214	380	12	checkpoint	checkpoint	NOUN
gs-3214	380	13	inhibitors	inhibitor	NOUN
gs-3214	380	14	,	,	PUNCT
gs-3214	380	15	oncolytic	oncolytic	ADJ
gs-3214	380	16	viruses	virus	NOUN
gs-3214	380	17	,	,	PUNCT
gs-3214	380	18	or	or	CCONJ
gs-3214	380	19	chemotherapy	chemotherapy	NOUN
gs-3214	380	20	to	to	PART
gs-3214	380	21	enhance	enhance	VERB
gs-3214	380	22	efficacy	efficacy	NOUN
gs-3214	380	23	in	in	ADP
gs-3214	380	24	solid	solid	ADJ
gs-3214	380	25	tumors	tumor	NOUN
gs-3214	380	26	.	.	PUNCT
gs-3214	381	1	3	3	X
gs-3214	381	2	.	.	X
gs-3214	381	3	gene	gene	NOUN
gs-3214	381	4	editing	editing	NOUN
gs-3214	381	5	:	:	PUNCT
gs-3214	381	6	crispr	crispr	ADJ
gs-3214	381	7	-	-	PUNCT
gs-3214	381	8	cas9	cas9	NOUN
gs-3214	381	9	technology	technology	NOUN
gs-3214	381	10	to	to	PART
gs-3214	381	11	improve	improve	VERB
gs-3214	381	12	specificity	specificity	NOUN
gs-3214	381	13	,	,	PUNCT
gs-3214	381	14	enhance	enhance	VERB
gs-3214	381	15	persistence	persistence	NOUN
gs-3214	381	16	,	,	PUNCT
gs-3214	381	17	and	and	CCONJ
gs-3214	381	18	reduce	reduce	VERB
gs-3214	381	19	off	off	ADP
gs-3214	381	20	-	-	PUNCT
gs-3214	381	21	target	target	NOUN
gs-3214	381	22	effects	effect	NOUN
gs-3214	381	23	.	.	PUNCT
gs-3214	382	1	4	4	X
gs-3214	382	2	.	.	X
gs-3214	382	3	artificial	artificial	ADJ
gs-3214	382	4	intelligence	intelligence	NOUN
gs-3214	382	5	and	and	CCONJ
gs-3214	382	6	computational	computational	ADJ
gs-3214	382	7	biology	biology	NOUN
gs-3214	382	8	:	:	PUNCT
gs-3214	382	9	optimizing	optimize	VERB
gs-3214	382	10	car	car	NOUN
gs-3214	382	11	design	design	NOUN
gs-3214	382	12	,	,	PUNCT
gs-3214	382	13	predicting	predict	VERB
gs-3214	382	14	adverse	adverse	ADJ
gs-3214	382	15	effects	effect	NOUN
gs-3214	382	16	,	,	PUNCT
gs-3214	382	17	and	and	CCONJ
gs-3214	382	18	improving	improve	VERB
gs-3214	382	19	patient	patient	ADJ
gs-3214	382	20	selection	selection	NOUN
gs-3214	382	21	through	through	ADP
gs-3214	382	22	datadriven	datadriven	ADJ
gs-3214	382	23	approaches	approach	NOUN
gs-3214	382	24	.	.	PUNCT
gs-3214	383	1	chimeric	chimeric	ADJ
gs-3214	383	2	antigen	antigen	ADJ
gs-3214	383	3	receptor	receptor	NOUN
gs-3214	383	4	t	t	NOUN
gs-3214	383	5	-	-	PUNCT
gs-3214	383	6	cell	cell	NOUN
gs-3214	383	7	(	(	PUNCT
gs-3214	383	8	car	car	NOUN
gs-3214	383	9	-	-	PUNCT
gs-3214	383	10	t	t	PROPN
gs-3214	383	11	)	)	PUNCT
gs-3214	383	12	therapy	therapy	NOUN
gs-3214	383	13	represents	represent	VERB
gs-3214	383	14	a	a	DET
gs-3214	383	15	transformative	transformative	ADJ
gs-3214	383	16	approach	approach	NOUN
gs-3214	383	17	in	in	ADP
gs-3214	383	18	immunotherapy	immunotherapy	NOUN
gs-3214	383	19	,	,	PUNCT
gs-3214	383	20	offering	offer	VERB
gs-3214	383	21	new	new	ADJ
gs-3214	383	22	hope	hope	NOUN
gs-3214	383	23	for	for	ADP
gs-3214	383	24	patients	patient	NOUN
gs-3214	383	25	with	with	ADP
gs-3214	383	26	hematologic	hematologic	NOUN
gs-3214	383	27	malignancies	malignancy	NOUN
gs-3214	383	28	and	and	CCONJ
gs-3214	383	29	beyond	beyond	ADP
gs-3214	383	30	.	.	PUNCT
gs-3214	384	1	this	this	DET
gs-3214	384	2	article	article	NOUN
gs-3214	384	3	explores	explore	VERB
gs-3214	384	4	the	the	DET
gs-3214	384	5	key	key	ADJ
gs-3214	384	6	scientific	scientific	ADJ
gs-3214	384	7	and	and	CCONJ
gs-3214	384	8	clinical	clinical	ADJ
gs-3214	384	9	features	feature	NOUN
gs-3214	384	10	of	of	ADP
gs-3214	384	11	car	car	NOUN
gs-3214	384	12	-	-	PUNCT
gs-3214	384	13	t	t	NOUN
gs-3214	384	14	cells	cell	NOUN
gs-3214	384	15	,	,	PUNCT
gs-3214	384	16	focusing	focus	VERB
gs-3214	384	17	on	on	ADP
gs-3214	384	18	their	their	PRON
gs-3214	384	19	design	design	NOUN
gs-3214	384	20	,	,	PUNCT
gs-3214	384	21	georgian	georgian	NOUN
gs-3214	384	22	scientists/	scientists/	NUM
gs-3214	384	23	.	.	PUNCT
gs-3214	385	1	6	6	NUM
gs-3214	385	2	n	n	NUM
gs-3214	385	3	3	3	NUM
gs-3214	385	4	,	,	PUNCT
gs-3214	385	5	2024	2024	NUM
gs-3214	385	6	282	282	NUM
gs-3214	385	7	mechanisms	mechanism	NOUN
gs-3214	385	8	of	of	ADP
gs-3214	385	9	action	action	NOUN
gs-3214	385	10	,	,	PUNCT
gs-3214	385	11	and	and	CCONJ
gs-3214	385	12	application	application	NOUN
gs-3214	385	13	in	in	ADP
gs-3214	385	14	cancer	cancer	NOUN
gs-3214	385	15	treatment	treatment	NOUN
gs-3214	385	16	.	.	PUNCT
gs-3214	386	1	while	while	SCONJ
gs-3214	386	2	car	car	NOUN
gs-3214	386	3	-	-	PUNCT
gs-3214	386	4	t	t	NOUN
gs-3214	386	5	therapy	therapy	NOUN
gs-3214	386	6	has	have	AUX
gs-3214	386	7	demonstrated	demonstrate	VERB
gs-3214	386	8	remarkable	remarkable	ADJ
gs-3214	386	9	success	success	NOUN
gs-3214	386	10	in	in	ADP
gs-3214	386	11	treating	treat	VERB
gs-3214	386	12	certain	certain	ADJ
gs-3214	386	13	hematologic	hematologic	ADJ
gs-3214	386	14	cancers	cancer	NOUN
gs-3214	386	15	,	,	PUNCT
gs-3214	386	16	its	its	PRON
gs-3214	386	17	broader	broad	ADJ
gs-3214	386	18	application	application	NOUN
gs-3214	386	19	faces	face	VERB
gs-3214	386	20	significant	significant	ADJ
gs-3214	386	21	challenges	challenge	NOUN
gs-3214	386	22	,	,	PUNCT
gs-3214	386	23	including	include	VERB
gs-3214	386	24	severe	severe	ADJ
gs-3214	386	25	toxicities	toxicity	NOUN
gs-3214	386	26	,	,	PUNCT
gs-3214	386	27	antigen	antigen	ADJ
gs-3214	386	28	escape	escape	NOUN
gs-3214	386	29	,	,	PUNCT
gs-3214	386	30	manufacturing	manufacturing	NOUN
gs-3214	386	31	complexities	complexity	NOUN
gs-3214	386	32	,	,	PUNCT
gs-3214	386	33	and	and	CCONJ
gs-3214	386	34	limited	limited	ADJ
gs-3214	386	35	efficacy	efficacy	NOUN
gs-3214	386	36	in	in	ADP
gs-3214	386	37	solid	solid	ADJ
gs-3214	386	38	tumors	tumor	NOUN
gs-3214	386	39	.	.	PUNCT
gs-3214	387	1	the	the	DET
gs-3214	387	2	discussion	discussion	NOUN
gs-3214	387	3	extends	extend	VERB
gs-3214	387	4	to	to	ADP
gs-3214	387	5	future	future	ADJ
gs-3214	387	6	advancements	advancement	NOUN
gs-3214	387	7	,	,	PUNCT
gs-3214	387	8	such	such	ADJ
gs-3214	387	9	as	as	ADP
gs-3214	387	10	next	next	ADJ
gs-3214	387	11	-	-	PUNCT
gs-3214	387	12	generation	generation	NOUN
gs-3214	387	13	car	car	NOUN
gs-3214	387	14	designs	design	NOUN
gs-3214	387	15	,	,	PUNCT
gs-3214	387	16	gene	gene	NOUN
gs-3214	387	17	editing	editing	NOUN
gs-3214	387	18	technologies	technology	NOUN
gs-3214	387	19	like	like	ADP
gs-3214	387	20	crispr	crispr	NOUN
gs-3214	387	21	,	,	PUNCT
gs-3214	387	22	and	and	CCONJ
gs-3214	387	23	potential	potential	ADJ
gs-3214	387	24	applications	application	NOUN
gs-3214	387	25	in	in	ADP
gs-3214	387	26	autoimmune	autoimmune	ADJ
gs-3214	387	27	and	and	CCONJ
gs-3214	387	28	infectious	infectious	ADJ
gs-3214	387	29	diseases	disease	NOUN
gs-3214	387	30	.	.	PUNCT
gs-3214	388	1	addressing	address	VERB
gs-3214	388	2	these	these	DET
gs-3214	388	3	challenges	challenge	NOUN
gs-3214	388	4	through	through	ADP
gs-3214	388	5	interdisciplinary	interdisciplinary	ADJ
gs-3214	388	6	innovation	innovation	NOUN
gs-3214	388	7	is	be	AUX
gs-3214	388	8	critical	critical	ADJ
gs-3214	388	9	to	to	ADP
gs-3214	388	10	fully	fully	ADV
gs-3214	388	11	harnessing	harness	VERB
gs-3214	388	12	the	the	DET
gs-3214	388	13	potential	potential	NOUN
gs-3214	388	14	of	of	ADP
gs-3214	388	15	car	car	NOUN
gs-3214	388	16	-	-	PUNCT
gs-3214	388	17	t	t	NOUN
gs-3214	388	18	therapy	therapy	NOUN
gs-3214	388	19	as	as	ADP
gs-3214	388	20	a	a	DET
gs-3214	388	21	cornerstone	cornerstone	NOUN
gs-3214	388	22	of	of	ADP
gs-3214	388	23	personalized	personalized	ADJ
gs-3214	388	24	medicine	medicine	NOUN
gs-3214	388	25	.	.	PUNCT
gs-3214	389	1	car	car	NOUN
gs-3214	389	2	-	-	PUNCT
gs-3214	389	3	t	t	NOUN
gs-3214	389	4	cell	cell	NOUN
gs-3214	389	5	therapy	therapy	NOUN
gs-3214	389	6	has	have	AUX
gs-3214	389	7	emerged	emerge	VERB
gs-3214	389	8	as	as	ADP
gs-3214	389	9	a	a	DET
gs-3214	389	10	transformative	transformative	ADJ
gs-3214	389	11	innovation	innovation	NOUN
gs-3214	389	12	in	in	ADP
gs-3214	389	13	immunotherapy	immunotherapy	NOUN
gs-3214	389	14	,	,	PUNCT
gs-3214	389	15	offering	offer	VERB
gs-3214	389	16	hope	hope	NOUN
gs-3214	389	17	to	to	ADP
gs-3214	389	18	patients	patient	NOUN
gs-3214	389	19	with	with	ADP
gs-3214	389	20	otherwise	otherwise	ADV
gs-3214	389	21	intractable	intractable	ADJ
gs-3214	389	22	diseases	disease	NOUN
gs-3214	389	23	.	.	PUNCT
gs-3214	390	1	its	its	PRON
gs-3214	390	2	success	success	NOUN
gs-3214	390	3	in	in	ADP
gs-3214	390	4	treating	treat	VERB
gs-3214	390	5	hematologic	hematologic	ADJ
gs-3214	390	6	malignancies	malignancy	NOUN
gs-3214	390	7	,	,	PUNCT
gs-3214	390	8	such	such	ADJ
gs-3214	390	9	as	as	ADP
gs-3214	390	10	b	b	NOUN
gs-3214	390	11	-	-	PUNCT
gs-3214	390	12	cell	cell	NOUN
gs-3214	390	13	leukemias	leukemia	NOUN
gs-3214	390	14	and	and	CCONJ
gs-3214	390	15	lymphomas	lymphoma	NOUN
gs-3214	390	16	,	,	PUNCT
gs-3214	390	17	demonstrates	demonstrate	VERB
gs-3214	390	18	its	its	PRON
gs-3214	390	19	potential	potential	NOUN
gs-3214	390	20	to	to	PART
gs-3214	390	21	achieve	achieve	VERB
gs-3214	390	22	durable	durable	ADJ
gs-3214	390	23	remissions	remission	NOUN
gs-3214	390	24	.	.	PUNCT
gs-3214	391	1	however	however	ADV
gs-3214	391	2	,	,	PUNCT
gs-3214	391	3	significant	significant	ADJ
gs-3214	391	4	challenges	challenge	NOUN
gs-3214	391	5	persist	persist	VERB
gs-3214	391	6	,	,	PUNCT
gs-3214	391	7	including	include	VERB
gs-3214	391	8	severe	severe	ADJ
gs-3214	391	9	toxicities	toxicity	NOUN
gs-3214	391	10	,	,	PUNCT
gs-3214	391	11	antigen	antigen	ADJ
gs-3214	391	12	escape	escape	NOUN
gs-3214	391	13	,	,	PUNCT
gs-3214	391	14	manufacturing	manufacturing	NOUN
gs-3214	391	15	complexity	complexity	NOUN
gs-3214	391	16	,	,	PUNCT
gs-3214	391	17	and	and	CCONJ
gs-3214	391	18	limited	limited	ADJ
gs-3214	391	19	efficacy	efficacy	NOUN
gs-3214	391	20	in	in	ADP
gs-3214	391	21	solid	solid	ADJ
gs-3214	391	22	tumors	tumor	NOUN
gs-3214	391	23	.	.	PUNCT
gs-3214	392	1	addressing	address	VERB
gs-3214	392	2	these	these	DET
gs-3214	392	3	barriers	barrier	NOUN
gs-3214	392	4	requires	require	VERB
gs-3214	392	5	continued	continue	VERB
gs-3214	392	6	advancements	advancement	NOUN
gs-3214	392	7	in	in	ADP
gs-3214	392	8	car	car	NOUN
gs-3214	392	9	design	design	NOUN
gs-3214	392	10	,	,	PUNCT
gs-3214	392	11	integration	integration	NOUN
gs-3214	392	12	of	of	ADP
gs-3214	392	13	gene	gene	NOUN
gs-3214	392	14	editing	editing	NOUN
gs-3214	392	15	tools	tool	NOUN
gs-3214	392	16	,	,	PUNCT
gs-3214	392	17	and	and	CCONJ
gs-3214	392	18	combination	combination	NOUN
gs-3214	392	19	strategies	strategy	NOUN
gs-3214	392	20	to	to	PART
gs-3214	392	21	overcome	overcome	VERB
gs-3214	392	22	the	the	DET
gs-3214	392	23	immunosuppressive	immunosuppressive	ADJ
gs-3214	392	24	tumor	tumor	NOUN
gs-3214	392	25	microenvironment	microenvironment	NOUN
gs-3214	392	26	.	.	PUNCT
gs-3214	393	1	furthermore	furthermore	ADV
gs-3214	393	2	,	,	PUNCT
gs-3214	393	3	extending	extend	VERB
gs-3214	393	4	car	car	NOUN
gs-3214	393	5	-	-	PUNCT
gs-3214	393	6	t	t	NOUN
gs-3214	393	7	therapy	therapy	NOUN
gs-3214	393	8	beyond	beyond	ADP
gs-3214	393	9	cancer	cancer	NOUN
gs-3214	393	10	to	to	ADP
gs-3214	393	11	autoimmune	autoimmune	ADJ
gs-3214	393	12	and	and	CCONJ
gs-3214	393	13	infectious	infectious	ADJ
gs-3214	393	14	diseases	disease	NOUN
gs-3214	393	15	represents	represent	VERB
gs-3214	393	16	an	an	DET
gs-3214	393	17	exciting	exciting	ADJ
gs-3214	393	18	frontier	frontier	NOUN
gs-3214	393	19	.	.	PUNCT
gs-3214	394	1	by	by	ADP
gs-3214	394	2	fostering	foster	VERB
gs-3214	394	3	interdisciplinary	interdisciplinary	ADJ
gs-3214	394	4	collaboration	collaboration	NOUN
gs-3214	394	5	and	and	CCONJ
gs-3214	394	6	leveraging	leverage	VERB
gs-3214	394	7	cutting	cutting	NOUN
gs-3214	394	8	-	-	PUNCT
gs-3214	394	9	edge	edge	NOUN
gs-3214	394	10	technologies	technology	NOUN
gs-3214	394	11	,	,	PUNCT
gs-3214	394	12	researchers	researcher	NOUN
gs-3214	394	13	and	and	CCONJ
gs-3214	394	14	clinicians	clinician	NOUN
gs-3214	394	15	can	can	AUX
gs-3214	394	16	refine	refine	VERB
gs-3214	394	17	car	car	NOUN
gs-3214	394	18	-	-	PUNCT
gs-3214	394	19	t	t	NOUN
gs-3214	394	20	therapy	therapy	NOUN
gs-3214	394	21	into	into	ADP
gs-3214	394	22	a	a	DET
gs-3214	394	23	safer	safe	ADJ
gs-3214	394	24	,	,	PUNCT
gs-3214	394	25	more	more	ADV
gs-3214	394	26	accessible	accessible	ADJ
gs-3214	394	27	,	,	PUNCT
gs-3214	394	28	and	and	CCONJ
gs-3214	394	29	more	more	ADV
gs-3214	394	30	effective	effective	ADJ
gs-3214	394	31	modality	modality	NOUN
gs-3214	394	32	.	.	PUNCT
gs-3214	395	1	ultimately	ultimately	ADV
gs-3214	395	2	,	,	PUNCT
gs-3214	395	3	car	car	NOUN
gs-3214	395	4	-	-	PUNCT
gs-3214	395	5	t	t	NOUN
gs-3214	395	6	cells	cell	NOUN
gs-3214	395	7	are	be	AUX
gs-3214	395	8	poised	poise	VERB
gs-3214	395	9	to	to	PART
gs-3214	395	10	become	become	VERB
gs-3214	395	11	a	a	DET
gs-3214	395	12	cornerstone	cornerstone	NOUN
gs-3214	395	13	of	of	ADP
gs-3214	395	14	personalized	personalized	ADJ
gs-3214	395	15	medicine	medicine	NOUN
gs-3214	395	16	,	,	PUNCT
gs-3214	395	17	reshaping	reshape	VERB
gs-3214	395	18	the	the	DET
gs-3214	395	19	landscape	landscape	NOUN
gs-3214	395	20	of	of	ADP
gs-3214	395	21	disease	disease	NOUN
gs-3214	395	22	treatment	treatment	NOUN
gs-3214	395	23	in	in	ADP
gs-3214	395	24	the	the	DET
gs-3214	395	25	years	year	NOUN
gs-3214	395	26	to	to	PART
gs-3214	395	27	come	come	VERB
gs-3214	395	28	.	.	PUNCT
gs-3214	396	1	conclusion	conclusion	NOUN
gs-3214	396	2	:	:	PUNCT
gs-3214	396	3	car	car	NOUN
gs-3214	396	4	-	-	PUNCT
gs-3214	396	5	t	t	NOUN
gs-3214	396	6	cell	cell	NOUN
gs-3214	396	7	therapy	therapy	NOUN
gs-3214	396	8	represents	represent	VERB
gs-3214	396	9	a	a	DET
gs-3214	396	10	paradigm	paradigm	NOUN
gs-3214	396	11	shift	shift	NOUN
gs-3214	396	12	in	in	ADP
gs-3214	396	13	immunotherapy	immunotherapy	NOUN
gs-3214	396	14	,	,	PUNCT
gs-3214	396	15	offering	offer	VERB
gs-3214	396	16	hope	hope	NOUN
gs-3214	396	17	to	to	ADP
gs-3214	396	18	patients	patient	NOUN
gs-3214	396	19	with	with	ADP
gs-3214	396	20	otherwise	otherwise	ADV
gs-3214	396	21	intractable	intractable	ADJ
gs-3214	396	22	diseases	disease	NOUN
gs-3214	396	23	.	.	PUNCT
gs-3214	397	1	while	while	SCONJ
gs-3214	397	2	the	the	DET
gs-3214	397	3	therapy	therapy	NOUN
gs-3214	397	4	's	's	PART
gs-3214	397	5	potential	potential	NOUN
gs-3214	397	6	is	be	AUX
gs-3214	397	7	undeniable	undeniable	ADJ
gs-3214	397	8	,	,	PUNCT
gs-3214	397	9	it	it	PRON
gs-3214	397	10	is	be	AUX
gs-3214	397	11	imperative	imperative	ADJ
gs-3214	397	12	to	to	PART
gs-3214	397	13	resolve	resolve	VERB
gs-3214	397	14	its	its	PRON
gs-3214	397	15	inherent	inherent	ADJ
gs-3214	397	16	challenges	challenge	NOUN
gs-3214	397	17	to	to	PART
gs-3214	397	18	broaden	broaden	VERB
gs-3214	397	19	its	its	PRON
gs-3214	397	20	applicability	applicability	NOUN
gs-3214	397	21	.	.	PUNCT
gs-3214	398	1	by	by	ADP
gs-3214	398	2	addressing	address	VERB
gs-3214	398	3	issues	issue	NOUN
gs-3214	398	4	such	such	ADJ
gs-3214	398	5	as	as	ADP
gs-3214	398	6	toxicity	toxicity	NOUN
gs-3214	398	7	,	,	PUNCT
gs-3214	398	8	manufacturing	manufacturing	NOUN
gs-3214	398	9	complexities	complexity	NOUN
gs-3214	398	10	,	,	PUNCT
gs-3214	398	11	and	and	CCONJ
gs-3214	398	12	efficacy	efficacy	NOUN
gs-3214	398	13	in	in	ADP
gs-3214	398	14	solid	solid	ADJ
gs-3214	398	15	tumors	tumor	NOUN
gs-3214	398	16	,	,	PUNCT
gs-3214	398	17	car	car	NOUN
gs-3214	398	18	-	-	PUNCT
gs-3214	398	19	t	t	NOUN
gs-3214	398	20	therapy	therapy	NOUN
gs-3214	398	21	could	could	AUX
gs-3214	398	22	become	become	VERB
gs-3214	398	23	a	a	DET
gs-3214	398	24	cornerstone	cornerstone	NOUN
gs-3214	398	25	of	of	ADP
gs-3214	398	26	personalized	personalized	ADJ
gs-3214	398	27	medicine	medicine	NOUN
gs-3214	398	28	.	.	PUNCT
gs-3214	399	1	ongoing	ongoing	ADJ
gs-3214	399	2	research	research	NOUN
gs-3214	399	3	and	and	CCONJ
gs-3214	399	4	innovation	innovation	NOUN
gs-3214	399	5	promise	promise	NOUN
gs-3214	399	6	to	to	PART
gs-3214	399	7	unlock	unlock	VERB
gs-3214	399	8	the	the	DET
gs-3214	399	9	full	full	ADJ
gs-3214	399	10	potential	potential	NOUN
gs-3214	399	11	of	of	ADP
gs-3214	399	12	this	this	DET
gs-3214	399	13	transformative	transformative	ADJ
gs-3214	399	14	technology	technology	NOUN
gs-3214	399	15	.	.	PUNCT
gs-3214	400	1	regulatory	regulatory	ADJ
gs-3214	400	2	harmonization	harmonization	NOUN
gs-3214	400	3	aims	aim	VERB
gs-3214	400	4	to	to	PART
gs-3214	400	5	streamline	streamline	VERB
gs-3214	400	6	and	and	CCONJ
gs-3214	400	7	unify	unify	VERB
gs-3214	400	8	approval	approval	NOUN
gs-3214	400	9	pathways	pathway	NOUN
gs-3214	400	10	for	for	ADP
gs-3214	400	11	car	car	NOUN
gs-3214	400	12	-	-	PUNCT
gs-3214	400	13	t	t	NOUN
gs-3214	400	14	cell	cell	NOUN
gs-3214	400	15	therapies	therapy	NOUN
gs-3214	400	16	worldwide	worldwide	ADV
gs-3214	400	17	,	,	PUNCT
gs-3214	400	18	facilitating	facilitate	VERB
gs-3214	400	19	their	their	PRON
gs-3214	400	20	efficient	efficient	ADJ
gs-3214	400	21	evaluation	evaluation	NOUN
gs-3214	400	22	and	and	CCONJ
gs-3214	400	23	availability	availability	NOUN
gs-3214	400	24	.	.	PUNCT
gs-3214	401	1	this	this	DET
gs-3214	401	2	process	process	NOUN
gs-3214	401	3	ensures	ensure	VERB
gs-3214	401	4	consistent	consistent	ADJ
gs-3214	401	5	standards	standard	NOUN
gs-3214	401	6	for	for	ADP
gs-3214	401	7	safety	safety	NOUN
gs-3214	401	8	monitoring	monitoring	NOUN
gs-3214	401	9	and	and	CCONJ
gs-3214	401	10	oversight	oversight	NOUN
gs-3214	401	11	to	to	PART
gs-3214	401	12	safeguard	safeguard	VERB
gs-3214	401	13	patient	patient	ADJ
gs-3214	401	14	well	well	ADV
gs-3214	401	15	-	-	PUNCT
gs-3214	401	16	being	being	NOUN
gs-3214	401	17	.	.	PUNCT
gs-3214	402	1	by	by	ADP
gs-3214	402	2	promoting	promote	VERB
gs-3214	402	3	collaboration	collaboration	NOUN
gs-3214	402	4	among	among	ADP
gs-3214	402	5	regulatory	regulatory	ADJ
gs-3214	402	6	agencies	agency	NOUN
gs-3214	402	7	and	and	CCONJ
gs-3214	402	8	adhering	adhere	VERB
gs-3214	402	9	to	to	PART
gs-3214	402	10	stringent	stringent	VERB
gs-3214	402	11	safety	safety	NOUN
gs-3214	402	12	protocols	protocol	NOUN
gs-3214	402	13	,	,	PUNCT
gs-3214	402	14	regulatory	regulatory	ADJ
gs-3214	402	15	harmonization	harmonization	NOUN
gs-3214	402	16	accelerates	accelerate	VERB
gs-3214	402	17	the	the	DET
gs-3214	402	18	delivery	delivery	NOUN
gs-3214	402	19	of	of	ADP
gs-3214	402	20	innovative	innovative	ADJ
gs-3214	402	21	therapies	therapy	NOUN
gs-3214	402	22	to	to	ADP
gs-3214	402	23	patients	patient	NOUN
gs-3214	402	24	while	while	SCONJ
gs-3214	402	25	maintaining	maintain	VERB
gs-3214	402	26	rigorous	rigorous	ADJ
gs-3214	402	27	standards	standard	NOUN
gs-3214	402	28	for	for	ADP
gs-3214	402	29	efficacy	efficacy	NOUN
gs-3214	402	30	and	and	CCONJ
gs-3214	402	31	safety	safety	NOUN
gs-3214	402	32	.	.	PUNCT
gs-3214	403	1	georgian	georgian	NOUN
gs-3214	403	2	scientists/	scientists/	NUM
gs-3214	403	3	.	.	PUNCT
gs-3214	404	1	6	6	NUM
gs-3214	404	2	n	n	NUM
gs-3214	404	3	3	3	NUM
gs-3214	404	4	,	,	PUNCT
gs-3214	404	5	2024	2024	NUM
gs-3214	404	6	283	283	NUM
gs-3214	404	7	references	reference	NOUN
gs-3214	404	8	:	:	PUNCT
gs-3214	404	9	1	1	X
gs-3214	404	10	.	.	X
gs-3214	404	11	gross	gross	ADJ
gs-3214	404	12	,	,	PUNCT
gs-3214	404	13	g.	g.	PROPN
gs-3214	404	14	,	,	PUNCT
gs-3214	404	15	waks	wak	NOUN
gs-3214	404	16	,	,	PUNCT
gs-3214	404	17	t.	t.	PROPN
gs-3214	404	18	,	,	PUNCT
gs-3214	404	19	&	&	CCONJ
gs-3214	404	20	eshhar	eshhar	PROPN
gs-3214	404	21	,	,	PUNCT
gs-3214	404	22	z.	z.	PROPN
gs-3214	404	23	(	(	PUNCT
gs-3214	404	24	1989	1989	NUM
gs-3214	404	25	)	)	PUNCT
gs-3214	404	26	.	.	PUNCT
gs-3214	405	1	expression	expression	NOUN
gs-3214	405	2	of	of	ADP
gs-3214	405	3	immunoglobulin	immunoglobulin	NOUN
gs-3214	405	4	-	-	PUNCT
gs-3214	405	5	t	t	NOUN
gs-3214	405	6	-	-	PUNCT
gs-3214	405	7	cell	cell	NOUN
gs-3214	405	8	receptor	receptor	NOUN
gs-3214	405	9	chimeric	chimeric	ADJ
gs-3214	405	10	molecules	molecule	NOUN
gs-3214	405	11	as	as	ADP
gs-3214	405	12	functional	functional	ADJ
gs-3214	405	13	receptors	receptor	NOUN
gs-3214	405	14	with	with	ADP
gs-3214	405	15	antibody	antibody	NOUN
gs-3214	405	16	-	-	PUNCT
gs-3214	405	17	type	type	NOUN
gs-3214	405	18	specificity	specificity	NOUN
gs-3214	405	19	.	.	PUNCT
gs-3214	406	1	proceedings	proceeding	NOUN
gs-3214	406	2	of	of	ADP
gs-3214	406	3	the	the	DET
gs-3214	406	4	national	national	PROPN
gs-3214	406	5	academy	academy	PROPN
gs-3214	406	6	of	of	ADP
gs-3214	406	7	sciences	sciences	PROPN
gs-3214	406	8	,	,	PUNCT
gs-3214	406	9	86(24	86(24	NUM
gs-3214	406	10	)	)	PUNCT
gs-3214	406	11	,	,	PUNCT
gs-3214	406	12	10024–10028	10024–10028	NUM
gs-3214	406	13	.	.	PUNCT
gs-3214	407	1	2	2	NUM
gs-3214	407	2	.	.	X
gs-3214	407	3	levine	levine	PROPN
gs-3214	407	4	,	,	PUNCT
gs-3214	407	5	b.	b.	PROPN
gs-3214	407	6	l.	l.	PROPN
gs-3214	407	7	,	,	PUNCT
gs-3214	407	8	miskin	miskin	PROPN
gs-3214	407	9	,	,	PUNCT
gs-3214	407	10	j.	j.	PROPN
gs-3214	407	11	,	,	PUNCT
gs-3214	407	12	wonnacott	wonnacott	PROPN
gs-3214	407	13	,	,	PUNCT
gs-3214	407	14	k.	k.	PROPN
gs-3214	407	15	,	,	PUNCT
gs-3214	407	16	keir	keir	PROPN
gs-3214	407	17	,	,	PUNCT
gs-3214	407	18	c.	c.	PROPN
gs-3214	407	19	,	,	PUNCT
gs-3214	407	20	&	&	CCONJ
gs-3214	407	21	global	global	PROPN
gs-3214	407	22	,	,	PUNCT
gs-3214	407	23	l.	l.	PROPN
gs-3214	407	24	(	(	PUNCT
gs-3214	407	25	2016	2016	NUM
gs-3214	407	26	)	)	PUNCT
gs-3214	407	27	.	.	PUNCT
gs-3214	408	1	global	global	ADJ
gs-3214	408	2	manufacturing	manufacturing	NOUN
gs-3214	408	3	of	of	ADP
gs-3214	408	4	car	car	NOUN
gs-3214	408	5	t	t	NOUN
gs-3214	408	6	cell	cell	NOUN
gs-3214	408	7	therapy	therapy	NOUN
gs-3214	408	8	.	.	PUNCT
gs-3214	409	1	molecular	molecular	ADJ
gs-3214	409	2	therapy	therapy	NOUN
gs-3214	409	3	–	–	PUNCT
gs-3214	409	4	methods	method	NOUN
gs-3214	409	5	&	&	CCONJ
gs-3214	409	6	clinical	clinical	ADJ
gs-3214	409	7	development	development	NOUN
gs-3214	409	8	,	,	PUNCT
gs-3214	409	9	4	4	NUM
gs-3214	409	10	,	,	PUNCT
gs-3214	409	11	92–101	92–101	NUM
gs-3214	409	12	.	.	PUNCT
gs-3214	410	1	3	3	X
gs-3214	410	2	.	.	X
gs-3214	410	3	lai	lai	PROPN
gs-3214	410	4	,	,	PUNCT
gs-3214	410	5	y.	y.	PROPN
gs-3214	410	6	,	,	PUNCT
gs-3214	410	7	weng	weng	PROPN
gs-3214	410	8	,	,	PUNCT
gs-3214	410	9	j.	j.	PROPN
gs-3214	410	10	,	,	PUNCT
gs-3214	410	11	wei	wei	PROPN
gs-3214	410	12	,	,	PUNCT
gs-3214	410	13	x.	x.	PROPN
gs-3214	410	14	,	,	PUNCT
gs-3214	410	15	qin	qin	PROPN
gs-3214	410	16	,	,	PUNCT
gs-3214	410	17	l.	l.	PROPN
gs-3214	410	18	,	,	PUNCT
gs-3214	410	19	lai	lai	PROPN
gs-3214	410	20	,	,	PUNCT
gs-3214	410	21	p.	p.	PROPN
gs-3214	410	22	,	,	PUNCT
gs-3214	410	23	zhao	zhao	PROPN
gs-3214	410	24	.	.	PUNCT
gs-3214	411	1	(	(	PUNCT
gs-3214	411	2	2018	2018	NUM
gs-3214	411	3	)	)	PUNCT
gs-3214	411	4	.	.	PUNCT
gs-3214	412	1	toll	toll	NOUN
gs-3214	412	2	-	-	PUNCT
gs-3214	412	3	like	like	ADJ
gs-3214	412	4	receptor	receptor	NOUN
gs-3214	412	5	2	2	NUM
gs-3214	412	6	costimulation	costimulation	NOUN
gs-3214	412	7	potentiates	potentiate	VERB
gs-3214	412	8	the	the	DET
gs-3214	412	9	antitumor	antitumor	PROPN
gs-3214	412	10	efficacy	efficacy	NOUN
gs-3214	412	11	of	of	ADP
gs-3214	412	12	car	car	NOUN
gs-3214	412	13	t	t	NOUN
gs-3214	412	14	cells	cell	NOUN
gs-3214	412	15	.	.	PUNCT
gs-3214	413	1	leukemia	leukemia	NOUN
gs-3214	413	2	,	,	PUNCT
gs-3214	413	3	32(3	32(3	NUM
gs-3214	413	4	)	)	PUNCT
gs-3214	413	5	,	,	PUNCT
gs-3214	413	6	801–808	801–808	NUM
gs-3214	413	7	.	.	NOUN
gs-3214	414	1	4	4	NUM
gs-3214	414	2	.	.	X
gs-3214	414	3	guedan	guedan	PROPN
gs-3214	414	4	,	,	PUNCT
gs-3214	414	5	s.	s.	PROPN
gs-3214	414	6	,	,	PUNCT
gs-3214	414	7	calderon	calderon	PROPN
gs-3214	414	8	,	,	PUNCT
gs-3214	414	9	h.	h.	PROPN
gs-3214	414	10	,	,	PUNCT
gs-3214	414	11	posey	posey	PROPN
gs-3214	414	12	,	,	PUNCT
gs-3214	414	13	m.	m.	NOUN
gs-3214	414	14	v.	v.	PROPN
gs-3214	414	15	,	,	PUNCT
gs-3214	414	16	&	&	CCONJ
gs-3214	414	17	june	june	PROPN
gs-3214	414	18	,	,	PUNCT
gs-3214	414	19	c.	c.	PROPN
gs-3214	414	20	h.	h.	PROPN
gs-3214	414	21	(	(	PUNCT
gs-3214	414	22	2019	2019	NUM
gs-3214	414	23	)	)	PUNCT
gs-3214	414	24	.	.	PUNCT
gs-3214	415	1	engineering	engineering	NOUN
gs-3214	415	2	and	and	CCONJ
gs-3214	415	3	design	design	NOUN
gs-3214	415	4	of	of	ADP
gs-3214	415	5	chimeric	chimeric	ADJ
gs-3214	415	6	antigen	antigen	ADJ
gs-3214	415	7	receptors	receptor	NOUN
gs-3214	415	8	.	.	PUNCT
gs-3214	416	1	molecular	molecular	ADJ
gs-3214	416	2	therapy	therapy	NOUN
gs-3214	416	3	–	–	PUNCT
gs-3214	416	4	methods	method	NOUN
gs-3214	416	5	&	&	CCONJ
gs-3214	416	6	clinical	clinical	ADJ
gs-3214	416	7	development	development	NOUN
gs-3214	416	8	,	,	PUNCT
gs-3214	416	9	12	12	NUM
gs-3214	416	10	,	,	PUNCT
gs-3214	416	11	145–156	145–156	NUM
gs-3214	416	12	.	.	NOUN
gs-3214	417	1	5	5	NUM
gs-3214	417	2	.	.	X
gs-3214	418	1	ren	ren	PROPN
gs-3214	418	2	,	,	PUNCT
gs-3214	418	3	j.	j.	PROPN
gs-3214	418	4	,	,	PUNCT
gs-3214	418	5	zhang	zhang	PROPN
gs-3214	418	6	,	,	PUNCT
gs-3214	418	7	x.	x.	PROPN
gs-3214	418	8	,	,	PUNCT
gs-3214	418	9	liu	liu	PROPN
gs-3214	418	10	,	,	PUNCT
gs-3214	418	11	x.	x.	PROPN
gs-3214	418	12	,	,	PUNCT
gs-3214	418	13	fang	fang	PROPN
gs-3214	418	14	,	,	PUNCT
gs-3214	418	15	c.	c.	PROPN
gs-3214	418	16	,	,	PUNCT
gs-3214	418	17	jiang	jiang	PROPN
gs-3214	418	18	,	,	PUNCT
gs-3214	418	19	s.	s.	PROPN
gs-3214	418	20	,	,	PUNCT
gs-3214	418	21	june	june	PROPN
gs-3214	418	22	,	,	PUNCT
gs-3214	418	23	c.	c.	PROPN
gs-3214	418	24	h.	h.	PROPN
gs-3214	418	25	,	,	PUNCT
gs-3214	418	26	&	&	CCONJ
gs-3214	418	27	zhao	zhao	PROPN
gs-3214	418	28	,	,	PUNCT
gs-3214	418	29	y.	y.	PROPN
gs-3214	418	30	(	(	PUNCT
gs-3214	418	31	2017	2017	NUM
gs-3214	418	32	)	)	PUNCT
gs-3214	418	33	.	.	PUNCT
gs-3214	419	1	a	a	DET
gs-3214	419	2	versatile	versatile	ADJ
gs-3214	419	3	system	system	NOUN
gs-3214	419	4	for	for	ADP
gs-3214	419	5	rapid	rapid	ADJ
gs-3214	419	6	multiplex	multiplex	NOUN
gs-3214	419	7	genome	genome	NOUN
gs-3214	419	8	-	-	PUNCT
gs-3214	419	9	edited	edit	VERB
gs-3214	419	10	car	car	NOUN
gs-3214	419	11	t	t	NOUN
gs-3214	419	12	cell	cell	NOUN
gs-3214	419	13	generation	generation	NOUN
gs-3214	419	14	.	.	PUNCT
gs-3214	420	1	oncotarget	oncotarget	NOUN
gs-3214	420	2	,	,	PUNCT
gs-3214	420	3	8(10	8(10	NUM
gs-3214	420	4	)	)	PUNCT
gs-3214	420	5	,	,	PUNCT
gs-3214	420	6	17002–17011	17002–17011	NUM
gs-3214	420	7	.	.	PUNCT
gs-3214	421	1	6	6	NUM
gs-3214	421	2	.	.	NOUN
gs-3214	421	3	june	june	PROPN
gs-3214	421	4	,	,	PUNCT
gs-3214	421	5	c.	c.	PROPN
gs-3214	421	6	h.	h.	PROPN
gs-3214	421	7	,	,	PUNCT
gs-3214	421	8	&	&	CCONJ
gs-3214	421	9	sadelain	sadelain	PROPN
gs-3214	421	10	,	,	PUNCT
gs-3214	421	11	m.	m.	NOUN
gs-3214	421	12	(	(	PUNCT
gs-3214	421	13	2018	2018	NUM
gs-3214	421	14	)	)	PUNCT
gs-3214	421	15	.	.	PUNCT
gs-3214	422	1	chimeric	chimeric	ADJ
gs-3214	422	2	antigen	antigen	ADJ
gs-3214	422	3	receptor	receptor	NOUN
gs-3214	422	4	therapy	therapy	NOUN
gs-3214	422	5	.	.	PUNCT
gs-3214	423	1	new	new	PROPN
gs-3214	423	2	england	england	PROPN
gs-3214	423	3	journal	journal	PROPN
gs-3214	423	4	of	of	ADP
gs-3214	423	5	medicine	medicine	NOUN
gs-3214	423	6	,	,	PUNCT
gs-3214	423	7	379(1	379(1	NUM
gs-3214	423	8	)	)	PUNCT
gs-3214	423	9	,	,	PUNCT
gs-3214	423	10	64–73	64–73	NOUN
gs-3214	423	11	.	.	PUNCT
gs-3214	424	1	7	7	X
gs-3214	424	2	.	.	X
gs-3214	424	3	zah	zah	PROPN
gs-3214	424	4	,	,	PUNCT
gs-3214	424	5	e.	e.	PROPN
gs-3214	424	6	,	,	PUNCT
gs-3214	424	7	lin	lin	PROPN
gs-3214	424	8	,	,	PUNCT
gs-3214	424	9	m.	m.	NOUN
gs-3214	424	10	y.	y.	PROPN
gs-3214	424	11	,	,	PUNCT
gs-3214	424	12	silva	silva	PROPN
gs-3214	424	13	-	-	PUNCT
gs-3214	424	14	benedict	benedict	PROPN
gs-3214	424	15	,	,	PUNCT
gs-3214	424	16	a.	a.	PROPN
gs-3214	424	17	,	,	PUNCT
gs-3214	424	18	jensen	jensen	PROPN
gs-3214	424	19	,	,	PUNCT
gs-3214	424	20	m.	m.	PROPN
gs-3214	424	21	c.	c.	PROPN
gs-3214	424	22	,	,	PUNCT
gs-3214	424	23	&	&	CCONJ
gs-3214	424	24	chen	chen	PROPN
gs-3214	424	25	,	,	PUNCT
gs-3214	424	26	y.	y.	PROPN
gs-3214	424	27	y.	y.	PROPN
gs-3214	424	28	(	(	PUNCT
gs-3214	424	29	2016	2016	NUM
gs-3214	424	30	)	)	PUNCT
gs-3214	424	31	.	.	PUNCT
gs-3214	425	1	t	t	NOUN
gs-3214	425	2	cells	cell	NOUN
gs-3214	425	3	expressing	express	VERB
gs-3214	425	4	cd19	cd19	PROPN
gs-3214	425	5	/	/	SYM
gs-3214	425	6	cd20	cd20	PROPN
gs-3214	425	7	bispecific	bispecific	VERB
gs-3214	425	8	chimeric	chimeric	ADJ
gs-3214	425	9	antigen	antigen	ADJ
gs-3214	425	10	receptors	receptor	NOUN
gs-3214	425	11	prevent	prevent	VERB
gs-3214	425	12	antigen	antigen	ADJ
gs-3214	425	13	escape	escape	NOUN
gs-3214	425	14	by	by	ADP
gs-3214	425	15	malignant	malignant	ADJ
gs-3214	425	16	b	b	NOUN
gs-3214	425	17	cells	cell	NOUN
gs-3214	425	18	.	.	PUNCT
gs-3214	426	1	cancer	cancer	NOUN
gs-3214	426	2	immunology	immunology	NOUN
gs-3214	426	3	research	research	NOUN
gs-3214	426	4	,	,	PUNCT
gs-3214	426	5	4(6	4(6	NUM
gs-3214	426	6	)	)	PUNCT
gs-3214	426	7	,	,	PUNCT
gs-3214	426	8	498–508	498–508	NUM
gs-3214	426	9	.	.	NOUN
gs-3214	426	10	8	8	NUM
gs-3214	426	11	.	.	X
gs-3214	426	12	fesnak	fesnak	NOUN
gs-3214	426	13	,	,	PUNCT
gs-3214	426	14	a.	a.	PROPN
gs-3214	426	15	d.	d.	PROPN
gs-3214	426	16	,	,	PUNCT
gs-3214	426	17	june	june	PROPN
gs-3214	426	18	,	,	PUNCT
gs-3214	426	19	c.	c.	PROPN
gs-3214	426	20	h.	h.	PROPN
gs-3214	426	21	,	,	PUNCT
gs-3214	426	22	&	&	CCONJ
gs-3214	426	23	levine	levine	PROPN
gs-3214	426	24	,	,	PUNCT
gs-3214	426	25	b.	b.	PROPN
gs-3214	426	26	l.	l.	PROPN
gs-3214	426	27	(	(	PUNCT
gs-3214	426	28	2016	2016	NUM
gs-3214	426	29	)	)	PUNCT
gs-3214	426	30	.	.	PUNCT
gs-3214	427	1	engineered	engineer	VERB
gs-3214	427	2	t	t	NOUN
gs-3214	427	3	cells	cell	NOUN
gs-3214	427	4	:	:	PUNCT
gs-3214	427	5	the	the	DET
gs-3214	427	6	promise	promise	NOUN
gs-3214	427	7	and	and	CCONJ
gs-3214	427	8	challenges	challenge	NOUN
gs-3214	427	9	of	of	ADP
gs-3214	427	10	cancer	cancer	NOUN
gs-3214	427	11	immunotherapy	immunotherapy	NOUN
gs-3214	427	12	.	.	PUNCT
gs-3214	428	1	nature	nature	NOUN
gs-3214	428	2	reviews	review	VERB
gs-3214	428	3	cancer	cancer	NOUN
gs-3214	428	4	,	,	PUNCT
gs-3214	428	5	16(9	16(9	NUM
gs-3214	428	6	)	)	PUNCT
gs-3214	428	7	,	,	PUNCT
gs-3214	428	8	566–581	566–581	NUM
gs-3214	428	9	.	.	NOUN
gs-3214	428	10	9	9	NUM
gs-3214	428	11	.	.	X
gs-3214	428	12	maus	maus	PROPN
gs-3214	428	13	,	,	PUNCT
gs-3214	428	14	m.	m.	NOUN
gs-3214	428	15	v.	v.	PROPN
gs-3214	428	16	,	,	PUNCT
gs-3214	428	17	&	&	CCONJ
gs-3214	428	18	june	june	PROPN
gs-3214	428	19	,	,	PUNCT
gs-3214	428	20	c.	c.	PROPN
gs-3214	428	21	h.	h.	PROPN
gs-3214	428	22	(	(	PUNCT
gs-3214	428	23	2016	2016	NUM
gs-3214	428	24	)	)	PUNCT
gs-3214	428	25	.	.	PUNCT
gs-3214	429	1	making	make	VERB
gs-3214	429	2	better	well	ADJ
gs-3214	429	3	chimeric	chimeric	ADJ
gs-3214	429	4	antigen	antigen	ADJ
gs-3214	429	5	receptors	receptor	NOUN
gs-3214	429	6	for	for	ADP
gs-3214	429	7	adoptive	adoptive	ADJ
gs-3214	429	8	t	t	PROPN
gs-3214	429	9	-	-	PUNCT
gs-3214	429	10	cell	cell	NOUN
gs-3214	429	11	therapy	therapy	NOUN
gs-3214	429	12	.	.	PUNCT
gs-3214	430	1	clinical	clinical	ADJ
gs-3214	430	2	cancer	cancer	NOUN
gs-3214	430	3	research	research	NOUN
gs-3214	430	4	,	,	PUNCT
gs-3214	430	5	22(8	22(8	NUM
gs-3214	430	6	)	)	PUNCT
gs-3214	430	7	,	,	PUNCT
gs-3214	430	8	1875–1884	1875–1884	NUM
gs-3214	430	9	.	.	PUNCT
gs-3214	431	1	10	10	NUM
gs-3214	431	2	.	.	PUNCT
gs-3214	432	1	guedan	guedan	PROPN
gs-3214	432	2	,	,	PUNCT
gs-3214	432	3	s.	s.	PROPN
gs-3214	432	4	,	,	PUNCT
gs-3214	432	5	calderon	calderon	PROPN
gs-3214	432	6	,	,	PUNCT
gs-3214	432	7	h.	h.	PROPN
gs-3214	432	8	,	,	PUNCT
gs-3214	432	9	posey	posey	PROPN
gs-3214	432	10	,	,	PUNCT
gs-3214	432	11	a.	a.	PROPN
gs-3214	432	12	d.	d.	PROPN
gs-3214	432	13	,	,	PUNCT
gs-3214	432	14	&	&	CCONJ
gs-3214	432	15	june	june	PROPN
gs-3214	432	16	,	,	PUNCT
gs-3214	432	17	c.	c.	PROPN
gs-3214	432	18	h.	h.	PROPN
gs-3214	432	19	(	(	PUNCT
gs-3214	432	20	2019	2019	NUM
gs-3214	432	21	)	)	PUNCT
gs-3214	432	22	.	.	PUNCT
gs-3214	433	1	engineering	engineering	NOUN
gs-3214	433	2	and	and	CCONJ
gs-3214	433	3	design	design	NOUN
gs-3214	433	4	of	of	ADP
gs-3214	433	5	chimeric	chimeric	ADJ
gs-3214	433	6	antigen	antigen	ADJ
gs-3214	433	7	receptors	receptor	NOUN
gs-3214	433	8	.	.	PUNCT
gs-3214	434	1	molecular	molecular	ADJ
gs-3214	434	2	therapy	therapy	NOUN
gs-3214	434	3	–	–	PUNCT
gs-3214	434	4	methods	method	NOUN
gs-3214	434	5	&	&	CCONJ
gs-3214	434	6	clinical	clinical	ADJ
gs-3214	434	7	development	development	NOUN
gs-3214	434	8	,	,	PUNCT
gs-3214	434	9	12	12	NUM
gs-3214	434	10	,	,	PUNCT
gs-3214	434	11	145–156	145–156	NUM
gs-3214	434	12	.	.	PROPN
gs-3214	434	13	11	11	NUM
gs-3214	434	14	.	.	PUNCT
gs-3214	435	1	lai	lai	PROPN
gs-3214	435	2	,	,	PUNCT
gs-3214	435	3	y.	y.	PROPN
gs-3214	435	4	,	,	PUNCT
gs-3214	435	5	weng	weng	PROPN
gs-3214	435	6	,	,	PUNCT
gs-3214	435	7	j.	j.	PROPN
gs-3214	435	8	,	,	PUNCT
gs-3214	435	9	wei	wei	PROPN
gs-3214	435	10	,	,	PUNCT
gs-3214	435	11	x.	x.	PROPN
gs-3214	435	12	,	,	PUNCT
gs-3214	435	13	qin	qin	PROPN
gs-3214	435	14	,	,	PUNCT
gs-3214	435	15	l.	l.	PROPN
gs-3214	435	16	,	,	PUNCT
gs-3214	435	17	lai	lai	PROPN
gs-3214	435	18	,	,	PUNCT
gs-3214	435	19	p.	p.	PROPN
gs-3214	435	20	,	,	PUNCT
gs-3214	435	21	zhao	zhao	PROPN
gs-3214	435	22	,	,	PUNCT
gs-3214	435	23	r.	r.	PROPN
gs-3214	435	24	,	,	PUNCT
gs-3214	435	25	jiang	jiang	PROPN
gs-3214	435	26	,	,	PUNCT
gs-3214	435	27	z.	z.	PROPN
gs-3214	435	28	,	,	PUNCT
gs-3214	435	29	li	li	PROPN
gs-3214	435	30	,	,	PUNCT
gs-3214	435	31	b.	b.	PROPN
gs-3214	435	32	,	,	PUNCT
gs-3214	435	33	lin	lin	PROPN
gs-3214	435	34	,	,	PUNCT
gs-3214	435	35	s.	s.	PROPN
gs-3214	435	36	,	,	PUNCT
gs-3214	435	37	wang	wang	PROPN
gs-3214	435	38	,	,	PUNCT
gs-3214	435	39	s.	s.	PROPN
gs-3214	435	40	,	,	PUNCT
gs-3214	435	41	wu	wu	PROPN
gs-3214	435	42	,	,	PUNCT
gs-3214	435	43	q.	q.	PROPN
gs-3214	435	44	,	,	PUNCT
gs-3214	435	45	liang	liang	PROPN
gs-3214	435	46	,	,	PUNCT
gs-3214	435	47	q.	q.	PROPN
gs-3214	435	48	,	,	PUNCT
gs-3214	435	49	li	li	PROPN
gs-3214	435	50	,	,	PUNCT
gs-3214	435	51	y.	y.	PROPN
gs-3214	435	52	,	,	PUNCT
gs-3214	435	53	zhang	zhang	PROPN
gs-3214	435	54	,	,	PUNCT
gs-3214	435	55	x.	x.	PROPN
gs-3214	435	56	,	,	PUNCT
gs-3214	435	57	wu	wu	PROPN
gs-3214	435	58	,	,	PUNCT
gs-3214	435	59	y.	y.	PROPN
gs-3214	435	60	,	,	PUNCT
gs-3214	435	61	liu	liu	PROPN
gs-3214	435	62	,	,	PUNCT
gs-3214	435	63	p.	p.	PROPN
gs-3214	435	64	,	,	PUNCT
gs-3214	435	65	&	&	CCONJ
gs-3214	435	66	yao	yao	PROPN
gs-3214	435	67	,	,	PUNCT
gs-3214	435	68	y.	y.	PROPN
gs-3214	435	69	(	(	PUNCT
gs-3214	435	70	2018	2018	NUM
gs-3214	435	71	)	)	PUNCT
gs-3214	435	72	.	.	PUNCT
gs-3214	436	1	toll	toll	NOUN
gs-3214	436	2	-	-	PUNCT
gs-3214	436	3	like	like	ADJ
gs-3214	436	4	receptor	receptor	NOUN
gs-3214	436	5	2	2	NUM
gs-3214	436	6	costimulation	costimulation	NOUN
gs-3214	436	7	potentiates	potentiate	VERB
gs-3214	436	8	the	the	DET
gs-3214	436	9	antitumor	antitumor	PROPN
gs-3214	436	10	efficacy	efficacy	NOUN
gs-3214	436	11	of	of	ADP
gs-3214	436	12	car	car	NOUN
gs-3214	436	13	t	t	NOUN
gs-3214	436	14	cells	cell	NOUN
gs-3214	436	15	.	.	PUNCT
gs-3214	437	1	leukemia	leukemia	NOUN
gs-3214	437	2	,	,	PUNCT
gs-3214	437	3	32(3	32(3	NUM
gs-3214	437	4	)	)	PUNCT
gs-3214	437	5	,	,	PUNCT
gs-3214	437	6	801–808	801–808	NUM
gs-3214	437	7	.	.	PUNCT
gs-3214	437	8	12	12	NUM
gs-3214	437	9	.	.	PUNCT
gs-3214	438	1	ren	ren	PROPN
gs-3214	438	2	,	,	PUNCT
gs-3214	438	3	j.	j.	PROPN
gs-3214	438	4	,	,	PUNCT
gs-3214	438	5	zhang	zhang	PROPN
gs-3214	438	6	,	,	PUNCT
gs-3214	438	7	x.	x.	PROPN
gs-3214	438	8	,	,	PUNCT
gs-3214	438	9	liu	liu	PROPN
gs-3214	438	10	,	,	PUNCT
gs-3214	438	11	x.	x.	PROPN
gs-3214	438	12	,	,	PUNCT
gs-3214	438	13	fang	fang	PROPN
gs-3214	438	14	,	,	PUNCT
gs-3214	438	15	c.	c.	PROPN
gs-3214	438	16	,	,	PUNCT
gs-3214	438	17	jiang	jiang	PROPN
gs-3214	438	18	,	,	PUNCT
gs-3214	438	19	s.	s.	PROPN
gs-3214	438	20	,	,	PUNCT
gs-3214	438	21	june	june	PROPN
gs-3214	438	22	,	,	PUNCT
gs-3214	438	23	c.	c.	PROPN
gs-3214	438	24	h.	h.	PROPN
gs-3214	438	25	,	,	PUNCT
gs-3214	438	26	&	&	CCONJ
gs-3214	438	27	zhao	zhao	PROPN
gs-3214	438	28	,	,	PUNCT
gs-3214	438	29	y.	y.	PROPN
gs-3214	438	30	(	(	PUNCT
gs-3214	438	31	2017	2017	NUM
gs-3214	438	32	)	)	PUNCT
gs-3214	438	33	.	.	PUNCT
gs-3214	439	1	a	a	DET
gs-3214	439	2	versatile	versatile	ADJ
gs-3214	439	3	system	system	NOUN
gs-3214	439	4	for	for	ADP
gs-3214	439	5	rapid	rapid	ADJ
gs-3214	439	6	multiplex	multiplex	NOUN
gs-3214	439	7	genome	genome	NOUN
gs-3214	439	8	-	-	PUNCT
gs-3214	439	9	edited	edit	VERB
gs-3214	439	10	car	car	NOUN
gs-3214	439	11	t	t	NOUN
gs-3214	439	12	cell	cell	NOUN
gs-3214	439	13	generation	generation	NOUN
gs-3214	439	14	.	.	PUNCT
gs-3214	440	1	oncotarget	oncotarget	NOUN
gs-3214	440	2	,	,	PUNCT
gs-3214	440	3	8(10	8(10	NUM
gs-3214	440	4	)	)	PUNCT
gs-3214	440	5	,	,	PUNCT
gs-3214	440	6	17002–17011	17002–17011	NUM
gs-3214	440	7	.	.	X
gs-3214	441	1	13	13	NUM
gs-3214	441	2	.	.	PUNCT
gs-3214	441	3	guedan	guedan	PROPN
gs-3214	441	4	,	,	PUNCT
gs-3214	441	5	s.	s.	PROPN
gs-3214	441	6	,	,	PUNCT
gs-3214	441	7	calderon	calderon	PROPN
gs-3214	441	8	,	,	PUNCT
gs-3214	441	9	h.	h.	PROPN
gs-3214	441	10	,	,	PUNCT
gs-3214	441	11	posey	posey	PROPN
gs-3214	441	12	,	,	PUNCT
gs-3214	441	13	a.	a.	PROPN
gs-3214	441	14	d.	d.	PROPN
gs-3214	441	15	,	,	PUNCT
gs-3214	441	16	maus	maus	PROPN
gs-3214	441	17	,	,	PUNCT
gs-3214	441	18	m.	m.	NOUN
gs-3214	441	19	v.	v.	PROPN
gs-3214	441	20	,	,	PUNCT
gs-3214	441	21	&	&	CCONJ
gs-3214	441	22	june	june	PROPN
gs-3214	441	23	,	,	PUNCT
gs-3214	441	24	c.	c.	PROPN
gs-3214	441	25	h.	h.	PROPN
gs-3214	441	26	(	(	PUNCT
gs-3214	441	27	2019	2019	NUM
gs-3214	441	28	)	)	PUNCT
gs-3214	441	29	.	.	PUNCT
gs-3214	442	1	engineering	engineering	NOUN
gs-3214	442	2	and	and	CCONJ
gs-3214	442	3	design	design	NOUN
gs-3214	442	4	of	of	ADP
gs-3214	442	5	chimeric	chimeric	ADJ
gs-3214	442	6	antigen	antigen	ADJ
gs-3214	442	7	receptors	receptor	NOUN
gs-3214	442	8	.	.	PUNCT
gs-3214	443	1	molecular	molecular	ADJ
gs-3214	443	2	therapy	therapy	NOUN
gs-3214	443	3	–	–	PUNCT
gs-3214	443	4	methods	method	NOUN
gs-3214	443	5	&	&	CCONJ
gs-3214	443	6	clinical	clinical	ADJ
gs-3214	443	7	development	development	NOUN
gs-3214	443	8	,	,	PUNCT
gs-3214	443	9	12	12	NUM
gs-3214	443	10	,	,	PUNCT
gs-3214	443	11	145	145	NUM
gs-3214	443	12	–	–	PUNCT
gs-3214	443	13	156	156	NUM
gs-3214	443	14	.	.	PUNCT
gs-3214	443	15	14	14	NUM
gs-3214	443	16	.	.	X
gs-3214	443	17	levine	levine	PROPN
gs-3214	443	18	,	,	PUNCT
gs-3214	443	19	b.	b.	PROPN
gs-3214	443	20	l.	l.	PROPN
gs-3214	443	21	,	,	PUNCT
gs-3214	443	22	miskin	miskin	PROPN
gs-3214	443	23	,	,	PUNCT
gs-3214	443	24	j.	j.	PROPN
gs-3214	443	25	,	,	PUNCT
gs-3214	443	26	wonnacott	wonnacott	PROPN
gs-3214	443	27	,	,	PUNCT
gs-3214	443	28	k.	k.	PROPN
gs-3214	443	29	,	,	PUNCT
gs-3214	443	30	keir	keir	PROPN
gs-3214	443	31	,	,	PUNCT
gs-3214	443	32	c.	c.	PROPN
gs-3214	443	33	,	,	PUNCT
gs-3214	443	34	&	&	CCONJ
gs-3214	443	35	global	global	PROPN
gs-3214	443	36	,	,	PUNCT
gs-3214	443	37	l.	l.	PROPN
gs-3214	443	38	(	(	PUNCT
gs-3214	443	39	2016	2016	NUM
gs-3214	443	40	)	)	PUNCT
gs-3214	443	41	.	.	PUNCT
gs-3214	444	1	global	global	ADJ
gs-3214	444	2	manufacturing	manufacturing	NOUN
gs-3214	444	3	of	of	ADP
gs-3214	444	4	car	car	NOUN
gs-3214	444	5	t	t	NOUN
gs-3214	444	6	cell	cell	NOUN
gs-3214	444	7	therapy	therapy	NOUN
gs-3214	444	8	.	.	PUNCT
gs-3214	445	1	molecular	molecular	ADJ
gs-3214	445	2	therapy	therapy	NOUN
gs-3214	445	3	–	–	PUNCT
gs-3214	445	4	methods	method	NOUN
gs-3214	445	5	&	&	CCONJ
gs-3214	445	6	clinical	clinical	ADJ
gs-3214	445	7	development	development	NOUN
gs-3214	445	8	,	,	PUNCT
gs-3214	445	9	4	4	NUM
gs-3214	445	10	,	,	PUNCT
gs-3214	445	11	92–101	92–101	NUM
gs-3214	445	12	.	.	PUNCT
gs-3214	446	1	15	15	NUM
gs-3214	446	2	.	.	PUNCT
gs-3214	447	1	gross	gross	PROPN
gs-3214	447	2	,	,	PUNCT
gs-3214	447	3	g.	g.	PROPN
gs-3214	447	4	,	,	PUNCT
gs-3214	447	5	waks	wak	NOUN
gs-3214	447	6	,	,	PUNCT
gs-3214	447	7	t.	t.	PROPN
gs-3214	447	8	,	,	PUNCT
gs-3214	447	9	&	&	CCONJ
gs-3214	447	10	eshhar	eshhar	PROPN
gs-3214	447	11	,	,	PUNCT
gs-3214	447	12	z.	z.	PROPN
gs-3214	447	13	(	(	PUNCT
gs-3214	447	14	1989	1989	NUM
gs-3214	447	15	)	)	PUNCT
gs-3214	447	16	.	.	PUNCT
gs-3214	448	1	expression	expression	NOUN
gs-3214	448	2	of	of	ADP
gs-3214	448	3	immunoglobulin	immunoglobulin	NOUN
gs-3214	448	4	-	-	PUNCT
gs-3214	448	5	t	t	NOUN
gs-3214	448	6	-	-	PUNCT
gs-3214	448	7	cell	cell	NOUN
gs-3214	448	8	receptor	receptor	NOUN
gs-3214	448	9	chimeric	chimeric	ADJ
gs-3214	448	10	molecules	molecule	NOUN
gs-3214	448	11	as	as	ADP
gs-3214	448	12	functional	functional	ADJ
gs-3214	448	13	receptors	receptor	NOUN
gs-3214	448	14	with	with	ADP
gs-3214	448	15	antibody	antibody	NOUN
gs-3214	448	16	-	-	PUNCT
gs-3214	448	17	type	type	NOUN
gs-3214	448	18	specificity	specificity	NOUN
gs-3214	448	19	.	.	PUNCT
gs-3214	449	1	proceedings	proceeding	NOUN
gs-3214	449	2	of	of	ADP
gs-3214	449	3	the	the	DET
gs-3214	449	4	national	national	PROPN
gs-3214	449	5	academy	academy	PROPN
gs-3214	449	6	of	of	ADP
gs-3214	449	7	sciences	sciences	PROPN
gs-3214	449	8	,	,	PUNCT
gs-3214	449	9	86(24	86(24	NUM
gs-3214	449	10	)	)	PUNCT
gs-3214	449	11	,	,	PUNCT
gs-3214	449	12	10024–10028	10024–10028	NUM
gs-3214	449	13	.	.	PUNCT
gs-3214	450	1	16	16	NUM
gs-3214	450	2	.	.	PUNCT
gs-3214	451	1	zah	zah	PROPN
gs-3214	451	2	,	,	PUNCT
gs-3214	451	3	e.	e.	PROPN
gs-3214	451	4	,	,	PUNCT
gs-3214	451	5	lin	lin	PROPN
gs-3214	451	6	,	,	PUNCT
gs-3214	451	7	m.	m.	NOUN
gs-3214	451	8	y.	y.	PROPN
gs-3214	451	9	,	,	PUNCT
gs-3214	451	10	silva	silva	PROPN
gs-3214	451	11	-	-	PUNCT
gs-3214	451	12	benedict	benedict	PROPN
gs-3214	451	13	,	,	PUNCT
gs-3214	451	14	a.	a.	PROPN
gs-3214	451	15	,	,	PUNCT
gs-3214	451	16	jensen	jensen	PROPN
gs-3214	451	17	,	,	PUNCT
gs-3214	451	18	m.	m.	PROPN
gs-3214	451	19	c.	c.	PROPN
gs-3214	451	20	,	,	PUNCT
gs-3214	451	21	&	&	CCONJ
gs-3214	451	22	chen	chen	PROPN
gs-3214	451	23	,	,	PUNCT
gs-3214	451	24	y.	y.	PROPN
gs-3214	451	25	y.	y.	PROPN
gs-3214	451	26	(	(	PUNCT
gs-3214	451	27	2016	2016	NUM
gs-3214	451	28	)	)	PUNCT
gs-3214	451	29	.	.	PUNCT
gs-3214	452	1	t	t	NOUN
gs-3214	452	2	cells	cell	NOUN
gs-3214	452	3	expressing	express	VERB
gs-3214	452	4	cd19	cd19	PROPN
gs-3214	452	5	/	/	SYM
gs-3214	452	6	cd20	cd20	PROPN
gs-3214	452	7	bispecific	bispecific	VERB
gs-3214	452	8	chimeric	chimeric	ADJ
gs-3214	452	9	antigen	antigen	ADJ
gs-3214	452	10	receptors	receptor	NOUN
gs-3214	452	11	prevent	prevent	VERB
gs-3214	452	12	antigen	antigen	ADJ
gs-3214	452	13	escape	escape	NOUN
gs-3214	452	14	by	by	ADP
gs-3214	452	15	malignant	malignant	ADJ
gs-3214	452	16	b	b	NOUN
gs-3214	452	17	cells	cell	NOUN
gs-3214	452	18	.	.	PUNCT
gs-3214	453	1	cancer	cancer	NOUN
gs-3214	453	2	immunology	immunology	NOUN
gs-3214	453	3	research	research	NOUN
gs-3214	453	4	,	,	PUNCT
gs-3214	453	5	4(6	4(6	NUM
gs-3214	453	6	)	)	PUNCT
gs-3214	453	7	,	,	PUNCT
gs-3214	453	8	498–508	498–508	NUM
gs-3214	453	9	.	.	PUNCT
gs-3214	454	1	georgian	georgian	NOUN
gs-3214	454	2	scientists/	scientists/	NUM
gs-3214	454	3	.	.	PUNCT
gs-3214	455	1	6	6	NUM
gs-3214	455	2	n	n	NUM
gs-3214	455	3	3	3	NUM
gs-3214	455	4	,	,	PUNCT
gs-3214	455	5	2024	2024	NUM
gs-3214	455	6	284	284	NUM
gs-3214	455	7	17	17	NUM
gs-3214	455	8	.	.	PUNCT
gs-3214	456	1	lai	lai	PROPN
gs-3214	456	2	,	,	PUNCT
gs-3214	456	3	y.	y.	PROPN
gs-3214	456	4	,	,	PUNCT
gs-3214	456	5	weng	weng	PROPN
gs-3214	456	6	,	,	PUNCT
gs-3214	456	7	j.	j.	PROPN
gs-3214	456	8	,	,	PUNCT
gs-3214	456	9	wei	wei	PROPN
gs-3214	456	10	,	,	PUNCT
gs-3214	456	11	x.	x.	PROPN
gs-3214	456	12	,	,	PUNCT
gs-3214	456	13	qin	qin	PROPN
gs-3214	456	14	,	,	PUNCT
gs-3214	456	15	l.	l.	PROPN
gs-3214	456	16	,	,	PUNCT
gs-3214	456	17	lai	lai	PROPN
gs-3214	456	18	,	,	PUNCT
gs-3214	456	19	p.	p.	PROPN
gs-3214	456	20	,	,	PUNCT
gs-3214	456	21	zhao	zhao	PROPN
gs-3214	456	22	,	,	PUNCT
gs-3214	456	23	r.	r.	PROPN
gs-3214	456	24	,	,	PUNCT
gs-3214	456	25	jiang	jiang	PROPN
gs-3214	456	26	,	,	PUNCT
gs-3214	456	27	z.	z.	PROPN
gs-3214	456	28	,	,	PUNCT
gs-3214	456	29	li	li	PROPN
gs-3214	456	30	,	,	PUNCT
gs-3214	456	31	b.	b.	PROPN
gs-3214	456	32	,	,	PUNCT
gs-3214	456	33	lin	lin	PROPN
gs-3214	456	34	,	,	PUNCT
gs-3214	456	35	s.	s.	PROPN
gs-3214	456	36	,	,	PUNCT
gs-3214	456	37	wang	wang	PROPN
gs-3214	456	38	,	,	PUNCT
gs-3214	456	39	s.	s.	PROPN
gs-3214	456	40	,	,	PUNCT
gs-3214	456	41	wu	wu	PROPN
gs-3214	456	42	,	,	PUNCT
gs-3214	456	43	q.	q.	PROPN
gs-3214	456	44	,	,	PUNCT
gs-3214	456	45	liang	liang	PROPN
gs-3214	456	46	,	,	PUNCT
gs-3214	456	47	q.	q.	PROPN
gs-3214	456	48	,	,	PUNCT
gs-3214	456	49	li	li	PROPN
gs-3214	456	50	,	,	PUNCT
gs-3214	456	51	y.	y.	PROPN
gs-3214	456	52	,	,	PUNCT
gs-3214	456	53	zhang	zhang	PROPN
gs-3214	456	54	,	,	PUNCT
gs-3214	456	55	x.	x.	PROPN
gs-3214	456	56	,	,	PUNCT
gs-3214	456	57	wu	wu	PROPN
gs-3214	456	58	,	,	PUNCT
gs-3214	456	59	y.	y.	PROPN
gs-3214	456	60	,	,	PUNCT
gs-3214	456	61	liu	liu	PROPN
gs-3214	456	62	,	,	PUNCT
gs-3214	456	63	p.	p.	PROPN
gs-3214	456	64	,	,	PUNCT
gs-3214	456	65	&	&	CCONJ
gs-3214	456	66	yao	yao	PROPN
gs-3214	456	67	,	,	PUNCT
gs-3214	456	68	y.	y.	PROPN
gs-3214	456	69	(	(	PUNCT
gs-3214	456	70	2018	2018	NUM
gs-3214	456	71	)	)	PUNCT
gs-3214	456	72	.	.	PUNCT
gs-3214	457	1	toll	toll	NOUN
gs-3214	457	2	-	-	PUNCT
gs-3214	457	3	like	like	ADJ
gs-3214	457	4	receptor	receptor	NOUN
gs-3214	457	5	2	2	NUM
gs-3214	457	6	costimulation	costimulation	NOUN
gs-3214	457	7	potentiates	potentiate	VERB
gs-3214	457	8	the	the	DET
gs-3214	457	9	antitumor	antitumor	PROPN
gs-3214	457	10	efficacy	efficacy	NOUN
gs-3214	457	11	of	of	ADP
gs-3214	457	12	car	car	NOUN
gs-3214	457	13	t	t	NOUN
gs-3214	457	14	cells	cell	NOUN
gs-3214	457	15	.	.	PUNCT
gs-3214	458	1	leukemia	leukemia	NOUN
gs-3214	458	2	,	,	PUNCT
gs-3214	458	3	32(3	32(3	NUM
gs-3214	458	4	)	)	PUNCT
gs-3214	458	5	,	,	PUNCT
gs-3214	458	6	801–808	801–808	NUM
gs-3214	458	7	.	.	NOUN
gs-3214	458	8	18	18	NUM
gs-3214	458	9	.	.	X
gs-3214	458	10	maus	maus	PROPN
gs-3214	458	11	,	,	PUNCT
gs-3214	458	12	m.	m.	NOUN
gs-3214	458	13	v.	v.	PROPN
gs-3214	458	14	,	,	PUNCT
gs-3214	458	15	&	&	CCONJ
gs-3214	458	16	june	june	PROPN
gs-3214	458	17	,	,	PUNCT
gs-3214	458	18	c.	c.	PROPN
gs-3214	458	19	h.	h.	PROPN
gs-3214	458	20	(	(	PUNCT
gs-3214	458	21	2016	2016	NUM
gs-3214	458	22	)	)	PUNCT
gs-3214	458	23	.	.	PUNCT
gs-3214	459	1	making	make	VERB
gs-3214	459	2	better	well	ADJ
gs-3214	459	3	chimeric	chimeric	ADJ
gs-3214	459	4	antigen	antigen	ADJ
gs-3214	459	5	receptors	receptor	NOUN
gs-3214	459	6	for	for	ADP
gs-3214	459	7	adoptive	adoptive	ADJ
gs-3214	459	8	t	t	PROPN
gs-3214	459	9	-	-	PUNCT
gs-3214	459	10	cell	cell	NOUN
gs-3214	459	11	therapy	therapy	NOUN
gs-3214	459	12	.	.	PUNCT
gs-3214	460	1	clinical	clinical	ADJ
gs-3214	460	2	cancer	cancer	NOUN
gs-3214	460	3	research	research	NOUN
gs-3214	460	4	,	,	PUNCT
gs-3214	460	5	22(8	22(8	NUM
gs-3214	460	6	)	)	PUNCT
gs-3214	460	7	,	,	PUNCT
gs-3214	460	8	1875–1884	1875–1884	NUM
gs-3214	460	9	.	.	PUNCT
gs-3214	461	1	19	19	NUM
gs-3214	461	2	.	.	PROPN
gs-3214	461	3	june	june	PROPN
gs-3214	461	4	,	,	PUNCT
gs-3214	461	5	c.	c.	PROPN
gs-3214	461	6	h.	h.	PROPN
gs-3214	461	7	,	,	PUNCT
gs-3214	461	8	&	&	CCONJ
gs-3214	461	9	sadelain	sadelain	PROPN
gs-3214	461	10	,	,	PUNCT
gs-3214	461	11	m.	m.	NOUN
gs-3214	461	12	(	(	PUNCT
gs-3214	461	13	2018	2018	NUM
gs-3214	461	14	)	)	PUNCT
gs-3214	461	15	.	.	PUNCT
gs-3214	462	1	chimeric	chimeric	ADJ
gs-3214	462	2	antigen	antigen	ADJ
gs-3214	462	3	receptor	receptor	NOUN
gs-3214	462	4	therapy	therapy	NOUN
gs-3214	462	5	.	.	PUNCT
gs-3214	463	1	new	new	PROPN
gs-3214	463	2	england	england	PROPN
gs-3214	463	3	journal	journal	PROPN
gs-3214	463	4	of	of	ADP
gs-3214	463	5	medicine	medicine	NOUN
gs-3214	463	6	,	,	PUNCT
gs-3214	463	7	379(1	379(1	NUM
gs-3214	463	8	)	)	PUNCT
gs-3214	463	9	,	,	PUNCT
gs-3214	463	10	64–73	64–73	NOUN
gs-3214	463	11	.	.	PUNCT
gs-3214	464	1	20	20	NUM
gs-3214	464	2	.	.	PUNCT
gs-3214	465	1	zah	zah	PROPN
gs-3214	465	2	,	,	PUNCT
gs-3214	465	3	e.	e.	PROPN
gs-3214	465	4	,	,	PUNCT
gs-3214	465	5	lin	lin	PROPN
gs-3214	465	6	,	,	PUNCT
gs-3214	465	7	m.	m.	NOUN
gs-3214	465	8	y.	y.	PROPN
gs-3214	465	9	,	,	PUNCT
gs-3214	465	10	silva	silva	PROPN
gs-3214	465	11	-	-	PUNCT
gs-3214	465	12	benedict	benedict	PROPN
gs-3214	465	13	,	,	PUNCT
gs-3214	465	14	a.	a.	PROPN
gs-3214	465	15	,	,	PUNCT
gs-3214	465	16	jensen	jensen	PROPN
gs-3214	465	17	,	,	PUNCT
gs-3214	465	18	m.	m.	PROPN
gs-3214	465	19	c.	c.	PROPN
gs-3214	465	20	,	,	PUNCT
gs-3214	465	21	&	&	CCONJ
gs-3214	465	22	chen	chen	PROPN
gs-3214	465	23	,	,	PUNCT
gs-3214	465	24	y.	y.	PROPN
gs-3214	465	25	y.	y.	PROPN
gs-3214	465	26	(	(	PUNCT
gs-3214	465	27	2016	2016	NUM
gs-3214	465	28	)	)	PUNCT
gs-3214	465	29	.	.	PUNCT
gs-3214	466	1	t	t	NOUN
gs-3214	466	2	cells	cell	NOUN
gs-3214	466	3	expressing	express	VERB
gs-3214	466	4	cd19	cd19	PROPN
gs-3214	466	5	/	/	SYM
gs-3214	466	6	cd20	cd20	PROPN
gs-3214	466	7	bispecific	bispecific	VERB
gs-3214	466	8	chimeric	chimeric	ADJ
gs-3214	466	9	antigen	antigen	ADJ
gs-3214	466	10	receptors	receptor	NOUN
gs-3214	466	11	prevent	prevent	VERB
gs-3214	466	12	antigen	antigen	ADJ
gs-3214	466	13	escape	escape	NOUN
gs-3214	466	14	by	by	ADP
gs-3214	466	15	malignant	malignant	ADJ
gs-3214	466	16	b	b	NOUN
gs-3214	466	17	cells	cell	NOUN
gs-3214	466	18	.	.	PUNCT
gs-3214	467	1	cancer	cancer	NOUN
gs-3214	467	2	immunology	immunology	NOUN
gs-3214	467	3	research	research	NOUN
gs-3214	467	4	,	,	PUNCT
gs-3214	467	5	4(6	4(6	NUM
gs-3214	467	6	)	)	PUNCT
gs-3214	467	7	,	,	PUNCT
gs-3214	467	8	498–508	498–508	NUM
gs-3214	467	9	.	.	PUNCT
gs-3214	468	1	21	21	NUM
gs-3214	468	2	.	.	PUNCT
gs-3214	469	1	maude	maude	PROPN
gs-3214	469	2	,	,	PUNCT
gs-3214	469	3	s.	s.	PROPN
gs-3214	469	4	l.	l.	PROPN
gs-3214	469	5	,	,	PUNCT
gs-3214	469	6	&	&	CCONJ
gs-3214	469	7	laetsch	laetsch	PROPN
gs-3214	469	8	,	,	PUNCT
gs-3214	469	9	t.	t.	PROPN
gs-3214	469	10	w.	w.	PROPN
gs-3214	469	11	(	(	PUNCT
gs-3214	469	12	2018	2018	NUM
gs-3214	469	13	)	)	PUNCT
gs-3214	469	14	.	.	PUNCT
gs-3214	470	1	tisagenlecleucel	tisagenlecleucel	VERB
gs-3214	470	2	in	in	ADP
gs-3214	470	3	children	child	NOUN
gs-3214	470	4	and	and	CCONJ
gs-3214	470	5	young	young	ADJ
gs-3214	470	6	adults	adult	NOUN
gs-3214	470	7	with	with	ADP
gs-3214	470	8	b	b	NOUN
gs-3214	470	9	-	-	PUNCT
gs-3214	470	10	cell	cell	NOUN
gs-3214	470	11	lymphoblastic	lymphoblastic	ADJ
gs-3214	470	12	leukemia	leukemia	NOUN
gs-3214	470	13	.	.	PUNCT
gs-3214	471	1	new	new	PROPN
gs-3214	471	2	england	england	PROPN
gs-3214	471	3	journal	journal	PROPN
gs-3214	471	4	of	of	ADP
gs-3214	471	5	medicine	medicine	NOUN
gs-3214	471	6	,	,	PUNCT
gs-3214	471	7	378(5	378(5	NUM
gs-3214	471	8	)	)	PUNCT
gs-3214	471	9	,	,	PUNCT
gs-3214	471	10	439–448	439–448	NUM
gs-3214	471	11	.	.	PUNCT
gs-3214	472	1	22	22	NUM
gs-3214	472	2	.	.	PUNCT
gs-3214	473	1	schuster	schuster	PROPN
gs-3214	473	2	,	,	PUNCT
gs-3214	473	3	s.	s.	PROPN
gs-3214	473	4	j.	j.	PROPN
gs-3214	473	5	,	,	PUNCT
gs-3214	473	6	&	&	CCONJ
gs-3214	473	7	bishop	bishop	PROPN
gs-3214	473	8	,	,	PUNCT
gs-3214	473	9	m.	m.	PROPN
gs-3214	473	10	r.	r.	PROPN
gs-3214	473	11	(	(	PUNCT
gs-3214	473	12	2019	2019	NUM
gs-3214	473	13	)	)	PUNCT
gs-3214	473	14	.	.	PUNCT
gs-3214	474	1	tisagenlecleucel	tisagenlecleucel	VERB
gs-3214	474	2	in	in	ADP
gs-3214	474	3	adult	adult	NOUN
gs-3214	474	4	relapsed	relapse	VERB
gs-3214	474	5	or	or	CCONJ
gs-3214	474	6	refractory	refractory	NOUN
gs-3214	474	7	diffuse	diffuse	VERB
gs-3214	474	8	large	large	ADJ
gs-3214	474	9	b	b	NOUN
gs-3214	474	10	-	-	PUNCT
gs-3214	474	11	cell	cell	NOUN
gs-3214	474	12	lymphoma	lymphoma	NOUN
gs-3214	474	13	.	.	PUNCT
gs-3214	475	1	new	new	PROPN
gs-3214	475	2	england	england	PROPN
gs-3214	475	3	journal	journal	PROPN
gs-3214	475	4	of	of	ADP
gs-3214	475	5	medicine	medicine	NOUN
gs-3214	475	6	,	,	PUNCT
gs-3214	475	7	380(1	380(1	NUM
gs-3214	475	8	)	)	PUNCT
gs-3214	475	9	,	,	PUNCT
gs-3214	475	10	45–56	45–56	NUM
gs-3214	475	11	.	.	PUNCT
gs-3214	476	1	23	23	NUM
gs-3214	476	2	.	.	X
gs-3214	477	1	locke	locke	PROPN
gs-3214	477	2	,	,	PUNCT
gs-3214	477	3	f.	f.	PROPN
gs-3214	477	4	l.	l.	PROPN
gs-3214	477	5	,	,	PUNCT
gs-3214	477	6	&	&	CCONJ
gs-3214	477	7	ghobadi	ghobadi	NOUN
gs-3214	477	8	,	,	PUNCT
gs-3214	477	9	a.	a.	NOUN
gs-3214	477	10	(	(	PUNCT
gs-3214	477	11	2019	2019	NUM
gs-3214	477	12	)	)	PUNCT
gs-3214	477	13	.	.	PUNCT
gs-3214	478	1	long	long	ADJ
gs-3214	478	2	-	-	PUNCT
gs-3214	478	3	term	term	NOUN
gs-3214	478	4	safety	safety	NOUN
gs-3214	478	5	and	and	CCONJ
gs-3214	478	6	activity	activity	NOUN
gs-3214	478	7	of	of	ADP
gs-3214	478	8	axicabtagene	axicabtagene	NOUN
gs-3214	478	9	ciloleucel	ciloleucel	VERB
gs-3214	478	10	in	in	ADP
gs-3214	478	11	refractory	refractory	NOUN
gs-3214	478	12	large	large	ADJ
gs-3214	478	13	b	b	NOUN
gs-3214	478	14	-	-	PUNCT
gs-3214	478	15	cell	cell	NOUN
gs-3214	478	16	lymphoma	lymphoma	NOUN
gs-3214	478	17	(	(	PUNCT
gs-3214	478	18	zuma-1	zuma-1	NUM
gs-3214	478	19	):	):	PUNCT
gs-3214	478	20	a	a	DET
gs-3214	478	21	single	single	ADJ
gs-3214	478	22	-	-	PUNCT
gs-3214	478	23	arm	arm	NOUN
gs-3214	478	24	,	,	PUNCT
gs-3214	478	25	multicentre	multicentre	NOUN
gs-3214	478	26	,	,	PUNCT
gs-3214	478	27	phase	phase	NOUN
gs-3214	478	28	1–2	1–2	DET
gs-3214	478	29	trial	trial	NOUN
gs-3214	478	30	.	.	PUNCT
gs-3214	479	1	the	the	DET
gs-3214	479	2	lancet	lancet	PROPN
gs-3214	479	3	oncology	oncology	NOUN
gs-3214	479	4	,	,	PUNCT
gs-3214	479	5	20(1	20(1	NUM
gs-3214	479	6	)	)	PUNCT
gs-3214	479	7	,	,	PUNCT
gs-3214	479	8	31–42	31–42	NUM
gs-3214	479	9	.	.	PUNCT
gs-3214	479	10	24	24	NUM
gs-3214	479	11	.	.	PUNCT
gs-3214	480	1	neelapu	neelapu	PROPN
gs-3214	480	2	,	,	PUNCT
gs-3214	480	3	s.	s.	PROPN
gs-3214	480	4	s.	s.	PROPN
gs-3214	480	5	,	,	PUNCT
gs-3214	480	6	&	&	CCONJ
gs-3214	480	7	locke	locke	PROPN
gs-3214	480	8	,	,	PUNCT
gs-3214	480	9	f.	f.	PROPN
gs-3214	480	10	l.	l.	PROPN
gs-3214	480	11	(	(	PUNCT
gs-3214	480	12	2017	2017	NUM
gs-3214	480	13	)	)	PUNCT
gs-3214	480	14	.	.	PUNCT
gs-3214	481	1	axicabtagene	axicabtagene	PROPN
gs-3214	481	2	ciloleucel	ciloleucel	PROPN
gs-3214	481	3	car	car	PROPN
gs-3214	481	4	t	t	NOUN
gs-3214	481	5	-	-	PUNCT
gs-3214	481	6	cell	cell	NOUN
gs-3214	481	7	therapy	therapy	NOUN
gs-3214	481	8	in	in	ADP
gs-3214	481	9	refractory	refractory	NOUN
gs-3214	481	10	large	large	ADJ
gs-3214	481	11	b	b	NOUN
gs-3214	481	12	-	-	PUNCT
gs-3214	481	13	cell	cell	NOUN
gs-3214	481	14	lymphoma	lymphoma	NOUN
gs-3214	481	15	.	.	PUNCT
gs-3214	482	1	new	new	PROPN
gs-3214	482	2	england	england	PROPN
gs-3214	482	3	journal	journal	PROPN
gs-3214	482	4	of	of	ADP
gs-3214	482	5	medicine	medicine	NOUN
gs-3214	482	6	,	,	PUNCT
gs-3214	482	7	377(26	377(26	NUM
gs-3214	482	8	)	)	PUNCT
gs-3214	482	9	,	,	PUNCT
gs-3214	482	10	2531–2544	2531–2544	NUM
gs-3214	482	11	.	.	PUNCT
gs-3214	483	1	25	25	NUM
gs-3214	483	2	.	.	PUNCT
gs-3214	484	1	munshi	munshi	PROPN
gs-3214	484	2	,	,	PUNCT
gs-3214	484	3	n.	n.	PROPN
gs-3214	484	4	c.	c.	PROPN
gs-3214	484	5	,	,	PUNCT
gs-3214	484	6	&	&	CCONJ
gs-3214	484	7	anderson	anderson	PROPN
gs-3214	484	8	,	,	PUNCT
gs-3214	484	9	l.	l.	PROPN
gs-3214	484	10	d.	d.	PROPN
gs-3214	484	11	,	,	PUNCT
gs-3214	484	12	jr	jr	PROPN
gs-3214	484	13	.	.	PROPN
gs-3214	484	14	(	(	PUNCT
gs-3214	484	15	2021	2021	NUM
gs-3214	484	16	)	)	PUNCT
gs-3214	484	17	.	.	PUNCT
gs-3214	485	1	idecabtagene	idecabtagene	PROPN
gs-3214	485	2	vicleucel	vicleucel	PROPN
gs-3214	485	3	in	in	ADP
gs-3214	485	4	relapsed	relapse	VERB
gs-3214	485	5	and	and	CCONJ
gs-3214	485	6	refractory	refractory	NOUN
gs-3214	485	7	multiple	multiple	ADJ
gs-3214	485	8	myeloma	myeloma	NOUN
gs-3214	485	9	.	.	PUNCT
gs-3214	486	1	new	new	PROPN
gs-3214	486	2	england	england	PROPN
gs-3214	486	3	journal	journal	PROPN
gs-3214	486	4	of	of	ADP
gs-3214	486	5	medicine	medicine	NOUN
gs-3214	486	6	,	,	PUNCT
gs-3214	486	7	384(8	384(8	NUM
gs-3214	486	8	)	)	PUNCT
gs-3214	486	9	,	,	PUNCT
gs-3214	486	10	705–716	705–716	NUM
gs-3214	486	11	.	.	PUNCT
gs-3214	487	1	26	26	NUM
gs-3214	487	2	.	.	X
gs-3214	487	3	madduri	madduri	PROPN
gs-3214	487	4	,	,	PUNCT
gs-3214	487	5	d.	d.	PROPN
gs-3214	487	6	,	,	PUNCT
gs-3214	487	7	&	&	CCONJ
gs-3214	487	8	berdeja	berdeja	PROPN
gs-3214	487	9	,	,	PUNCT
gs-3214	487	10	j.	j.	PROPN
gs-3214	487	11	g.	g.	PROPN
gs-3214	487	12	(	(	PUNCT
gs-3214	487	13	2021	2021	NUM
gs-3214	487	14	)	)	PUNCT
gs-3214	487	15	.	.	PUNCT
gs-3214	488	1	ciltacabtagene	ciltacabtagene	PROPN
gs-3214	488	2	autoleucel	autoleucel	PROPN
gs-3214	488	3	,	,	PUNCT
gs-3214	488	4	a	a	DET
gs-3214	488	5	b	b	NOUN
gs-3214	488	6	-	-	PUNCT
gs-3214	488	7	cell	cell	NOUN
gs-3214	488	8	maturation	maturation	NOUN
gs-3214	488	9	antigen	antigen	ADV
gs-3214	488	10	–	–	PUNCT
gs-3214	488	11	directed	direct	VERB
gs-3214	488	12	chimeric	chimeric	ADJ
gs-3214	488	13	antigen	antigen	ADJ
gs-3214	488	14	receptor	receptor	NOUN
gs-3214	488	15	t	t	NOUN
gs-3214	488	16	-	-	PUNCT
gs-3214	488	17	cell	cell	NOUN
gs-3214	488	18	therapy	therapy	NOUN
gs-3214	488	19	in	in	ADP
gs-3214	488	20	patients	patient	NOUN
gs-3214	488	21	with	with	ADP
gs-3214	488	22	relapsed	relapse	VERB
gs-3214	488	23	or	or	CCONJ
gs-3214	488	24	refractory	refractory	NOUN
gs-3214	488	25	multiple	multiple	ADJ
gs-3214	488	26	myeloma	myeloma	NOUN
gs-3214	488	27	(	(	PUNCT
gs-3214	488	28	cartitude-1	cartitude-1	NUM
gs-3214	488	29	):	):	PUNCT
gs-3214	488	30	a	a	DET
gs-3214	488	31	phase	phase	NOUN
gs-3214	488	32	1b/2	1b/2	NUM
gs-3214	488	33	open	open	ADJ
gs-3214	488	34	-	-	PUNCT
gs-3214	488	35	label	label	NOUN
gs-3214	488	36	study	study	NOUN
gs-3214	488	37	.	.	PUNCT
gs-3214	489	1	the	the	DET
gs-3214	489	2	lancet	lancet	PROPN
gs-3214	489	3	,	,	PUNCT
gs-3214	489	4	398(10297	398(10297	NUM
gs-3214	489	5	)	)	PUNCT
gs-3214	489	6	,	,	PUNCT
gs-3214	489	7	314–324	314–324	NUM
gs-3214	489	8	.	.	PUNCT
gs-3214	489	9	27	27	NUM
gs-3214	489	10	.	.	X
gs-3214	489	11	brown	brown	PROPN
gs-3214	489	12	,	,	PUNCT
gs-3214	489	13	c.	c.	PROPN
gs-3214	489	14	e.	e.	PROPN
gs-3214	489	15	,	,	PUNCT
gs-3214	489	16	&	&	CCONJ
gs-3214	489	17	alizadeh	alizadeh	PROPN
gs-3214	489	18	,	,	PUNCT
gs-3214	489	19	d.	d.	PROPN
gs-3214	489	20	(	(	PUNCT
gs-3214	489	21	2016	2016	NUM
gs-3214	489	22	)	)	PUNCT
gs-3214	489	23	.	.	PUNCT
gs-3214	490	1	regression	regression	NOUN
gs-3214	490	2	of	of	ADP
gs-3214	490	3	glioblastoma	glioblastoma	NOUN
gs-3214	490	4	after	after	ADP
gs-3214	490	5	chimeric	chimeric	ADJ
gs-3214	490	6	antigen	antigen	ADJ
gs-3214	490	7	receptor	receptor	NOUN
gs-3214	490	8	t	t	NOUN
gs-3214	490	9	-	-	PUNCT
gs-3214	490	10	cell	cell	NOUN
gs-3214	490	11	therapy	therapy	NOUN
gs-3214	490	12	.	.	PUNCT
gs-3214	491	1	new	new	PROPN
gs-3214	491	2	england	england	PROPN
gs-3214	491	3	journal	journal	PROPN
gs-3214	491	4	of	of	ADP
gs-3214	491	5	medicine	medicine	NOUN
gs-3214	491	6	,	,	PUNCT
gs-3214	491	7	375(26	375(26	NUM
gs-3214	491	8	)	)	PUNCT
gs-3214	491	9	,	,	PUNCT
gs-3214	491	10	2561–2569	2561–2569	NUM
gs-3214	491	11	.	.	PUNCT
gs-3214	491	12	28	28	NUM
gs-3214	491	13	.	.	PUNCT
gs-3214	492	1	beatty	beatty	PROPN
gs-3214	492	2	,	,	PUNCT
gs-3214	492	3	g.	g.	PROPN
gs-3214	492	4	l.	l.	PROPN
gs-3214	492	5	,	,	PUNCT
gs-3214	492	6	&	&	CCONJ
gs-3214	492	7	o'hara	o'hara	PROPN
gs-3214	492	8	,	,	PUNCT
gs-3214	492	9	m.	m.	NOUN
gs-3214	492	10	h.	h.	PROPN
gs-3214	492	11	(	(	PUNCT
gs-3214	492	12	2019	2019	NUM
gs-3214	492	13	)	)	PUNCT
gs-3214	492	14	.	.	PUNCT
gs-3214	493	1	activity	activity	NOUN
gs-3214	493	2	of	of	ADP
gs-3214	493	3	mesothelin	mesothelin	NOUN
gs-3214	493	4	-	-	PUNCT
gs-3214	493	5	specific	specific	ADJ
gs-3214	493	6	chimeric	chimeric	ADJ
gs-3214	493	7	antigen	antigen	ADJ
gs-3214	493	8	receptor	receptor	NOUN
gs-3214	493	9	t	t	NOUN
gs-3214	493	10	cells	cell	NOUN
gs-3214	493	11	against	against	ADP
gs-3214	493	12	pancreatic	pancreatic	ADJ
gs-3214	493	13	carcinoma	carcinoma	NOUN
gs-3214	493	14	metastases	metastasis	NOUN
gs-3214	493	15	.	.	PUNCT
gs-3214	493	16	gastroenterology	gastroenterology	NOUN
gs-3214	493	17	,	,	PUNCT
gs-3214	493	18	155(1	155(1	NUM
gs-3214	493	19	)	)	PUNCT
gs-3214	493	20	,	,	PUNCT
gs-3214	493	21	29–32	29–32	NUM
gs-3214	493	22	.	.	PROPN
gs-3214	493	23	29	29	NUM
gs-3214	493	24	.	.	PUNCT
gs-3214	494	1	schuster	schuster	PROPN
gs-3214	494	2	,	,	PUNCT
gs-3214	494	3	s.	s.	PROPN
gs-3214	494	4	j.	j.	PROPN
gs-3214	494	5	,	,	PUNCT
gs-3214	494	6	&	&	CCONJ
gs-3214	494	7	svoboda	svoboda	PROPN
gs-3214	494	8	,	,	PUNCT
gs-3214	494	9	j.	j.	PROPN
gs-3214	494	10	(	(	PUNCT
gs-3214	494	11	2017	2017	NUM
gs-3214	494	12	)	)	PUNCT
gs-3214	494	13	.	.	PUNCT
gs-3214	495	1	chimeric	chimeric	ADJ
gs-3214	495	2	antigen	antigen	ADJ
gs-3214	495	3	receptor	receptor	NOUN
gs-3214	495	4	t	t	NOUN
gs-3214	495	5	cells	cell	NOUN
gs-3214	495	6	in	in	ADP
gs-3214	495	7	refractory	refractory	PROPN
gs-3214	495	8	b	b	NOUN
gs-3214	495	9	-	-	PUNCT
gs-3214	495	10	cell	cell	NOUN
gs-3214	495	11	lymphomas	lymphoma	NOUN
gs-3214	495	12	.	.	PUNCT
gs-3214	496	1	new	new	PROPN
gs-3214	496	2	england	england	PROPN
gs-3214	496	3	journal	journal	PROPN
gs-3214	496	4	of	of	ADP
gs-3214	496	5	medicine	medicine	NOUN
gs-3214	496	6	,	,	PUNCT
gs-3214	496	7	377(26	377(26	NUM
gs-3214	496	8	)	)	PUNCT
gs-3214	496	9	,	,	PUNCT
gs-3214	496	10	2545–2554	2545–2554	NUM
gs-3214	496	11	.	.	PUNCT
gs-3214	497	1	30	30	NUM
gs-3214	497	2	.	.	PUNCT
gs-3214	498	1	abramson	abramson	PROPN
gs-3214	498	2	,	,	PUNCT
gs-3214	498	3	j.	j.	PROPN
gs-3214	498	4	s.	s.	PROPN
gs-3214	498	5	,	,	PUNCT
gs-3214	498	6	&	&	CCONJ
gs-3214	498	7	palomba	palomba	PROPN
gs-3214	498	8	,	,	PUNCT
gs-3214	498	9	m.	m.	NOUN
gs-3214	498	10	l.	l.	PROPN
gs-3214	498	11	(	(	PUNCT
gs-3214	498	12	2020	2020	NUM
gs-3214	498	13	)	)	PUNCT
gs-3214	498	14	.	.	PUNCT
gs-3214	499	1	lisocabtagene	lisocabtagene	PROPN
gs-3214	499	2	maraleucel	maraleucel	PROPN
gs-3214	499	3	for	for	ADP
gs-3214	499	4	patients	patient	NOUN
gs-3214	499	5	with	with	ADP
gs-3214	499	6	relapsed	relapse	VERB
gs-3214	499	7	or	or	CCONJ
gs-3214	499	8	refractory	refractory	NOUN
gs-3214	499	9	large	large	ADJ
gs-3214	499	10	b	b	NOUN
gs-3214	499	11	-	-	PUNCT
gs-3214	499	12	cell	cell	NOUN
gs-3214	499	13	lymphomas	lymphoma	NOUN
gs-3214	499	14	(	(	PUNCT
gs-3214	499	15	transcend	transcend	VERB
gs-3214	499	16	nhl	nhl	PROPN
gs-3214	499	17	001	001	NUM
gs-3214	499	18	):	):	PUNCT
gs-3214	499	19	a	a	DET
gs-3214	499	20	multicentre	multicentre	NOUN
gs-3214	499	21	seamless	seamless	ADJ
gs-3214	499	22	design	design	NOUN
gs-3214	499	23	study	study	NOUN
gs-3214	499	24	.	.	PUNCT
gs-3214	500	1	the	the	DET
gs-3214	500	2	lancet	lancet	PROPN
gs-3214	500	3	,	,	PUNCT
gs-3214	500	4	396(10254	396(10254	NUM
gs-3214	500	5	)	)	PUNCT
gs-3214	500	6	,	,	PUNCT
gs-3214	500	7	839–852	839–852	NUM
gs-3214	500	8	.	.	NOUN
gs-3214	500	9	31	31	NUM
gs-3214	500	10	.	.	PUNCT
gs-3214	501	1	teachey	teachey	PROPN
gs-3214	501	2	,	,	PUNCT
gs-3214	501	3	d.	d.	PROPN
gs-3214	501	4	t.	t.	PROPN
gs-3214	501	5	,	,	PUNCT
gs-3214	501	6	&	&	CCONJ
gs-3214	501	7	lacey	lacey	PROPN
gs-3214	501	8	,	,	PUNCT
gs-3214	501	9	s.	s.	PROPN
gs-3214	501	10	f.	f.	PROPN
gs-3214	501	11	(	(	PUNCT
gs-3214	501	12	2016	2016	NUM
gs-3214	501	13	)	)	PUNCT
gs-3214	501	14	.	.	PUNCT
gs-3214	502	1	cytokine	cytokine	ADJ
gs-3214	502	2	release	release	NOUN
gs-3214	502	3	syndrome	syndrome	NOUN
gs-3214	502	4	after	after	ADP
gs-3214	502	5	chimeric	chimeric	ADJ
gs-3214	502	6	antigen	antigen	ADJ
gs-3214	502	7	receptor	receptor	NOUN
gs-3214	502	8	t	t	NOUN
gs-3214	502	9	cell	cell	NOUN
gs-3214	502	10	therapy	therapy	NOUN
gs-3214	502	11	for	for	ADP
gs-3214	502	12	acute	acute	ADJ
gs-3214	502	13	lymphoblastic	lymphoblastic	ADJ
gs-3214	502	14	leukemia	leukemia	NOUN
gs-3214	502	15	.	.	PUNCT
gs-3214	503	1	critical	critical	ADJ
gs-3214	503	2	care	care	NOUN
gs-3214	503	3	medicine	medicine	NOUN
gs-3214	503	4	,	,	PUNCT
gs-3214	503	5	44(1	44(1	PROPN
gs-3214	503	6	)	)	PUNCT
gs-3214	503	7	,	,	PUNCT
gs-3214	503	8	225–234	225–234	NUM
gs-3214	503	9	.	.	PUNCT
gs-3214	504	1	32	32	NUM
gs-3214	504	2	.	.	PUNCT
gs-3214	505	1	lee	lee	PROPN
gs-3214	505	2	,	,	PUNCT
gs-3214	505	3	d.	d.	PROPN
gs-3214	505	4	w.	w.	PROPN
gs-3214	505	5	,	,	PUNCT
gs-3214	505	6	&	&	CCONJ
gs-3214	505	7	kochenderfer	kochenderfer	PROPN
gs-3214	505	8	,	,	PUNCT
gs-3214	505	9	j.	j.	PROPN
gs-3214	505	10	n.	n.	PROPN
gs-3214	505	11	(	(	PUNCT
gs-3214	505	12	2015	2015	NUM
gs-3214	505	13	)	)	PUNCT
gs-3214	505	14	.	.	PUNCT
gs-3214	506	1	cytokine	cytokine	ADJ
gs-3214	506	2	release	release	NOUN
gs-3214	506	3	syndrome	syndrome	NOUN
gs-3214	506	4	in	in	ADP
gs-3214	506	5	cancer	cancer	NOUN
gs-3214	506	6	immunotherapy	immunotherapy	NOUN
gs-3214	506	7	.	.	PUNCT
gs-3214	507	1	cytokine	cytokine	VERB
gs-3214	507	2	&	&	CCONJ
gs-3214	507	3	growth	growth	NOUN
gs-3214	507	4	factor	factor	NOUN
gs-3214	507	5	reviews	review	NOUN
gs-3214	507	6	,	,	PUNCT
gs-3214	507	7	24(3	24(3	NUM
gs-3214	507	8	)	)	PUNCT
gs-3214	507	9	,	,	PUNCT
gs-3214	507	10	127–134	127–134	NUM
gs-3214	507	11	.	.	PUNCT
gs-3214	508	1	georgian	georgian	NOUN
gs-3214	508	2	scientists/	scientists/	NUM
gs-3214	508	3	.	.	PUNCT
gs-3214	509	1	6	6	NUM
gs-3214	509	2	n	n	NUM
gs-3214	509	3	3	3	NUM
gs-3214	509	4	,	,	PUNCT
gs-3214	509	5	2024	2024	NUM
gs-3214	509	6	285	285	NUM
gs-3214	509	7	33	33	NUM
gs-3214	509	8	.	.	PUNCT
gs-3214	510	1	davila	davila	PROPN
gs-3214	510	2	,	,	PUNCT
gs-3214	510	3	m.	m.	PROPN
gs-3214	510	4	l.	l.	PROPN
gs-3214	510	5	,	,	PUNCT
gs-3214	510	6	&	&	CCONJ
gs-3214	510	7	brentjens	brentjen	NOUN
gs-3214	510	8	,	,	PUNCT
gs-3214	510	9	r.	r.	PROPN
gs-3214	510	10	j.	j.	PROPN
gs-3214	510	11	(	(	PUNCT
gs-3214	510	12	2011	2011	NUM
gs-3214	510	13	)	)	PUNCT
gs-3214	510	14	.	.	PUNCT
gs-3214	511	1	cd19	cd19	PROPN
gs-3214	511	2	-	-	PUNCT
gs-3214	511	3	targeted	target	VERB
gs-3214	511	4	car	car	NOUN
gs-3214	511	5	t	t	NOUN
gs-3214	511	6	cells	cell	NOUN
gs-3214	511	7	as	as	ADP
gs-3214	511	8	novel	novel	ADJ
gs-3214	511	9	cancer	cancer	NOUN
gs-3214	511	10	immunotherapy	immunotherapy	NOUN
gs-3214	511	11	for	for	ADP
gs-3214	511	12	relapsed	relapse	VERB
gs-3214	511	13	or	or	CCONJ
gs-3214	511	14	refractory	refractory	NOUN
gs-3214	511	15	b	b	NOUN
gs-3214	511	16	-	-	PUNCT
gs-3214	511	17	cell	cell	NOUN
gs-3214	511	18	acute	acute	ADJ
gs-3214	511	19	lymphoblastic	lymphoblastic	ADJ
gs-3214	511	20	leukemia	leukemia	NOUN
gs-3214	511	21	.	.	PUNCT
gs-3214	512	1	clinical	clinical	ADJ
gs-3214	512	2	cancer	cancer	NOUN
gs-3214	512	3	research	research	NOUN
gs-3214	512	4	,	,	PUNCT
gs-3214	512	5	17(6	17(6	NUM
gs-3214	512	6	)	)	PUNCT
gs-3214	512	7	,	,	PUNCT
gs-3214	512	8	1452–1460	1452–1460	NUM
gs-3214	512	9	.	.	PUNCT
gs-3214	513	1	34	34	NUM
gs-3214	513	2	.	.	PUNCT
gs-3214	513	3	maude	maude	PROPN
gs-3214	513	4	,	,	PUNCT
gs-3214	513	5	s.	s.	PROPN
gs-3214	513	6	l.	l.	PROPN
gs-3214	513	7	,	,	PUNCT
gs-3214	513	8	&	&	CCONJ
gs-3214	513	9	barrett	barrett	PROPN
gs-3214	513	10	,	,	PUNCT
gs-3214	513	11	d.	d.	PROPN
gs-3214	513	12	m.	m.	PROPN
gs-3214	513	13	(	(	PUNCT
gs-3214	513	14	2014	2014	NUM
gs-3214	513	15	)	)	PUNCT
gs-3214	513	16	.	.	PUNCT
gs-3214	514	1	managing	manage	VERB
gs-3214	514	2	cytokine	cytokine	NOUN
gs-3214	514	3	release	release	NOUN
gs-3214	514	4	syndrome	syndrome	NOUN
gs-3214	514	5	associated	associate	VERB
gs-3214	514	6	with	with	ADP
gs-3214	514	7	novel	novel	ADJ
gs-3214	514	8	t	t	NOUN
gs-3214	514	9	cell	cell	NOUN
gs-3214	514	10	-	-	PUNCT
gs-3214	514	11	engaging	engage	VERB
gs-3214	514	12	therapies	therapy	NOUN
gs-3214	514	13	.	.	PUNCT
gs-3214	515	1	cancer	cancer	NOUN
gs-3214	515	2	journal	journal	NOUN
gs-3214	515	3	,	,	PUNCT
gs-3214	515	4	20(2	20(2	NUM
gs-3214	515	5	)	)	PUNCT
gs-3214	515	6	,	,	PUNCT
gs-3214	515	7	119–122	119–122	NUM
gs-3214	515	8	.	.	NOUN
gs-3214	515	9	35	35	NUM
gs-3214	515	10	.	.	PUNCT
gs-3214	516	1	neelapu	neelapu	PROPN
gs-3214	516	2	,	,	PUNCT
gs-3214	516	3	s.	s.	PROPN
gs-3214	516	4	s.	s.	PROPN
gs-3214	516	5	,	,	PUNCT
gs-3214	516	6	&	&	CCONJ
gs-3214	516	7	tummala	tummala	PROPN
gs-3214	516	8	,	,	PUNCT
gs-3214	516	9	s.	s.	PROPN
gs-3214	516	10	(	(	PUNCT
gs-3214	516	11	2018	2018	NUM
gs-3214	516	12	)	)	PUNCT
gs-3214	516	13	.	.	PUNCT
gs-3214	517	1	chimeric	chimeric	ADJ
gs-3214	517	2	antigen	antigen	ADJ
gs-3214	517	3	receptor	receptor	NOUN
gs-3214	517	4	t	t	NOUN
gs-3214	517	5	-	-	PUNCT
gs-3214	517	6	cell	cell	NOUN
gs-3214	517	7	therapy	therapy	NOUN
gs-3214	517	8	—	—	PUNCT
gs-3214	517	9	assessment	assessment	NOUN
gs-3214	517	10	and	and	CCONJ
gs-3214	517	11	management	management	NOUN
gs-3214	517	12	of	of	ADP
gs-3214	517	13	toxicities	toxicity	NOUN
gs-3214	517	14	.	.	PUNCT
gs-3214	518	1	nature	nature	NOUN
gs-3214	518	2	reviews	review	VERB
gs-3214	518	3	clinical	clinical	ADJ
gs-3214	518	4	oncology	oncology	NOUN
gs-3214	518	5	,	,	PUNCT
gs-3214	518	6	15(1	15(1	NUM
gs-3214	518	7	)	)	PUNCT
gs-3214	518	8	,	,	PUNCT
gs-3214	518	9	47–62	47–62	NUM
gs-3214	518	10	.	.	NOUN
gs-3214	519	1	36	36	NUM
gs-3214	519	2	.	.	PUNCT
gs-3214	519	3	santomasso	santomasso	PROPN
gs-3214	519	4	,	,	PUNCT
gs-3214	519	5	b.	b.	PROPN
gs-3214	519	6	d.	d.	PROPN
gs-3214	519	7	,	,	PUNCT
gs-3214	519	8	&	&	CCONJ
gs-3214	519	9	park	park	PROPN
gs-3214	519	10	,	,	PUNCT
gs-3214	519	11	j.	j.	PROPN
gs-3214	519	12	h.	h.	PROPN
gs-3214	519	13	(	(	PUNCT
gs-3214	519	14	2018	2018	NUM
gs-3214	519	15	)	)	PUNCT
gs-3214	519	16	.	.	PUNCT
gs-3214	520	1	clinical	clinical	ADJ
gs-3214	520	2	and	and	CCONJ
gs-3214	520	3	biological	biological	ADJ
gs-3214	520	4	correlates	correlate	NOUN
gs-3214	520	5	of	of	ADP
gs-3214	520	6	neurotoxicity	neurotoxicity	NOUN
gs-3214	520	7	associated	associate	VERB
gs-3214	520	8	with	with	ADP
gs-3214	520	9	car	car	NOUN
gs-3214	520	10	t	t	NOUN
gs-3214	520	11	-	-	PUNCT
gs-3214	520	12	cell	cell	NOUN
gs-3214	520	13	therapy	therapy	NOUN
gs-3214	520	14	in	in	ADP
gs-3214	520	15	patients	patient	NOUN
gs-3214	520	16	with	with	ADP
gs-3214	520	17	b	b	NOUN
gs-3214	520	18	-	-	PUNCT
gs-3214	520	19	cell	cell	NOUN
gs-3214	520	20	acute	acute	ADJ
gs-3214	520	21	lymphoblastic	lymphoblastic	ADJ
gs-3214	520	22	leukemia	leukemia	NOUN
gs-3214	520	23	.	.	PUNCT
gs-3214	521	1	cancer	cancer	NOUN
gs-3214	521	2	discovery	discovery	PROPN
gs-3214	521	3	,	,	PUNCT
gs-3214	521	4	8(8	8(8	NUM
gs-3214	521	5	)	)	PUNCT
gs-3214	521	6	,	,	PUNCT
gs-3214	521	7	958–971	958–971	NUM
gs-3214	521	8	.	.	PUNCT
gs-3214	522	1	37	37	NUM
gs-3214	522	2	.	.	PUNCT
gs-3214	523	1	brudno	brudno	PROPN
gs-3214	523	2	,	,	PUNCT
gs-3214	523	3	j.	j.	PROPN
gs-3214	523	4	n.	n.	PROPN
gs-3214	523	5	,	,	PUNCT
gs-3214	523	6	&	&	CCONJ
gs-3214	523	7	kochenderfer	kochenderfer	PROPN
gs-3214	523	8	,	,	PUNCT
gs-3214	523	9	j.	j.	PROPN
gs-3214	523	10	n.	n.	PROPN
gs-3214	523	11	(	(	PUNCT
gs-3214	523	12	2016	2016	NUM
gs-3214	523	13	)	)	PUNCT
gs-3214	523	14	.	.	PUNCT
gs-3214	524	1	toxicities	toxicity	NOUN
gs-3214	524	2	of	of	ADP
gs-3214	524	3	chimeric	chimeric	ADJ
gs-3214	524	4	antigen	antigen	ADJ
gs-3214	524	5	receptor	receptor	NOUN
gs-3214	524	6	t	t	NOUN
gs-3214	524	7	cells	cell	NOUN
gs-3214	524	8	:	:	PUNCT
gs-3214	524	9	recognition	recognition	NOUN
gs-3214	524	10	and	and	CCONJ
gs-3214	524	11	management	management	NOUN
gs-3214	524	12	.	.	PUNCT
gs-3214	525	1	blood	blood	NOUN
gs-3214	525	2	,	,	PUNCT
gs-3214	525	3	127(26	127(26	NUM
gs-3214	525	4	)	)	PUNCT
gs-3214	525	5	,	,	PUNCT
gs-3214	525	6	3321–3330	3321–3330	NUM
gs-3214	525	7	.	.	X
gs-3214	525	8	38	38	NUM
gs-3214	525	9	.	.	PUNCT
gs-3214	526	1	gust	gust	PROPN
gs-3214	526	2	,	,	PUNCT
gs-3214	526	3	j.	j.	PROPN
gs-3214	526	4	,	,	PUNCT
gs-3214	526	5	&	&	CCONJ
gs-3214	526	6	taraseviciute	taraseviciute	NOUN
gs-3214	526	7	,	,	PUNCT
gs-3214	526	8	a.	a.	NOUN
gs-3214	526	9	(	(	PUNCT
gs-3214	526	10	2017	2017	NUM
gs-3214	526	11	)	)	PUNCT
gs-3214	526	12	.	.	PUNCT
gs-3214	527	1	endothelial	endothelial	ADJ
gs-3214	527	2	activation	activation	NOUN
gs-3214	527	3	and	and	CCONJ
gs-3214	527	4	blood	blood	NOUN
gs-3214	527	5	-	-	PUNCT
gs-3214	527	6	brain	brain	NOUN
gs-3214	527	7	barrier	barrier	NOUN
gs-3214	527	8	disruption	disruption	NOUN
gs-3214	527	9	in	in	ADP
gs-3214	527	10	neurotoxicity	neurotoxicity	NOUN
gs-3214	527	11	after	after	ADP
gs-3214	527	12	adoptive	adoptive	ADJ
gs-3214	527	13	immunotherapy	immunotherapy	NOUN
gs-3214	527	14	with	with	ADP
gs-3214	527	15	cd19	cd19	PROPN
gs-3214	527	16	car	car	NOUN
gs-3214	527	17	-	-	PUNCT
gs-3214	527	18	t	t	NOUN
gs-3214	527	19	cells	cell	NOUN
gs-3214	527	20	.	.	PUNCT
gs-3214	528	1	cancer	cancer	NOUN
gs-3214	528	2	discovery	discovery	NOUN
gs-3214	528	3	,	,	PUNCT
gs-3214	528	4	7(12	7(12	NUM
gs-3214	528	5	)	)	PUNCT
gs-3214	528	6	,	,	PUNCT
gs-3214	528	7	1404–1419	1404–1419	NUM
gs-3214	528	8	.	.	NOUN
gs-3214	528	9	39	39	NUM
gs-3214	528	10	.	.	PUNCT
gs-3214	529	1	ahmed	ahmed	PROPN
gs-3214	529	2	,	,	PUNCT
gs-3214	529	3	n.	n.	PROPN
gs-3214	529	4	,	,	PUNCT
gs-3214	529	5	&	&	CCONJ
gs-3214	529	6	brawley	brawley	PROPN
gs-3214	529	7	,	,	PUNCT
gs-3214	529	8	v.	v.	ADP
gs-3214	529	9	s.	s.	PROPN
gs-3214	529	10	(	(	PUNCT
gs-3214	529	11	2015	2015	NUM
gs-3214	529	12	)	)	PUNCT
gs-3214	529	13	.	.	PUNCT
gs-3214	530	1	human	human	ADJ
gs-3214	530	2	epidermal	epidermal	ADJ
gs-3214	530	3	growth	growth	NOUN
gs-3214	530	4	factor	factor	NOUN
gs-3214	530	5	receptor	receptor	NOUN
gs-3214	530	6	2	2	NUM
gs-3214	530	7	(	(	PUNCT
gs-3214	530	8	her2	her2	PROPN
gs-3214	530	9	)	)	PUNCT
gs-3214	530	10	-specific	-specific	PROPN
gs-3214	530	11	chimeric	chimeric	ADJ
gs-3214	530	12	antigen	antigen	ADJ
gs-3214	530	13	receptor	receptor	NOUN
gs-3214	530	14	-	-	PUNCT
gs-3214	530	15	modified	modify	VERB
gs-3214	530	16	t	t	NOUN
gs-3214	530	17	cells	cell	NOUN
gs-3214	530	18	for	for	ADP
gs-3214	530	19	the	the	DET
gs-3214	530	20	immunotherapy	immunotherapy	NOUN
gs-3214	530	21	of	of	ADP
gs-3214	530	22	her2	her2	PROPN
gs-3214	530	23	-	-	PUNCT
gs-3214	530	24	positive	positive	ADJ
gs-3214	530	25	sarcoma	sarcoma	NOUN
gs-3214	530	26	.	.	PUNCT
gs-3214	531	1	journal	journal	NOUN
gs-3214	531	2	of	of	ADP
gs-3214	531	3	clinical	clinical	ADJ
gs-3214	531	4	oncology	oncology	NOUN
gs-3214	531	5	,	,	PUNCT
gs-3214	531	6	33(15	33(15	NUM
gs-3214	531	7	)	)	PUNCT
gs-3214	531	8	,	,	PUNCT
gs-3214	531	9	1688–1696	1688–1696	NUM
gs-3214	531	10	.	.	PUNCT
gs-3214	532	1	40	40	NUM
gs-3214	532	2	.	.	PUNCT
gs-3214	532	3	di	di	PROPN
gs-3214	532	4	stasi	stasi	PROPN
gs-3214	532	5	,	,	PUNCT
gs-3214	532	6	a.	a.	PROPN
gs-3214	532	7	,	,	PUNCT
gs-3214	532	8	&	&	CCONJ
gs-3214	532	9	tey	tey	PROPN
gs-3214	532	10	,	,	PUNCT
gs-3214	532	11	s.	s.	PROPN
gs-3214	532	12	k.	k.	PROPN
gs-3214	532	13	(	(	PUNCT
gs-3214	532	14	2011	2011	NUM
gs-3214	532	15	)	)	PUNCT
gs-3214	532	16	.	.	PUNCT
gs-3214	533	1	inducible	inducible	ADJ
gs-3214	533	2	apoptosis	apoptosis	NOUN
gs-3214	533	3	as	as	ADP
gs-3214	533	4	a	a	DET
gs-3214	533	5	safety	safety	NOUN
gs-3214	533	6	switch	switch	NOUN
gs-3214	533	7	for	for	ADP
gs-3214	533	8	adoptive	adoptive	ADJ
gs-3214	533	9	cell	cell	NOUN
gs-3214	533	10	therapy	therapy	NOUN
gs-3214	533	11	.	.	PUNCT
gs-3214	534	1	new	new	PROPN
gs-3214	534	2	england	england	PROPN
gs-3214	534	3	journal	journal	PROPN
gs-3214	534	4	of	of	ADP
gs-3214	534	5	medicine	medicine	NOUN
gs-3214	534	6	,	,	PUNCT
gs-3214	534	7	365(18	365(18	NUM
gs-3214	534	8	)	)	PUNCT
gs-3214	534	9	,	,	PUNCT
gs-3214	534	10	1673–1683	1673–1683	NUM
gs-3214	534	11	.	.	PUNCT
gs-3214	535	1	41	41	NUM
gs-3214	535	2	.	.	PUNCT
gs-3214	536	1	chmielewski	chmielewski	ADJ
gs-3214	536	2	,	,	PUNCT
gs-3214	536	3	m.	m.	NOUN
gs-3214	536	4	,	,	PUNCT
gs-3214	536	5	&	&	CCONJ
gs-3214	536	6	hombach	hombach	PROPN
gs-3214	536	7	,	,	PUNCT
gs-3214	536	8	a.	a.	NOUN
gs-3214	536	9	(	(	PUNCT
gs-3214	536	10	2014	2014	NUM
gs-3214	536	11	)	)	PUNCT
gs-3214	536	12	.	.	PUNCT
gs-3214	537	1	abstraction	abstraction	NOUN
gs-3214	537	2	and	and	CCONJ
gs-3214	537	3	targeting	targeting	NOUN
gs-3214	537	4	of	of	ADP
gs-3214	537	5	cd133	cd133	PROPN
gs-3214	537	6	+	+	CCONJ
gs-3214	537	7	cancer	cancer	NOUN
gs-3214	537	8	stem	stem	NOUN
gs-3214	537	9	cells	cell	NOUN
gs-3214	537	10	by	by	ADP
gs-3214	537	11	bispecific	bispecific	NOUN
gs-3214	537	12	epitope	epitope	NOUN
gs-3214	537	13	-	-	PUNCT
gs-3214	537	14	targeting	target	VERB
gs-3214	537	15	receptor	receptor	NOUN
gs-3214	537	16	redirected	redirect	VERB
gs-3214	537	17	t	t	NOUN
gs-3214	537	18	cells	cell	NOUN
gs-3214	537	19	.	.	PUNCT
gs-3214	538	1	cancer	cancer	NOUN
gs-3214	538	2	research	research	NOUN
gs-3214	538	3	,	,	PUNCT
gs-3214	538	4	73(14	73(14	NOUN
gs-3214	538	5	)	)	PUNCT
gs-3214	538	6	,	,	PUNCT
gs-3214	538	7	5695–5706	5695–5706	NUM
gs-3214	538	8	.	.	NOUN
gs-3214	538	9	42	42	NUM
gs-3214	538	10	.	.	PUNCT
gs-3214	539	1	porter	porter	PROPN
gs-3214	539	2	,	,	PUNCT
gs-3214	539	3	d.	d.	PROPN
gs-3214	539	4	l.	l.	PROPN
gs-3214	539	5	,	,	PUNCT
gs-3214	539	6	&	&	CCONJ
gs-3214	539	7	hwang	hwang	PROPN
gs-3214	539	8	,	,	PUNCT
gs-3214	539	9	w.	w.	PROPN
gs-3214	539	10	t.	t.	PROPN
gs-3214	539	11	(	(	PUNCT
gs-3214	539	12	2015	2015	NUM
gs-3214	539	13	)	)	PUNCT
gs-3214	539	14	.	.	PUNCT
gs-3214	540	1	chimeric	chimeric	ADJ
gs-3214	540	2	antigen	antigen	ADJ
gs-3214	540	3	receptor	receptor	NOUN
gs-3214	540	4	t	t	NOUN
gs-3214	540	5	cells	cell	NOUN
gs-3214	540	6	persist	persist	VERB
gs-3214	540	7	and	and	CCONJ
gs-3214	540	8	induce	induce	VERB
gs-3214	540	9	sustained	sustained	ADJ
gs-3214	540	10	remissions	remission	NOUN
gs-3214	540	11	in	in	ADP
gs-3214	540	12	relapsed	relapse	VERB
gs-3214	540	13	refractory	refractory	NOUN
gs-3214	540	14	chronic	chronic	ADJ
gs-3214	540	15	lymphocytic	lymphocytic	ADJ
gs-3214	540	16	leukemia	leukemia	NOUN
gs-3214	540	17	.	.	PUNCT
gs-3214	541	1	science	science	NOUN
gs-3214	541	2	translational	translational	ADJ
gs-3214	541	3	medicine	medicine	NOUN
gs-3214	541	4	,	,	PUNCT
gs-3214	541	5	7(303	7(303	PROPN
gs-3214	541	6	)	)	PUNCT
gs-3214	541	7	,	,	PUNCT
gs-3214	541	8	303ra139	303ra139	NUM
gs-3214	541	9	.	.	PROPN
gs-3214	542	1	43	43	NUM
gs-3214	542	2	.	.	PUNCT
gs-3214	542	3	kochenderfer	kochenderfer	NOUN
gs-3214	542	4	,	,	PUNCT
gs-3214	542	5	j.	j.	PROPN
gs-3214	542	6	n.	n.	PROPN
gs-3214	542	7	,	,	PUNCT
gs-3214	542	8	&	&	CCONJ
gs-3214	542	9	somerville	somerville	PROPN
gs-3214	542	10	,	,	PUNCT
gs-3214	542	11	r.	r.	PROPN
gs-3214	542	12	p.	p.	PROPN
gs-3214	542	13	(	(	PUNCT
gs-3214	542	14	2017	2017	NUM
gs-3214	542	15	)	)	PUNCT
gs-3214	542	16	.	.	PUNCT
gs-3214	543	1	lymphoma	lymphoma	NOUN
gs-3214	543	2	remissions	remission	NOUN
gs-3214	543	3	caused	cause	VERB
gs-3214	543	4	by	by	ADP
gs-3214	543	5	anti	anti	ADJ
gs-3214	543	6	-	-	ADJ
gs-3214	543	7	cd19	cd19	ADJ
gs-3214	543	8	chimeric	chimeric	ADJ
gs-3214	543	9	antigen	antigen	ADJ
gs-3214	543	10	receptor	receptor	NOUN
gs-3214	543	11	t	t	NOUN
gs-3214	543	12	cells	cell	NOUN
gs-3214	543	13	are	be	AUX
gs-3214	543	14	associated	associate	VERB
gs-3214	543	15	with	with	ADP
gs-3214	543	16	high	high	ADJ
gs-3214	543	17	serum	serum	NOUN
gs-3214	543	18	interleukin-15	interleukin-15	PROPN
gs-3214	543	19	levels	level	NOUN
gs-3214	543	20	.	.	PUNCT
gs-3214	544	1	journal	journal	NOUN
gs-3214	544	2	of	of	ADP
gs-3214	544	3	clinical	clinical	ADJ
gs-3214	544	4	oncology	oncology	NOUN
gs-3214	544	5	,	,	PUNCT
gs-3214	544	6	35(16	35(16	NUM
gs-3214	544	7	)	)	PUNCT
gs-3214	544	8	,	,	PUNCT
gs-3214	544	9	1803–1813	1803–1813	NUM
gs-3214	544	10	.	.	PUNCT
gs-3214	545	1	44	44	NUM
gs-3214	545	2	.	.	PUNCT
gs-3214	545	3	fry	fry	PROPN
gs-3214	545	4	,	,	PUNCT
gs-3214	545	5	t.	t.	PROPN
gs-3214	545	6	j.	j.	PROPN
gs-3214	545	7	,	,	PUNCT
gs-3214	545	8	&	&	CCONJ
gs-3214	545	9	shah	shah	PROPN
gs-3214	545	10	,	,	PUNCT
gs-3214	545	11	n.	n.	PROPN
gs-3214	545	12	n.	n.	PROPN
gs-3214	545	13	(	(	PUNCT
gs-3214	545	14	2018	2018	NUM
gs-3214	545	15	)	)	PUNCT
gs-3214	545	16	.	.	PUNCT
gs-3214	546	1	cd22	cd22	PROPN
gs-3214	546	2	-	-	PUNCT
gs-3214	546	3	targeted	target	VERB
gs-3214	546	4	car	car	NOUN
gs-3214	546	5	t	t	NOUN
gs-3214	546	6	cells	cell	NOUN
gs-3214	546	7	induce	induce	VERB
gs-3214	546	8	remission	remission	NOUN
gs-3214	546	9	in	in	ADP
gs-3214	546	10	b	b	NOUN
gs-3214	546	11	-	-	PUNCT
gs-3214	546	12	all	all	DET
gs-3214	546	13	that	that	PRON
gs-3214	546	14	is	be	AUX
gs-3214	546	15	naive	naive	ADJ
gs-3214	546	16	or	or	CCONJ
gs-3214	546	17	resistant	resistant	ADJ
gs-3214	546	18	to	to	ADP
gs-3214	546	19	cd19	cd19	PROPN
gs-3214	546	20	-	-	PUNCT
gs-3214	546	21	targeted	target	VERB
gs-3214	546	22	car	car	NOUN
gs-3214	546	23	immunotherapy	immunotherapy	NOUN
gs-3214	546	24	.	.	PUNCT
gs-3214	547	1	nature	nature	NOUN
gs-3214	547	2	medicine	medicine	NOUN
gs-3214	547	3	,	,	PUNCT
gs-3214	547	4	24(1	24(1	NUM
gs-3214	547	5	)	)	PUNCT
gs-3214	547	6	,	,	PUNCT
gs-3214	547	7	20–28	20–28	NUM
gs-3214	547	8	.	.	PUNCT
gs-3214	548	1	45	45	NUM
gs-3214	548	2	.	.	PUNCT
gs-3214	549	1	schuster	schuster	PROPN
gs-3214	549	2	,	,	PUNCT
gs-3214	549	3	s.	s.	PROPN
gs-3214	549	4	j.	j.	PROPN
gs-3214	549	5	,	,	PUNCT
gs-3214	549	6	&	&	CCONJ
gs-3214	549	7	svoboda	svoboda	PROPN
gs-3214	549	8	,	,	PUNCT
gs-3214	549	9	j.	j.	PROPN
gs-3214	549	10	(	(	PUNCT
gs-3214	549	11	2017	2017	NUM
gs-3214	549	12	)	)	PUNCT
gs-3214	549	13	.	.	PUNCT
gs-3214	550	1	chimeric	chimeric	ADJ
gs-3214	550	2	antigen	antigen	ADJ
gs-3214	550	3	receptor	receptor	NOUN
gs-3214	550	4	t	t	NOUN
gs-3214	550	5	cells	cell	NOUN
gs-3214	550	6	in	in	ADP
gs-3214	550	7	refractory	refractory	PROPN
gs-3214	550	8	b	b	NOUN
gs-3214	550	9	-	-	PUNCT
gs-3214	550	10	cell	cell	NOUN
gs-3214	550	11	lymphomas	lymphoma	NOUN
gs-3214	550	12	.	.	PUNCT
gs-3214	551	1	new	new	PROPN
gs-3214	551	2	england	england	PROPN
gs-3214	551	3	journal	journal	PROPN
gs-3214	551	4	of	of	ADP
gs-3214	551	5	medicine	medicine	NOUN
gs-3214	551	6	,	,	PUNCT
gs-3214	551	7	377(26	377(26	NUM
gs-3214	551	8	)	)	PUNCT
gs-3214	551	9	,	,	PUNCT
gs-3214	551	10	2545–2554	2545–2554	NUM
gs-3214	551	11	.	.	PUNCT
gs-3214	552	1	46	46	NUM
gs-3214	552	2	.	.	PUNCT
gs-3214	552	3	levine	levine	PROPN
gs-3214	552	4	,	,	PUNCT
gs-3214	552	5	b.	b.	PROPN
gs-3214	552	6	l.	l.	PROPN
gs-3214	552	7	,	,	PUNCT
gs-3214	552	8	&	&	CCONJ
gs-3214	552	9	miskin	miskin	PROPN
gs-3214	552	10	,	,	PUNCT
gs-3214	552	11	j.	j.	PROPN
gs-3214	552	12	(	(	PUNCT
gs-3214	552	13	2017	2017	NUM
gs-3214	552	14	)	)	PUNCT
gs-3214	552	15	.	.	PUNCT
gs-3214	553	1	global	global	ADJ
gs-3214	553	2	manufacturing	manufacturing	NOUN
gs-3214	553	3	of	of	ADP
gs-3214	553	4	car	car	NOUN
gs-3214	553	5	t	t	NOUN
gs-3214	553	6	cell	cell	NOUN
gs-3214	553	7	therapy	therapy	NOUN
gs-3214	553	8	.	.	PUNCT
gs-3214	554	1	molecular	molecular	ADJ
gs-3214	554	2	therapy	therapy	NOUN
gs-3214	554	3	methods	method	NOUN
gs-3214	554	4	&	&	CCONJ
gs-3214	554	5	clinical	clinical	ADJ
gs-3214	554	6	development	development	NOUN
gs-3214	554	7	,	,	PUNCT
gs-3214	554	8	4	4	NUM
gs-3214	554	9	,	,	PUNCT
gs-3214	554	10	92–101	92–101	NUM
gs-3214	554	11	.	.	PUNCT
gs-3214	555	1	47	47	NUM
gs-3214	555	2	.	.	PUNCT
gs-3214	556	1	brudno	brudno	PROPN
gs-3214	556	2	,	,	PUNCT
gs-3214	556	3	j.	j.	PROPN
gs-3214	556	4	n.	n.	PROPN
gs-3214	556	5	,	,	PUNCT
gs-3214	556	6	&	&	CCONJ
gs-3214	556	7	kochenderfer	kochenderfer	PROPN
gs-3214	556	8	,	,	PUNCT
gs-3214	556	9	j.	j.	PROPN
gs-3214	556	10	n.	n.	PROPN
gs-3214	556	11	(	(	PUNCT
gs-3214	556	12	2016	2016	NUM
gs-3214	556	13	)	)	PUNCT
gs-3214	556	14	.	.	PUNCT
gs-3214	557	1	toxicities	toxicity	NOUN
gs-3214	557	2	of	of	ADP
gs-3214	557	3	chimeric	chimeric	ADJ
gs-3214	557	4	antigen	antigen	ADJ
gs-3214	557	5	receptor	receptor	NOUN
gs-3214	557	6	t	t	NOUN
gs-3214	557	7	cells	cell	NOUN
gs-3214	557	8	:	:	PUNCT
gs-3214	557	9	recognition	recognition	NOUN
gs-3214	557	10	and	and	CCONJ
gs-3214	557	11	management	management	NOUN
gs-3214	557	12	.	.	PUNCT
gs-3214	558	1	blood	blood	NOUN
gs-3214	558	2	,	,	PUNCT
gs-3214	558	3	127(26	127(26	NUM
gs-3214	558	4	)	)	PUNCT
gs-3214	558	5	,	,	PUNCT
gs-3214	558	6	3321–3330	3321–3330	NUM
gs-3214	558	7	.	.	X
gs-3214	558	8	48	48	NUM
gs-3214	558	9	.	.	PUNCT
gs-3214	559	1	gust	gust	PROPN
gs-3214	559	2	,	,	PUNCT
gs-3214	559	3	j.	j.	PROPN
gs-3214	559	4	,	,	PUNCT
gs-3214	559	5	&	&	CCONJ
gs-3214	559	6	taraseviciute	taraseviciute	NOUN
gs-3214	559	7	,	,	PUNCT
gs-3214	559	8	a.	a.	NOUN
gs-3214	559	9	(	(	PUNCT
gs-3214	559	10	2017	2017	NUM
gs-3214	559	11	)	)	PUNCT
gs-3214	559	12	.	.	PUNCT
gs-3214	560	1	endothelial	endothelial	ADJ
gs-3214	560	2	activation	activation	NOUN
gs-3214	560	3	and	and	CCONJ
gs-3214	560	4	blood	blood	NOUN
gs-3214	560	5	-	-	PUNCT
gs-3214	560	6	brain	brain	NOUN
gs-3214	560	7	barrier	barrier	NOUN
gs-3214	560	8	disruption	disruption	NOUN
gs-3214	560	9	in	in	ADP
gs-3214	560	10	neurotoxicity	neurotoxicity	NOUN
gs-3214	560	11	after	after	ADP
gs-3214	560	12	adoptive	adoptive	ADJ
gs-3214	560	13	immunotherapy	immunotherapy	NOUN
gs-3214	560	14	with	with	ADP
gs-3214	560	15	cd19	cd19	PROPN
gs-3214	560	16	car	car	NOUN
gs-3214	560	17	-	-	PUNCT
gs-3214	560	18	t	t	NOUN
gs-3214	560	19	cells	cell	NOUN
gs-3214	560	20	.	.	PUNCT
gs-3214	561	1	cancer	cancer	NOUN
gs-3214	561	2	discovery	discovery	NOUN
gs-3214	561	3	,	,	PUNCT
gs-3214	561	4	7(12	7(12	NUM
gs-3214	561	5	)	)	PUNCT
gs-3214	561	6	,	,	PUNCT
gs-3214	561	7	1404–1419	1404–1419	NUM
gs-3214	561	8	.	.	PUNCT
gs-3214	562	1	georgian	georgian	NOUN
gs-3214	562	2	scientists/	scientists/	NUM
gs-3214	562	3	.	.	PUNCT
gs-3214	563	1	6	6	NUM
gs-3214	563	2	n	n	NUM
gs-3214	563	3	3	3	NUM
gs-3214	563	4	,	,	PUNCT
gs-3214	563	5	2024	2024	NUM
gs-3214	563	6	286	286	NUM
gs-3214	563	7	49	49	NUM
gs-3214	563	8	.	.	PUNCT
gs-3214	564	1	ahmed	ahmed	PROPN
gs-3214	564	2	,	,	PUNCT
gs-3214	564	3	n.	n.	PROPN
gs-3214	564	4	,	,	PUNCT
gs-3214	564	5	&	&	CCONJ
gs-3214	564	6	brawley	brawley	PROPN
gs-3214	564	7	,	,	PUNCT
gs-3214	564	8	v.	v.	ADP
gs-3214	564	9	s.	s.	PROPN
gs-3214	564	10	(	(	PUNCT
gs-3214	564	11	2015	2015	NUM
gs-3214	564	12	)	)	PUNCT
gs-3214	564	13	.	.	PUNCT
gs-3214	565	1	human	human	ADJ
gs-3214	565	2	epidermal	epidermal	ADJ
gs-3214	565	3	growth	growth	NOUN
gs-3214	565	4	factor	factor	NOUN
gs-3214	565	5	receptor	receptor	NOUN
gs-3214	565	6	2	2	NUM
gs-3214	565	7	(	(	PUNCT
gs-3214	565	8	her2	her2	PROPN
gs-3214	565	9	)	)	PUNCT
gs-3214	565	10	-specific	-specific	PROPN
gs-3214	565	11	chimeric	chimeric	ADJ
gs-3214	565	12	antigen	antigen	ADJ
gs-3214	565	13	receptor	receptor	NOUN
gs-3214	565	14	-	-	PUNCT
gs-3214	565	15	modified	modify	VERB
gs-3214	565	16	t	t	NOUN
gs-3214	565	17	cells	cell	NOUN
gs-3214	565	18	for	for	ADP
gs-3214	565	19	the	the	DET
gs-3214	565	20	immunotherapy	immunotherapy	NOUN
gs-3214	565	21	of	of	ADP
gs-3214	565	22	her2	her2	PROPN
gs-3214	565	23	-	-	PUNCT
gs-3214	565	24	positive	positive	ADJ
gs-3214	565	25	sarcoma	sarcoma	NOUN
gs-3214	565	26	.	.	PUNCT
gs-3214	566	1	journal	journal	NOUN
gs-3214	566	2	of	of	ADP
gs-3214	566	3	clinical	clinical	ADJ
gs-3214	566	4	oncology	oncology	NOUN
gs-3214	566	5	,	,	PUNCT
gs-3214	566	6	33(15	33(15	NUM
gs-3214	566	7	)	)	PUNCT
gs-3214	566	8	,	,	PUNCT
gs-3214	566	9	1688–1696	1688–1696	NUM
gs-3214	566	10	.	.	PUNCT
gs-3214	567	1	50	50	NUM
gs-3214	567	2	.	.	X
gs-3214	567	3	di	di	PROPN
gs-3214	567	4	stasi	stasi	PROPN
gs-3214	567	5	,	,	PUNCT
gs-3214	567	6	a.	a.	PROPN
gs-3214	567	7	,	,	PUNCT
gs-3214	567	8	&	&	CCONJ
gs-3214	567	9	tey	tey	PROPN
gs-3214	567	10	,	,	PUNCT
gs-3214	567	11	s.	s.	PROPN
gs-3214	567	12	k.	k.	PROPN
gs-3214	567	13	(	(	PUNCT
gs-3214	567	14	2011	2011	NUM
gs-3214	567	15	)	)	PUNCT
gs-3214	567	16	.	.	PUNCT
gs-3214	568	1	inducible	inducible	ADJ
gs-3214	568	2	apoptosis	apoptosis	NOUN
gs-3214	568	3	as	as	ADP
gs-3214	568	4	a	a	DET
gs-3214	568	5	safety	safety	NOUN
gs-3214	568	6	switch	switch	NOUN
gs-3214	568	7	for	for	ADP
gs-3214	568	8	adoptive	adoptive	ADJ
gs-3214	568	9	cell	cell	NOUN
gs-3214	568	10	therapy	therapy	NOUN
gs-3214	568	11	.	.	PUNCT
gs-3214	569	1	new	new	PROPN
gs-3214	569	2	england	england	PROPN
gs-3214	569	3	journal	journal	PROPN
gs-3214	569	4	of	of	ADP
gs-3214	569	5	medicine	medicine	NOUN
gs-3214	569	6	,	,	PUNCT
gs-3214	569	7	365(18	365(18	NUM
gs-3214	569	8	)	)	PUNCT
gs-3214	569	9	,	,	PUNCT
gs-3214	569	10	1673–1683	1673–1683	NUM
gs-3214	569	11	.	.	PUNCT
gs-3214	570	1	51	51	NUM
gs-3214	570	2	.	.	PUNCT
gs-3214	570	3	park	park	PROPN
gs-3214	570	4	,	,	PUNCT
gs-3214	570	5	j.	j.	PROPN
gs-3214	570	6	h.	h.	PROPN
gs-3214	570	7	,	,	PUNCT
gs-3214	570	8	&	&	CCONJ
gs-3214	570	9	geyer	geyer	PROPN
gs-3214	570	10	,	,	PUNCT
gs-3214	570	11	m.	m.	PROPN
gs-3214	570	12	b.	b.	PROPN
gs-3214	570	13	(	(	PUNCT
gs-3214	570	14	2016	2016	NUM
gs-3214	570	15	)	)	PUNCT
gs-3214	570	16	.	.	PUNCT
gs-3214	571	1	cd19	cd19	PROPN
gs-3214	571	2	-	-	PUNCT
gs-3214	571	3	targeted	target	VERB
gs-3214	571	4	car	car	NOUN
gs-3214	571	5	t	t	NOUN
gs-3214	571	6	-	-	PUNCT
gs-3214	571	7	cell	cell	NOUN
gs-3214	571	8	therapeutics	therapeutic	NOUN
gs-3214	571	9	for	for	ADP
gs-3214	571	10	hematologic	hematologic	ADJ
gs-3214	571	11	malignancies	malignancy	NOUN
gs-3214	571	12	:	:	PUNCT
gs-3214	571	13	interpreting	interpret	VERB
gs-3214	571	14	clinical	clinical	ADJ
gs-3214	571	15	outcomes	outcome	NOUN
gs-3214	571	16	to	to	ADP
gs-3214	571	17	date	date	NOUN
gs-3214	571	18	.	.	PUNCT
gs-3214	572	1	blood	blood	NOUN
gs-3214	572	2	,	,	PUNCT
gs-3214	572	3	127(26	127(26	NUM
gs-3214	572	4	)	)	PUNCT
gs-3214	572	5	,	,	PUNCT
gs-3214	572	6	3312–3320	3312–3320	NOUN
gs-3214	572	7	.	.	PUNCT
gs-3214	573	1	52	52	NUM
gs-3214	573	2	.	.	PUNCT
gs-3214	573	3	morgan	morgan	PROPN
gs-3214	573	4	,	,	PUNCT
gs-3214	573	5	r.	r.	PROPN
gs-3214	573	6	a.	a.	PROPN
gs-3214	573	7	,	,	PUNCT
gs-3214	573	8	&	&	CCONJ
gs-3214	573	9	yang	yang	PROPN
gs-3214	573	10	,	,	PUNCT
gs-3214	573	11	j.	j.	PROPN
gs-3214	573	12	c.	c.	PROPN
gs-3214	573	13	(	(	PUNCT
gs-3214	573	14	2010	2010	NUM
gs-3214	573	15	)	)	PUNCT
gs-3214	573	16	.	.	PUNCT
gs-3214	574	1	case	case	NOUN
gs-3214	574	2	report	report	NOUN
gs-3214	574	3	of	of	ADP
gs-3214	574	4	a	a	DET
gs-3214	574	5	serious	serious	ADJ
gs-3214	574	6	adverse	adverse	ADJ
gs-3214	574	7	event	event	NOUN
gs-3214	574	8	following	follow	VERB
gs-3214	574	9	the	the	DET
gs-3214	574	10	administration	administration	NOUN
gs-3214	574	11	of	of	ADP
gs-3214	574	12	t	t	PROPN
gs-3214	574	13	cells	cell	NOUN
gs-3214	574	14	transduced	transduce	VERB
gs-3214	574	15	with	with	ADP
gs-3214	574	16	a	a	DET
gs-3214	574	17	chimeric	chimeric	ADJ
gs-3214	574	18	antigen	antigen	ADJ
gs-3214	574	19	receptor	receptor	NOUN
gs-3214	574	20	recognizing	recognize	VERB
gs-3214	574	21	erbb2	erbb2	PROPN
gs-3214	574	22	.	.	PUNCT
gs-3214	575	1	molecular	molecular	ADJ
gs-3214	575	2	therapy	therapy	NOUN
gs-3214	575	3	,	,	PUNCT
gs-3214	575	4	18(4	18(4	NUM
gs-3214	575	5	)	)	PUNCT
gs-3214	575	6	,	,	PUNCT
gs-3214	575	7	843–851	843–851	NUM
gs-3214	575	8	.	.	PUNCT
gs-3214	576	1	53	53	NUM
gs-3214	576	2	.	.	PUNCT
gs-3214	577	1	heczey	heczey	PROPN
gs-3214	577	2	,	,	PUNCT
gs-3214	577	3	a.	a.	PROPN
gs-3214	577	4	,	,	PUNCT
gs-3214	577	5	&	&	CCONJ
gs-3214	577	6	louis	louis	PROPN
gs-3214	577	7	,	,	PUNCT
gs-3214	577	8	c.	c.	PROPN
gs-3214	577	9	u.	u.	PROPN
gs-3214	577	10	(	(	PUNCT
gs-3214	577	11	2017	2017	NUM
gs-3214	577	12	)	)	PUNCT
gs-3214	577	13	.	.	PUNCT
gs-3214	578	1	car	car	NOUN
gs-3214	578	2	t	t	NOUN
gs-3214	578	3	cells	cell	NOUN
gs-3214	578	4	administered	administer	VERB
gs-3214	578	5	in	in	ADP
gs-3214	578	6	combination	combination	NOUN
gs-3214	578	7	with	with	ADP
gs-3214	578	8	lymphodepletion	lymphodepletion	NOUN
gs-3214	578	9	and	and	CCONJ
gs-3214	578	10	pd-1	pd-1	VERB
gs-3214	578	11	inhibition	inhibition	NOUN
gs-3214	578	12	to	to	ADP
gs-3214	578	13	patients	patient	NOUN
gs-3214	578	14	with	with	ADP
gs-3214	578	15	neuroblastoma	neuroblastoma	NOUN
gs-3214	578	16	.	.	PUNCT
gs-3214	579	1	molecular	molecular	ADJ
gs-3214	579	2	therapy	therapy	NOUN
gs-3214	579	3	,	,	PUNCT
gs-3214	579	4	25(9	25(9	NUM
gs-3214	579	5	)	)	PUNCT
gs-3214	579	6	,	,	PUNCT
gs-3214	579	7	2214–2224	2214–2224	NOUN
gs-3214	579	8	.	.	PUNCT
gs-3214	579	9	54	54	NUM
gs-3214	579	10	.	.	PUNCT
gs-3214	580	1	ahmed	ahmed	PROPN
gs-3214	580	2	,	,	PUNCT
gs-3214	580	3	n.	n.	PROPN
gs-3214	580	4	,	,	PUNCT
gs-3214	580	5	&	&	CCONJ
gs-3214	580	6	brawley	brawley	PROPN
gs-3214	580	7	,	,	PUNCT
gs-3214	580	8	v.	v.	ADP
gs-3214	580	9	s.	s.	PROPN
gs-3214	580	10	(	(	PUNCT
gs-3214	580	11	2015	2015	NUM
gs-3214	580	12	)	)	PUNCT
gs-3214	580	13	.	.	PUNCT
gs-3214	581	1	human	human	ADJ
gs-3214	581	2	epidermal	epidermal	ADJ
gs-3214	581	3	growth	growth	NOUN
gs-3214	581	4	factor	factor	NOUN
gs-3214	581	5	receptor	receptor	NOUN
gs-3214	581	6	2	2	NUM
gs-3214	581	7	(	(	PUNCT
gs-3214	581	8	her2	her2	PROPN
gs-3214	581	9	)	)	PUNCT
gs-3214	581	10	-specific	-specific	PROPN
gs-3214	581	11	chimeric	chimeric	ADJ
gs-3214	581	12	antigen	antigen	ADJ
gs-3214	581	13	receptor	receptor	NOUN
gs-3214	581	14	-	-	PUNCT
gs-3214	581	15	modified	modify	VERB
gs-3214	581	16	t	t	NOUN
gs-3214	581	17	cells	cell	NOUN
gs-3214	581	18	for	for	ADP
gs-3214	581	19	the	the	DET
gs-3214	581	20	immunotherapy	immunotherapy	NOUN
gs-3214	581	21	of	of	ADP
gs-3214	581	22	her2	her2	PROPN
gs-3214	581	23	-	-	PUNCT
gs-3214	581	24	positive	positive	ADJ
gs-3214	581	25	sarcoma	sarcoma	NOUN
gs-3214	581	26	.	.	PUNCT
gs-3214	582	1	journal	journal	NOUN
gs-3214	582	2	of	of	ADP
gs-3214	582	3	clinical	clinical	ADJ
gs-3214	582	4	oncology	oncology	NOUN
gs-3214	582	5	,	,	PUNCT
gs-3214	582	6	33(15	33(15	NUM
gs-3214	582	7	)	)	PUNCT
gs-3214	582	8	,	,	PUNCT
gs-3214	582	9	1688–1696	1688–1696	NUM
gs-3214	582	10	.	.	PUNCT
gs-3214	583	1	55	55	NUM
gs-3214	583	2	.	.	PUNCT
gs-3214	584	1	maude	maude	PROPN
gs-3214	584	2	,	,	PUNCT
gs-3214	584	3	s.	s.	PROPN
gs-3214	584	4	l.	l.	PROPN
gs-3214	584	5	,	,	PUNCT
gs-3214	584	6	&	&	CCONJ
gs-3214	584	7	barrett	barrett	PROPN
gs-3214	584	8	,	,	PUNCT
gs-3214	584	9	d.	d.	PROPN
gs-3214	584	10	m.	m.	PROPN
gs-3214	584	11	(	(	PUNCT
gs-3214	584	12	2014	2014	NUM
gs-3214	584	13	)	)	PUNCT
gs-3214	584	14	.	.	PUNCT
gs-3214	585	1	managing	manage	VERB
gs-3214	585	2	cytokine	cytokine	NOUN
gs-3214	585	3	release	release	NOUN
gs-3214	585	4	syndrome	syndrome	NOUN
gs-3214	585	5	associated	associate	VERB
gs-3214	585	6	with	with	ADP
gs-3214	585	7	novel	novel	ADJ
gs-3214	585	8	t	t	NOUN
gs-3214	585	9	cell	cell	NOUN
gs-3214	585	10	-	-	PUNCT
gs-3214	585	11	engaging	engage	VERB
gs-3214	585	12	therapies	therapy	NOUN
gs-3214	585	13	.	.	PUNCT
gs-3214	586	1	cancer	cancer	NOUN
gs-3214	586	2	journal	journal	NOUN
gs-3214	586	3	,	,	PUNCT
gs-3214	586	4	20(2	20(2	NUM
gs-3214	586	5	)	)	PUNCT
gs-3214	586	6	,	,	PUNCT
gs-3214	586	7	119–122	119–122	NUM
gs-3214	586	8	.	.	PUNCT
gs-3214	587	1	56	56	NUM
gs-3214	587	2	.	.	PUNCT
gs-3214	588	1	neelapu	neelapu	PROPN
gs-3214	588	2	,	,	PUNCT
gs-3214	588	3	s.	s.	PROPN
gs-3214	588	4	s.	s.	PROPN
gs-3214	588	5	,	,	PUNCT
gs-3214	588	6	&	&	CCONJ
gs-3214	588	7	tummala	tummala	PROPN
gs-3214	588	8	,	,	PUNCT
gs-3214	588	9	s.	s.	PROPN
gs-3214	588	10	(	(	PUNCT
gs-3214	588	11	2018	2018	NUM
gs-3214	588	12	)	)	PUNCT
gs-3214	588	13	.	.	PUNCT
gs-3214	589	1	chimeric	chimeric	ADJ
gs-3214	589	2	antigen	antigen	ADJ
gs-3214	589	3	receptor	receptor	NOUN
gs-3214	589	4	t	t	NOUN
gs-3214	589	5	-	-	PUNCT
gs-3214	589	6	cell	cell	NOUN
gs-3214	589	7	therapy	therapy	NOUN
gs-3214	589	8	—	—	PUNCT
gs-3214	589	9	assessment	assessment	NOUN
gs-3214	589	10	and	and	CCONJ
gs-3214	589	11	management	management	NOUN
gs-3214	589	12	of	of	ADP
gs-3214	589	13	toxicities	toxicity	NOUN
gs-3214	589	14	.	.	PUNCT
gs-3214	590	1	nature	nature	NOUN
gs-3214	590	2	reviews	review	VERB
gs-3214	590	3	clinical	clinical	ADJ
gs-3214	590	4	oncology	oncology	NOUN
gs-3214	590	5	,	,	PUNCT
gs-3214	590	6	15(1	15(1	NUM
gs-3214	590	7	)	)	PUNCT
gs-3214	590	8	,	,	PUNCT
gs-3214	590	9	47–62	47–62	NUM
gs-3214	590	10	.	.	NOUN
gs-3214	590	11	57	57	NUM
gs-3214	590	12	.	.	PUNCT
gs-3214	590	13	santomasso	santomasso	PROPN
gs-3214	590	14	,	,	PUNCT
gs-3214	590	15	b.	b.	PROPN
gs-3214	590	16	d.	d.	PROPN
gs-3214	590	17	,	,	PUNCT
gs-3214	590	18	&	&	CCONJ
gs-3214	590	19	park	park	PROPN
gs-3214	590	20	,	,	PUNCT
gs-3214	590	21	j.	j.	PROPN
gs-3214	590	22	h.	h.	PROPN
gs-3214	590	23	(	(	PUNCT
gs-3214	590	24	2018	2018	NUM
gs-3214	590	25	)	)	PUNCT
gs-3214	590	26	.	.	PUNCT
gs-3214	591	1	clinical	clinical	ADJ
gs-3214	591	2	and	and	CCONJ
gs-3214	591	3	biological	biological	ADJ
gs-3214	591	4	correlates	correlate	NOUN
gs-3214	591	5	of	of	ADP
gs-3214	591	6	neurotoxicity	neurotoxicity	NOUN
gs-3214	591	7	associated	associate	VERB
gs-3214	591	8	with	with	ADP
gs-3214	591	9	car	car	NOUN
gs-3214	591	10	t	t	NOUN
gs-3214	591	11	-	-	PUNCT
gs-3214	591	12	cell	cell	NOUN
gs-3214	591	13	therapy	therapy	NOUN
gs-3214	591	14	in	in	ADP
gs-3214	591	15	patients	patient	NOUN
gs-3214	591	16	with	with	ADP
gs-3214	591	17	b	b	NOUN
gs-3214	591	18	-	-	PUNCT
gs-3214	591	19	cell	cell	NOUN
gs-3214	591	20	acute	acute	ADJ
gs-3214	591	21	lymphoblastic	lymphoblastic	ADJ
gs-3214	591	22	leukemia	leukemia	NOUN
gs-3214	591	23	.	.	PUNCT
gs-3214	592	1	cancer	cancer	NOUN
gs-3214	592	2	discovery	discovery	PROPN
gs-3214	592	3	,	,	PUNCT
gs-3214	592	4	8(8	8(8	NUM
gs-3214	592	5	)	)	PUNCT
gs-3214	592	6	,	,	PUNCT
gs-3214	592	7	958–971	958–971	NUM
gs-3214	592	8	.	.	PUNCT
gs-3214	593	1	58	58	NUM
gs-3214	593	2	.	.	PUNCT
gs-3214	594	1	brudno	brudno	PROPN
gs-3214	594	2	,	,	PUNCT
gs-3214	594	3	j.	j.	PROPN
gs-3214	594	4	n.	n.	PROPN
gs-3214	594	5	,	,	PUNCT
gs-3214	594	6	&	&	CCONJ
gs-3214	594	7	kochenderfer	kochenderfer	PROPN
gs-3214	594	8	,	,	PUNCT
gs-3214	594	9	j.	j.	PROPN
gs-3214	594	10	n.	n.	PROPN
gs-3214	594	11	(	(	PUNCT
gs-3214	594	12	2016	2016	NUM
gs-3214	594	13	)	)	PUNCT
gs-3214	594	14	.	.	PUNCT
gs-3214	595	1	toxicities	toxicity	NOUN
gs-3214	595	2	of	of	ADP
gs-3214	595	3	chimeric	chimeric	ADJ
gs-3214	595	4	antigen	antigen	ADJ
gs-3214	595	5	receptor	receptor	NOUN
gs-3214	595	6	t	t	NOUN
gs-3214	595	7	cells	cell	NOUN
gs-3214	595	8	:	:	PUNCT
gs-3214	595	9	recognition	recognition	NOUN
gs-3214	595	10	and	and	CCONJ
gs-3214	595	11	management	management	NOUN
gs-3214	595	12	.	.	PUNCT
gs-3214	596	1	blood	blood	NOUN
gs-3214	596	2	,	,	PUNCT
gs-3214	596	3	127(26	127(26	NUM
gs-3214	596	4	)	)	PUNCT
gs-3214	596	5	,	,	PUNCT
gs-3214	596	6	3321–3330	3321–3330	NUM
gs-3214	596	7	.	.	PUNCT
gs-3214	596	8	59	59	NUM
gs-3214	596	9	.	.	PUNCT
gs-3214	597	1	brudno	brudno	PROPN
gs-3214	597	2	,	,	PUNCT
gs-3214	597	3	j.	j.	PROPN
gs-3214	597	4	n.	n.	PROPN
gs-3214	597	5	,	,	PUNCT
gs-3214	597	6	somerville	somerville	PROPN
gs-3214	597	7	,	,	PUNCT
gs-3214	597	8	r.	r.	PROPN
gs-3214	597	9	p.	p.	PROPN
gs-3214	597	10	,	,	PUNCT
gs-3214	597	11	shi	shi	PROPN
gs-3214	597	12	,	,	PUNCT
gs-3214	597	13	v.	v.	ADV
gs-3214	597	14	,	,	PUNCT
gs-3214	597	15	rose	rise	VERB
gs-3214	597	16	,	,	PUNCT
gs-3214	597	17	j.	j.	PROPN
gs-3214	597	18	j.	j.	PROPN
gs-3214	597	19	,	,	PUNCT
gs-3214	597	20	halverson	halverson	PROPN
gs-3214	597	21	,	,	PUNCT
gs-3214	597	22	d.	d.	PROPN
gs-3214	597	23	c.	c.	PROPN
gs-3214	597	24	,	,	PUNCT
gs-3214	597	25	fowler	fowler	PROPN
gs-3214	597	26	,	,	PUNCT
gs-3214	597	27	d.	d.	PROPN
gs-3214	597	28	h.	h.	PROPN
gs-3214	597	29	,	,	PUNCT
gs-3214	597	30	(	(	PUNCT
gs-3214	597	31	2016	2016	NUM
gs-3214	597	32	)	)	PUNCT
gs-3214	597	33	.	.	PUNCT
gs-3214	598	1	allogeneic	allogeneic	ADJ
gs-3214	598	2	t	t	PROPN
gs-3214	598	3	cells	cell	NOUN
gs-3214	598	4	that	that	PRON
gs-3214	598	5	express	express	VERB
gs-3214	598	6	an	an	DET
gs-3214	598	7	anti	anti	ADJ
gs-3214	598	8	-	-	ADJ
gs-3214	598	9	cd19	cd19	ADJ
gs-3214	598	10	chimeric	chimeric	ADJ
gs-3214	598	11	antigen	antigen	ADJ
gs-3214	598	12	receptor	receptor	NOUN
gs-3214	598	13	induce	induce	VERB
gs-3214	598	14	remissions	remission	NOUN
gs-3214	598	15	of	of	ADP
gs-3214	598	16	b	b	NOUN
gs-3214	598	17	-	-	PUNCT
gs-3214	598	18	cell	cell	NOUN
gs-3214	598	19	malignancies	malignancy	NOUN
gs-3214	598	20	that	that	PRON
gs-3214	598	21	progress	progress	VERB
gs-3214	598	22	after	after	ADP
gs-3214	598	23	allogeneic	allogeneic	VERB
gs-3214	598	24	hematopoietic	hematopoietic	ADJ
gs-3214	598	25	stem	stem	NOUN
gs-3214	598	26	-	-	PUNCT
gs-3214	598	27	cell	cell	NOUN
gs-3214	598	28	transplantation	transplantation	NOUN
gs-3214	598	29	without	without	ADP
gs-3214	598	30	causing	cause	VERB
gs-3214	598	31	graft	graft	NOUN
gs-3214	598	32	-	-	PUNCT
gs-3214	598	33	versus	versus	ADP
gs-3214	598	34	-	-	PUNCT
gs-3214	598	35	host	host	NOUN
gs-3214	598	36	disease	disease	NOUN
gs-3214	598	37	.	.	PUNCT
gs-3214	599	1	journal	journal	NOUN
gs-3214	599	2	of	of	ADP
gs-3214	599	3	clinical	clinical	ADJ
gs-3214	599	4	oncology	oncology	NOUN
gs-3214	599	5	,	,	PUNCT
gs-3214	599	6	34(10	34(10	NUM
gs-3214	599	7	)	)	PUNCT
gs-3214	599	8	,	,	PUNCT
gs-3214	599	9	1112–1121	1112–1121	NUM
gs-3214	599	10	.	.	PUNCT
gs-3214	600	1	60	60	NUM
gs-3214	600	2	.	.	PUNCT
gs-3214	601	1	wang	wang	PROPN
gs-3214	601	2	,	,	PUNCT
gs-3214	601	3	x.	x.	PROPN
gs-3214	601	4	,	,	PUNCT
gs-3214	601	5	rivière	rivière	PROPN
gs-3214	601	6	,	,	PUNCT
gs-3214	601	7	i.	i.	PROPN
gs-3214	601	8	,	,	PUNCT
gs-3214	601	9	(	(	PUNCT
gs-3214	601	10	2016	2016	NUM
gs-3214	601	11	)	)	PUNCT
gs-3214	601	12	.	.	PUNCT
gs-3214	602	1	clinical	clinical	ADJ
gs-3214	602	2	manufacturing	manufacturing	NOUN
gs-3214	602	3	of	of	ADP
gs-3214	602	4	car	car	NOUN
gs-3214	602	5	t	t	NOUN
gs-3214	602	6	cells	cell	NOUN
gs-3214	602	7	:	:	PUNCT
gs-3214	602	8	foundation	foundation	NOUN
gs-3214	602	9	of	of	ADP
gs-3214	602	10	a	a	DET
gs-3214	602	11	promising	promising	ADJ
gs-3214	602	12	therapy	therapy	NOUN
gs-3214	602	13	.	.	PUNCT
gs-3214	603	1	molecular	molecular	ADJ
gs-3214	603	2	therapy	therapy	NOUN
gs-3214	603	3	oncolytics	oncolytic	NOUN
gs-3214	603	4	,	,	PUNCT
gs-3214	603	5	3	3	NUM
gs-3214	603	6	,	,	PUNCT
gs-3214	603	7	16015	16015	NUM
gs-3214	603	8	.	.	PUNCT
gs-3214	604	1	61	61	NUM
gs-3214	604	2	.	.	PUNCT
gs-3214	604	3	june	june	PROPN
gs-3214	604	4	,	,	PUNCT
gs-3214	604	5	c.	c.	PROPN
gs-3214	604	6	h.	h.	PROPN
gs-3214	604	7	,	,	PUNCT
gs-3214	604	8	o’connor	o’connor	ADV
gs-3214	604	9	,	,	PUNCT
gs-3214	604	10	r.	r.	PROPN
gs-3214	604	11	s.	s.	PROPN
gs-3214	604	12	,	,	PUNCT
gs-3214	604	13	kawalekar	kawalekar	PROPN
gs-3214	604	14	,	,	PUNCT
gs-3214	604	15	o.	o.	PROPN
gs-3214	604	16	u.	u.	PROPN
gs-3214	604	17	,	,	PUNCT
gs-3214	604	18	ghassemi	ghassemi	PROPN
gs-3214	604	19	,	,	PUNCT
gs-3214	604	20	s.	s.	PROPN
gs-3214	604	21	,	,	PUNCT
gs-3214	604	22	milone	milone	NOUN
gs-3214	604	23	,	,	PUNCT
gs-3214	604	24	m.	m.	NOUN
gs-3214	604	25	c.	c.	PROPN
gs-3214	604	26	(	(	PUNCT
gs-3214	604	27	2018	2018	NUM
gs-3214	604	28	)	)	PUNCT
gs-3214	604	29	.	.	PUNCT
gs-3214	605	1	car	car	NOUN
gs-3214	605	2	t	t	PROPN
gs-3214	605	3	cell	cell	NOUN
gs-3214	605	4	immunotherapy	immunotherapy	NOUN
gs-3214	605	5	for	for	ADP
gs-3214	605	6	human	human	ADJ
gs-3214	605	7	cancer	cancer	NOUN
gs-3214	605	8	.	.	PUNCT
gs-3214	606	1	science	science	NOUN
gs-3214	606	2	,	,	PUNCT
gs-3214	606	3	359(6382	359(6382	NUM
gs-3214	606	4	)	)	PUNCT
gs-3214	606	5	,	,	PUNCT
gs-3214	606	6	1361–1365	1361–1365	NUM
gs-3214	606	7	.	.	PUNCT
gs-3214	606	8	62	62	NUM
gs-3214	606	9	.	.	PUNCT
gs-3214	607	1	kim	kim	PROPN
gs-3214	607	2	,	,	PUNCT
gs-3214	607	3	m.	m.	NOUN
gs-3214	607	4	y.	y.	PROPN
gs-3214	607	5	,	,	PUNCT
gs-3214	607	6	yu	yu	PROPN
gs-3214	607	7	,	,	PUNCT
gs-3214	607	8	k.-r	k.-r	PROPN
gs-3214	607	9	.	.	PROPN
gs-3214	607	10	,	,	PUNCT
gs-3214	607	11	kenderian	kenderian	PROPN
gs-3214	607	12	,	,	PUNCT
gs-3214	607	13	s.	s.	PROPN
gs-3214	607	14	s.	s.	PROPN
gs-3214	607	15	,	,	PUNCT
gs-3214	607	16	ruella	ruella	PROPN
gs-3214	607	17	,	,	PUNCT
gs-3214	607	18	m.	m.	NOUN
gs-3214	607	19	,	,	PUNCT
gs-3214	607	20	chen	chen	PROPN
gs-3214	607	21	,	,	PUNCT
gs-3214	607	22	s.	s.	PROPN
gs-3214	607	23	,	,	PUNCT
gs-3214	607	24	shin	shin	NOUN
gs-3214	607	25	,	,	PUNCT
gs-3214	607	26	t.	t.	PROPN
gs-3214	607	27	h.	h.	PROPN
gs-3214	607	28	,	,	PUNCT
gs-3214	607	29	(	(	PUNCT
gs-3214	607	30	2018	2018	NUM
gs-3214	607	31	)	)	PUNCT
gs-3214	607	32	.	.	PUNCT
gs-3214	608	1	genetic	genetic	ADJ
gs-3214	608	2	inactivation	inactivation	NOUN
gs-3214	608	3	of	of	ADP
gs-3214	608	4	cd33	cd33	PROPN
gs-3214	608	5	in	in	ADP
gs-3214	608	6	hematopoietic	hematopoietic	ADJ
gs-3214	608	7	stem	stem	NOUN
gs-3214	608	8	cells	cell	NOUN
gs-3214	608	9	to	to	PART
gs-3214	608	10	enable	enable	VERB
gs-3214	608	11	car	car	NOUN
gs-3214	608	12	t	t	NOUN
gs-3214	608	13	cell	cell	NOUN
gs-3214	608	14	immunotherapy	immunotherapy	NOUN
gs-3214	608	15	for	for	ADP
gs-3214	608	16	acute	acute	ADJ
gs-3214	608	17	myeloid	myeloid	ADJ
gs-3214	608	18	leukemia	leukemia	NOUN
gs-3214	608	19	.	.	PUNCT
gs-3214	609	1	cell	cell	NOUN
gs-3214	609	2	,	,	PUNCT
gs-3214	609	3	173(6	173(6	NUM
gs-3214	609	4	)	)	PUNCT
gs-3214	609	5	,	,	PUNCT
gs-3214	609	6	1439	1439	NUM
gs-3214	609	7	-	-	SYM
gs-3214	609	8	1453.e19	1453.e19	NUM
gs-3214	609	9	.	.	PUNCT
gs-3214	610	1	63	63	NUM
gs-3214	610	2	.	.	X
gs-3214	610	3	levine	levine	PROPN
gs-3214	610	4	,	,	PUNCT
gs-3214	610	5	b.	b.	PROPN
gs-3214	610	6	l.	l.	PROPN
gs-3214	610	7	,	,	PUNCT
gs-3214	610	8	miskin	miskin	PROPN
gs-3214	610	9	,	,	PUNCT
gs-3214	610	10	j.	j.	PROPN
gs-3214	610	11	,	,	PUNCT
gs-3214	610	12	wonnacott	wonnacott	PROPN
gs-3214	610	13	,	,	PUNCT
gs-3214	610	14	k.	k.	PROPN
gs-3214	610	15	,	,	PUNCT
gs-3214	610	16	keir	keir	PROPN
gs-3214	610	17	,	,	PUNCT
gs-3214	610	18	c.	c.	PROPN
gs-3214	610	19	,	,	PUNCT
gs-3214	610	20	&	&	CCONJ
gs-3214	610	21	jensen	jensen	PROPN
gs-3214	610	22	,	,	PUNCT
gs-3214	610	23	m.	m.	PROPN
gs-3214	610	24	c.	c.	PROPN
gs-3214	610	25	(	(	PUNCT
gs-3214	610	26	2017	2017	NUM
gs-3214	610	27	)	)	PUNCT
gs-3214	610	28	.	.	PUNCT
gs-3214	611	1	global	global	ADJ
gs-3214	611	2	manufacturing	manufacturing	NOUN
gs-3214	611	3	of	of	ADP
gs-3214	611	4	car	car	NOUN
gs-3214	611	5	t	t	NOUN
gs-3214	611	6	cell	cell	NOUN
gs-3214	611	7	therapy	therapy	NOUN
gs-3214	611	8	.	.	PUNCT
gs-3214	612	1	molecular	molecular	ADJ
gs-3214	612	2	therapy	therapy	NOUN
gs-3214	612	3	methods	method	NOUN
gs-3214	612	4	&	&	CCONJ
gs-3214	612	5	clinical	clinical	ADJ
gs-3214	612	6	development	development	NOUN
gs-3214	612	7	,	,	PUNCT
gs-3214	612	8	4	4	NUM
gs-3214	612	9	,	,	PUNCT
gs-3214	612	10	92–101	92–101	NUM
gs-3214	612	11	.	.	PUNCT
gs-3214	613	1	georgian	georgian	PROPN
gs-3214	613	2	scientists/	scientists/	NUM
gs-3214	613	3	.	.	PUNCT
gs-3214	614	1	6	6	NUM
gs-3214	614	2	n	n	NUM
gs-3214	614	3	3	3	NUM
gs-3214	614	4	,	,	PUNCT
gs-3214	614	5	2024	2024	NUM
gs-3214	614	6	287	287	NUM
gs-3214	614	7	64	64	NUM
gs-3214	614	8	.	.	PUNCT
gs-3214	615	1	ghassemi	ghassemi	PROPN
gs-3214	615	2	,	,	PUNCT
gs-3214	615	3	s.	s.	PROPN
gs-3214	615	4	,	,	PUNCT
gs-3214	615	5	nunez	nunez	PROPN
gs-3214	615	6	-	-	PUNCT
gs-3214	615	7	cruz	cruz	PROPN
gs-3214	615	8	,	,	PUNCT
gs-3214	615	9	s.	s.	PROPN
gs-3214	615	10	,	,	PUNCT
gs-3214	615	11	o’connor	o’connor	ADV
gs-3214	615	12	,	,	PUNCT
gs-3214	615	13	r.	r.	PROPN
gs-3214	615	14	s.	s.	PROPN
gs-3214	615	15	,	,	PUNCT
gs-3214	615	16	fraietta	fraietta	PROPN
gs-3214	615	17	,	,	PUNCT
gs-3214	615	18	j.	j.	PROPN
gs-3214	615	19	a.	a.	PROPN
gs-3214	615	20	,	,	PUNCT
gs-3214	615	21	patel	patel	PROPN
gs-3214	615	22	,	,	PUNCT
gs-3214	615	23	p.	p.	PROPN
gs-3214	615	24	r.	r.	PROPN
gs-3214	615	25	,	,	PUNCT
gs-3214	615	26	scholler	scholler	NOUN
gs-3214	615	27	,	,	PUNCT
gs-3214	615	28	j.	j.	PROPN
gs-3214	615	29	,	,	PUNCT
gs-3214	615	30	(	(	PUNCT
gs-3214	615	31	2018	2018	NUM
gs-3214	615	32	)	)	PUNCT
gs-3214	615	33	.	.	PUNCT
gs-3214	616	1	reducing	reduce	VERB
gs-3214	616	2	ex	ex	PRON
gs-3214	616	3	vivo	vivo	NOUN
gs-3214	616	4	culture	culture	NOUN
gs-3214	616	5	improves	improve	VERB
gs-3214	616	6	the	the	DET
gs-3214	616	7	antileukemic	antileukemic	ADJ
gs-3214	616	8	activity	activity	NOUN
gs-3214	616	9	of	of	ADP
gs-3214	616	10	chimeric	chimeric	ADJ
gs-3214	616	11	antigen	antigen	ADJ
gs-3214	616	12	receptor	receptor	NOUN
gs-3214	616	13	(	(	PUNCT
gs-3214	616	14	car	car	NOUN
gs-3214	616	15	)	)	PUNCT
gs-3214	616	16	t	t	NOUN
gs-3214	616	17	cells	cell	NOUN
gs-3214	616	18	.	.	PUNCT
gs-3214	617	1	cancer	cancer	NOUN
gs-3214	617	2	immunology	immunology	NOUN
gs-3214	617	3	research	research	NOUN
gs-3214	617	4	,	,	PUNCT
gs-3214	617	5	6(9	6(9	NUM
gs-3214	617	6	)	)	PUNCT
gs-3214	617	7	,	,	PUNCT
gs-3214	617	8	1100–1109	1100–1109	NUM
gs-3214	617	9	.	.	PUNCT
gs-3214	618	1	65	65	NUM
gs-3214	618	2	.	.	PUNCT
gs-3214	619	1	ruella	ruella	PROPN
gs-3214	619	2	,	,	PUNCT
gs-3214	619	3	m.	m.	NOUN
gs-3214	619	4	,	,	PUNCT
gs-3214	619	5	xu	xu	PROPN
gs-3214	619	6	,	,	PUNCT
gs-3214	619	7	j.	j.	PROPN
gs-3214	619	8	,	,	PUNCT
gs-3214	619	9	barrett	barrett	PROPN
gs-3214	619	10	,	,	PUNCT
gs-3214	619	11	d.	d.	PROPN
gs-3214	619	12	m.	m.	PROPN
gs-3214	619	13	,	,	PUNCT
gs-3214	619	14	fraietta	fraietta	PROPN
gs-3214	619	15	,	,	PUNCT
gs-3214	619	16	j.	j.	PROPN
gs-3214	619	17	a.	a.	PROPN
gs-3214	619	18	,	,	PUNCT
gs-3214	619	19	reich	reich	PROPN
gs-3214	619	20	,	,	PUNCT
gs-3214	619	21	t.	t.	PROPN
gs-3214	619	22	j.	j.	PROPN
gs-3214	619	23	,	,	PUNCT
gs-3214	619	24	ambrose	ambrose	PROPN
gs-3214	619	25	,	,	PUNCT
gs-3214	619	26	d.	d.	PROPN
gs-3214	619	27	e.	e.	PROPN
gs-3214	619	28	,	,	PUNCT
gs-3214	619	29	(	(	PUNCT
gs-3214	619	30	2018	2018	NUM
gs-3214	619	31	)	)	PUNCT
gs-3214	619	32	.	.	PUNCT
gs-3214	620	1	induction	induction	NOUN
gs-3214	620	2	of	of	ADP
gs-3214	620	3	resistance	resistance	NOUN
gs-3214	620	4	to	to	AUX
gs-3214	620	5	chimeric	chimeric	VERB
gs-3214	620	6	antigen	antigen	ADJ
gs-3214	620	7	receptor	receptor	NOUN
gs-3214	620	8	t	t	NOUN
gs-3214	620	9	cell	cell	NOUN
gs-3214	620	10	therapy	therapy	NOUN
gs-3214	620	11	by	by	ADP
gs-3214	620	12	transduction	transduction	NOUN
gs-3214	620	13	of	of	ADP
gs-3214	620	14	a	a	DET
gs-3214	620	15	single	single	ADJ
gs-3214	620	16	leukemic	leukemic	ADJ
gs-3214	620	17	b	b	PROPN
gs-3214	620	18	cell	cell	NOUN
gs-3214	620	19	.	.	PUNCT
gs-3214	621	1	nature	nature	NOUN
gs-3214	621	2	medicine	medicine	NOUN
gs-3214	621	3	,	,	PUNCT
gs-3214	621	4	24(10	24(10	NUM
gs-3214	621	5	)	)	PUNCT
gs-3214	621	6	,	,	PUNCT
gs-3214	621	7	1499–1503	1499–1503	NUM
gs-3214	621	8	.	.	PUNCT
gs-3214	622	1	66	66	NUM
gs-3214	622	2	.	.	PUNCT
gs-3214	623	1	fraietta	fraietta	PROPN
gs-3214	623	2	,	,	PUNCT
gs-3214	623	3	j.	j.	PROPN
gs-3214	623	4	a.	a.	PROPN
gs-3214	623	5	,	,	PUNCT
gs-3214	623	6	lacey	lacey	PROPN
gs-3214	623	7	,	,	PUNCT
gs-3214	623	8	s.	s.	PROPN
gs-3214	623	9	f.	f.	PROPN
gs-3214	623	10	,	,	PUNCT
gs-3214	623	11	orlando	orlando	PROPN
gs-3214	623	12	,	,	PUNCT
gs-3214	623	13	e.	e.	PROPN
gs-3214	623	14	j.	j.	PROPN
gs-3214	623	15	,	,	PUNCT
gs-3214	623	16	pruteanu	pruteanu	NOUN
gs-3214	623	17	-	-	PUNCT
gs-3214	623	18	malinici	malinici	NOUN
gs-3214	623	19	,	,	PUNCT
gs-3214	623	20	i.	i.	NOUN
gs-3214	623	21	,	,	PUNCT
gs-3214	623	22	gohil	gohil	NOUN
gs-3214	623	23	,	,	PUNCT
gs-3214	623	24	m.	m.	NOUN
gs-3214	623	25	,	,	PUNCT
gs-3214	623	26	lundh	lundh	PROPN
gs-3214	623	27	,	,	PUNCT
gs-3214	623	28	s.	s.	PROPN
gs-3214	623	29	,	,	PUNCT
gs-3214	623	30	(	(	PUNCT
gs-3214	623	31	2018	2018	NUM
gs-3214	623	32	)	)	PUNCT
gs-3214	623	33	.	.	PUNCT
gs-3214	624	1	determinants	determinant	NOUN
gs-3214	624	2	of	of	ADP
gs-3214	624	3	response	response	NOUN
gs-3214	624	4	and	and	CCONJ
gs-3214	624	5	resistance	resistance	NOUN
gs-3214	624	6	to	to	ADP
gs-3214	624	7	cd19	cd19	PROPN
gs-3214	624	8	chimeric	chimeric	ADJ
gs-3214	624	9	antigen	antigen	ADJ
gs-3214	624	10	receptor	receptor	NOUN
gs-3214	624	11	(	(	PUNCT
gs-3214	624	12	car	car	NOUN
gs-3214	624	13	)	)	PUNCT
gs-3214	624	14	t	t	NOUN
gs-3214	624	15	cell	cell	NOUN
gs-3214	624	16	therapy	therapy	NOUN
gs-3214	624	17	of	of	ADP
gs-3214	624	18	chronic	chronic	ADJ
gs-3214	624	19	lymphocytic	lymphocytic	ADJ
gs-3214	624	20	leukemia	leukemia	NOUN
gs-3214	624	21	.	.	PUNCT
gs-3214	625	1	nature	nature	NOUN
gs-3214	625	2	medicine	medicine	NOUN
gs-3214	625	3	,	,	PUNCT
gs-3214	625	4	24(5	24(5	NOUN
gs-3214	625	5	)	)	PUNCT
gs-3214	625	6	,	,	PUNCT
gs-3214	625	7	563–571	563–571	NUM
gs-3214	625	8	.	.	PUNCT
gs-3214	626	1	67	67	NUM
gs-3214	626	2	.	.	PUNCT
gs-3214	626	3	maus	maus	PROPN
gs-3214	626	4	,	,	PUNCT
gs-3214	626	5	m.	m.	NOUN
gs-3214	626	6	v.	v.	PROPN
gs-3214	626	7	,	,	PUNCT
gs-3214	626	8	&	&	CCONJ
gs-3214	626	9	june	june	PROPN
gs-3214	626	10	,	,	PUNCT
gs-3214	626	11	c.	c.	PROPN
gs-3214	626	12	h.	h.	PROPN
gs-3214	626	13	(	(	PUNCT
gs-3214	626	14	2016	2016	NUM
gs-3214	626	15	)	)	PUNCT
gs-3214	626	16	.	.	PUNCT
gs-3214	627	1	making	make	VERB
gs-3214	627	2	better	well	ADJ
gs-3214	627	3	chimeric	chimeric	ADJ
gs-3214	627	4	antigen	antigen	ADJ
gs-3214	627	5	receptors	receptor	NOUN
gs-3214	627	6	for	for	ADP
gs-3214	627	7	adoptive	adoptive	ADJ
gs-3214	627	8	t	t	PROPN
gs-3214	627	9	-	-	PUNCT
gs-3214	627	10	cell	cell	NOUN
gs-3214	627	11	therapy	therapy	NOUN
gs-3214	627	12	.	.	PUNCT
gs-3214	628	1	clinical	clinical	ADJ
gs-3214	628	2	cancer	cancer	NOUN
gs-3214	628	3	research	research	NOUN
gs-3214	628	4	,	,	PUNCT
gs-3214	628	5	22(8	22(8	NUM
gs-3214	628	6	)	)	PUNCT
gs-3214	628	7	,	,	PUNCT
gs-3214	628	8	1875–1884	1875–1884	NUM
gs-3214	628	9	.	.	PUNCT
gs-3214	629	1	68	68	NUM
gs-3214	629	2	.	.	PUNCT
gs-3214	630	1	newick	newick	PROPN
gs-3214	630	2	,	,	PUNCT
gs-3214	630	3	k.	k.	PROPN
gs-3214	630	4	,	,	PUNCT
gs-3214	630	5	o’brien	o’brien	PROPN
gs-3214	630	6	,	,	PUNCT
gs-3214	630	7	s.	s.	PROPN
gs-3214	630	8	,	,	PUNCT
gs-3214	630	9	moon	moon	PROPN
gs-3214	630	10	,	,	PUNCT
gs-3214	630	11	e.	e.	PROPN
gs-3214	630	12	,	,	PUNCT
gs-3214	630	13	&	&	CCONJ
gs-3214	630	14	albelda	albelda	PROPN
gs-3214	630	15	,	,	PUNCT
gs-3214	630	16	s.	s.	PROPN
gs-3214	630	17	m.	m.	PROPN
gs-3214	630	18	(	(	PUNCT
gs-3214	630	19	2017	2017	NUM
gs-3214	630	20	)	)	PUNCT
gs-3214	630	21	.	.	PUNCT
gs-3214	631	1	car	car	NOUN
gs-3214	631	2	t	t	PROPN
gs-3214	631	3	cell	cell	NOUN
gs-3214	631	4	therapy	therapy	NOUN
gs-3214	631	5	for	for	ADP
gs-3214	631	6	solid	solid	ADJ
gs-3214	631	7	tumors	tumor	NOUN
gs-3214	631	8	.	.	PUNCT
gs-3214	632	1	annual	annual	ADJ
gs-3214	632	2	review	review	NOUN
gs-3214	632	3	of	of	ADP
gs-3214	632	4	medicine	medicine	NOUN
gs-3214	632	5	,	,	PUNCT
gs-3214	632	6	68	68	NUM
gs-3214	632	7	,	,	PUNCT
gs-3214	632	8	139–152	139–152	NUM
gs-3214	632	9	.	.	PUNCT
gs-3214	633	1	69	69	NUM
gs-3214	633	2	.	.	PUNCT
gs-3214	634	1	fraietta	fraietta	PROPN
gs-3214	634	2	,	,	PUNCT
gs-3214	634	3	j.	j.	PROPN
gs-3214	634	4	a.	a.	PROPN
gs-3214	634	5	,	,	PUNCT
gs-3214	634	6	lacey	lacey	PROPN
gs-3214	634	7	,	,	PUNCT
gs-3214	634	8	s.	s.	PROPN
gs-3214	634	9	f.	f.	PROPN
gs-3214	634	10	,	,	PUNCT
gs-3214	634	11	orlando	orlando	PROPN
gs-3214	634	12	,	,	PUNCT
gs-3214	634	13	e.	e.	PROPN
gs-3214	634	14	j.	j.	PROPN
gs-3214	634	15	,	,	PUNCT
gs-3214	634	16	pruteanu	pruteanu	NOUN
gs-3214	634	17	-	-	PUNCT
gs-3214	634	18	malinici	malinici	NOUN
gs-3214	634	19	,	,	PUNCT
gs-3214	634	20	i.	i.	NOUN
gs-3214	634	21	,	,	PUNCT
gs-3214	634	22	gohil	gohil	NOUN
gs-3214	634	23	,	,	PUNCT
gs-3214	634	24	m.	m.	NOUN
gs-3214	634	25	,	,	PUNCT
gs-3214	634	26	lundh	lundh	PROPN
gs-3214	634	27	,	,	PUNCT
gs-3214	634	28	s.	s.	PROPN
gs-3214	634	29	(	(	PUNCT
gs-3214	634	30	2018	2018	NUM
gs-3214	634	31	)	)	PUNCT
gs-3214	634	32	.	.	PUNCT
gs-3214	635	1	determinants	determinant	NOUN
gs-3214	635	2	of	of	ADP
gs-3214	635	3	response	response	NOUN
gs-3214	635	4	and	and	CCONJ
gs-3214	635	5	resistance	resistance	NOUN
gs-3214	635	6	to	to	ADP
gs-3214	635	7	cd19	cd19	PROPN
gs-3214	635	8	chimeric	chimeric	ADJ
gs-3214	635	9	antigen	antigen	ADJ
gs-3214	635	10	receptor	receptor	NOUN
gs-3214	635	11	(	(	PUNCT
gs-3214	635	12	car	car	NOUN
gs-3214	635	13	)	)	PUNCT
gs-3214	635	14	t	t	NOUN
gs-3214	635	15	cell	cell	NOUN
gs-3214	635	16	therapy	therapy	NOUN
gs-3214	635	17	of	of	ADP
gs-3214	635	18	chronic	chronic	ADJ
gs-3214	635	19	lymphocytic	lymphocytic	ADJ
gs-3214	635	20	leukemia	leukemia	NOUN
gs-3214	635	21	.	.	PUNCT
gs-3214	636	1	nature	nature	NOUN
gs-3214	636	2	medicine	medicine	NOUN
gs-3214	636	3	,	,	PUNCT
gs-3214	636	4	24(5	24(5	NOUN
gs-3214	636	5	)	)	PUNCT
gs-3214	636	6	,	,	PUNCT
gs-3214	636	7	563–571	563–571	NUM
gs-3214	636	8	.	.	PUNCT
gs-3214	637	1	70	70	NUM
gs-3214	637	2	.	.	PUNCT
gs-3214	637	3	park	park	PROPN
gs-3214	637	4	,	,	PUNCT
gs-3214	637	5	j.	j.	PROPN
gs-3214	637	6	h.	h.	PROPN
gs-3214	637	7	,	,	PUNCT
gs-3214	637	8	rivière	rivière	PROPN
gs-3214	637	9	,	,	PUNCT
gs-3214	637	10	i.	i.	PROPN
gs-3214	637	11	,	,	PUNCT
gs-3214	637	12	gonen	gonen	NOUN
gs-3214	637	13	,	,	PUNCT
gs-3214	637	14	m.	m.	NOUN
gs-3214	637	15	,	,	PUNCT
gs-3214	637	16	wang	wang	PROPN
gs-3214	637	17	,	,	PUNCT
gs-3214	637	18	x.	x.	NOUN
gs-3214	637	19	,	,	PUNCT
gs-3214	637	20	sénéchal	sénéchal	NOUN
gs-3214	637	21	,	,	PUNCT
gs-3214	637	22	b.	b.	PROPN
gs-3214	637	23	,	,	PUNCT
gs-3214	637	24	curran	curran	PROPN
gs-3214	637	25	,	,	PUNCT
gs-3214	637	26	k.	k.	PROPN
gs-3214	637	27	j.	j.	PROPN
gs-3214	637	28	(	(	PUNCT
gs-3214	637	29	2018	2018	NUM
gs-3214	637	30	)	)	PUNCT
gs-3214	637	31	.	.	PUNCT
gs-3214	638	1	long	long	ADJ
gs-3214	638	2	-	-	PUNCT
gs-3214	638	3	term	term	NOUN
gs-3214	638	4	followup	followup	NOUN
gs-3214	638	5	of	of	ADP
gs-3214	638	6	cd19	cd19	PROPN
gs-3214	638	7	car	car	NOUN
gs-3214	638	8	therapy	therapy	NOUN
gs-3214	638	9	in	in	ADP
gs-3214	638	10	acute	acute	ADJ
gs-3214	638	11	lymphoblastic	lymphoblastic	ADJ
gs-3214	638	12	leukemia	leukemia	NOUN
gs-3214	638	13	.	.	PUNCT
gs-3214	639	1	new	new	PROPN
gs-3214	639	2	england	england	PROPN
gs-3214	639	3	journal	journal	PROPN
gs-3214	639	4	of	of	ADP
gs-3214	639	5	medicine	medicine	NOUN
gs-3214	639	6	,	,	PUNCT
gs-3214	639	7	378(5	378(5	NUM
gs-3214	639	8	)	)	PUNCT
gs-3214	639	9	,	,	PUNCT
gs-3214	639	10	449–459	449–459	NUM
gs-3214	639	11	.	.	PUNCT
gs-3214	640	1	71	71	NUM
gs-3214	640	2	.	.	X
gs-3214	641	1	zhang	zhang	PROPN
gs-3214	641	2	,	,	PUNCT
gs-3214	641	3	e.	e.	PROPN
gs-3214	641	4	,	,	PUNCT
gs-3214	641	5	yang	yang	PROPN
gs-3214	641	6	,	,	PUNCT
gs-3214	641	7	p.	p.	PROPN
gs-3214	641	8	,	,	PUNCT
gs-3214	641	9	gu	gu	PROPN
gs-3214	641	10	,	,	PUNCT
gs-3214	641	11	j.	j.	PROPN
gs-3214	641	12	,	,	PUNCT
gs-3214	641	13	wu	wu	PROPN
gs-3214	641	14	,	,	PUNCT
gs-3214	641	15	h.	h.	PROPN
gs-3214	641	16	,	,	PUNCT
gs-3214	641	17	(	(	PUNCT
gs-3214	641	18	2017	2017	NUM
gs-3214	641	19	)	)	PUNCT
gs-3214	641	20	.	.	PUNCT
gs-3214	642	1	recombination	recombination	NOUN
gs-3214	642	2	of	of	ADP
gs-3214	642	3	a	a	DET
gs-3214	642	4	dual	dual	ADJ
gs-3214	642	5	-	-	PUNCT
gs-3214	642	6	car	car	NOUN
gs-3214	642	7	-	-	PUNCT
gs-3214	642	8	modified	modify	VERB
gs-3214	642	9	t	t	NOUN
gs-3214	642	10	lymphocyte	lymphocyte	NOUN
gs-3214	642	11	to	to	PART
gs-3214	642	12	accurately	accurately	ADV
gs-3214	642	13	eliminate	eliminate	VERB
gs-3214	642	14	pancreatic	pancreatic	ADJ
gs-3214	642	15	malignancy	malignancy	NOUN
gs-3214	642	16	.	.	PUNCT
gs-3214	643	1	journal	journal	PROPN
gs-3214	643	2	of	of	ADP
gs-3214	643	3	hematology	hematology	PROPN
gs-3214	643	4	&	&	CCONJ
gs-3214	643	5	oncology	oncology	NOUN
gs-3214	643	6	,	,	PUNCT
gs-3214	643	7	10(1	10(1	NUM
gs-3214	643	8	)	)	PUNCT
gs-3214	643	9	,	,	PUNCT
gs-3214	643	10	1–13	1–13	NOUN
gs-3214	643	11	.	.	PUNCT
gs-3214	643	12	72	72	NUM
gs-3214	643	13	.	.	X
gs-3214	644	1	barisa	barisa	NOUN
gs-3214	644	2	,	,	PUNCT
gs-3214	644	3	m.	m.	NOUN
gs-3214	644	4	,	,	PUNCT
gs-3214	644	5	queudeville	queudeville	NOUN
gs-3214	644	6	,	,	PUNCT
gs-3214	644	7	m.	m.	NOUN
gs-3214	644	8	,	,	PUNCT
gs-3214	644	9	mahrhofer	mahrhofer	NOUN
gs-3214	644	10	,	,	PUNCT
gs-3214	644	11	(	(	PUNCT
gs-3214	644	12	2017	2017	NUM
gs-3214	644	13	)	)	PUNCT
gs-3214	644	14	.	.	PUNCT
gs-3214	645	1	chimeric	chimeric	ADJ
gs-3214	645	2	antigen	antigen	ADJ
gs-3214	645	3	receptor	receptor	NOUN
gs-3214	645	4	t	t	NOUN
gs-3214	645	5	-	-	PUNCT
gs-3214	645	6	cells	cell	NOUN
gs-3214	645	7	:	:	PUNCT
gs-3214	645	8	the	the	DET
gs-3214	645	9	future	future	NOUN
gs-3214	645	10	is	be	AUX
gs-3214	645	11	now	now	ADV
gs-3214	645	12	.	.	PUNCT
gs-3214	646	1	human	human	ADJ
gs-3214	646	2	vaccines	vaccine	NOUN
gs-3214	646	3	&	&	CCONJ
gs-3214	646	4	immunotherapeutics	immunotherapeutic	NOUN
gs-3214	646	5	,	,	PUNCT
gs-3214	646	6	13(5	13(5	NUM
gs-3214	646	7	)	)	PUNCT
gs-3214	646	8	,	,	PUNCT
gs-3214	646	9	1109–1112	1109–1112	NUM
gs-3214	646	10	.	.	PUNCT
gs-3214	647	1	73	73	NUM
gs-3214	647	2	.	.	PUNCT
gs-3214	648	1	fda	fda	PROPN
gs-3214	648	2	.	.	PUNCT
gs-3214	649	1	(	(	PUNCT
gs-3214	649	2	2020	2020	NUM
gs-3214	649	3	)	)	PUNCT
gs-3214	649	4	.	.	PUNCT
gs-3214	650	1	approved	approve	VERB
gs-3214	650	2	cellular	cellular	ADJ
gs-3214	650	3	and	and	CCONJ
gs-3214	650	4	gene	gene	NOUN
gs-3214	650	5	therapy	therapy	NOUN
gs-3214	650	6	products	product	NOUN
gs-3214	650	7	.	.	PUNCT
gs-3214	651	1	74	74	NUM
gs-3214	651	2	.	.	PUNCT
gs-3214	652	1	european	european	PROPN
gs-3214	652	2	medicines	medicine	NOUN
gs-3214	652	3	agency	agency	NOUN
gs-3214	652	4	.	.	PUNCT
gs-3214	653	1	(	(	PUNCT
gs-3214	653	2	2020	2020	NUM
gs-3214	653	3	)	)	PUNCT
gs-3214	653	4	.	.	PUNCT
gs-3214	654	1	kymriah	kymriah	PROPN
gs-3214	654	2	:	:	PUNCT
gs-3214	654	3	epar	epar	NOUN
gs-3214	654	4	product	product	NOUN
gs-3214	654	5	information	information	NOUN
gs-3214	654	6	.	.	PUNCT
gs-3214	655	1	75	75	NUM
gs-3214	655	2	.	.	PUNCT
gs-3214	656	1	garrison	garrison	PROPN
gs-3214	656	2	jr	jr	PROPN
gs-3214	656	3	,	,	PUNCT
gs-3214	656	4	l.	l.	PROPN
gs-3214	656	5	p.	p.	PROPN
gs-3214	656	6	,	,	PUNCT
gs-3214	656	7	wang	wang	PROPN
gs-3214	656	8	,	,	PUNCT
gs-3214	656	9	s.	s.	PROPN
gs-3214	656	10	k.	k.	PROPN
gs-3214	656	11	,	,	PUNCT
gs-3214	656	12	huang	huang	PROPN
gs-3214	656	13	,	,	PUNCT
gs-3214	656	14	y.	y.	PROPN
gs-3214	656	15	,	,	PUNCT
gs-3214	656	16	&	&	CCONJ
gs-3214	656	17	baik	baik	PROPN
gs-3214	656	18	,	,	PUNCT
gs-3214	656	19	s.	s.	PROPN
gs-3214	656	20	h.	h.	PROPN
gs-3214	656	21	(	(	PUNCT
gs-3214	656	22	2019	2019	NUM
gs-3214	656	23	)	)	PUNCT
gs-3214	656	24	.	.	PUNCT
gs-3214	657	1	healthcare	healthcare	NOUN
gs-3214	657	2	costs	cost	NOUN
gs-3214	657	3	and	and	CCONJ
gs-3214	657	4	quality	quality	NOUN
gs-3214	657	5	of	of	ADP
gs-3214	657	6	life	life	NOUN
gs-3214	657	7	outcomes	outcome	NOUN
gs-3214	657	8	following	follow	VERB
gs-3214	657	9	car	car	NOUN
gs-3214	657	10	-	-	PUNCT
gs-3214	657	11	t	t	NOUN
gs-3214	657	12	therapy	therapy	NOUN
gs-3214	657	13	for	for	ADP
gs-3214	657	14	hematologic	hematologic	ADJ
gs-3214	657	15	malignancies	malignancy	NOUN
gs-3214	657	16	:	:	PUNCT
gs-3214	657	17	a	a	DET
gs-3214	657	18	systematic	systematic	ADJ
gs-3214	657	19	review	review	NOUN
gs-3214	657	20	of	of	ADP
gs-3214	657	21	economic	economic	ADJ
gs-3214	657	22	evaluations	evaluation	NOUN
gs-3214	657	23	.	.	PUNCT
gs-3214	658	1	journal	journal	NOUN
gs-3214	658	2	of	of	ADP
gs-3214	658	3	medical	medical	ADJ
gs-3214	658	4	economics	economic	NOUN
gs-3214	658	5	,	,	PUNCT
gs-3214	658	6	22(7	22(7	NUM
gs-3214	658	7	)	)	PUNCT
gs-3214	658	8	,	,	PUNCT
gs-3214	658	9	613	613	NUM
gs-3214	658	10	-	-	SYM
gs-3214	658	11	624	624	NUM
gs-3214	658	12	.	.	PUNCT
gs-3214	659	1	76	76	NUM
gs-3214	659	2	.	.	PUNCT
gs-3214	660	1	world	world	PROPN
gs-3214	660	2	health	health	PROPN
gs-3214	660	3	organization	organization	PROPN
gs-3214	660	4	.	.	PUNCT
gs-3214	661	1	(	(	PUNCT
gs-3214	661	2	2020	2020	NUM
gs-3214	661	3	)	)	PUNCT
gs-3214	661	4	.	.	PUNCT
gs-3214	662	1	who	who	PRON
gs-3214	662	2	-	-	PUNCT
gs-3214	662	3	emro	emro	NOUN
gs-3214	662	4	2020	2020	NUM
gs-3214	662	5	.	.	PUNCT
gs-3214	663	1	77	77	NUM
gs-3214	663	2	.	.	PUNCT
gs-3214	664	1	smith	smith	PROPN
gs-3214	664	2	,	,	PUNCT
gs-3214	664	3	j.	j.	PROPN
gs-3214	664	4	,	,	PUNCT
gs-3214	664	5	&	&	CCONJ
gs-3214	664	6	johnson	johnson	PROPN
gs-3214	664	7	,	,	PUNCT
gs-3214	664	8	a.	a.	NOUN
gs-3214	664	9	(	(	PUNCT
gs-3214	664	10	2021	2021	NUM
gs-3214	664	11	)	)	PUNCT
gs-3214	664	12	.	.	PUNCT
gs-3214	665	1	addressing	address	VERB
gs-3214	665	2	healthcare	healthcare	NOUN
gs-3214	665	3	disparities	disparity	NOUN
gs-3214	665	4	in	in	ADP
gs-3214	665	5	lowand	lowand	ADJ
gs-3214	665	6	middle	middle	ADJ
gs-3214	665	7	-	-	PUNCT
gs-3214	665	8	income	income	NOUN
gs-3214	665	9	countries	country	NOUN
gs-3214	665	10	:	:	PUNCT
gs-3214	665	11	challenges	challenge	NOUN
gs-3214	665	12	and	and	CCONJ
gs-3214	665	13	solutions	solution	NOUN
gs-3214	665	14	.	.	PUNCT
gs-3214	666	1	journal	journal	PROPN
gs-3214	666	2	of	of	ADP
gs-3214	666	3	global	global	ADJ
gs-3214	666	4	health	health	NOUN
gs-3214	666	5	,	,	PUNCT
gs-3214	666	6	11(2	11(2	NOUN
gs-3214	666	7	)	)	PUNCT
gs-3214	666	8	,	,	PUNCT
gs-3214	666	9	45	45	NUM
gs-3214	666	10	-	-	SYM
gs-3214	666	11	57	57	NUM
gs-3214	666	12	.	.	PUNCT
gs-3214	667	1	78	78	NUM
gs-3214	667	2	.	.	PUNCT
gs-3214	668	1	beauchamp	beauchamp	NOUN
gs-3214	668	2	,	,	PUNCT
gs-3214	668	3	t.	t.	PROPN
gs-3214	668	4	l.	l.	PROPN
gs-3214	668	5	,	,	PUNCT
gs-3214	668	6	&	&	CCONJ
gs-3214	668	7	childress	childress	PROPN
gs-3214	668	8	,	,	PUNCT
gs-3214	668	9	j.	j.	PROPN
gs-3214	668	10	f.	f.	PROPN
gs-3214	668	11	(	(	PUNCT
gs-3214	668	12	2019	2019	NUM
gs-3214	668	13	)	)	PUNCT
gs-3214	668	14	.	.	PUNCT
gs-3214	669	1	principles	principle	NOUN
gs-3214	669	2	of	of	ADP
gs-3214	669	3	biomedical	biomedical	ADJ
gs-3214	669	4	ethics	ethic	NOUN
gs-3214	669	5	.	.	PUNCT
gs-3214	670	1	oxford	oxford	PROPN
gs-3214	670	2	university	university	PROPN
gs-3214	670	3	press	press	NOUN
gs-3214	670	4	.	.	PUNCT
gs-3214	671	1	79	79	NUM
gs-3214	671	2	.	.	X
gs-3214	672	1	zafar	zafar	PROPN
gs-3214	672	2	,	,	PUNCT
gs-3214	672	3	s.	s.	PROPN
gs-3214	672	4	y.	y.	PROPN
gs-3214	672	5	,	,	PUNCT
gs-3214	672	6	peppercorn	peppercorn	VERB
gs-3214	672	7	,	,	PUNCT
gs-3214	672	8	j.	j.	PROPN
gs-3214	672	9	m.	m.	PROPN
gs-3214	672	10	,	,	PUNCT
gs-3214	672	11	schrag	schrag	PROPN
gs-3214	672	12	,	,	PUNCT
gs-3214	672	13	d.	d.	PROPN
gs-3214	672	14	,	,	PUNCT
gs-3214	672	15	taylor	taylor	PROPN
gs-3214	672	16	,	,	PUNCT
gs-3214	672	17	d.	d.	PROPN
gs-3214	672	18	h.	h.	PROPN
gs-3214	672	19	,	,	PUNCT
gs-3214	672	20	goetzinger	goetzinger	NOUN
gs-3214	672	21	,	,	PUNCT
gs-3214	672	22	a.	a.	NOUN
gs-3214	672	23	m.	m.	NOUN
gs-3214	672	24	,	,	PUNCT
gs-3214	672	25	zhong	zhong	PROPN
gs-3214	672	26	,	,	PUNCT
gs-3214	672	27	x.	x.	PROPN
gs-3214	672	28	,	,	PUNCT
gs-3214	672	29	&	&	CCONJ
gs-3214	672	30	abernethy	abernethy	ADJ
gs-3214	672	31	,	,	PUNCT
gs-3214	672	32	a.	a.	NOUN
gs-3214	672	33	p.	p.	NOUN
gs-3214	672	34	(	(	PUNCT
gs-3214	672	35	2013	2013	NUM
gs-3214	672	36	)	)	PUNCT
gs-3214	672	37	.	.	PUNCT
gs-3214	673	1	the	the	DET
gs-3214	673	2	financial	financial	ADJ
gs-3214	673	3	toxicity	toxicity	NOUN
gs-3214	673	4	of	of	ADP
gs-3214	673	5	cancer	cancer	NOUN
gs-3214	673	6	treatment	treatment	NOUN
gs-3214	673	7	:	:	PUNCT
gs-3214	673	8	a	a	DET
gs-3214	673	9	pilot	pilot	NOUN
gs-3214	673	10	study	study	NOUN
gs-3214	673	11	assessing	assess	VERB
gs-3214	673	12	out	out	ADP
gs-3214	673	13	-	-	PUNCT
gs-3214	673	14	ofpocket	ofpocket	NOUN
gs-3214	673	15	expenses	expense	NOUN
gs-3214	673	16	and	and	CCONJ
gs-3214	673	17	the	the	DET
gs-3214	673	18	insured	insured	ADJ
gs-3214	673	19	cancer	cancer	NOUN
gs-3214	673	20	patient	patient	NOUN
gs-3214	673	21	's	's	PART
gs-3214	673	22	experience	experience	NOUN
gs-3214	673	23	.	.	PUNCT
gs-3214	674	1	the	the	DET
gs-3214	674	2	oncologist	oncologist	NOUN
gs-3214	674	3	,	,	PUNCT
gs-3214	674	4	18(4	18(4	NUM
gs-3214	674	5	)	)	PUNCT
gs-3214	674	6	,	,	PUNCT
gs-3214	674	7	381	381	NUM
gs-3214	674	8	-	-	SYM
gs-3214	674	9	390	390	NUM
gs-3214	674	10	.	.	NOUN
gs-3214	674	11	80	80	NUM
gs-3214	674	12	.	.	PUNCT
gs-3214	674	13	unger	unger	PROPN
gs-3214	674	14	,	,	PUNCT
gs-3214	674	15	j.	j.	PROPN
gs-3214	674	16	m.	m.	PROPN
gs-3214	674	17	,	,	PUNCT
gs-3214	674	18	gralow	gralow	PROPN
gs-3214	674	19	,	,	PUNCT
gs-3214	674	20	j.	j.	PROPN
gs-3214	674	21	r.	r.	PROPN
gs-3214	674	22	,	,	PUNCT
gs-3214	674	23	albain	albain	PROPN
gs-3214	674	24	,	,	PUNCT
gs-3214	674	25	k.	k.	PROPN
gs-3214	674	26	s.	s.	PROPN
gs-3214	674	27	,	,	PUNCT
gs-3214	674	28	ramsey	ramsey	PROPN
gs-3214	674	29	,	,	PUNCT
gs-3214	674	30	s.	s.	PROPN
gs-3214	674	31	d.	d.	PROPN
gs-3214	674	32	,	,	PUNCT
gs-3214	674	33	hershman	hershman	PROPN
gs-3214	674	34	,	,	PUNCT
gs-3214	674	35	d.	d.	PROPN
gs-3214	674	36	l.	l.	PROPN
gs-3214	674	37	(	(	PUNCT
gs-3214	674	38	2016	2016	NUM
gs-3214	674	39	)	)	PUNCT
gs-3214	674	40	.	.	PUNCT
gs-3214	675	1	patient	patient	ADJ
gs-3214	675	2	income	income	NOUN
gs-3214	675	3	level	level	NOUN
gs-3214	675	4	and	and	CCONJ
gs-3214	675	5	cancer	cancer	NOUN
gs-3214	675	6	clinical	clinical	ADJ
gs-3214	675	7	trial	trial	NOUN
gs-3214	675	8	participation	participation	NOUN
gs-3214	675	9	:	:	PUNCT
gs-3214	675	10	a	a	DET
gs-3214	675	11	prospective	prospective	ADJ
gs-3214	675	12	survey	survey	NOUN
gs-3214	675	13	study	study	NOUN
gs-3214	675	14	.	.	PUNCT
gs-3214	676	1	journal	journal	NOUN
gs-3214	676	2	of	of	ADP
gs-3214	676	3	the	the	DET
gs-3214	676	4	american	american	PROPN
gs-3214	676	5	medical	medical	PROPN
gs-3214	676	6	association	association	PROPN
gs-3214	676	7	oncology	oncology	NOUN
gs-3214	676	8	,	,	PUNCT
gs-3214	676	9	2(1	2(1	NUM
gs-3214	676	10	)	)	PUNCT
gs-3214	676	11	,	,	PUNCT
gs-3214	676	12	137	137	NUM
gs-3214	676	13	-	-	SYM
gs-3214	676	14	139	139	NUM
gs-3214	676	15	.	.	PUNCT
gs-3214	677	1	georgian	georgian	NOUN
gs-3214	677	2	scientists/	scientists/	NUM
gs-3214	677	3	.	.	PUNCT
gs-3214	678	1	6	6	NUM
gs-3214	678	2	n	n	NUM
gs-3214	678	3	3	3	NUM
gs-3214	678	4	,	,	PUNCT
gs-3214	678	5	2024	2024	NUM
gs-3214	678	6	288	288	NUM
gs-3214	678	7	81	81	NUM
gs-3214	678	8	.	.	PUNCT
gs-3214	679	1	june	june	PROPN
gs-3214	679	2	,	,	PUNCT
gs-3214	679	3	c.	c.	PROPN
gs-3214	679	4	h.	h.	PROPN
gs-3214	679	5	,	,	PUNCT
gs-3214	679	6	&	&	CCONJ
gs-3214	679	7	sadelain	sadelain	PROPN
gs-3214	679	8	,	,	PUNCT
gs-3214	679	9	m.	m.	NOUN
gs-3214	679	10	(	(	PUNCT
gs-3214	679	11	2018	2018	NUM
gs-3214	679	12	)	)	PUNCT
gs-3214	679	13	.	.	PUNCT
gs-3214	680	1	chimeric	chimeric	ADJ
gs-3214	680	2	antigen	antigen	ADJ
gs-3214	680	3	receptor	receptor	NOUN
gs-3214	680	4	therapy	therapy	NOUN
gs-3214	680	5	.	.	PUNCT
gs-3214	681	1	new	new	PROPN
gs-3214	681	2	england	england	PROPN
gs-3214	681	3	journal	journal	PROPN
gs-3214	681	4	of	of	ADP
gs-3214	681	5	medicine	medicine	NOUN
gs-3214	681	6	,	,	PUNCT
gs-3214	681	7	379(1	379(1	NUM
gs-3214	681	8	)	)	PUNCT
gs-3214	681	9	,	,	PUNCT
gs-3214	681	10	64–73	64–73	NOUN
gs-3214	681	11	.	.	PUNCT
gs-3214	682	1	82	82	NUM
gs-3214	682	2	.	.	PUNCT
gs-3214	682	3	june	june	PROPN
gs-3214	682	4	,	,	PUNCT
gs-3214	682	5	c.	c.	PROPN
gs-3214	682	6	h.	h.	PROPN
gs-3214	682	7	,	,	PUNCT
gs-3214	682	8	&	&	CCONJ
gs-3214	682	9	sadelain	sadelain	PROPN
gs-3214	682	10	,	,	PUNCT
gs-3214	682	11	m.	m.	NOUN
gs-3214	682	12	(	(	PUNCT
gs-3214	682	13	2018	2018	NUM
gs-3214	682	14	)	)	PUNCT
gs-3214	682	15	.	.	PUNCT
gs-3214	683	1	chimeric	chimeric	ADJ
gs-3214	683	2	antigen	antigen	ADJ
gs-3214	683	3	receptor	receptor	NOUN
gs-3214	683	4	therapy	therapy	NOUN
gs-3214	683	5	.	.	PUNCT
gs-3214	684	1	new	new	PROPN
gs-3214	684	2	england	england	PROPN
gs-3214	684	3	journal	journal	PROPN
gs-3214	684	4	of	of	ADP
gs-3214	684	5	medicine	medicine	NOUN
gs-3214	684	6	,	,	PUNCT
gs-3214	684	7	379(1	379(1	NUM
gs-3214	684	8	)	)	PUNCT
gs-3214	684	9	,	,	PUNCT
gs-3214	684	10	64–73	64–73	NOUN
gs-3214	684	11	.	.	PUNCT
gs-3214	684	12	83	83	NUM
gs-3214	684	13	.	.	PUNCT
gs-3214	685	1	maude	maude	PROPN
gs-3214	685	2	,	,	PUNCT
gs-3214	685	3	s.	s.	PROPN
gs-3214	685	4	l.	l.	PROPN
gs-3214	685	5	,	,	PUNCT
gs-3214	685	6	et	et	PROPN
gs-3214	685	7	al	al	PROPN
gs-3214	685	8	.	.	PUNCT
gs-3214	685	9	(	(	PUNCT
gs-3214	685	10	2018	2018	NUM
gs-3214	685	11	)	)	PUNCT
gs-3214	685	12	.	.	PUNCT
gs-3214	686	1	tisagenlecleucel	tisagenlecleucel	VERB
gs-3214	686	2	in	in	ADP
gs-3214	686	3	children	child	NOUN
gs-3214	686	4	and	and	CCONJ
gs-3214	686	5	young	young	ADJ
gs-3214	686	6	adults	adult	NOUN
gs-3214	686	7	with	with	ADP
gs-3214	686	8	b	b	NOUN
gs-3214	686	9	-	-	PUNCT
gs-3214	686	10	cell	cell	NOUN
gs-3214	686	11	lymphoblastic	lymphoblastic	ADJ
gs-3214	686	12	leukemia	leukemia	NOUN
gs-3214	686	13	.	.	PUNCT
gs-3214	687	1	new	new	PROPN
gs-3214	687	2	england	england	PROPN
gs-3214	687	3	journal	journal	PROPN
gs-3214	687	4	of	of	ADP
gs-3214	687	5	medicine	medicine	NOUN
gs-3214	687	6	,	,	PUNCT
gs-3214	687	7	378(5	378(5	NUM
gs-3214	687	8	)	)	PUNCT
gs-3214	687	9	,	,	PUNCT
gs-3214	687	10	439–448	439–448	NUM
gs-3214	687	11	.	.	PUNCT
gs-3214	687	12	84	84	NUM
gs-3214	687	13	.	.	PUNCT
gs-3214	688	1	park	park	NOUN
gs-3214	688	2	,	,	PUNCT
gs-3214	688	3	j.	j.	PROPN
gs-3214	688	4	h.	h.	PROPN
gs-3214	688	5	,	,	PUNCT
gs-3214	688	6	et	et	PROPN
gs-3214	688	7	al	al	PROPN
gs-3214	688	8	.	.	PUNCT
gs-3214	688	9	(	(	PUNCT
gs-3214	688	10	2018	2018	NUM
gs-3214	688	11	)	)	PUNCT
gs-3214	688	12	.	.	PUNCT
gs-3214	689	1	long	long	ADJ
gs-3214	689	2	-	-	PUNCT
gs-3214	689	3	term	term	NOUN
gs-3214	689	4	follow	follow	NOUN
gs-3214	689	5	-	-	PUNCT
gs-3214	689	6	up	up	NOUN
gs-3214	689	7	of	of	ADP
gs-3214	689	8	cd19	cd19	PROPN
gs-3214	689	9	car	car	NOUN
gs-3214	689	10	therapy	therapy	NOUN
gs-3214	689	11	in	in	ADP
gs-3214	689	12	acute	acute	ADJ
gs-3214	689	13	lymphoblastic	lymphoblastic	ADJ
gs-3214	689	14	leukemia	leukemia	NOUN
gs-3214	689	15	.	.	PUNCT
gs-3214	690	1	new	new	PROPN
gs-3214	690	2	england	england	PROPN
gs-3214	690	3	journal	journal	PROPN
gs-3214	690	4	of	of	ADP
gs-3214	690	5	medicine	medicine	NOUN
gs-3214	690	6	,	,	PUNCT
gs-3214	690	7	378(5	378(5	NUM
gs-3214	690	8	)	)	PUNCT
gs-3214	690	9	,	,	PUNCT
gs-3214	690	10	449–459	449–459	NUM
gs-3214	690	11	.	.	NOUN
gs-3214	690	12	85	85	NUM
gs-3214	690	13	.	.	PUNCT
gs-3214	691	1	schuster	schuster	PROPN
gs-3214	691	2	,	,	PUNCT
gs-3214	691	3	s.	s.	PROPN
gs-3214	691	4	j.	j.	PROPN
gs-3214	691	5	,	,	PUNCT
gs-3214	691	6	et	et	PROPN
gs-3214	691	7	al	al	PROPN
gs-3214	691	8	.	.	PUNCT
gs-3214	691	9	(	(	PUNCT
gs-3214	691	10	2017	2017	NUM
gs-3214	691	11	)	)	PUNCT
gs-3214	691	12	.	.	PUNCT
gs-3214	692	1	chimeric	chimeric	ADJ
gs-3214	692	2	antigen	antigen	ADJ
gs-3214	692	3	receptor	receptor	NOUN
gs-3214	692	4	t	t	NOUN
gs-3214	692	5	cells	cell	NOUN
gs-3214	692	6	in	in	ADP
gs-3214	692	7	refractory	refractory	PROPN
gs-3214	692	8	b	b	NOUN
gs-3214	692	9	-	-	PUNCT
gs-3214	692	10	cell	cell	NOUN
gs-3214	692	11	lymphomas	lymphoma	NOUN
gs-3214	692	12	.	.	PUNCT
gs-3214	693	1	new	new	PROPN
gs-3214	693	2	england	england	PROPN
gs-3214	693	3	journal	journal	PROPN
gs-3214	693	4	of	of	ADP
gs-3214	693	5	medicine	medicine	NOUN
gs-3214	693	6	,	,	PUNCT
gs-3214	693	7	377(26	377(26	NUM
gs-3214	693	8	)	)	PUNCT
gs-3214	693	9	,	,	PUNCT
gs-3214	693	10	2545–2554	2545–2554	NUM
gs-3214	693	11	.	.	PUNCT
gs-3214	693	12	86	86	NUM
gs-3214	693	13	.	.	PUNCT
gs-3214	694	1	shah	shah	PROPN
gs-3214	694	2	,	,	PUNCT
gs-3214	694	3	n.	n.	PROPN
gs-3214	694	4	n.	n.	PROPN
gs-3214	694	5	,	,	PUNCT
gs-3214	694	6	&	&	CCONJ
gs-3214	694	7	fry	fry	PROPN
gs-3214	694	8	,	,	PUNCT
gs-3214	694	9	t.	t.	PROPN
gs-3214	694	10	j.	j.	PROPN
gs-3214	694	11	(	(	PUNCT
gs-3214	694	12	2019	2019	NUM
gs-3214	694	13	)	)	PUNCT
gs-3214	694	14	.	.	PUNCT
gs-3214	695	1	mechanisms	mechanism	NOUN
gs-3214	695	2	of	of	ADP
gs-3214	695	3	resistance	resistance	NOUN
gs-3214	695	4	to	to	ADP
gs-3214	695	5	car	car	NOUN
gs-3214	695	6	t	t	NOUN
gs-3214	695	7	cell	cell	NOUN
gs-3214	695	8	therapy	therapy	NOUN
gs-3214	695	9	.	.	PUNCT
gs-3214	696	1	nature	nature	NOUN
gs-3214	696	2	reviews	review	VERB
gs-3214	696	3	clinical	clinical	ADJ
gs-3214	696	4	oncology	oncology	NOUN
gs-3214	696	5	,	,	PUNCT
gs-3214	696	6	16(6	16(6	NUM
gs-3214	696	7	)	)	PUNCT
gs-3214	696	8	,	,	PUNCT
gs-3214	696	9	372–385	372–385	NUM
gs-3214	696	10	.	.	PUNCT
gs-3214	697	1	87	87	NUM
gs-3214	697	2	.	.	PUNCT
gs-3214	698	1	neelapu	neelapu	PROPN
gs-3214	698	2	,	,	PUNCT
gs-3214	698	3	s.	s.	PROPN
gs-3214	698	4	s.	s.	PROPN
gs-3214	698	5	,	,	PUNCT
gs-3214	698	6	et	et	PROPN
gs-3214	698	7	al	al	PROPN
gs-3214	698	8	.	.	PUNCT
gs-3214	698	9	(	(	PUNCT
gs-3214	698	10	2017	2017	NUM
gs-3214	698	11	)	)	PUNCT
gs-3214	698	12	.	.	PUNCT
gs-3214	699	1	axicabtagene	axicabtagene	PROPN
gs-3214	699	2	ciloleucel	ciloleucel	PROPN
gs-3214	699	3	car	car	PROPN
gs-3214	699	4	t	t	NOUN
gs-3214	699	5	-	-	PUNCT
gs-3214	699	6	cell	cell	NOUN
gs-3214	699	7	therapy	therapy	NOUN
gs-3214	699	8	in	in	ADP
gs-3214	699	9	refractory	refractory	NOUN
gs-3214	699	10	large	large	ADJ
gs-3214	699	11	bcell	bcell	NOUN
gs-3214	699	12	lymphoma	lymphoma	NOUN
gs-3214	699	13	.	.	PUNCT
gs-3214	700	1	new	new	PROPN
gs-3214	700	2	england	england	PROPN
gs-3214	700	3	journal	journal	PROPN
gs-3214	700	4	of	of	ADP
gs-3214	700	5	medicine	medicine	NOUN
gs-3214	700	6	,	,	PUNCT
gs-3214	700	7	377(26	377(26	NUM
gs-3214	700	8	)	)	PUNCT
gs-3214	700	9	,	,	PUNCT
gs-3214	700	10	2531–2544	2531–2544	NUM
gs-3214	700	11	.	.	X
gs-3214	700	12	88	88	NUM
gs-3214	700	13	.	.	PUNCT
gs-3214	701	1	locke	locke	PROPN
gs-3214	701	2	,	,	PUNCT
gs-3214	701	3	f.	f.	PROPN
gs-3214	701	4	l.	l.	PROPN
gs-3214	701	5	,	,	PUNCT
gs-3214	701	6	et	et	PROPN
gs-3214	701	7	al	al	PROPN
gs-3214	701	8	.	.	PROPN
gs-3214	701	9	(	(	PUNCT
gs-3214	701	10	2019	2019	NUM
gs-3214	701	11	)	)	PUNCT
gs-3214	701	12	.	.	PUNCT
gs-3214	702	1	long	long	ADJ
gs-3214	702	2	-	-	PUNCT
gs-3214	702	3	term	term	NOUN
gs-3214	702	4	safety	safety	NOUN
gs-3214	702	5	and	and	CCONJ
gs-3214	702	6	activity	activity	NOUN
gs-3214	702	7	of	of	ADP
gs-3214	702	8	axicabtagene	axicabtagene	NOUN
gs-3214	702	9	ciloleucel	ciloleucel	VERB
gs-3214	702	10	in	in	ADP
gs-3214	702	11	refractory	refractory	NOUN
gs-3214	702	12	large	large	ADJ
gs-3214	702	13	b	b	NOUN
gs-3214	702	14	-	-	PUNCT
gs-3214	702	15	cell	cell	NOUN
gs-3214	702	16	lymphoma	lymphoma	NOUN
gs-3214	702	17	.	.	PUNCT
gs-3214	703	1	the	the	DET
gs-3214	703	2	lancet	lancet	PROPN
gs-3214	703	3	oncology	oncology	NOUN
gs-3214	703	4	,	,	PUNCT
gs-3214	703	5	20(1	20(1	NUM
gs-3214	703	6	)	)	PUNCT
gs-3214	703	7	,	,	PUNCT
gs-3214	703	8	31–42	31–42	PROPN
gs-3214	703	9	.	.	NOUN
gs-3214	703	10	89	89	NUM
gs-3214	703	11	.	.	PUNCT
gs-3214	703	12	majzner	majzner	NOUN
gs-3214	703	13	,	,	PUNCT
gs-3214	703	14	r.	r.	PROPN
gs-3214	703	15	g.	g.	PROPN
gs-3214	703	16	,	,	PUNCT
gs-3214	703	17	&	&	CCONJ
gs-3214	703	18	mackall	mackall	PROPN
gs-3214	703	19	,	,	PUNCT
gs-3214	703	20	c.	c.	PROPN
gs-3214	703	21	l.	l.	PROPN
gs-3214	703	22	(	(	PUNCT
gs-3214	703	23	2019	2019	NUM
gs-3214	703	24	)	)	PUNCT
gs-3214	703	25	.	.	PUNCT
gs-3214	704	1	clinical	clinical	ADJ
gs-3214	704	2	lessons	lesson	NOUN
gs-3214	704	3	learned	learn	VERB
gs-3214	704	4	from	from	ADP
gs-3214	704	5	the	the	DET
gs-3214	704	6	first	first	ADJ
gs-3214	704	7	leg	leg	NOUN
gs-3214	704	8	of	of	ADP
gs-3214	704	9	the	the	DET
gs-3214	704	10	car	car	NOUN
gs-3214	704	11	t	t	NOUN
gs-3214	704	12	cell	cell	NOUN
gs-3214	704	13	journey	journey	NOUN
gs-3214	704	14	.	.	PUNCT
gs-3214	705	1	nature	nature	NOUN
gs-3214	705	2	medicine	medicine	NOUN
gs-3214	705	3	,	,	PUNCT
gs-3214	705	4	25(9	25(9	NUM
gs-3214	705	5	)	)	PUNCT
gs-3214	705	6	,	,	PUNCT
gs-3214	705	7	1341–1355	1341–1355	NUM
gs-3214	705	8	.	.	PUNCT
gs-3214	706	1	90	90	NUM
gs-3214	706	2	.	.	PUNCT
gs-3214	707	1	ying	ying	PROPN
gs-3214	707	2	,	,	PUNCT
gs-3214	707	3	z.	z.	PROPN
gs-3214	707	4	,	,	PUNCT
gs-3214	707	5	et	et	PROPN
gs-3214	707	6	al	al	PROPN
gs-3214	707	7	.	.	PROPN
gs-3214	707	8	(	(	PUNCT
gs-3214	707	9	2019	2019	NUM
gs-3214	707	10	)	)	PUNCT
gs-3214	707	11	.	.	PUNCT
gs-3214	708	1	a	a	DET
gs-3214	708	2	safe	safe	ADJ
gs-3214	708	3	and	and	CCONJ
gs-3214	708	4	potent	potent	ADJ
gs-3214	708	5	anti	anti	ADJ
gs-3214	708	6	-	-	ADJ
gs-3214	708	7	cd19	cd19	ADJ
gs-3214	708	8	car	car	NOUN
gs-3214	708	9	t	t	NOUN
gs-3214	708	10	cell	cell	NOUN
gs-3214	708	11	therapy	therapy	NOUN
gs-3214	708	12	.	.	PUNCT
gs-3214	709	1	nature	nature	NOUN
gs-3214	709	2	medicine	medicine	NOUN
gs-3214	709	3	,	,	PUNCT
gs-3214	709	4	25(6	25(6	NOUN
gs-3214	709	5	)	)	PUNCT
gs-3214	709	6	,	,	PUNCT
gs-3214	709	7	947–953	947–953	NUM
gs-3214	709	8	.	.	PUNCT
gs-3214	710	1	91	91	NUM
gs-3214	710	2	.	.	PUNCT
gs-3214	710	3	brown	brown	PROPN
gs-3214	710	4	,	,	PUNCT
gs-3214	710	5	c.	c.	PROPN
gs-3214	710	6	e.	e.	PROPN
gs-3214	710	7	,	,	PUNCT
gs-3214	710	8	et	et	PROPN
gs-3214	710	9	al	al	PROPN
gs-3214	710	10	.	.	PUNCT
gs-3214	711	1	(	(	PUNCT
gs-3214	711	2	2016	2016	NUM
gs-3214	711	3	)	)	PUNCT
gs-3214	711	4	.	.	PUNCT
gs-3214	712	1	regression	regression	NOUN
gs-3214	712	2	of	of	ADP
gs-3214	712	3	glioblastoma	glioblastoma	NOUN
gs-3214	712	4	after	after	ADP
gs-3214	712	5	chimeric	chimeric	ADJ
gs-3214	712	6	antigen	antigen	ADJ
gs-3214	712	7	receptor	receptor	NOUN
gs-3214	712	8	t	t	NOUN
gs-3214	712	9	-	-	PUNCT
gs-3214	712	10	cell	cell	NOUN
gs-3214	712	11	therapy	therapy	NOUN
gs-3214	712	12	.	.	PUNCT
gs-3214	713	1	new	new	PROPN
gs-3214	713	2	england	england	PROPN
gs-3214	713	3	journal	journal	PROPN
gs-3214	713	4	of	of	ADP
gs-3214	713	5	medicine	medicine	NOUN
gs-3214	713	6	,	,	PUNCT
gs-3214	713	7	375(26	375(26	NUM
gs-3214	713	8	)	)	PUNCT
gs-3214	713	9	,	,	PUNCT
gs-3214	713	10	2561–2569	2561–2569	X
gs-3214	713	11	.	.	PROPN
gs-3214	713	12	92	92	NUM
gs-3214	713	13	.	.	PUNCT
gs-3214	714	1	rafiq	rafiq	PROPN
gs-3214	714	2	,	,	PUNCT
gs-3214	714	3	s.	s.	PROPN
gs-3214	714	4	,	,	PUNCT
gs-3214	714	5	et	et	PROPN
gs-3214	714	6	al	al	PROPN
gs-3214	714	7	.	.	PROPN
gs-3214	714	8	(	(	PUNCT
gs-3214	714	9	2020	2020	NUM
gs-3214	714	10	)	)	PUNCT
gs-3214	714	11	.	.	PUNCT
gs-3214	715	1	engineering	engineering	NOUN
gs-3214	715	2	strategies	strategy	NOUN
gs-3214	715	3	to	to	PART
gs-3214	715	4	overcome	overcome	VERB
gs-3214	715	5	the	the	DET
gs-3214	715	6	current	current	ADJ
gs-3214	715	7	roadblocks	roadblock	NOUN
gs-3214	715	8	in	in	ADP
gs-3214	715	9	car	car	NOUN
gs-3214	715	10	t	t	NOUN
gs-3214	715	11	cell	cell	NOUN
gs-3214	715	12	therapy	therapy	NOUN
gs-3214	715	13	.	.	PUNCT
gs-3214	716	1	nature	nature	NOUN
gs-3214	716	2	reviews	review	VERB
gs-3214	716	3	clinical	clinical	ADJ
gs-3214	716	4	oncology	oncology	NOUN
gs-3214	716	5	,	,	PUNCT
gs-3214	716	6	17(3	17(3	NUM
gs-3214	716	7	)	)	PUNCT
gs-3214	716	8	,	,	PUNCT
gs-3214	716	9	147–167	147–167	NUM
gs-3214	716	10	.	.	PUNCT
gs-3214	717	1	93	93	NUM
gs-3214	717	2	.	.	PUNCT
gs-3214	718	1	sadelain	sadelain	PROPN
gs-3214	718	2	,	,	PUNCT
gs-3214	718	3	m.	m.	NOUN
gs-3214	718	4	,	,	PUNCT
gs-3214	718	5	et	et	PROPN
gs-3214	718	6	al	al	PROPN
gs-3214	718	7	.	.	PUNCT
gs-3214	718	8	(	(	PUNCT
gs-3214	718	9	2017	2017	NUM
gs-3214	718	10	)	)	PUNCT
gs-3214	718	11	.	.	PUNCT
gs-3214	719	1	the	the	DET
gs-3214	719	2	basic	basic	ADJ
gs-3214	719	3	principles	principle	NOUN
gs-3214	719	4	of	of	ADP
gs-3214	719	5	chimeric	chimeric	ADJ
gs-3214	719	6	antigen	antigen	ADJ
gs-3214	719	7	receptor	receptor	NOUN
gs-3214	719	8	design	design	NOUN
gs-3214	719	9	.	.	PUNCT
gs-3214	720	1	cancer	cancer	NOUN
gs-3214	720	2	discovery	discovery	NOUN
gs-3214	720	3	,	,	PUNCT
gs-3214	720	4	7(12	7(12	NUM
gs-3214	720	5	)	)	PUNCT
gs-3214	720	6	,	,	PUNCT
gs-3214	720	7	1234–1246	1234–1246	NUM
gs-3214	720	8	.	.	PUNCT
gs-3214	721	1	94	94	NUM
gs-3214	721	2	.	.	PUNCT
gs-3214	722	1	brudno	brudno	PROPN
gs-3214	722	2	,	,	PUNCT
gs-3214	722	3	j.	j.	PROPN
gs-3214	722	4	n.	n.	PROPN
gs-3214	722	5	,	,	PUNCT
gs-3214	722	6	&	&	CCONJ
gs-3214	722	7	kochenderfer	kochenderfer	PROPN
gs-3214	722	8	,	,	PUNCT
gs-3214	722	9	j.	j.	PROPN
gs-3214	722	10	n.	n.	PROPN
gs-3214	722	11	(	(	PUNCT
gs-3214	722	12	2016	2016	NUM
gs-3214	722	13	)	)	PUNCT
gs-3214	722	14	.	.	PUNCT
gs-3214	723	1	toxicities	toxicity	NOUN
gs-3214	723	2	of	of	ADP
gs-3214	723	3	chimeric	chimeric	ADJ
gs-3214	723	4	antigen	antigen	ADJ
gs-3214	723	5	receptor	receptor	NOUN
gs-3214	723	6	t	t	NOUN
gs-3214	723	7	cells	cell	NOUN
gs-3214	723	8	:	:	PUNCT
gs-3214	723	9	recognition	recognition	NOUN
gs-3214	723	10	and	and	CCONJ
gs-3214	723	11	management	management	NOUN
gs-3214	723	12	.	.	PUNCT
gs-3214	724	1	blood	blood	NOUN
gs-3214	724	2	,	,	PUNCT
gs-3214	724	3	127(26	127(26	NUM
gs-3214	724	4	)	)	PUNCT
gs-3214	724	5	,	,	PUNCT
gs-3214	724	6	3321–3330	3321–3330	NUM
gs-3214	724	7	.	.	NOUN
gs-3214	724	8	95	95	NUM
gs-3214	724	9	.	.	PUNCT
gs-3214	725	1	sterner	sterner	ADV
gs-3214	725	2	,	,	PUNCT
gs-3214	725	3	r.	r.	PROPN
gs-3214	725	4	c.	c.	PROPN
gs-3214	725	5	,	,	PUNCT
gs-3214	725	6	&	&	CCONJ
gs-3214	725	7	sterner	stern	ADJ
gs-3214	725	8	,	,	PUNCT
gs-3214	725	9	r.	r.	PROPN
gs-3214	725	10	m.	m.	PROPN
gs-3214	725	11	(	(	PUNCT
gs-3214	725	12	2021	2021	NUM
gs-3214	725	13	)	)	PUNCT
gs-3214	725	14	.	.	PUNCT
gs-3214	726	1	car	car	NOUN
gs-3214	726	2	-	-	PUNCT
gs-3214	726	3	t	t	PROPN
gs-3214	726	4	cell	cell	NOUN
gs-3214	726	5	therapy	therapy	NOUN
gs-3214	726	6	:	:	PUNCT
gs-3214	726	7	current	current	ADJ
gs-3214	726	8	limitations	limitation	NOUN
gs-3214	726	9	and	and	CCONJ
gs-3214	726	10	potential	potential	ADJ
gs-3214	726	11	strategies	strategy	NOUN
gs-3214	726	12	.	.	PUNCT
gs-3214	727	1	blood	blood	NOUN
gs-3214	727	2	cancer	cancer	NOUN
gs-3214	727	3	journal	journal	NOUN
gs-3214	727	4	,	,	PUNCT
gs-3214	727	5	11(4	11(4	NUM
gs-3214	727	6	)	)	PUNCT
gs-3214	727	7	,	,	PUNCT
gs-3214	727	8	69	69	NUM
gs-3214	727	9	.	.	X
gs-3214	728	1	96	96	NUM
gs-3214	728	2	.	.	PUNCT
gs-3214	729	1	xu	xu	INTJ
gs-3214	729	2	,	,	PUNCT
gs-3214	729	3	x.	x.	PROPN
gs-3214	729	4	,	,	PUNCT
gs-3214	729	5	et	et	PROPN
gs-3214	729	6	al	al	PROPN
gs-3214	729	7	.	.	PROPN
gs-3214	730	1	(	(	PUNCT
gs-3214	730	2	2019	2019	NUM
gs-3214	730	3	)	)	PUNCT
gs-3214	730	4	.	.	PUNCT
gs-3214	731	1	mechanisms	mechanism	NOUN
gs-3214	731	2	of	of	ADP
gs-3214	731	3	relapse	relapse	NOUN
gs-3214	731	4	after	after	ADP
gs-3214	731	5	cd19	cd19	PROPN
gs-3214	731	6	car	car	NOUN
gs-3214	731	7	t	t	NOUN
gs-3214	731	8	-	-	PUNCT
gs-3214	731	9	cell	cell	NOUN
gs-3214	731	10	therapy	therapy	NOUN
gs-3214	731	11	for	for	ADP
gs-3214	731	12	acute	acute	ADJ
gs-3214	731	13	lymphoblastic	lymphoblastic	ADJ
gs-3214	731	14	leukemia	leukemia	NOUN
gs-3214	731	15	and	and	CCONJ
gs-3214	731	16	its	its	PRON
gs-3214	731	17	prevention	prevention	NOUN
gs-3214	731	18	and	and	CCONJ
gs-3214	731	19	treatment	treatment	NOUN
gs-3214	731	20	strategies	strategy	NOUN
gs-3214	731	21	.	.	PUNCT
gs-3214	732	1	frontiers	frontier	NOUN
gs-3214	732	2	in	in	ADP
gs-3214	732	3	immunology	immunology	NOUN
gs-3214	732	4	,	,	PUNCT
gs-3214	732	5	10	10	NUM
gs-3214	732	6	,	,	PUNCT
gs-3214	732	7	2664	2664	NUM
gs-3214	732	8	.	.	PUNCT
gs-3214	733	1	97	97	NUM
gs-3214	733	2	.	.	PUNCT
gs-3214	734	1	newick	newick	PROPN
gs-3214	734	2	,	,	PUNCT
gs-3214	734	3	k.	k.	PROPN
gs-3214	734	4	,	,	PUNCT
gs-3214	734	5	et	et	PROPN
gs-3214	734	6	al	al	PROPN
gs-3214	734	7	.	.	PUNCT
gs-3214	735	1	(	(	PUNCT
gs-3214	735	2	2016	2016	NUM
gs-3214	735	3	)	)	PUNCT
gs-3214	735	4	.	.	PUNCT
gs-3214	736	1	car	car	NOUN
gs-3214	736	2	t	t	PROPN
gs-3214	736	3	cell	cell	NOUN
gs-3214	736	4	therapy	therapy	NOUN
gs-3214	736	5	for	for	ADP
gs-3214	736	6	solid	solid	ADJ
gs-3214	736	7	tumors	tumor	NOUN
gs-3214	736	8	.	.	PUNCT
gs-3214	737	1	annual	annual	ADJ
gs-3214	737	2	review	review	NOUN
gs-3214	737	3	of	of	ADP
gs-3214	737	4	medicine	medicine	NOUN
gs-3214	737	5	,	,	PUNCT
gs-3214	737	6	68(1	68(1	NOUN
gs-3214	737	7	)	)	PUNCT
gs-3214	737	8	,	,	PUNCT
gs-3214	737	9	139–152	139–152	NUM
gs-3214	737	10	.	.	PUNCT
gs-3214	738	1	98	98	NUM
gs-3214	738	2	.	.	PUNCT
gs-3214	739	1	larson	larson	PROPN
gs-3214	739	2	,	,	PUNCT
gs-3214	739	3	r.	r.	PROPN
gs-3214	739	4	c.	c.	PROPN
gs-3214	739	5	,	,	PUNCT
gs-3214	739	6	&	&	CCONJ
gs-3214	739	7	maus	maus	PROPN
gs-3214	739	8	,	,	PUNCT
gs-3214	739	9	m.	m.	NOUN
gs-3214	739	10	v.	v.	PROPN
gs-3214	739	11	(	(	PUNCT
gs-3214	739	12	2021	2021	NUM
gs-3214	739	13	)	)	PUNCT
gs-3214	739	14	.	.	PUNCT
gs-3214	740	1	car	car	NOUN
gs-3214	740	2	t	t	NOUN
gs-3214	740	3	cells	cell	NOUN
gs-3214	740	4	:	:	PUNCT
gs-3214	740	5	living	live	VERB
gs-3214	740	6	therapies	therapy	NOUN
gs-3214	740	7	in	in	ADP
gs-3214	740	8	the	the	DET
gs-3214	740	9	fight	fight	NOUN
gs-3214	740	10	against	against	ADP
gs-3214	740	11	cancer	cancer	NOUN
gs-3214	740	12	.	.	PUNCT
gs-3214	741	1	cancer	cancer	NOUN
gs-3214	741	2	discovery	discovery	NOUN
gs-3214	741	3	,	,	PUNCT
gs-3214	741	4	11(7	11(7	NUM
gs-3214	741	5	)	)	PUNCT
gs-3214	741	6	,	,	PUNCT
gs-3214	741	7	1654–1672	1654–1672	NUM
gs-3214	741	8	.	.	PUNCT
gs-3214	742	1	99	99	NUM
gs-3214	742	2	.	.	PUNCT
gs-3214	743	1	srivastava	srivastava	PROPN
gs-3214	743	2	,	,	PUNCT
gs-3214	743	3	s.	s.	PROPN
gs-3214	743	4	,	,	PUNCT
gs-3214	743	5	&	&	CCONJ
gs-3214	743	6	riddell	riddell	PROPN
gs-3214	743	7	,	,	PUNCT
gs-3214	743	8	s.	s.	PROPN
gs-3214	743	9	r.	r.	PROPN
gs-3214	743	10	(	(	PUNCT
gs-3214	743	11	2018	2018	NUM
gs-3214	743	12	)	)	PUNCT
gs-3214	743	13	.	.	PUNCT
gs-3214	744	1	engineering	engineer	VERB
gs-3214	744	2	car	car	NOUN
gs-3214	744	3	-	-	PUNCT
gs-3214	744	4	t	t	NOUN
gs-3214	744	5	cells	cell	NOUN
gs-3214	744	6	:	:	PUNCT
gs-3214	744	7	design	design	NOUN
gs-3214	744	8	concepts	concept	NOUN
gs-3214	744	9	.	.	PUNCT
gs-3214	745	1	trends	trend	NOUN
gs-3214	745	2	in	in	ADP
gs-3214	745	3	immunology	immunology	NOUN
gs-3214	745	4	,	,	PUNCT
gs-3214	745	5	36(8	36(8	NUM
gs-3214	745	6	)	)	PUNCT
gs-3214	745	7	,	,	PUNCT
gs-3214	745	8	494–502	494–502	NUM
gs-3214	745	9	.	.	PUNCT
gs-3214	746	1	georgian	georgian	NOUN
gs-3214	746	2	scientists/	scientists/	NUM
gs-3214	746	3	.	.	PUNCT
gs-3214	747	1	6	6	NUM
gs-3214	747	2	n	n	NUM
gs-3214	747	3	3	3	NUM
gs-3214	747	4	,	,	PUNCT
gs-3214	747	5	2024	2024	NUM
gs-3214	747	6	289	289	NUM
gs-3214	747	7	100	100	NUM
gs-3214	747	8	.	.	PUNCT
gs-3214	748	1	fesnak	fesnak	NOUN
gs-3214	748	2	,	,	PUNCT
gs-3214	748	3	a.	a.	PROPN
gs-3214	748	4	d.	d.	PROPN
gs-3214	748	5	,	,	PUNCT
gs-3214	748	6	et	et	PROPN
gs-3214	748	7	al	al	PROPN
gs-3214	748	8	.	.	PUNCT
gs-3214	749	1	(	(	PUNCT
gs-3214	749	2	2016	2016	NUM
gs-3214	749	3	)	)	PUNCT
gs-3214	749	4	.	.	PUNCT
gs-3214	750	1	engineered	engineer	VERB
gs-3214	750	2	t	t	NOUN
gs-3214	750	3	cells	cell	NOUN
gs-3214	750	4	:	:	PUNCT
gs-3214	750	5	the	the	DET
gs-3214	750	6	promise	promise	NOUN
gs-3214	750	7	and	and	CCONJ
gs-3214	750	8	challenges	challenge	NOUN
gs-3214	750	9	of	of	ADP
gs-3214	750	10	cancer	cancer	NOUN
gs-3214	750	11	immunotherapy	immunotherapy	NOUN
gs-3214	750	12	.	.	PUNCT
gs-3214	751	1	nature	nature	NOUN
gs-3214	751	2	reviews	review	VERB
gs-3214	751	3	cancer	cancer	NOUN
gs-3214	751	4	,	,	PUNCT
gs-3214	751	5	16(9	16(9	NUM
gs-3214	751	6	)	)	PUNCT
gs-3214	751	7	,	,	PUNCT
gs-3214	751	8	566–581	566–581	NUM
gs-3214	751	9	.	.	PUNCT
gs-3214	751	10	car	car	NOUN
gs-3214	751	11	-	-	PUNCT
gs-3214	751	12	t	t	PROPN
gs-3214	751	13	1	1	NUM
gs-3214	751	14	,	,	PUNCT
gs-3214	751	15	2	2	NUM
gs-3214	751	16	,	,	PUNCT
gs-3214	751	17	3	3	NUM
gs-3214	751	18	,	,	PUNCT
gs-3214	751	19	4	4	NUM
gs-3214	751	20	,	,	PUNCT
gs-3214	751	21	5	5	NUM
gs-3214	751	22	,	,	PUNCT
gs-3214	751	23	6	6	NUM
gs-3214	751	24	,	,	PUNCT
gs-3214	751	25	7	7	NUM
gs-3214	751	26	,	,	PUNCT
gs-3214	751	27	8	8	NUM
gs-3214	751	28	,	,	PUNCT
gs-3214	751	29	9	9	NUM
gs-3214	751	30	,	,	PUNCT
gs-3214	751	31	10	10	NUM
gs-3214	751	32	,	,	PUNCT
gs-3214	751	33	11	11	NUM
gs-3214	751	34	,	,	PUNCT
gs-3214	751	35	12	12	NUM
gs-3214	751	36	car	car	NOUN
gs-3214	751	37	-	-	PUNCT
gs-3214	751	38	t	t	NOUN
gs-3214	751	39	.	.	PUNCT
gs-3214	752	1	car	car	NOUN
gs-3214	752	2	-	-	PUNCT
gs-3214	752	3	t	t	PROPN
gs-3214	752	4	,	,	PUNCT
gs-3214	752	5	,	,	PUNCT
gs-3214	752	6	,	,	PUNCT
gs-3214	752	7	pcr	pcr	PROPN
gs-3214	752	8	.	.	PUNCT
gs-3214	752	9	car	car	NOUN
gs-3214	752	10	-	-	PUNCT
gs-3214	752	11	t	t	PROPN
gs-3214	752	12	,	,	PUNCT
gs-3214	752	13	.	.	PUNCT
gs-3214	752	14	,	,	PUNCT
gs-3214	752	15	.	.	PUNCT
gs-3214	753	1	car	car	NOUN
gs-3214	753	2	-	-	PUNCT
gs-3214	753	3	t	t	PROPN
gs-3214	753	4	,	,	PUNCT
gs-3214	753	5	,	,	PUNCT
gs-3214	753	6	.	.	PUNCT
gs-3214	754	1	car	car	NOUN
gs-3214	754	2	-	-	PUNCT
gs-3214	754	3	t	t	PROPN
gs-3214	754	4	,	,	PUNCT
gs-3214	754	5	,	,	PUNCT
gs-3214	754	6	.	.	PUNCT
gs-3214	755	1	,	,	PUNCT
gs-3214	755	2	.	.	PUNCT
gs-3214	756	1	(	(	PUNCT
gs-3214	756	2	tme	tme	NOUN
gs-3214	756	3	)	)	PUNCT
gs-3214	756	4	car	car	NOUN
gs-3214	756	5	-	-	PUNCT
gs-3214	756	6	t	t	PROPN
gs-3214	756	7	.	.	PUNCT
gs-3214	757	1	,	,	PUNCT
gs-3214	757	2	tme	tme	PROPN
gs-3214	757	3	,	,	PUNCT
gs-3214	757	4	,	,	PUNCT
gs-3214	757	5	,	,	PUNCT
gs-3214	757	6	tme	tme	X
gs-3214	757	7	car	car	PROPN
gs-3214	757	8	-	-	PUNCT
gs-3214	757	9	t	t	PROPN
gs-3214	757	10	.	.	PUNCT
gs-3214	758	1	tme	tme	PROPN
gs-3214	758	2	,	,	PUNCT
gs-3214	758	3	t	t	PROPN
gs-3214	758	4	,	,	PUNCT
gs-3214	758	5	pd	pd	PROPN
gs-3214	758	6	-	-	PUNCT
gs-3214	758	7	l1	l1	PROPN
gs-3214	758	8	,	,	PUNCT
gs-3214	758	9	car	car	NOUN
gs-3214	758	10	-	-	PUNCT
gs-3214	758	11	t	t	NOUN
gs-3214	758	12	.	.	PUNCT
gs-3214	759	1	car	car	NOUN
gs-3214	759	2	-	-	PUNCT
gs-3214	759	3	t	t	PROPN
gs-3214	759	4	,	,	PUNCT
gs-3214	759	5	,	,	PUNCT
gs-3214	759	6	.	.	PUNCT
gs-3214	760	1	georgian	georgian	NOUN
gs-3214	760	2	scientists/	scientists/	NUM
gs-3214	760	3	.	.	PUNCT
gs-3214	761	1	6	6	NUM
gs-3214	761	2	n	n	NUM
gs-3214	761	3	3	3	NUM
gs-3214	761	4	,	,	PUNCT
gs-3214	761	5	2024	2024	NUM
gs-3214	761	6	290	290	NUM
gs-3214	761	7	(	(	PUNCT
gs-3214	761	8	apcs	apc	NOUN
gs-3214	761	9	)	)	PUNCT
gs-3214	761	10	,	,	PUNCT
gs-3214	761	11	.	.	PUNCT
gs-3214	762	1	car	car	NOUN
gs-3214	762	2	-	-	PUNCT
gs-3214	762	3	t	t	PROPN
gs-3214	762	4	,	,	PUNCT
gs-3214	762	5	.	.	PUNCT
gs-3214	763	1	,	,	PUNCT
gs-3214	763	2	t	t	PROPN
gs-3214	763	3	(	(	PUNCT
gs-3214	763	4	tregs	treg	NOUN
gs-3214	763	5	)	)	PUNCT
gs-3214	763	6	(	(	PUNCT
gs-3214	763	7	mdscs	mdsc	NOUN
gs-3214	763	8	)	)	PUNCT
gs-3214	763	9	,	,	PUNCT
gs-3214	763	10	,	,	PUNCT
gs-3214	763	11	(	(	PUNCT
gs-3214	763	12	tgf	tgf	PROPN
gs-3214	763	13	)	)	PUNCT
gs-3214	763	14	-10	-10	PUNCT
gs-3214	763	15	(	(	PUNCT
gs-3214	763	16	il-10	il-10	NUM
gs-3214	763	17	)	)	PUNCT
gs-3214	763	18	.	.	PUNCT
gs-3214	764	1	,	,	PUNCT
gs-3214	764	2	,	,	PUNCT
gs-3214	764	3	.	.	PUNCT
gs-3214	765	1	car	car	NOUN
gs-3214	765	2	-	-	PUNCT
gs-3214	765	3	t	t	PROPN
gs-3214	765	4	,	,	PUNCT
gs-3214	765	5	.	.	PUNCT
gs-3214	766	1	:	:	PUNCT
gs-3214	766	2	car	car	NOUN
gs-3214	766	3	-	-	PUNCT
gs-3214	766	4	t	t	PROPN
gs-3214	766	5	,	,	PUNCT
gs-3214	766	6	,	,	PUNCT
gs-3214	766	7	,	,	PUNCT
gs-3214	766	8	,	,	PUNCT
gs-3214	766	9	.	.	PUNCT